



OPEN  ACCESS


ISSN 2587-3458
e-ISSN 2587-3466



9 772587 346000 > 9 772587 345003 >


OH_&RM ONE HEALTH & RISK MANAGEMENT

THE SCIENTIFIC JOURNAL OF THE
MOLDAVIAN BIOSAFETY AND BIOSECURITY ASSOCIATION



**SPECIAL EDITION
JANUARY 2024**

Pha•eland



External
Advisory
Board



HR EXCELLENCE IN RESEARCH

jpiamr



REZUMAT

PhageLand își propune să dezvolte o nouă strategie de intervenție

combinând capacitatea de purificare ieftină și ecologică a sistemelor pasive de tratare, și anume a zonelor umede construite (ZUC), cu un tratament dedicat pe bază de fagi pentru a preveni transmiterea rezistenței la antibiotice (RA) din apele uzate în apele de suprafață.

PhageLand include investigații de sănătate publică care vizează agenți patogeni bacterieni multirezistenți la medicamente (RAM) în țările cu venituri medii scăzute (low-middle income countries - LMIC) din Europa de Est. Tratamentul pe bază de fagi va fi adaptat în mod special pentru a elimina acești agenți patogeni multirezistenți la medicamente din apele uzate. În paralel, PhageLand își propune să evalueze: a) capacitatea de auto-purificare a modelelor de CW la scară largă care operează în Spania și Moldova în îndepărtarea reziduurilor de antibiotice, ARB și a genelor de rezistență la antibiotice (RAG); și b) riscul potențial asociat cu diseminarea RAM și RAG în cadrul comunităților bacteriene indigene și printre animalele care locuiesc în ZUC.

Tipărit din resurse financiare ale proiectului transnațional multilateral **„Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters (PhageLand)”**, 22.80013.8007.1M.

Conținutul și opiniile exprimate în publicație aparțin autorilor și nu reflectă în mod necesar viziunea și politicile JPIAMR HARISSA/ Joint Program Initiatives (JPI).



P R O G R A M

Conferința națională

„Sănătatea și fenomenul rezistenței la antimicrobiene în țările cu venituri mici și medii din Europa de Est”

(Rezultatele intermediare ale proiectului *PhageLand*)

27 ianuarie 2024



în cadrul

Proiectului transnațional multilateral „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters (*PhageLand*)”, 22.80013.8007.1M.

Descrierea conferinței

Conferința națională „**Sănătatea și fenomenul rezistenței la antimicrobiene în țările cu venituri mici și medii din Europa de Est**” este organizată de Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Institutul Național de Cercetare în Medicină și Sănătate (INCMS), în cadrul Apelului multilateral **JPIAMR HARISSA/ Joint Program Initiative (JPI) Antimicrobial Resistance** „One Health Interventions to prevent or reduce the development and transmission of Antimicrobial Resistance, AMR”, Proiectului transnațional multilateral „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters (**PhageLand**)”, 22.80013.8007.1M.

Finanțator: Comisia Europeană

Acțiune de cofinanțare: JPIAMR-Action


Acronim: PhageLand

Coordonator: VETENSKAPSRADET (SRC), Suedia

Perioada de implementare: 2021- 2025

Partenerii internaționali aprobați prin Consorțiu:

- 1) Catalan Institute for Water Research, Department of Water Quality, Spain
- 2) University of Warsaw, Faculty of Biology, Institute of Microbiology, Dept. of Environmental Microbiology and Biotechnology, Poland
- 3) Warsaw University of Life Sciences (SGGW), Department of Biochemistry and Microbiology, Poland
- 4) KU Leuven, Laboratory of Gene Technology, Leuven, Belgium
- 5) Quadram Institute Bioscience, Norwich Research Park, Rosalind Franklin Road, Norwich, the United Kingdom
- 6) Delft University of Technology, Department of Biotechnology, the Netherlands
- 7) *Nicolae Testemitanu* State University of Medicine and Pharmacy, National Institute for Health and Medical Research, Republic of Moldova



MEMBRII DE ONOARE

Angela PARASCHIV, dr. hab. șt. med., conf. univ., secretar de stat, Ministerul Sănătății al RM

Emil CEBAN, dr. hab. șt. med., prof. univ., rector, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, din RM, membru corespondent al Academiei de Științe a Moldovei (AȘM)

COMITETUL ORGANIZATORIC

Emil CEBAN dr. hab. șt. med., prof. univ., rector, USMF „Nicolae Testemițanu” RM, membru corespondent AȘM

Stanislav GROPPA dr. hab. șt. med., prof. univ., prorector pentru activitatea de cercetare, USMF „Nicolae Testemițanu”, RM, Institutul Național de Cercetare în Medicină și Sănătate, academician AȘM

Alina FERDOHLEB dr. șt. med., conf. univ., coordonator național *PhageLand*, președinta Conferinței proiectului transnațional multilateral *PhageLand*

Mihail TODIRAȘ dr. hab. șt. med., cercetător științific principal, USMF „Nicolae Testemițanu”, RM, Institutul Național de Cercetare în Medicină și Sănătate, vice președinte al Conferinței proiectului multilateral *PhageLand*

Greta BĂLAN dr. hab. șt. med., conf. univ., Disciplina de microbiologie și imunologie, Departamentul Medicină Preventivă, USMF „Nicolae Testemițanu”, RM

Elena CIOBANU dr. șt. med., conf. univ., Disciplina de igienă, Departamentul Medicină Preventivă, USMF „Nicolae Testemițanu”, RM

Cătălina CROITORU dr. șt. med., conf. univ., Disciplina de igienă, Departamentul Medicină Preventivă, USMF „Nicolae Testemițanu”, RM

Olga BURDUNIUC dr. hab. șt. med., conf. cerc., Direcția diagnostic de laborator în sănătate publică, Agenția Națională pentru Sănătate Publică, RM

COMITETUL ȘTIINȚIFIC

Stanislav GROPPA dr. hab. șt. med., prof. univ., prorector pentru activitatea de cercetare, USMF „Nicolae Testemițanu”, RM, Institutul Național de Cercetare în Medicină și Sănătate, academician AȘM

Angela PARASCHI dr. hab. șt. med., conf. univ., secretar de stat, MS al RM

Andrei UNCUȚA dr. șt. med., director IMSP SCR „Timofei Moșneaga”, RM

Nicolae JELAMSCHI dr. șt. med., director Agenția Națională pentru Sănătate Publică, RM

Elena RAEVSCHI dr. hab. șt. med., conf. univ., Catedra de medicină socială și management „Nicolae Testemițanu”, Institutul Național de Cercetare în Medicină și Sănătate, USMF „Nicolae Testemițanu”, RM

Mihail TODIRAȘ dr. hab. șt. med., cerc. șt. princ., Institutul Național de Cercetare în Medicină și Sănătate, USMF „Nicolae Testemițanu”, RM

Olga TAGADIUC dr. hab. șt. med., prof. univ., Catedra de biochimie și biochimie clinică, USMF „Nicolae Testemițanu”, RM

Larisa SPINEI dr. hab. șt. med., prof. univ., Catedra de medicina socială și management „Nicolae Testemițanu”, USMF „Nicolae Testemițanu”, RM

Nicolae BACINSCHI dr. hab. șt. med., conf. univ., Catedra de farmacologie și farmacologie clinică, USMF „Nicolae Testemițanu”, RM

Serghei CEBANU	dr. hab. șt. med., conf. univ., Disciplina de igienă, Departamentul Medicină Preventivă, USMF „Nicolae Testemițanu”, RM
Greta BĂLAN	dr. hab. șt. med., conf. univ., Disciplina de microbiologie și imunologie, Departamentul Medicină Preventivă, USMF „Nicolae Testemițanu”, RM
Olga BURDUNIUC	dr. hab. șt. med., conf. cerc., Direcția diagnostic de laborator în sănătate publică, Agenția Națională pentru Sănătate Publică, RM
Elena CIOBANU	dr. șt. med., conf. univ., Disciplina de igienă, Departamentul Medicină Preventivă, USMF „Nicolae Testemițanu”, RM
Cătălina CROITORU	dr. șt. med., conf. univ., Disciplina de igienă, Departamentul Medicină Preventivă, USMF „Nicolae Testemițanu”, RM
Carolina LOZAN-TÎRȘU	dr. șt. med., conf. univ., Disciplina de microbiologie și imunologie, Departamentul Medicină Preventivă, USMF „Nicolae Testemițanu”, RM
Olga PENINA	dr. hab. șt. med., conf. univ., Catedra de medicina socială și management „Nicolae Testemițanu”, USMF „Nicolae Testemițanu”, RM
Alina FERDOHLEB	dr. șt. med., conf. univ., Catedra de medicina socială și management „Nicolae Testemițanu”, USMF „Nicolae Testemițanu”, RM
Tatiana NOVAC	dr. șt. med., conf. univ., Catedra de medicina socială și management „Nicolae Testemițanu”, USMF „Nicolae Testemițanu”, RM
Leonid VLASYK	dr. hab. șt. med., prof. univ., Departamentul de Igienă și Ecologie, USM din Bucovina, Cernăuți, Ucraina
Alexandru FERDOHLEB	dr. hab. șt. med., conf. univ., vice director medical IMSP SCR „Timofei Moșneaga”, RM
Lyubov VLASYK	dr. șt. med., conf. univ., Departamentul de Medicină Socială și Sănătate Publică, USM din Bucovina, Cernăuți, Ucraina
Corina SCUTARI	dr. șt. med., conf. univ., Catedra de farmacologie și farmacie clinică, USMF „Nicolae Testemițanu”, RM
Cornelia LAZĂR	dr. șt. med., conf. univ., Catedra de biochimie și farmacie clinică, USMF „Nicolae Testemițanu”, RM
Anastasia BENDELIC	dr. șt. med., Catedra de anatomie și anatomie clinică, USMF „Nicolae Testemițanu”, RM
Nina IZIUMOV	dr. șt. med., conf. cerc., Agenția Națională pentru Sănătate Publică, RM
Vladimir BERNIC	dr. șt. med., conf. cerc., Agenția Națională pentru Sănătate Publică, RM

Link de acces: <https://meet.google.com/pcr-wkza-czc?hs=122&authuser=0>

9.00-9.15	ÎNREGISTRAREA PARTICIPANȚILOR (online)	
9.15-9.30	Cuvânt de deschidere Angela PARASCHIV Liliana CONDRATICOVA Aurelia HANGANU Emil CEBAN Stanislav GROPPA	Moderatori: Mihail TODIRAȘ Alina FERDOHLEB
9.30-10.00	Prezentare plenară Alina FERDOHLEB <i>Prezentarea generală a proiectului transnațional multilateral PhageLand</i>	Moderator: Mihail TODIRAȘ

Link de acces: <https://meet.google.com/tir-dzoz-bwo?hs=122&authuser=0>

10.00-11.00	Sesiunea 1 ABORDAREA MULTISECTORIALĂ ÎN FENOMENUL DE REZISTENȚĂ LA ANTIMICROBIENE (RAM)	Moderatori: Greta BĂLAN Olga BURDUNIUC
	- Maria ANTON <i>Sistemul de supraveghere epidemiologică a rezistenței microorganismelor la antimicrobiene în Republica Moldova</i> <u>Oana-Simina IACONI</u>, Greta BĂLAN, Alina FERDOHLEB <i>Terapia cu bacteriofagi: metodă de combatere a rezistenței la antimicrobiene</i> - Olga SOFRONIE <i>Diagnosticul de laborator în infecția cu virusul encefalitei transmise de căpușe</i> <u>Svetlana COLAC</u>, Mariana ULINICI, Olga BURDUNIUC <i>Analiza diversității genetice a virusului SARS-CoV-2</i> <u>Lucia GALBEN</u>, Oana-Simina IACONI, Greta BĂLAN <i>Utilizarea potențială a bacteriofagilor la bioaugmentarea proceselor biologice de epurare a apelor uzate</i> <u>Lucia TURCAN</u>, Svetlana LATUS, Anastasia CARACAS <i>Resistance of pathogens causing urinary tract infections in children</i> - Nicolae BACINSCHI, <u>Anastasia CARACAS</u>, Svetlana LATUS, Eugenia VASILACHE <i>Rational use of antibacterials in pleural empyema</i> - Nicolae PUȘCAȘ <i>Procedee de determinare rapidă a microorganismelor în medicamente</i> <u>Dmitri IUNAC</u>, Greta BĂLAN <i>Acțiunea sinergică a compușilor chimici și extractelor din spirulină</i>	

- Valentina CRETU, Olga BURDUNIUC, NICOLAE STARCIUC
A review on prevalence and antimicrobial resistance of Salmonella spp. and Campylobacter spp: one health perspective

Link de acces: <https://meet.google.com/yhm-qmkn-oxq?hs=122&authuser=0>

11.00-12.00 **Sesiunea 2**

**ABORDAREA O SINGURĂ SĂNĂTATE ȘI ACTUALI-
TĂȚII ÎN SĂNĂTATEA PUBLICĂ** **Moderatori:**
Cătălina CROITORU
Elena CIOBANU

- Doina MACARI, Corina SCUTARI, Simona NEGREȘ, Mihail TODIRĂȘ *Mapping the antibiotic consumption in the Republic of Moldova*
- Alina FERDOHLEB, Elena BUCATA, Vladimir BERNIC
Benefits and challenges in using wetlands for wastewater treatment
- Lilia ANDRONACHE, Valeriana PANTEA, Aurelian GULEA, Olga TAGADIUC, Valerii MATCOVSCHI, Valentin GUDUMAC
Use of micromolecular copper complexes of thiosemicarbazidates as an endogenous catalase inducer/activator
- Ana VÎLCOVA
Rezistența la antibiotice: factor de risc în mediul ocupațional al lucrătorilor medicali
- Ioana CALIGA
Maladii bacteriene cu manifestări neurologice influențate de schimbarea climei
- Cătălina CROITORU
Microorganisme, boli infecțioase și relația cu schimbările climatice
- Elena CIOBANU
Efectele schimbărilor climatice asupra calității apei potabile

Link de acces: <https://meet.google.com/fcj-jkxa-sxo?hs=122&authuser=0>

12.00-13.00 **Sesiunea 3**

**PROMOVAREA CALITĂȚII VIETII POPULAȚIEI ÎN
ȚĂRILE CU VENITURI MICI ȘI MEDII (LMIC)** **Moderatori:**
Larisa SPINEI
Alina FERDOHLEB

- Livia ȚAPU, Alina FERDOHLEB, Larisa SPINEI, Carles M. BORREGO
Cunoștințe, atitudini și practici privind rezistența la antimicrobiene în țările cu venit mic și mediu
- Raisa PUIA, Galina BUTA, Alina FERDOHLEB, Mihail TODIRAS
The concept of the biobank information system of Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova
- Lyubov VLASYK, Natalia RYNHACH, Anastasiya SUKHOLOTYUK, Svitlana MARINOVA, Leonid VLASYK
Changes in young people's attitudes to the problem of COVID-19, flu and other upper respiratory infections during the war in Ukraine

- Iulianna LUPASCO, Tatiana GHEIMICI, Ludmila GOLOVATIUC
Investigation of pancreatic activity parameters in patients during COVID-infection in Republic of Moldova
- Elina ȘOR
Assessment of the life quality after surgery for perforated gastroduodenal ulcer
- Elena BEREZOVSICAIA
Indicii calității vieții la bolnavii cu hepatopatii cronice din Republica Moldova
- Ludmila GOMA
Strategii de promovare în marketingul cabinetului stomatologic
- Mariana CERNIȚANU
Methods for stimulating the cognitive abilities used by students
- Ecaterina GÎNCOTA, Ludmila MURZAC, Larisa SPINEI
Case presentation - unilateral dyskinetic cerebral palsy: time for a change in cerebral palsy classification?
- Stela RACOVITA, Veaceslav MOȘIN , Mariana SPRÎNCEAN
Cytogenetic study in men from the population of the Republic of Moldova
- Anastasia BENDELIC, Valentin BENDELIC, Iliia CATERENIUC
Riscul varicelor recidivante și variantele anatomice ale venei safene mari

Link de acces: <https://meet.google.com/mve-vpdw-hfw?hs=122&authuser=0>

13.00-13.30 Închiderea lucrărilor conferinței

Moderatori:
Alina FERDOHLEB
Greta BĂLAN
Olga BURDUNIUC
Cătălina CROITORU
Elena CIOBANU
Larisa SPINEI

CUPRINS

CUVÂNT ÎNAINTE

Olga TAGADIUC. **The joint transnational call for proposals 2021, JPIAMR HARISSA**

Sveatoslav POSTORONCĂ. **Proiectul multilateral transnațional „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters” (PhageLand)**

ARTICOLE

Carles M. BORREGO, Lukasz DZIEWIT, Malgorzata GRZESIUK-BIENIEK3, Rob LAVIGNE, Evelien ADRIAENSSENS, David WEISSBRODT, Alina FERDOHLEB. <i>Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters (PhageLand)</i>	15
Oana-Simina IACONI, Greta BĂLAN, Alina FERDOHLEB. <i>Terapia cu bacteriofagi: metodă de combatere a rezistenței la antimicrobiene (analiză narativă)</i>	37
Livia ȚAPU, Alina FERDOHLEB, Larisa SPINEI, Carles M. BORREGO. <i>Cunoștințe, atitudini și practici privind rezistența la antimicrobiene în țările cu venit mic și mediu: sinteză narativă</i>	47
Doina MACARI, Corina SCUTARI, Simona NEGRES, Mihail TODIRAS. <i>Mapping the antibiotic consumption in the Republic of Moldova</i>	54
Nicolae BACINSCHI, Anastasia CARACAS, Svetlana LATUS, Eugenia VASILACHE. <i>Rational use of antibacterials in pleural empyema</i>	61
Raisa PUIA, Galina BUTA, Alina FERDOHLEB, Mihail TODIRAS. <i>The concept of the biobank information system at Nicolae Testemitanu State University of Medicine and Pharmacy, Republic of Moldova</i>	70
Nicolae PUSCAS. <i>A new procedure for the rapid determination of Pseudomonas aeruginosa bacteria in medications</i>	76
Catalina CROITORU, Ioana CALIGA. <i>Bacterial neurological diseases influenced by global warming</i>	83
Ecaterina GINCOTA, Ludmila MURZAC, Larisa SPINEI. <i>Case presentation – unilateral dyskinetic cerebral palsy: time for a change in cerebral palsy classification?</i>	89
Lyubov VLASYK, Natalia RYNHACH, Anastasiya SUKHOLOTYUK, Svitlana MARI-NOVA, Leonid VLASYK. <i>Changes in young people's attitudes to the problem of COVID-19, flu, and other upper respiratory infections during the war in Ukraine</i>	94
Dmitri IUNAC, Greta BALAN. <i>Synergistic action of chemical compounds and spirulina extracts</i>	101
Mariana CERNITANU. <i>Methods for stimulating cognitive abilities used by students</i>	111
Lilia ANDRONACHE, Valeriana PANTEA, Aurelian GULEA, Olga TAGADIUC, Valerii MATCOVSCHI, Valentin GUDUMAC. <i>Use of micromolecular copper complexes of thiosemicarbazides as an endogenous catalase inducer/activator</i>	117

REZUMATE

Lucia GALBEN, Oana-Simina IACONI, Greta BĂLAN. <i>Utilizarea potențială a bacteriofagilor la bioaugmentarea proceselor biologice de epurare a apelor uzate</i>	124
Valentina CRETU, Olga BURDUNIUC, Nicolae STARCIUC. <i>A review on prevalence and antimicrobial resistance of Salmonella spp. and Campylobacter spp: one health perspective</i>	125
Mihail RULEVSCHI, Dmitri IUNAC, Greta BĂLAN. <i>Rezistența la antimicrobiene și factorii de patogenitate ai tulpinilor clinice de Staphylococcus spp.</i>	126
Cristina SÎRBU, Nicolae STARCIUC, Olga BURDUNIUC. <i>Evaluarea practicilor de utilizare a antibacterienelor de către medicii veterinari din Republica Moldova</i>	127
Lucia GALBEN, Eugeniu CHEPTENE, Alexandru FERDOHLEB. <i>Spectrul și rezistența la antimicrobiene ale infecțiilor tractului urinar asociate cateterizării</i>	128
Nicolae PUȘCAȘ. <i>Calitatea microbiologică a produselor farmaceutice nesterile</i>	129
Anastasia ALEXANDROV, Greta BĂLAN. <i>Impactul metodelor microbiologice asupra diagnosticului infecției cu Clostridiodes difficile</i>	130
Ana VÎLCOVA. <i>Problema rezistenței la antibiotice în mediul ocupațional al lucrătorilor medicali: sinteză narativă</i>	131
Lucia TURCAN, Svetlana LATUS, Anastasia CARACAS. <i>Resistance of pathogens causing urinary tract infections in children</i>	132
Ioana CALIGA. <i>Maladii bacteriene cu manifestări neurologice influențate de schimbarea climei</i>	133
Alina FERDOHLEB, Elena BUCATA, Vladimir BERNIC. <i>Benefits and challenges in using wetlands for wastewater treatment</i>	134
Angela PARASCHIV, Vasili GALBEN. <i>Aspecte epidemiologice a infecțiilor de situs chirurgical: analiză narativă</i>	135
Svetlana COLAC, Mariana ULINICI, Olga BURDUNIUC. <i>Analiza diversității genetice a virusului SARS-CoV-2: revista literaturii</i>	136
Iana COVACI, Ludmila GOMA. <i>Marketing social în campaniile de vaccinare</i>	137
Stela RACOVITA, Veaceslav MOSIN, Mariana SPRINCEAN. <i>Cytogenetic study in men from the population of the Republic of Moldova</i>	138
Anastasia BENDELIC, Valentin BENDELIC, Ilia CATERENIUC. <i>Riscul varicelor recidivante și variantele anatomice ale venei safene mari</i>	139
Elina SHOR. <i>Assessment of the life quality after surgery for perforated gastroduodenal ulcer</i>	140
Elena BEREZOVSCAIA. <i>Indicii calității vieții la bolnavii cu hepatopatii cronice din Republica Moldova</i>	141
Elena CIOBANU. <i>Efectele schimbărilor climatice asupra calității apei potabile</i>	142
Iulianna LUPASCO, Tatiana GHELMICI, Ludmila GOLOVATIUC. <i>Investigation of pancreatic activity parameters in patients during COVID-infection in Republic of Moldova</i>	143
Elena STEPICO, Maria PATRANAC, Alexandrina FERDOHLEB, Cristina DUMITRAS. <i>Dental education for medical students</i>	144
Ludmila GOMA. <i>Strategii de promovare în marketingul cabinetului stomatologic</i>	145

The joint transnational call for proposals 2021, JPIAMR HARISSA



Olga TAGADIUC,
PhD in medical science, university professor,
Chair of Biochemistry and Clinical Biochemistry discipline,
Nicolae Testemitanu State University of Medicine and Pharmacy,
Chisinau, Republic of Moldova

Joint programming (JP) has been a significant tool for planning and implementing research and development actions in Europe in this millennium. The European Union, along with its Member States and partners from associated and third countries, has endeavored to adopt a more coordinated approach to financing, planning, and implementing research and innovation activities through joint actions.

The Joint Program Initiative on Antimicrobial Resistance, JPIAMR, is an international collaborative platform involving 29 countries and the European Commission in the fight against antimicrobial resistance (AMR). JPIAMR coordinates national research funding and supports collaborative efforts to address AMR knowledge gaps from the One Health perspective. The JPIAMR program identifies key areas that require attention and provides guidance to countries, aiming to harmonize national and international AMR research programs to combat antimicrobial resistance globally. Aligned with the six strategic directions of the general research and innovation agenda of JPIAMR, the partnership engages in a wide range of activities with a One Health approach, seeking and supporting solutions to reduce the transmission of antimicrobial-resistant bacteria.

The Moldovan team from the Nicolae Testemitanu State University of Medicine and Pharmacy, Republic of Moldova, is a partner in an international consortium implementing the project Phage treatment and wetland technology as an intervention strategy to prevent the dissemination of antibiotic resistance in surface waters (PhageLand). This initiative is part of the Joint Transnational Call for Proposals 2021, titled “One Health interventions to prevent or reduce the development and transmission of antimicrobial resistance” (JPIAMR HARISSA).

PhageLand aims to develop a novel intervention strategy that combines the cost-effective and envi-

ronmentally friendly treatment capabilities of constructed wetlands with specific phage-based treatments. The goal is to prevent the transfer of antibiotic resistance from wastewater to surface water. The PhageLand project, a multi-stakeholder study, utilizes public health methods to identify multidrug-resistant bacterial pathogens in the Republic of Moldova. Phage-based treatments have been adapted to eliminate these multidrug-resistant pathogens from wastewater. Simultaneously, PhageLand assesses, in Spain and Moldova, the capacity of real-scale wetlands to self-purify from antibiotic residues, antibiotic-resistant bacteria, and antibiotic resistance genes. The project also explores the potential risks associated with the dissemination of the latter in native bacterial communities and among wetland animals.

The project serves as a commendable model for the involvement of researchers from the Republic of Moldova in multilateral projects addressing significant global and national issues. It facilitates the development of capacities among Moldovan researchers, fosters the establishment of networks with colleagues from various countries, and enhances the visibility of Moldovan researchers on the international stage.



Proiectul multilateral transnațional „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters” (*PhageLand*)



Sveatoslav POSTORONCĂ,

Direcția cooperare internațională și dezvoltare durabilă,
Agenția Națională pentru Cercetare și Dezvoltare
Membru în Consiliul de administrare al I.C.P. RAM
Chișinău, Republica Moldova

Stimate cititor,

În condițiile actuale, caracterizate de profunde crize sistemice globale, în contextul cărora ne confruntăm cu serioase provocări și amenințări pentru cele mai importante ramuri vitale ale societății, așa ca: sănătate, climă, securitate alimentară, cibernetică, militară și energetică, exercițiul de alocare a finanțărilor din fondurile naționale sau internaționale, dedicate activităților științifice necesită implicare profesionistă. Pentru a crește gradul de reziliență, performanță și competitivitate economică a unei societăți, subiectele de utilizare cât mai eficientă a resurselor alocate, au fost și rămân „cap-de-listă” pe agendele managementului sistemului domeniilor de cercetare și inovare. La fel de important este și rolul prioritizării tematicilor procesate de comunitatea științifică. În urma analizelor statisticilor ce cuantifică prejudiciile aduse la nivel mondial atât omului, cât și mediu ambiant în care el vețuiește, ca urmare a utilizării insuficient de rațională a preparatelor antibiotice, domeniul Rezistenței la Antimicrobiene (RAM) se plasează pe un loc distinct. Savanții au descifrat deja foarte bine circuitul preparatelor folosite de acest gen în natură, ajungând la concluzia că răspândirea efectelor RAM nu se supun limitărilor condiționate de hotare dintre țări sau părți ale lumii, tipuri de organizare a orânduirilor sociale, nivelul de dezvoltare economică a țărilor etc. Anume din aceste considerente și sunt constituite instituții la nivel internațional, cu mandat dedicat de gestionare a arealului de probleme de acest gen. Important este exemplul implicării Organizației Mondiale a Sănătății, Organizației Națiunilor Unite prin intermediul ODD-urilor și a altor asociații profesionale de anvergură. Același format participativ persistă și la partea de activități de cercetare, urmărind consolidarea efortului oamenilor de știință într-o manieră sistematizată, focusată pe sănătatea oamenilor, a animalelor și pe starea mediului, vizi-

ne care a formulat conceptul „O Singură Sănătate” („One Health”).

Programul-cadru pentru cercetare și inovare Orizont Europa al UE este în derulare, al nouălea la număr, de-a lungul anilor. Calea parcursă în organizarea și desfășurarea activităților de cercetare și inovare pe continentul European, totodată stabilind legături de colaborare pe întregul mapamond a permis crearea unor mecanisme și instrumente capabile de a lansa acțiuni de finanțare a proiectelor realizate în comun de consorțiile transnaționale, practică preluată de la programele anterioare. În lista acestora se regăsesc cele zece Inițiative Comune de Program, din care face parte Rezistența la Antimicrobiene (Joint Programme Initiatives on Antimicrobial Resistance - JPIAMR). I.C.P. RAM este o platformă internațională colaborativă, ce întrunește Comisia Europeană cu 29 de state ale lumii în dezideratul de a contracara fenomenul RAM, unde, din afara continentului European fac parte Canada, Argentina, Chile, India, Japonia, Coreea de Sud, Africa de Sud și Egipt. Anual, în cadrul inițiativei RAM sunt lansate concursuri multilaterale pentru propuneri de proiecte prin intermediul acțiunilor de co-finanțare din bugetele naționale ale țărilor participante, cu contribuția CE. Foarte important este de a menționa faptul implicării tot atât de colaborative a tuturor reprezentanților țărilor semnatare în procesul de elaborare nu doar a documentelor pentru lansarea concursurilor, proces în care sunt agreate toate condițiile expuse de parteneri pentru a se conforma la prevederile cadrului legal național din domeniu, dar și a documentelor strategice și operaționale de politici, ce reglementează dezvoltarea științifică a domeniului. Respectiv, în asemenea exercițiu sunt implicați alături de reprezentanții managementului în cercetare și inovare, experți din rândurile savanților cu recunoaștere internațională.

Republica Moldova, prin adresarea scrisorii de intenție din partea Agenției Naționale pentru Cercetare și Dezvoltare (ANCD) către organele de guvernanță ale I.C.P. RAM, în 2019 a fost acceptată în calitate de membru cu drepturi depline, astfel, în perioada anului 2020, participând în procesul de prefigurare a concursului pentru anul 2021. Este un rezultat reprezentativ al colaborării ANCD cu reprezentanții organizațiilor naționale din domeniile cercetării și inovării, precum Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Agenția Națională pentru Sănătate Publică și a altor instituții din sistem, exemplu ce merită a fi propagat și replicat în rândurile comunității științifice din țară. La momentul de debut al țării noastre în concursul I.C.P RAM, lansat în 2021 cu genericul „Intervenția abordării O Singură Sănătate pentru a preveni sau a reduce evoluția și transmisia Rezistenței la Antimicrobiene” din lista celor depuse, câștigătoare a fost

propunerea proiectului „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters” cu acronimul „PhageLand”, având USMF „Nicolae Testemițanu” ca partener cu instituțiile omoloage din Spania, Polonia, Belgia, Principatele Unite și Țările de Jos. Un alt exemplu de colaborare a cercetătorilor moldoveni este proiectul „Bench, Bedside, Business, and Beyond: innovative solutions for AMR diagnostics” cu acronimul „B2B2B AMRDx”, unde sunt implicați reprezentanții Institutului de Ftiziopneumologie „Chiril Draganiuc”. Participarea ANCD la concursurile lansate de I.C.P. RAM continuă. Anul curent 2024 suntem iarăși parte a noului apel „Intervenții care avansează pentru a promova acțiuni pentru a contracara apariția și răspândirea rezistenței bacteriene și fungice și pentru a îmbunătăți tratamentele”. Nutrim speranțe în depunerea noilor propuneri reușite, cu accesarea granturilor de finanțare pentru implementarea proiectelor.

Revenind la cele menționate la începutul acestui mesaj, este cazul de a reitera despre faptul conștientizării autorităților asupra necesității finanțării tematicilor menționate în context, ca fiind din aria celor de importanță majoră pentru sănătatea populației țării, integrată în sănătatea la nivel global. Despre aceasta mărturisește și direcția „Supravegherea și controlul rezistenței la preparatele antimicrobiene” din cadrul priorității strategice dedicată sănătății, regăsindu-se în documentul recent aprobat la nivel de țară „Programul național în domeniile cercetării și inovării pentru anii 2024-2027”. De asemenea, la partea de cooperare internațională, ANCD intenționează participarea în noi forme de parteneriate profesionale dedicate combaterii RAM.

Mult succes cercetătorilor și inovatorilor, celor care aspiră către explorarea platformelor unor asemenea activități în cooperare, apreciată implicare cu dăruire, ce ne asigură o societate sănătoasă și prosperă.



PHAGE TREATMENT AND WETLAND TECHNOLOGY AS INTERVENTION STRATEGY TO PREVENT DISSEMINATION OF ANTIBIOTIC RESISTANCE IN SURFACE WATERS (PhageLand)

Carles M. BORREGO¹, Lukasz DZIEWIT², Malgorzata GRZESIUK-BIENIEK³, Rob LAVIGNE⁴, Evelien ADRIAENSSENS⁵, David WEISSBRODT⁶, Alina FERDOHLEB⁷

¹Catalan Institute for Water Research (ICRA-CERCA), Institute of Aquatic Ecology, University of Girona, Girona, Spain

²Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland

³Warsaw University of Life Sciences (SGGW), Warsaw, Poland

⁴Laboratory of Gene Technology, KU Leuven, Leuven, Belgium

⁵Quadram Institute Bioscience, Norwich Research Park, Norwich, UK

⁶Delft University of Technology, Delft, the Netherlands

⁷Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Alina Ferdohleb, e-mail: alina.ferdohleb@usmf.md

BACKGROUND

PhageLand aims to develop a novel intervention strategy combining the low-cost and eco-friendly purification capacity of passive treatment systems, namely constructed wetlands (CW), with a dedicated phage-based treatment to prevent the transmission of antibiotic resistance (AR) from wastewater into surface waters. *PhageLand* includes public health investigations targeting multidrug resistant bacterial (ARB) pathogens in low-middle income countries (LMICs) in Eastern Europe. The phage-based treatment will be specifically tailored to eliminate these multidrug-resistant pathogens from wastewater. In parallel, *PhageLand* aims to assess: (i) the self-purification capacity of model full-scale CWs operating in Spain and Moldova in removing antibiotic residues, ARB and antibiotic resistance genes (ARGs); and (ii) the potential risk associated with the dissemination of ARB and ARGs within indigenous bacterial communities and among animals inhabiting CWs. Experimental tasks will include field and laboratory experiments involving cutting-edge chemical, biotechnological and (meta)genomic techniques as well as animal testing. Finally, a pilot-scale infrastructure will be used to scale-up the *PhageLand* technology and to assess its performance under real environmental conditions. This proof-of-concept will be used to demonstrate the efficacy and scalability of this nature-based technology for combating AR and to encourage stakeholders for its implementation in wastewater treatment, particularly in LMICs where costly and power-demanding treatment plants are difficult to set up.

One-Health areas relevant:

- Human Health,
- Animal Health,
- Environment.

Scientific area:

- Understand the impact of interventions on the development and transmission of antibiotic resistance in, and/or between, at least two One Health settings.
- Design, implement, evaluate, and/or compare innovative interventions to control the development and transmission of antibiotic resistance in, and/or or between, at least two One Health settings.

PROJECT DESCRIPTION

Antibiotic resistance (AR) is widespread and difficult, if not impossible, to limit by biological, physical or geographical barriers. This is the reason behind the “One Health” approach that guides all regulations and research plans on AR worldwide (United Nations, 2016 Political Declaration of the high-level meeting of the General Assembly on Antimicrobial Resistance. New York, USA). The misuse and overuse of antibiotics in human medicine, veterinary practices, animal husbandry, agriculture and aquaculture have traditionally been targeted as the main reasons for its global spread but other factors such as poor sanitation and poor governance have recently been identified as compelling contributors to high AR levels across countries (1). Currently, much higher rates of infection by multidrug-resistant pathogens and resistance prevalence have been observed in coun-

tries spending less on water sanitation, community infrastructure and public health. Unfortunately, the majority of these countries correspond to a group of low-income and middle-income countries (LMICs).

Wastewater discharges as source of chemical and biological pollutants

In urban areas, humans are the main source of antibiotic residues, antibiotic-resistant bacteria (ARB) and antibiotic resistance genes (ARGs), which are excreted through feces and conveyed in sewers from individual toilets to wastewater treatment plants (WWTPs). Although these facilities effectively reduce the nutrient content and bacterial loads from wastewater to acceptable levels before discharge, conventional treatments are far from optimal in the removal of pharmaceutical compounds (including antibiotics), ARB and ARGs (2, 3, 4). This inefficient removal results in a chronic input of a vast array of both antibiotic residues and wastewater-associated ARB (including multidrug-resistant pathogens) into the receiving environments (5, 6), regardless of the treatment technology applied (7). Many studies have highlighted the role of environmental settings (e.g., water or soil) as reservoirs and conduits for the acquisition and dissemination of AR between environmental bacteria but also from them to wildlife and, eventually, to humans (8,9). Needless to mention that this situation is even worse in LMICs where sewage is often discharged untreated (or partially treated) into the environment due to the lack of treatment infrastructures caused by their high-power consumption and overall maintenance costs.

According to the World Bank list of economies announced in 2021 (<https://www.worldbank.org>), the low income countries (LICs) are defined as those with a Gross National Income (GNI) per capita of \$1,035 and lower middle-income countries (LMICs) are those with a GNI per capita between \$1,036 and \$4,045. Currently, there are 29 LICs and 50 LMICs, mostly in Africa and Asia and only two in Europe (Moldova and Ukraine). Then, among upper middle-income countries (UMICs), 12 out of 56 countries (i.e., Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Kazakhstan, Kosovo, Montenegro, North Macedonia, Russian Federation, and Serbia) are European ones. However, careful inspection of their economy locates them close to the upper

threshold of LMICs, highlighting their relative low income per capita. Summarizing, 14 (30%) out of 46 European countries can be classified as borderline low-and middle income economies, with limited funds spent on waste treatment and environmental protection. Further investigation for sustainable and cost-effective waste treatment technologies is urgently needed worldwide, including Europe, which is usually omitted when considering low-income economies.

Constructed wetlands as eco-friendly alternative to wastewater treatment

Compared to conventional treatment technologies (i.e., WWTP), constructed wetlands (CW) are passive treatment systems that offer a cost-efficient and eco-friendly solution for the remediation of wastewaters of various origins (10, 11). Despite their low power consumption and low maintenance requirements, their application is far from widespread. This may be a consequence of their dependence on many factors, including operational (system configuration, hydraulic retention time), abiotic (temperature, irradiation, water chemistry, substrate used, type of pollutant) and biotic (vegetation type, composition of microbial communities and wastewater origin) (12 – 17). This variability of influencing factors leads to ambiguous results among studies, not only for chemical pollutants (pesticides and emerging contaminants, including antibiotics), but also in the removal of wastewater-derived microbes, including ARB and ARGs (18 – 21). However, most studies have been carried out in lab-type CWs or pilot plants, posing serious limitations to the extrapolation of their results to full-scale CW. Although these studies have provided valuable information, comprehensive field studies and insight into genetic processes (e.g., *horizontal gene transfer*) in CWs are needed to assess its performance and effectiveness. Nevertheless, scientists and engineers accordingly point out that, as nature-based and cost-effective solutions, CWs form a highly promising, scalable technology for the removal of emerging pollutants, especially in LMICs.

In order to assess the performance and effectiveness of CWs, interactions between environmental factors, both within and between biotic and abiotic compartments should be taken into account. This is essential considering that these systems utilize the symbiotic and/or synergistic effects of

plants, microorganisms, animals, and substrates to improve water quality. Natural wetlands represent one of the ecosystems with the richest biodiversity. In fact, wetlands cover 6-8% of the Earth's surface, which are naturally inhabited by up to 40% of the world's flora and fauna species. Like natural wetlands, CWs provide habitats for a large diversity of wildlife species. Most animals inhabiting CWs are benthic invertebrates and fish, which may promote the efficiency of pollutant removal by plants and influence microbial diversity (22). However, it has been shown that aquatic animals may act as vectors for ARB and ARGs (23), thus it is crucial to evaluate their role and potential epidemiological risks that may be generated in CWs. Constructed wetlands functioning relies on their self-purification capacity, specific metabolic properties and complex biodiversity. Thus, these systems are perfect objects to study the biotic resistance hypothesis, that describes the chances of the invasive species to be successful in the novel environments and assumes that the species diverse environments are more resistant to invasive species. It seems that this hypothesis is important to investigate the dissemination of ARB (as invasive species) in various environmental settings and the role of biodiversity in preventing their spread. In *PhageLand* we will evaluate if naturally biodiverse CWs are resistant to invasion by ARB and thus create a barrier against the spread of AR into surface waters. Moreover, we will evaluate the benefits, drawbacks and trade-offs of application of phage treatment in CWs, and how these bio-agents influence the biodiversity and self-purification capacity of CWs.

Bacteriophages as tool for improving wastewater sanitation

Lytic bacteriophages (phages) are bacteria-infecting viruses that prey on their host to replicate and ultimately lyse it. Phages are naturally present in wastewater and WWTPs, but, like many other viruses, they are not efficiently removed (24). Advances in sequencing technologies are now allowing bacterial and phage communities to be investigated using metagenomics and viromics (metagenomics of the viral fraction (25, 26)). Long-term viromic analyses of wastewater not only showed that phages are a major viral component but also showed temporal dynamics indicative of active bacterial predation (27). Similarly,

metagenomics allows the study of the acquisition and mobilization of ARGs and shows that without intervention the ARG profile is persistent over time (28, 29). By coupling these two observations, we may conclude that an active system for the elimination of ARB/ARGs is needed and phages, as natural bacteria killers, constitute a promising tool. In parallel to the medical sector (30, 31), phage therapy is used in environmental engineering to control biofilms and combat biofouling of membrane systems during drinking water treatment (32, 33).

The specificity and self-replicating nature of phages also make them also ideal alternatives to disinfectants with minimal collateral damage to ecosystems. This opens an opportunity to selectively track specific groups of ARB (e.g., the six highly virulent and antibiotic-resistant pathogens *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter spp.* – referred to as ESKAPE) by carefully using selected phage cocktails (34). In fact, phages and phage-inspired technologies are currently being explored as a complement to antibiotic treatment in human and veterinary medicine as well as sustainable biocontrol agents in agriculture (35 - 38). Thus, their usage in wastewater treatment for targeted removal of ARB can result in a natural consequence of previous applications.

Knowledge gaps and intervention strategy addressed by PhageLand

Despite the wealth of information on the use of CW as a cost-effective alternative to conventional wastewater treatments, many knowledge gaps still exist regarding their optimal configuration and biological composition for the efficient removal of ARB and associated ARGs. Despite being proposed as a safe alternative to antibiotic therapy to combat infections caused by multidrug-resistant pathogens, the efficacy and safety of phages as “silver bullets” to eliminate problematic ARB in environmental settings remain unknown.

The aim of *PhageLand* is to combine the self-purification capacity of constructed wetlands and the specificity of phages to remove ARB, including well-known multidrug-resistant human pathogens, and their resistance genes from wastewater before discharge into surface waters. This tech-

nology will be evaluated in terms of: (i) efficacy in the removal of target ARB (including ESKAPE pathogens); and (ii) ecological safety (i.e., preservation of natural bacterial diversity, lack of side effects on ARG dissemination between environmental bacteria and from them to animals). The *PhageLand* technology will be implemented in a scaled-up pilot infrastructure to be used as a proof-of-concept of a cost-effective and eco-friendly intervention strategy to reduce the burden of ARB and ARG that chronically pollute surface waters and to mitigate the environmental transmission of AR determinants.

PhageLand plans to develop a safe, cost-effective, scalable and sustainable technology that could be easily deployed in LMICs where economic constraints impede the construction of costly and high-power demanding treatment technologies (fig. 1). In this regard, *PhageLand* will focus on

post-soviet Eastern European countries that have traditionally been overlooked when thinking about LMICs (usually recognized only as Asian or African countries), which we identify as a huge gap in perception of global needs. In this project, Moldova will be used as a model country, representing European LMICs.

However, proposed technology will be universal, thus may be easily transferred to other countries, irrespectively of their economic status. *PhageLand* is specially committed to provide effective solutions that help on preventing the transmission of AR through different “One Health” compartments (human, animal, environment) by combining field and laboratory experiments, classical microbiology, environmental chemistry, cutting-edge genomic techniques, microfluidics, animal testing and environmental engineering.




Figure 1. Conceptual framework of *PhageLand*.

Urban wastewater contains antibiotic residues and human-derived microorganisms (including well-known human pathogens resistant to antibiotics) that may withstand either traditional treatment in WWTPs or passive treatment in CW. The *PhageLand* technology will improve the nature-based purification capacity of CW by applying an specific phage bio-treatment to specifically remove ARB (including ESKAPE pathogens) thus providing environmentally safe water and minimizing the risk of dissemination of AR determinants across “One Health” compartments (human-animal-environment).

The main objectives in order of priority

Aim No.	Description	Partner(s) responsible for the aim /workload (fig. 2)
PL-1	Develop a practical nature-based technology based on self-purification capacity of CW and phage specificity against multidrug-resistant pathogens as a cost-effective and eco-friendly intervention strategy to reduce the risk of dissemination of AR into the environment. <i>Addressed in Work Packages 3, 4, 5, 6.</i>	All
PL-2	Evaluate the capacity of CWs for the removal of chemical (antibiotic residues) and biological pollutants (ARB and ARGs) from communal wastes. <i>Addressed in Work Package 3</i>	All
PL-3	Select specific phages targeting wastewater-derived ARB – focusing on multidrug-resistant ESKAPE pathogens— and to assess their efficacy on the removal ARB/ARGs from communal wastes. <i>Addressed in Work Package 4</i>	KUL, QIB
PL-4	Design and scale-up a pilot infrastructure to implement the proposed PhageLand technology and to assess its efficiency in the removal of antibiotic residues and multidrug-resistant pathogens from well-defined laboratory to complex, real environmental conditions. <i>Addressed in Work Package 6</i>	TUD, UW
PL-5	Assess to what extent animals feeding on or inhabiting CWs accumulate wastewater-derived ARBs/ARGs in their microbiota. <i>Addressed in Work Package 5</i>	ICRA, UW, SGGW, QIB
PL-6	Evaluate the epidemiological risk of communal wastes as a source of ARB in relation to public health focusing on Eastern European LMICs. <i>Addressed in Work Package 2</i>	NTSU
PL-7	Develop a novel method of tracking horizontal transfer of ARGs in various environments by coupling droplet microfluidics and high-throughput fusion PCR amplicon sequencing. <i>Addressed in Work Package 3</i>	UW

Note: ICRA - Catalan Institute for Water Research; UW - University of Warsaw; SGGW - Warsaw University of Life Sciences; KUL - KU Leuven; QIB - Quadram Institute Bioscience; TUD - Delft University of Technology; NTSU – Nicolae Testemitanu State University of Medicine and Pharmacy.

WORK PLAN

PhageLand is structured in 7 work-packages (WP) including those related to the coordination (WP1) and dissemination of results (WP7).

WP1. Coordination

Lead Partner: ICRA

Participation: all other partners

Objectives: To establish procedures enabling fruitful cooperation between project partners and then to implement them into practice during project realization.



Figure 2. Partners responsible for the aim / workload.

Coordination, interaction and communication between project partners

ICRA will, as coordinating partner, take charge of all tasks required for the successful development of the project, including administrative services, the organization of project meetings, and progress monitoring. In collaboration with all partners, ICRA will manage contingency plans to face potential risks and to avoid delays in reaching milestones and deliverables. The coordinator will also write the reports after collecting data from all partners.

The project will start with a Kick-Off meeting at ICRA (Spain) to set the goals and discuss priorities in terms of materials, time schedule and milestones. The External Advisory Board will be invited to the kick off to introduce the consortium members and to discuss base elements for the project and planned activities.

Every 3 months, partner PIs will participate in online Steering Committee Meetings (SCM) to re

solve experimental uncertainties, agreements on internships, assess achievement of goals and milestones, determine completion of deliverables, administrative issues, and dissemination and communication activities (Exploitation and Dissemination of Results). SCM will be recorded and summarized in minutes by the coordinator and shared via a teamwork hub platform (Microsoft Teams, MT). Mid-Term (UW, Poland) and Final (ICRA, Spain) meetings will be held to monitor the progress of the project and its overall degree of achievement, respectively. In both meetings, partners will present project results to the consortium, the invited stakeholders and the External Advisory Board. The participation of stakeholders will ensure essential feedback regarding the utility of the proposed intervention (*Phage-Land* technology) to reduce the dissemination of AR. Meeting notes, presentations, and agreements will be shared among assistants using MT.

External Advisory Board and Intellectual Property Management

We will create an External Advisory Board to help in the decision-making process within the *Phage-Land* framework and to evaluate its outcomes from the perspective of their expertise.

Within the WP1 we will also establish an internal committee to evaluate Intellectual Property Right (IPR) and Knowledge Management Strategy. For this committee, each partner will select one representative and the decisions about the possible

patenting and public presentations of key achievements will be made by simple majority of votes taken. Results will be reviewed by an IPR expert to evaluate their potential patentable contents and to support the project partners in protecting their innovations by providing information and contacts to responsible authorities, taking into account variable IPR regulations in participating countries.

Specific tasks

- 1.1. Coordination of activities across partners and WPs.
- 1.2. Evaluation of IPR and Knowledge Management strategy.

Milestones

- M1. Creation of the internal committee on IPR.
- M2. Creation of External Advisory Board.

Deliverables

- D1. Efficient coordination of both scientific, financial and administrative activities.
- D2. Evaluation plans for IPR and Knowledge Management Strategy.

WP2. PUBLIC HEALTH INVESTIGATIONS IN EUROPEAN LMICs

Lead Partner: NTSU

Participation: ICRA, UW

Objectives: To provide an updated picture of the situation of AR in relation to human health in Moldova as well as other Eastern Europe LMICs. Specific goals are: (i) to carry out a meta-analysis of antibiotic consumption data as well as the preva-

lence and risk of infections caused by ARB in Eastern Europe LMICs; (ii) to select prevalent multi-drug-resistant bacterial pathogens from a collection of isolates already available at the NTSU to be used in WP4 and WP5.

Description: This WP is divided in two parts, as follows:

a) meta-analysis of available data on antibiotic consumption and the epidemiological risk of infection by antibiotic-resistant pathogens in Moldova and neighboring countries (representing European LMICs/UMICs). This meta-analysis will also include a Knowledge, Attitudes and Practices (KAP) survey in areas with high antibiotic consumption across Moldova, which will be treated as a model country in planned studies. An additional survey will also be conducted in areas with low antibiotic consumption as a control group. The meta-analysis is planned to include all medical institutions in Moldova (370–385) to estimate the defined daily dose (DDD)/1000 inhabitants/day for each antibiotic separately and thus it will be organized as a cross-sectional qualitative

research, including a standardized questionnaire (for 3- 5 thousand respondents: general population, healthcare professionals and veterinarians) in high-risk areas. Before conducting the survey, we will carry out a pilot study on randomly selected participants (n=30) in order to test the clarity, reliability, and validity of the questionnaire, which will be revised accordingly. The questionnaire will include three main sections: (i) general data; (ii) data on recent antibiotic consumption; and (iii) data on knowledge, attitude and practice regarding antimicrobial resistance. More importantly, this survey will also involve the local population assisted by the Orhei constructed wetland, used as model CW in WP3. In this regard, we will also carry out a sanitary epi-

demiological evaluation of the localities assisted by the Orhei CW (ca. 26,000 inhabitants) to allow a better characterization of the communal wastes treated by this CW. Statistical analyses will be carried out using Epi Info™ (<https://www.cdc.gov/epiinfo/index.html>) and IBM SPSS Statistics. This will be the first global study on antibiotic consumption in Moldova.

b) screening of a large collection of multidrug-resistant bacterial isolates available Partner 7 (NTSU) to identify, select and characterize representatives of *E. coli*, *K. pneumoniae*, *A. baumannii* and *P. aeruginosa* for their use in WP4 and WP5. It is expected that between 5 and 10 isolates from each species, originally obtained from patients with infectious diseases, will be selected for further analysis. Prior to selection, the isolates will be identified and characterized phenotypically by the NTSU team. Moreover, antimicrobial susceptibility testing will be performed and interpreted according to the EUCAST breakpoints (https://www.eucast.org/clinical_breakpoints/). Confirmatory testing will also be performed on isolates in which the extended-spectrum β -lactamase

(ESBL) screen may indicate ESBL production. Among them, the following tests will be performed: (i) double-disc synergy and combo confirmatory tests for ESBL detection; (ii) AmpC detection tests; (iii) colorimetric tests for carbapenemase production (CARBA PAcE); (iv) immunochromatographic tests targeting OXA-23 in *Acinetobacter* spp., and OXA-48 and MBL in *Enterobacteriaceae* and *P. aeruginosa*; and (v) PCR tests for the detection of KPC, OXA-48, IMP, NDM and VIM carbapenemase genes. All isolates will be stored at -80°C in Cryoinstant tubes. Subsequently, the isolates will be sent by courier (e.g., DHL or FedEx) to Partner 2 (UW) for their genomic characterization (whole genome sequencing) to properly identify ARGs content and their genetic context (chromosomal or plasmid origin) and to Partners 4 (KUL) and 5 (QIB) for phage isolation and host range analyses. The isolates will be dispatched in double pack containers to the UW team, according to the respective national biosecurity and biosafety regulations, and the International Air Transport Association regulations as UN 3373 (Biological Substance, Category B).

Specific tasks

- 2.1. Meta-analysis of antibiotic consumption in European LMICs.
- 2.2. Characterization of MDR bacteria from Moldova.

Milestones

M3. Design of questionnaire to survey the antibiotic consumption and knowledge, attitude and practice (KAP) on antimicrobial resistance.

Deliverables

- D3. Map showing areas with high antibiotic consumption across Moldova.
- D4. Report on KAP in areas with high antibiotic consumption across Moldova.
- D5. Estimated risk of infection by antibiotic-resistant pathogens in Eastern Europe LMICs.
- D6. Collection of multidrug-resistant bacterial isolates (including ESKAPE pathogens) fully characterized in terms of phenotypic and genotypic antibiotic resistance profiles.

WP3. PERFORMANCE OF CONSTRUCTED WETLANDS IN FIELD CONDITIONS

Lead Partner: ICRA/NTSU

Participation: UW, QIB

Objectives: The main goal of WP3 is to assess the overall capacity of two model, full-scale CWs operating in two geographically, climatically and economically contrasting regions (Spain and Mol-

dova) on the removal of chemical (antibiotic residues) and biological (ARB and ARGs) emerging pollutants.

Description: All activities of this WP will be carried out in two CW operating in Spain (Em-

puriabrava, Girona, NE Spain) and Moldova (Orhei Constructed Wetland) that will be used as

model systems. The Empuriabrava constructed wetland (ECW, Girona, Spain) was constructed from 80% public (European Union's Cohesion Funds) and 20% private funds (Consorti Costa Brava, <https://www.cacbgi.cat>) and operates since 1998 as a tertiary treatment of the effluent of the Empuriabrava WWTP (67,000 population equivalents). The ECW effluent is pumped to an 18-ha artificial pond located at the entrance of the natural preserved area of Els Aiguamolls de l'Empordà to provide additional water to the protected area in summer (39). The Orhei Constructed Wetland (OCW; <https://is.gd/j4Bb08>) is the biggest treatment system entirely based on CWs in the world. It provides service to about

26,000 inhabitants plus a few agro-industries and it consists of 4 lines operating in parallel, each composed of two vertical flow stages in series. The large area covered by both model CWs (and especially OCW) makes it impossible to carry out a comprehensive analysis of target analyses in the framework of the current project. Thus, we will carry out a dedicated collection of samples along a spatial transect from the inlet to the final outlet in both CWs with particular focus at the differential treatment stages (fig. 3). Sampling along this horizontal transect will include water and sediments at the ECW and water and bed substrata at the OCW (all samples will be collected in triplicate).




Figure 3. Schematic drawing of (A) the Empuriabrava wastewater treatment plant (WWTP) and the adjacent constructed free-water surface constructed wetland system; and (B) the CW wastewater treatment plant at Orhei (Moldova). RBF: FRB: French reed bed system (First stage); VF: Vertical Flow (second stage). In both cases yellow dots indicate the location of planned sampling points along the influent-effluent transect

Water, and sediment/bed substrates will be collected and processed, according to the International Organization for Standardization recommendations (*ISO 5667-1:2020*), before sending them to ICRA and UW teams for chemical and molecular analysis, respectively. Briefly, antibiotic residues will be quantified by Partner 1 (ICRA) solely in water samples after solid phase extraction followed by liquid chromatography coupled to mass spectrometry. For molecular analysis, sediment and bed substrata from each site will be collected in sterile Falcon tubes and stored at -20°C until shipping to Partner 2 (UW) and 3 (SGGW). For water samples, 100–500 mL will be filtered through 0.22- μm nylon membrane filters, which will be then stored at -20°C . Moreover,

from both CWs invertebrate animals (daphnids and snails) will be collected to test for the presence of ARGs in their gut microbiota. Animals will be classified and preserved by freezing at -20°C before shipment. All frozen samples and filters will be shipped to the UW team for DNA extraction and metagenomic analysis. Extracted DNAs will be subjected to Illumina (*NovaSeq 6000*) sequencing and additional Nanopore sequencing to improve scaffolding of short Illumina reads. After curation, reads will be assembled using SPAdes to characterize the resistome, mobilome and bacterial and phage community composition at each sampling site. Additionally, a subset of samples will be delivered to Partner 5 (QIB) for targeted viromic analyses. Several ARGs of clinical relevan-

ce (*bla_{KPC}*, *bla_{NDM}*, *bla_{OXA-48}*, *qnrS*, *mcr-1*) will be subjected to quantitative analysis using qPCR. All samples will be sent by courier (DHL) to the respective partners according to national biosecurity and biosafety regulations, and the International Air Transport Association (IATA) regulations as UN 3373 (Biological Substance, Category B).

When studying the dissemination of AR determinants in the environment, it is of paramount importance to couple the identified ARGs with their bacterial hosts since their linkage may indicate the possible directions and range of the horizontal gene transfer. However, the use of shotgun metagenomics seriously limits the assignments of contigs to their bacterial host since the short contigs generated by this sequencing technique are troublesome. Moreover, ARGs are frequently present within plasmids and their assignment to the original host requires a targeted, more complex approach. In PhageLand we intend to develop a novel method to investigate the hosts of identified ARGs and to track their horizontal transfer by applying a modification of epicPCR. More specifically, we will apply a high-throughput approach involving droplet microfluidics and ligation by PCR (fusion PCR) of selected ARGs with a molecular marker gene (16S rRNA gene, V4 region) coupled with droplet sorting and massive sequencing of the fusion PCR amplicons. The proposed method is based on fusion PCR (like epicPCR), but enables multiplexing and high-throughput analysis. The method was named – dmPCR (from droplet multiplex fusion PCR). In the dmPCR, bacterial

cells will be encapsulated into picoliter droplets together with the lysis buffer. Next, after off-chip lysis, the droplets will be fused at high-throughput with droplets containing PCR mix, primers (complementary to V4 region of 16S rDNA and selected target genes, including ARGs, especially these of clinical relevance) and Taqman probes complementary to the genes of interest (i.e. other than 16S rDNA) for generation of PCR products and fluorescent signal. The off-chip emulsion (fusion) PCR will be followed by on-chip fluorescence activated droplet sorting for enrichment of single cell lysates with fused PCR amplicons of genes of interest (i.e. 16S rDNA and the target genes). Microfluidic selection will be based on the fluorescent signal from degraded Taqman probes and sorted droplets will contain at least one kind of the fused PCR amplicons. By applying multiplexing, we will be able to identify bacterial taxa (and possibly even multidrug resistant bacteria) carrying various ARGs. Emulsion of selected droplets with PCR amplicons will be next broken and amplicons will be subjected to Illumina sequencing. Sequencing data will be analysed using in-house bioinformatics pipelines. Proposed system can operate with the throughput of at least 1,000 droplets per second, which will result in the profiling of around 1,000,000 cells per hour in a single experiment (assuming encapsulation rate equal 0.35). Several thousands of amplicons will be sequenced after the sorting step, which guarantees needed coverage during MiSeq Illumina sequencing.

Specific tasks

- 3.1. Sampling of Empuriabrava CW (Spain).
- 3.2. Sampling of Orhei CW (Moldova).
- 3.3. Sample processing, analyses and sequencing.
- 3.4. Bioinformatic analysis of resistome, mobilome and bacterial/phage community structure.
- 3.5. Assessment of CW performance.

Milestones

M4. Development of a novel method of tracking horizontal transfer of ARGs in various environments by coupling microfluidics and high-throughput PCR amplicon sequencing (dmPCR).

Deliverables

- D7. Characterization of bacterial and viral communities, bacterial resistomes and mobilomes at each sampling site.
- D8. Comparison of bacterial resistomes and mobilomes across compartments and stages of model CWs.
- D9. Assessment of the capacity of model CW to remove antibiotic residues, wastewater-associated bacterial pathogens, ARBs and ARGs.

WP4. PHAGE-BASED BIOPURIFICATION

Lead Partner: KUL / QIB

Participation: UW, TUD

Objectives: Identification, characterization, selection of phages and production of phages cocktails

Description: The aim of this WP is to create a *PhageLand* Biobank of bacteriophages that can be used in the bioremediation of ARBs and prevent mobilization of ARGs in CWs. The WP will be jointly led by the KUL and QIB partners who have compatible and complementary expertise and a long history of phage discovery, characterization, production and use. The principal targets for the Biobank are the WHO priority ESKAPE pathogens that are most critical for the spread of antimicrobial resistance, for which both partners already have an extensive collection of characterized phages (tab. 1).

First, we will isolate new bacteriophages and test our current collection (tab. 1) for a selected set of ESKAPE strains, including and informed by the public health investigation of WP2 (sent by Partner 7 NTSU). Using in-house whole genome sequencing (Illumina), we will assess the diversity of phage types and exclude temperate phages that can integrate into the bacterial genome and spread ABR genes through transduction.

Next, we will select a subset of phages fit for environmental bioremediation. The extended collection will be characterized for the specific conditions that will be encountered in the CWs, including biophysical stability tests to establish the active pH and temperature range, activity under anaerobic conditions and inactivation by soil compounds. We will also use these specific conditions to “train” phages to be more environmentally robust and stable using directed evolution experiments currently employed at KUL. Additional characterizations will focus on the selection of bacteriophages that can degrade the host genome during phage infection and the absence of generalized transduction. We are specifically assembling a phage collection appropriate for environmental applications and excluding phages that are in use for treatment of clinical infections in hospital settings.

Specific tasks

4.1. Creation of extended ESKAPE phage collection.

targeting wastewater-borne ARB, especially ESKAPE pathogens.

Table 1: Existing phage collection. Extended = phage for additional species in genus.

	Bacteria	QIB	KUL	extended
E	<i>Enterococcus faecium</i>	2	0	6
S	<i>Staphylococcus aureus</i>	0	3	0
K	<i>Klebsiella pneumoniae</i>	6	3	29
A	<i>Acinetobacter baumannii</i>	0	2	0
P	<i>Pseudomonas aeruginosa</i>	0	18	0
E	<i>Enterobacteriaceae sp.</i>	16	27	NA

For the selected phages, protocols will be developed for phage monitoring. We will therefore develop qPCR primer and probe sets that will be used to monitor the presence (qPCR) and activity (RT-qPCR) of the selected *PhageLand* Biobank phages in the lab and pilot-scale CWs (WP5 & WP6). The target genes for the (RT-q)PCR will be informed by the high-quality genome annotations (identified earlier in this WP) and transcriptomic analyses that will identify highly expressed phage genes during infection. The latter will be identified using an Nanopore-Cappable sequencing approach developed at KUL (unpublished data), which is a cost-efficient RNAseq approach based on Oxford Nanopore sequencing. This technique will allow to establish the full transcription scheme and regulatory elements involved during phage infection.

Finally, Pilot-scale production of the selected *PhageLand* phage cocktails will be performed using disposable airlift 8L bioreactors (*Cellexus*) as already implemented at KUL. Dosage and concentration of the phages in the cocktail will be informed by experiments of WP5. Additional purification of the phage preparations can be performed according to our own previously established protocols. Validation of the cocktails will be via metagenomic real-time sequencing on the Nanopore platform and time-series plaque assays.

- 4.2. Characterization of phages for bioremediation.
- 4.3. Development of qPCR assays for phage monitoring.
- 4.4. Development of application-ready phage cocktail.

Milestones

M5. Development of phage cocktails targeting ESKAPE pathogens and optimized for ARB bioremediation.

Deliverables

- D10. Extended collection of ~50 phages covering the ESKAPE pathogens and high-quality phage genome annotations.
- D11. Development of the PhageLand Biobank (15-20 phages).
- D12. Design of qPCR primers and probes for Biobank phages testing.
- D13. Standard Operating Procedures (SOP) for the application of phage cocktails.
- D14. Application-ready phage cocktail and assessment on the effectiveness of phage cocktails for the removal of target ARBs.

WP5. RISK ANALYSIS

Lead Partner: SGGW / ICRA

Participation: UW, KUL, QIB, TUD

Objectives: (i) to experimentally evaluate the capacity of CWs for the removal of antibiotics, ARB and ARGs from communal wastes; (ii) to assess the risk of potential transmission of AR determinants (including horizontal transfer of ARGs) in CWs; (iii) to experimentally assess to what extent animals inhabiting CWs accumulate wastewater-

derived ARB/ARGs in their microbiota and disseminate them through the trophic chain; (iv) to determine the impact of phage treatment on functioning, structure and resistome of microbiomes inhabiting CWs; and (v) to optimize phage dosages for an efficient and safe bio-treatment of communal wastes.

Description: Microcosm experiments will simulate functioning of natural CWs by using wastewater spiked with multidrug-resistant (ESKAPE) pathogens from Moldova and *E. coli* carrying multidrug resistant (chloramphenicol, streptomycin, sulfonamides), self-transmissible, broad-host-range plasmid RA3 of the IncU group the plasmid can transfer between, replicate in, and be maintained in representatives of Alpha-, Beta-, and Gammaproteobacteria). These experiments will show if CWs, according to the biotic resistance hypothesis, —as environments rich in biodiversity — are stable ecosystems resistant to invasion of ARB, ARGs and ARG-carrying plasmids and to what extent these entities influence the functioning of CWs. A second round of microcosm experiments aim to assess the efficacy of phage cocktails for the treatment of wastewater spiked with target microorganisms (ESKAPE pathogens and *E. coli* carrying RA3 plasmid) (see above) while entering the lab-scale CWs. Thus, we will be able to evaluate the efficacy of the com-

bined bio-treatment of wastes with phages and CWs, and the impact of such intervention onto the overall removal of ARB/ARGs. Microcosm experiments will be performed for 50 days in the laboratory-scale constructed wetland systems (fig. 4) with the capacity of 5-8 L of wastes depending on the system filling and with the flow rate adjusted to obtain the retention time in the reactor of 3-7 days (depending of the wastewater type). For the simulation experiments, raw sewage and secondary effluents originated from urban WWTP will be used. Usage of raw sewage will simulate the situation when the CW is the sole treatment (*similarly to Orhei CW in Moldova*), while secondary effluents will be used to simulate the application of CW as tertiary treatment (*Empuriabrava CW in Spain*). While operating, various chemical and molecular analyses will be performed. For the molecular screening the following analyses are planned: a) high-throughput 16S rDNA metabarcoding for general microbial diversity investigation that is needed for evaluating the influence of

phage treatment on the CWs' microbiome (sequencing by Partner 2 UW); b) qPCR for the quantitative analysis of ARGs introduced with ESKAPE pathogens and the RA3 plasmid and the maintenance of these genes in CWs, as well as the added phages from the cocktails (WP4); c) dmfPCR for identifying possible transfer of ARGs introduced with ESKAPE pathogens and the RA3 plasmid to

novel hosts in CWs. Moreover, full chemical monitoring of antibiotic residues (WP3) will be performed to evaluate the purification capacity of CWs and their proper functioning. All analyses will be performed at T0 and T50. At this stage an optimization of dosing of phage cocktails will be performed.



Figure 4. Images of the laboratory scale wetlands (operating at Partner 2 – UW on a regular basis) aimed to carry out manipulative experiments in WP5. (A) The layered configuration of the system. (B) Peristaltic pump operating in the system. The UW's know-how concerning this lab-scale CWs will be transferred internally to other partners involved in the project.

In a second stage, we will assess the accumulation of ARB/ARGs in the microbiota of animals potentially inhabiting CWs (*daphnids* and *snails*) or receiving waters (fish), assuming their role as dissemination vectors. Accordingly, effluents from CW-treated or phage+CW-treated systems will be used for culturing filter feeders (*daphnids*), foraging mollusks (snails) and fish (*Rutilus rutilus*) to assess the accumulation of ARB and ARGs in these animals and to evaluate transmission risks. In all experiments we will focus on: (a) genes conferring resistances to clinically relevant antibiotics, including drugs of last resort (e.g., *carbapenems*, *colistin*) that may be acquired from wastewater purified in tested CWs, and (b) ARGs previously detected in ESKAPE pathogens and the RA3 plasmid used for the spiking. Animals will be cultured in dynamic, flow-through systems to enable water exchange for the removal of metabolic products of animals. The experiments will be conducted under constant conditions, i.e., temperature of 20°C and summer photoperiod (18 h light:6 h dark) to ensure optimal conditions for animals. Each sys-

tem will operate for 50 days. Experiments will be carried out in at least three replicates with excess of animals in case of unplanned deaths. Isolation of DNA from daphnids, snails and fish carries the risk of “loosing” microbiome data by contamination coming from the eukaryotic host DNA sequencing. To overcome this difficulty, we plan to carefully extract the content of intestine of snails and fish and to isolate the whole intestine from daphnids (extraction of the content only is almost impossible due to the size and morphology of *Daphnia*). Only this material will be used for the DNA extraction and further analyses, including sequencing. This should minimize contamination with the host DNA. Same as above, the following molecular analyses are planned: (a) high-throughput 16S rDNA metabarcoding, (b) qPCR for selected ARGs (including these introduced with ESKAPE pathogens and the RA3 plasmid) and (c) dmfPCR. Analyses will be performed at T0 and T50. Pooled samples will be used for virome sequencing (Partner 5 QIB).

Summarizing, analyses planned in both stages of WP5 enable a complex insight into microbiomes (including the resistome, mobilome and virome)

from CWs (*phage-treated and untreated*) and from tested animals.

Specific tasks

- 5.1. Microcosm experiments (lab-scale CW and CW + phages).
- 5.2. Bioinformatic analysis of resistome, mobilome and bacterial/phage community structure.
- 5.3. Assessment of phage biopurification.
- 5.4. Assessment of accumulation of ARB/ARG in model animals.

Milestones

M6. Setting up the experimental microcosms mimicking the functioning of CWs.

Deliverables

- D15. Report on the comparative functioning of lab-scale CWs —with or without preliminary treatment with phages— on the removal of antibiotics, ARB and ARGs.
- D16. Characterization of microbiomes, resistomes and mobilomes in model animals inhabiting CW after cultivation with effluent water resulting from both system configurations (CW and Phage+CW).
- D17. Comparative assessment of the potential accumulation of ARB/ARGs of clinical concern in lab-scale CWs and model animals.

WP6. PROOF-OF-CONCEPT

Lead Partner: TUD/UW

Participation: ICRA, QIB

Objectives: (i) to test phage therapy on microbial communities containing ARB in well-controlled bioreactors at wet lab; (ii) to develop a pilot scale passive treatment system (i.e., constructed wetland) and test the phage-based biotechnology developed for the removal of ARB/ARGs under real

operation conditions; (iii) to up-scale the CW technology with calculation of its cost effectiveness and operational capacity; and (iv) to evaluate the long-term effect of phages on CW functioning as well as the structure of the microbiome and resistome of CWs.

Description: WP6 will include the construction of the scaled-up pilot plant that will operate at UW (Poland) using specifically delivered communal wastes. It will be composed of 3 containers mounted in series and filled with various substrates. The combination of horizontal and vertical filtering will be applied for the system.

The container installation will enable operation at a flow rate of 0.5m³/day and hydraulic retention time of 1–5 days. Members of the UW research team are experienced developers of passive treatment systems: they have been responsible for building of such installations in the past (e.g., for the company Gradir Montenegro D.O.O. within the copper and nickel mining sector) (fig. 5). The CW system will operate using municipal wastes. Experiments will be performed sequentially, i.e., first experiment without and the second with

phage treatment. The pilot testing will be accompanied by wet-lab experiments conducted in well-controlled bioreactors and fixed-bed columns at TUD in order to develop a detailed scientific understanding on the effects of phage therapy on the removal of ARB from engineered microbial communities involved in biological wastewater treatment. While operating, the following parameters will be measured for CW: biological oxygen demand (BOD₅), chemical oxygen demand, suspended solids, total nitrogen, ammonia, nitrates, and total phosphorus. This allows the screening of the proper functioning and waste purification capacity of CW.

Besides, we will measure the concentration and diversity of antibiotics, ARB and ARGs at the influent and effluent of the system as described in WP3 and WP5. The pilot scale installation will enable a

long-term operation to test the removal/accumulation of ARB/ARGs and the influence of phages on the CW functioning under dynamic environmental conditions. The characterization of bacterial and viral communities, analysis of their resistome/mobilome, the quantification of target ARGs and the identification of bacterial hosts carrying ARGs will be done by (a) high-throughput 16S rDNA metabarcoding, (b) shotgun metagenomics, (c) qPCR for selected ARGs (based on results of the shotgun metagenomics, and (d)

dmfPCR for selected genes (based on results of the shotgun metagenomics), respectively. Fluorescence microscopy as developed by Rossi et al. (1994) will be used to track the total number of phages moving across the pilot system. The targeted phages will be monitored specifically by combining deep metagenomic sequencing (see above) and phage-targeted qPCR screening to specifically detect the spiked phages out of the baseline of phages naturally occurring in the system.




Figure 5. Design and images of the constructed wetland pilot plant currently operating in Gradir (Montenegro) under the supervision of Partner 2 (UW). A similar design will be used for the construction of the pilot plant planned as proof-of-concept for *PhageLand* technology.

Specific tasks

- 6.1. Construction of a scaled-up pilot plant.
- 6.2. Assessment of bio-purification.

Milestones

M7. Construction of the scaled-up pilot plant fully operating under real environmental conditions.

Deliverables

- D18. SOP describing the optimal configuration and operational conditions of the pilot plant.
- D19. Assessment on the removal of nutrients and chemical pollutants (antibiotic residues) by the pilot plant.
- D20. Assessment on the removal of biological pollutants (ARB and ARGs) under real conditions.
- D21. Assessment on the effectiveness of the phage intervention for the removal of ARB and ARG under real conditions.

WP 7. DISSEMINATION AND COMMUNICATION

Lead Partner: All

Objectives: To disseminate results of PhageLand to the scientific community, stakeholders (environmental protection agencies, wastewater ma-

nagement companies), policy makers, academia, and lay audiences (40).

Description: WP7 aims to achieve optimal dissemination of results, including the creation of a project website and a Twitter account, periodical press releases at all partner's websites and beyond (if possible), attendance at scientific meetings and publications in SCI journals, meetings with stakeholders, and outreach activities to disseminate results to academia and lay audiences. Importantly, in the PhageLand project, data and knowledge asset management will follow published best-practices for reproducible science. F.A.I.R. policy will be implemented through Open Access publications, plus (if possible) laboratory protocols and data workflows will be published in Protocols.io (<https://www.protocols.io/>), to obtain a DOI and F.A.I.R. metadata. We will organize training workshops for PhD students, postdoc researchers and lab technicians interested in the

analysis of metagenomes/metaviromes and the isolation and propagation of phages for the specific removal of bacterial pathogens. Moreover, in the PhageLand project we assumed exchange of the scientific staff between partners to enable gaining competences. For this purpose, short-term research stays conducted in a form of the regular lab-works (active form) or shadowing (passive form) will be implemented. Important, part of the PhageLand project is reaching stakeholders from different fields. We already attract the attention of some companies specializing in environmental biotechnology, however, during the project we plan to extend a database of possible stakeholders and approach them with newsletters (*produced every 6 months*) and inviting for a project meeting.

Specific tasks

- 7.1. Organization of project meetings.
- 7.2. Communication with stakeholders.
- 7.3. Outreach to academia and the general public.

Milestones

M8. Engagement of stakeholders from partner countries and Eastern European LMICs for the implementation of the PhageLand technology in wastewater treatment.

Deliverables

- D22. Training workshops on the analysis of metagenomes/ metaviromes for the analysis of antibiotic resistance in environmental settings.
- D23. Training workshops on the isolation and propagation of phages for the specific removal of bacterial pathogens.
- D24. Dissemination of project results to the scientific community as well as professional and lay audiences.
- D25. Dissemination of project results to wastewater management companies and policy makers from Eastern European LMICs.

WORK PLAN AND TIMELINE AS A DIAGRAM

IMPACT

PhageLand will create impact by integrating low-cost, scalable CW technologies and phage therapy intervention to clean-up wastewater in European LMICs and simultaneously mitigating the dischar-

ge of AR determinants into surface water resources. *PhageLand* will drive specific outcomes for wastewater based epidemiology and engineering sectors, leading to significant societal impacts.




Figure 6. Scheme of the *PhageLand* workplan showing the interactions between work packages and project partners. Partner 2 (UW) will act as sequencing hub for the entire consortium, while Partner 3 (SGGW) and Partner 5 (QIB) are sequencing-supporting units.

PhageLand is specially committed to provide effective solutions that help to prevent the transmission of AR through different “One Health” compartments, particularly:

a) Human: *PhageLand* will provide, for the first time, a comprehensive report on antibiotic consumption and AR prevalence in Moldova and neighboring countries, filling the current knowledge gap on the situation of AR in Eastern European LMICs and, especially, in post-soviet economies. Also, by studying and characterizing multidrug-resistant isolates from human samples collected in Moldova, we will provide the first characterization of resistance genes and virulence factors in these ARB, thus obtaining precious information for the assessment of prevalent ARB in the country but also for its extrapolation to other post-soviet, Eastern European LMICs. Moreover, we will provide the first globally accessible study on antibiotic consumption in Moldova, which will be also used here as a model for other post-soviet LMICs. Both studies will provide substantial support for politicians and policy makers involved in the “Global Action Plan on Antimicrobial Resistance” and the “EU One Health Action Plan”. The clinical data obtained here

will be analyzed and compared with detailed surveillance data on ARB and ARGs in the Orhei CW, and tested for potential correlations.

b) Animal: *PhageLand* will provide relevant data on the potential accumulation of ARB and ARGs in animals inhabiting CW. This information will allow a better assessment of the risks that the planned technology may bring to animals and, eventually, to human health. Importantly, this will also provide information on how frequent transfer of wastewater-derived ARGs into the microbiota of aquatic animals occurs under natural conditions, which will deliver invaluable data on the transmission of ARGs along the trophic chain in wetland/aquatic ecosystems.

c) Environment: Results of the *PhageLand* project will allow a better understanding on the efficacy of CWs in the removal of AR determinants, including well-known human pathogens, as well as on their ecological safety in terms of preservation of the natural bacteri-

al diversity in such systems and the lack of side effects on the dissemination of ARGs in the environment. Overall, the PhageLand technology will be implemented in a scaled-up pilot infrastructure to be used as a proof-of-concept of a cost-effective and eco-friendly intervention strategy to reduce the burden of ARB and ARG that chronically pollute surface waters and to mitigate the environmental transmission of AR determinants. From the strictly scientific point of view the *PhageLand* project will act as a proof-of-concept for the biotic resistance hypothesis. Proving effectiveness of CWs (preferentially with phages) in ARB and ARGs removal will be a significant step toward nature-based solutions stimulating natural biodiversity preservation or restoration as a way of preventing the dissemination of AR.

Implementation of the *PhageLand* technology can lead to a broad impact on the well-being of local communities in LICs, LMICs and selected UMICs, where CWs or CWs + phage (as cost-effective, long-term maintaining and eco-friendly plants) may become primary wastewater purification systems. We especially see direct benefits for communities inhabiting rural areas and small and medium cities with limited industry, where CWs may function as sole wastewater treatment systems. This definition corresponds to socio-economic status of lower-/middle-income countries, where large cities or metropolises are rare. Of course, developed technology may be applied in every country (regardless its economic status) and every population inhabiting the region directly linked with CW may get benefits.

The use of phages as biocontrol treatment for ARBs is gaining global popularity, however, the current applications are limited to a small number of clinical infections in humans and applications in the food chain.

As such, *PhageLand* technology will serve as a proof-of-concept for phages as natural, cheap, and accessible bioremediation tools.

Besides, *PhageLand* will have a direct impact on the engineering sector and wastewater management companies that are currently facing the critical challenge of operating at the highest

treatment standards while adapting their practices to new pollutants and emerging threats. Particularly, we envisage a direct impact of *PhageLand* on different communities, stakeholders and sectors such as:

- Scientists working on AR in both research and clinical centers, particularly in Moldova and other European LMICs/UMICs.
- Scientists involved in combating the transmission of antimicrobial resistance across One Health compartments.
- Scientists working on wastewater treatment, wastewater-based epidemiology as well as environmental and clinical bioinformaticians.
- Companies (including academia-based SMEs), authorities and other stakeholders interested in wastewater treatment and management.
- Scholars, teachers, science popularizers, ecology activists.
- Politicians and policy makers involved in the “Global Action Plan on Antimicrobial Resistance” and the “EU One Health Action Plan”.
- End-users in both High, Middle and Low-income Countries.

The *PhageLand* consortium is composed of research groups from different European countries that endorse an excellent transnational collaboration by including countries differing in their geographic, demographic and economic settings as well as legislation and public awareness in regard to AR dissemination and its influence on public health. The inclusion of a partner from Moldova is a significant added value to this collaboration since this is a representative of post-soviet, Eastern European LMICs that have usually been overlooked when thinking about these economies (usually recognized only as Asian or African countries). PhageLand is committed to fill this huge gap in the perception of global needs regarding prevention of antibiotic resistance spreading. Moreover, the presence of Moldavian partner specializing in public health is critical for the whole project and other partners to correctly understand conditionings and recognize the needs of European lower-income economies regarding general environmental protection, waste purification and bioremediation. PhageLand will create planned outcomes in different economy and society sectors in ad-

dition to providing new data (including cutting-edge molecular tools and optimized protocols) to scientists interested in combating the transmission of antimicrobial resistance across the three One Health compartments. Besides, the resulting knowledge will allow better training in academic and water-related sectors.

The proposed *PhageLand* technology could be easily scaled, implemented and deployed in LMICs where costly and power-demanding wastewater treatment technologies are difficult to set up and maintain. The technology developed here may be even more acceptable in post-soviet countries where there is a tradition and social acceptance for phage therapy in human medicine. Despite this main target, we do consider that the

intervention strategy proposed has a broader impact, may be universal and easily implemented in many countries, irrespectively of their economic status, demographic condition or geographical location.

Overall, *PhageLand* is fully aligned with the One-Health approach and its results will be useful not only at each national level but also at international level since they will be relevant on the scope of the “One Health” Action Plan of the European Commission, the Global Action Plan on Antimicrobial Resistance of the Food and Agriculture Organization of the United Nations (FAO), World Organization for Animal Health (OIE) and World Health Organization (WHO).

REFERENCES

- Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. *The Lancet Planetary Health*. 2018;2(9):e398-e405. doi:10.1016/S2542-5196(18)30186-4
- Hultman J, Tamminen M, Pärnänen K, Cairns J, Karkman A, Virta M. Host range of antibiotic resistance genes in wastewater treatment plant influent and effluent. *FEMS Microbiology Ecology*. 2018;94(4). doi:10.1093/femsec/fiy038
- Pallares-Vega R, Blaak H, van der Plaats R, et al. Determinants of presence and removal of antibiotic resistance genes during WWTP treatment: A cross-sectional study. *Water Research*. 2019;161:319-328. doi:10.1016/j.watres.2019.05.100
- Pallares-Vega R, Hernandez Leal L, Fletcher BN, et al. Annual dynamics of antimicrobials and resistance determinants in flocculent and aerobic granular sludge treatment systems. *Water Research*. 2021;190:116752. doi:10.1016/j.watres.2020.116752
- Rizzo L, Manaia C, Merlin C, et al. Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: A review. *Science of The Total Environment*. 2013;447:345-360. doi:10.1016/j.scitotenv.2013.01.032
- Cacace D, Fatta-Kassinos D, Manaia CM, et al. Antibiotic resistance genes in treated wastewater and in the receiving water bodies: A pan-European survey of urban settings. *Water Research*. 2019;162:320-330. doi:10.1016/j.watres.2019.06.039
- Di Cesare A, Fontaneto D, Doppelbauer J, Corno G. Fitness and Recovery of Bacterial Communities and Antibiotic Resistance Genes in Urban Wastewaters Exposed to Classical Disinfection Treatments. *Environmental Science & Technology*. 2016; 50(18): 10153-10161. doi:doi.org/10.1021/acs.est.6b02268
- Allen HK, Donato J, Wang HH, Cloud-Hansen KA, Davies J, Handelsman J. Call of the wild: antibiotic resistance genes in natural environments. *Nature Reviews Microbiology*. 2010;8(4):251-259. doi:10.1038/nrmicro2312
- Manaia CM. Assessing the Risk of Antibiotic Resistance Transmission from the Environment to Humans: Non-Direct Proportionality between Abundance and Risk. *Trends in Microbiology*. 2017; 25(3):173-181. doi:10.1016/j.tim.2016.11.014
- Wu H, Zhang J, Ngo HH, et al. A review on the sustainability of constructed wetlands for wastewater treatment: Design and operation. *Bioresource Technology*. 2015;175:594-601. doi:10.1016/j.biortech.2014.10.068
- Liu X, Guo X, Liu Y, et al. A review on removing antibiotics and antibiotic resistance genes from wastewater by constructed wetlands: Performance and microbial response. *Environmental Pollution*. 2019;254:112996. doi:10.1016/j.envpol.2019.112996
- Vacca G, Wand H, Nikolausz M, Kusch P, Kästner M. Effect of plants and filter materials on bacteria removal in pilot-scale constructed wetlands. *Water Research*. 2005;39(7):1361-1373. doi:10.1016/j.watres.2005.01.005
- Faulwetter JL, Gagnon V, Sundberg C, et al. Microbial processes influencing performance of treatment wetlands: A review. *Ecological Engineering*. 2009;35(6):987-1004. doi:10.1016/j.ecoleng.2008.12.030
- Verlicchi P, Zambello E. How efficient are constructed wetlands in removing pharmaceuticals from untreated and treated urban wastewaters? A review. *Science of The Total Environment*.

- 2014;470-471:1281-1306.
doi:10.1016/j.scitotenv.2013.10.085
15. Chen J, Ying GG, Wei XD, et al. Removal of antibiotics and antibiotic resistance genes from domestic sewage by constructed wetlands: Effect of flow configuration and plant species. *Science of The Total Environment*. 2016;571:974-982. doi:10.1016/j.scitotenv.2016.07.085
 16. Chen Q, An X, Li H, Su J, Ma Y, Zhu YG. Long-term field application of sewage sludge increases the abundance of antibiotic resistance genes in soil. *Environment International*. 2016;92-93:1-10. doi:10.1016/j.envint.2016.03.026
 17. Gorito AM, Ribeiro AR, Almeida CMR, Silva AMT. A review on the application of constructed wetlands for the removal of priority substances and contaminants of emerging concern listed in recently launched EU legislation. *Environmental Pollution*. 2017;227:428-443. doi:10.1016/j.envpol.2017.04.060
 18. Nölvak H, Truu M, Tiirik K, et al. Dynamics of antibiotic resistance genes and their relationships with system treatment efficiency in a horizontal subsurface flow constructed wetland. *Science of The Total Environment*. 2013;461-462:636-644. doi:10.1016/j.scitotenv.2013.05.052
 19. Berglund B, Khan GA, Weisner SEB, Ehde PM, Fick J, Lindgren PE. Efficient removal of antibiotics in surface-flow constructed wetlands, with no observed impact on antibiotic resistance genes. *Science of The Total Environment*. 2014;476-477:29-37. doi:10.1016/j.scitotenv.2013.12.128
 20. He Y, Sabri Nurul, Schmitt H, et al. Evaluation of attenuation of pharmaceuticals, toxic potency, and antibiotic resistance genes in constructed wetlands treating wastewater effluents. 2018;631-632:1572-1581. doi:10.1016/j.scitotenv.2018.03.083
 21. Ávila C, García-Galán MJ, Borrego CM, Rodríguez-Mozaz S, García J, Barceló D. New insights on the combined removal of antibiotics and ARGs in urban wastewater through the use of two configurations of vertical subsurface flow constructed wetlands. *Science of The Total Environment*. 2021;755:142554. doi:10.1016/j.scitotenv.2020.142554
 22. Li Q, Long Z, Wang H, Zhang G. Functions of constructed wetland animals in water environment protection – A critical review. *Science of The Total Environment*. 2021;760:144038. doi:10.1016/j.scitotenv.2020.144038
 23. Eckert EM, Di Cesare A, Stenzel B, Fontaneto D, Corno G. Daphnia as a refuge for an antibiotic resistance gene in an experimental freshwater community. *The Science of the Total Environment*. 2016;571:77-81. doi:10.1016/j.scitotenv.2016.07.141
 24. Farkas K, Walker DI, Adriaenssens EM, et al. Viral indicators for tracking domestic wastewater contamination in the aquatic environment. *Water Research*. 2020;181:115926. doi:10.1016/j.watres.2020.115926
 25. Adriaenssens EM, Farkas K, Harrison C, Jones DL, Allison HE, McCarthy AJ. Viromic Analysis of Wastewater Input to a River Catchment Reveals a Diverse Assemblage of RNA Viruses. *Knipe DM, ed. mSystems*. 2018;3(3). doi:10.1128/msystems.00025-18
 26. Adriaenssens EM, Farkas K, McDonald JE, Jones DL, Allison HE, McCarthy AJ. Tracing the fate of wastewater viruses reveals catchment-scale virome diversity and connectivity. *Water Research*. 2021;203:117568. doi:10.1016/j.watres.2021.117568
 27. Wang Y, Jiang X, Liu L, Li B, Zhang T. High-Resolution Temporal and Spatial Patterns of Virome in Wastewater Treatment Systems. *Environmental Science & Technology*. 2018;52(18):10337-10346. doi:10.1021/acs.est.8b03446
 28. Chu BTT, Petrovich ML, Chaudhary A, et al. Metagenomics Reveals the Impact of Wastewater Treatment Plants on the Dispersal of Microorganisms and Genes in Aquatic Sediments. Löffler FE, ed. *Applied and Environmental Microbiology*. 2018;84(5). doi:10.1128/aem.02168-17
 29. Yin X, Deng Y, Ma L, Wang Y, Chan LYL, Zhang T. Exploration of the antibiotic resistome in a wastewater treatment plant by a nine-year longitudinal metagenomic study. *Environment International*. 2019;133:105270. doi:10.1016/j.envint.2019.105270
 30. Górski A, Bollyky PL, Przybylski M, et al. Perspectives of Phage Therapy in Non-bacterial Infections. *Frontiers in Microbiology*. 2019;9. doi:10.3389/fmicb.2018.03306
 31. Luong T, Salabarria AC, Roach DR. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going? *Clinical Therapeutics*. 2020;42(9):1659-1680. doi:10.1016/j.clinthera.2020.07.014
 32. Bhattacharjee AS, Choi J, Motlagh AM, Mukherji ST, Goel R. Bacteriophage therapy for membrane biofouling in membrane bioreactors and antibiotic-resistant bacterial biofilms. *Biotechnology and Bioengineering*. 2015;112(8):1644-1654. doi:10.1002/bit.25574
 33. Motlagh AM, Bhattacharjee AS, Goel R. Biofilm control with natural and genetically-modified phages. *World Journal of Microbiology and Biotechnology*. 2016;32(4). doi:10.1007/s11274-016-2009-4
 34. Mathieu J, Yu P, Zuo P, Da Silva MLB, Alvarez PJJ. Going Viral: Emerging Opportunities for Phage-Based Bacterial Control in Water Treatment and Reuse. *Accounts of Chemical Research*. 2019;52(4):849-857. doi:10.1021/acs.accounts.8b00576
 35. Adriaenssens EM, Van Vaerenbergh J, Vandenheu-

- vel D, et al. T4-Related Bacteriophage LIMestone Isolates for the Control of Soft Rot on Potato Caused by "Dickeya solani." Johnson EA, ed. *PLoS ONE*. 2012;7(3):e33227. doi:10.1371/journal.pone.0033227
36. Tsonos J, Vandenheuvel D, Briers Y, De Greve H, Hernalsteens JP, Lavigne R. Hurdles in bacteriophage therapy: Deconstructing the parameters. *Veterinary Microbiology*. 2014;171(3-4):460-469. doi:10.1016/j.vetmic.2013.11.001
37. Onsea, Soentjens, Djebara, et al. Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. *Viruses*. 2019; 11(10):891. doi:doi.org/10.3390/v11100891
38. Holtappels D, Kerremans A, Yoni Busschots, et al. Preparing for the KIL: Receptor Analysis of Pseudomonas syringae pv. porri Phages and Their Impact on Bacterial Virulence. *International Journal of Molecular Sciences*. 2020;21(8):2930-2930. doi:10.3390/ijms21082930
39. Seguí L, Alfranca O, García J. Techno-economical evaluation of water reuse for wetland restoration: a case study in a natural park in Catalonia, North-eastern Spain. *Desalination*. 2009;246(1-3):179-189. doi:10.1016/j.desal.2008.03.051
40. Ciobanu E, Croitoru C, Balan G, Bernic V, Burduniuc O, Ferdohleb A. „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters”- a project launch in low-middle in-come countries of Eastern Europe. *One Health & Risk Management*. 2022;3(2S):28-28. doi:https://doi.org/10.38045/ohrm.2022.2.05

IMPACT PATHWAY

Research outputs	Indicators	Research outcomes	Indicators	Impact
1. Comprehensive report on antibiotic consumption and AR prevalence in Moldova and other post-soviet countries	- Conducted surveys on target population in Moldova - 1 Open Access (OA) publication on antibiotic consumption and awareness to AR in Eastern Europe. - 1 communication at scientific conferences. - Policy brief for the Moldavian public health authorities	- First assessment of antibiotic consumption data in Eastern European LMIC - Improved assessment of countries/regions with high consumption of antibiotics in Eastern Europe - First assessment on society awareness of antibiotic resistance threats in Eastern European LMIC	- Feedback from stakeholders and policy makers on the assessment data - Compiled database of Eastern European antibiotic consumption	- Changing national policies on AMR tracing and targets as well as control of antibiotic consumption in Eastern European countries - Defining future research targets and strategy for antibiotic surveillance in European low-income economies
2. Characterization of income economies. ARGs and virulence factors in multidrug resistant isolates obtained from human samples collected in Moldova	- 2-4 scientific publications on prevalence of AR-bacterial pathogens in Moldova. - 2 communications at national and international conferences on AR	- Improved capacity of LMICs from Eastern Europe to deploy AR surveillance - First assessment of dissemination of genes conferring resistance to clinically important antibiotics in European LMICs	- Approval of novel recommendations for ARGs screening in clinical isolates in Moldova and/or other Eastern Europeans low-income economies	
3. Characterization of bacterial and viral communities and their resistomes/mobi	- OA protocol of sequence analysis of metagenomic and	- Improved knowledge on the efficacy of CW on the removal of AR determinants	- Best practice guideline document (white paper)	- Reported change in guidelines, policy or practice on construction and management of CW to

lomesin model CWs and aquatic animals	- metaviromic datasets. - 2–4 scientific publications. - 2–4 communications at scientific meetings. - 1-2 training workshops on phage biotechnology and metagenomics	- Better assessment of the performance of CW on the removal of biological emerging pollutants - Better understanding of the risks posed to animals associated to the treatment of wastewater in CWs	- reduce the dissemination of AR. - Broadening of knowledge of academics in the field of phage biotechnology and metagenomics
4. Microfluidic-based technology for screening horizontal transfer of ARGs in various environmental settings	- OA protocol on dmfPCR and its application to assess HGT of ARGs. - 1 scientific publication	- Implementation of the new protocol for the monitoring of AR dissemination in environmental or clinical settings	- Number of downloads of the OA protocol as a proxy of interest by the scientific community - Pointing out the need for identification of hosts of ARGs. - Changing of the perception concerning high-throughput screening of hosts of ARGs among scientific community
5. BioBank of phages targeting multidrug resistant pathogens to be used in wastewater treatment	- High titer stocks of individual phage preparations - Genome sequences of selected phages. - 1 publication on phage BioBank including viral genomic character - Possible patent application phage cocktail formulation	- Availability of a collection of phages targeting ESKAPE pathogens for the specific removal of bacterial pathogens from wastewater	- Requests for phage cocktails for testing / research consultancy from external parties - Request for licensing of phage cocktail - Availability of a commercial product (phage cocktail) for a wide range of stakeholders (wastewater treatment plants, environmental remediation companies, phage application companies) - Improved societal acceptance of the use of phages for treatment purposes
6. Pilot-scale CW installation for testing biotic resistance, self-purification capacity and phage impact under natural environmental conditions	- 1 scientific publication - Pilot installation - Possibly patent application	- Identification of key factors affecting the optimal functioning of CW using PhageLand technology. - Recognizing a self-purification capacity of CW in antibiotics and ARB/ARGs removal	- Interest of the wastewater managers in using the PhageLand technology - Learning through experience and progressing the PhageLand technology successfully - Acceptance of PhageLand technology for the production of safe water - Implementation of the PhageLand technology by wastewater managers

TERAPIA CU BACTERIOFAGI: METODĂ DE COMBATERE A REZISTENȚEI LA ANTIMICROBIENE (ANALIZĂ NARATIVĂ)

Oana-Simina IACONI, Greta BĂLAN, Alina FERDOHLEB

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Autor corespondent: Oana-Simina Iaconi, e-mail: oanasimina.iaconi@usmf.md

Keywords: bacteriophages, phage therapy, antimicrobial resistance, human health.

BACTERIOPHAGE THERAPY: A METHOD TO COMBAT ANTIMICROBIAL RESISTANCE (NARRATIVE ANALYSIS)

Introduction. Antimicrobial resistance is a 50-year pandemic requiring interventions that are harmless to human health. In this context, bacteriophage therapy has been rediscovered, which, according to the literature, is considered the optimal solution to mitigate this phenomenon.

The aim of this literature review is to construct a clear understanding of the possibilities, challenges, and needs that this innovation presents in terms of reducing antibiotic resistance.

Material and methods. For this study, a search of the SCOPUS and PubMed databases was conducted using the keywords and BOOLEAN operators "AND," "OR," and "NOT." The search yielded 911 scientific papers. After applying the inclusion/exclusion criteria, 40 papers were ultimately included in the final stage of the study.

Results. Based on the literature reviewed, a SWOT analysis of the potential of bacteriophage therapy as a method to combat antimicrobial resistance was conducted. The research identified several advantages in favor of bacteriophages, such as high specificity and low toxicity, among others. Additionally, the study revealed several opportunities that modern medicine can exploit, including personalized therapy assisted by genetic engineering and the use of phages as adjuvants in antimicrobial and antifungal therapy.

Conclusions. Antimicrobial resistance poses a significant global public health challenge, demanding prompt action. Bacteriophage therapy emerges as an alternative with multiple advantages and a promising long-term perspective.

Cuvinte-cheie: bacteriofagi, terapia cu fagi, rezistența antimicrobiană, sănătatea umană.

Introduction. Rezistența antimicrobiană este o pandemie care durează 50 de ani și necesită intervenții inofensive pentru sănătatea umană. În acest context, a fost redescoperită terapia cu bacteriofagi care, conform datelor din literatură, este soluția optimă pentru a reduce acest fenomen.

Scopul acestui studiu de sinteză a literaturii este de a construi o imagine clară cu privire la posibilitățile și, pe care le aduce această inovație în materie de reducere a antibiotezistenței.

Material și metode. În cadrul acestui studiu s-a efectuat o căutare în bazele de date SCOPUS și PubMed utilizând cuvintele-cheie și operatorii BOOLEAN „AND”, „OR” și „NOT”. Căutarea a generat 911 lucrări științifice. După aplicarea criteriilor de includere/excludere, în etapa finală a studiului au fost incluse 40 de lucrări.

Rezultate. Pe baza literaturii cercetate a fost realizată analiza SWOT a potențialului terapiei cu bacteriofagi ca metodă de combatere a rezistenței la antimicrobiene. Cercetarea a determinat mai multe avantaje în favoarea utilizării bacteriofagilor – specificitate înaltă, toxicitate scăzută etc., și câteva oportunități pe care medicina modernă le poate valorifica: terapia personalizată asistată de inginerie genetică, utilizarea fagilor ca adjuvanți în terapia antimicrobiană și antifungică.

Concluzii. Rezistența antimicrobiană este o problemă de sănătate publică globală care necesită o intervenție promptă. Terapia cu bacteriofagi este o alternativă cu multiple avantaje și o perspectivă favorabilă.

Abrevieri: ADN – acid dezoxiribonucleic; IDSA – Societatea de Boli Infecțioase a Americii (eng. Infectious Disease Society of America); EMA – Agenția Europeană a Medicamentului; FDA – Administrația Alimentelor și a Medicamentelor (eng. Food and Drug Administration); GMO (eng.) – organism modificat genetic; MDR (eng.) – bacterii multi-drog rezistente; OMS – Organizația Mondială a Sănătății; PDR (eng.) – bacterii panrezistente; PRISMA – elemente de raportare preferate pentru revizuirii sistematice și meta-analize (eng. Preferred Reporting Items for Systematic Reviews and Meta-Analyses); RAM – rezistența la antimicrobiene; SWOT – puncte tari, puncte slabe, oportunități, amenințări (eng. Strengths, Weaknesses, Opportunities, Threats); UE – Uniunea Europeană.

INTRODUCERE

Descoperirea penicilinei acum 95 de ani a revoluționat medicina la nivel global, mai ales după ce Howard Florey și Ernst Chain au reușit, un deceniu mai târziu, să producă penicilina industrială (1). Astfel, începând cu anii '40, descoperirea și producerea pe scară largă a antimicrobienei a permis eradicarea sau, cel puțin, controlul bolilor infecțioase. Până în anii 1960 au fost descoperite în jur de 20 de clase de antibiotice. Pe parcursul anilor, ritmul descoperirii și aprobării produselor farmaceutice cu efect antimicrobian a scăzut de aproximativ opt ori (1, 2, 3).

Utilizarea excesivă și necorespunzătoare a antibioticelor a indus dezvoltarea de către agenții patogeni a rezistenței la antibiotice (RAM). Acum 15 ani, Societatea de Boli Infecțioase a Americii (IDSA) a catalogat RAM drept o criză globală, iar OMS, la rândul său, a clasificat rezistența la antimicrobiene drept o problemă majoră de sănătate publică din cauza căreia sunt înregistrate aproape cinci milioane de decese și pierderi economice de aproape 20 de miliarde de dolari (4–7). Evoluția agenților patogeni, combinată cu consumul crescut de antibiotice (cu sau fără indicație terapeutică) a favorizat, începând cu anul 1942 când a fost depistată prima tulpină de *S.aureus* rezistentă la penicilină, apariția tulpinilor bacteriene rezistente, multirezistente (MDR) și chiar panrezistente (PDR). Aceste tulpini reprezintă o problemă a sistemului sanitar la nivel mondial (3, 4, 5). Printre toți agenții patogeni care prezintă rezistență, OMS a identificat 12 bacterii, grupate în trei clase de prioritate care urgent necesită dezvoltarea de noi antibiotice sau de metode alternative pentru a fi contracarate. Primele cinci poziții sunt ocupate de patogenii din grupul ESKAPE care înglobează *Acinetobacter* spp., *Pseudomonas aeruginosa* și Enterobacteriaceae (*Klebsiella pneumoniae* și *Escherichia coli*) din grupul cu prioritate critică și *Enterococcus faecium* și *Staphylococcus aureus* din clasa cu prioritate înaltă (8, 9).

Necesitatea intervențiilor rapide, în contextul în

care RAM devine și o problemă de mediu, a determinat cercetătorii să reexploreze capacitățile bacteriofagilor de a elimina bacteriile, mai ales cele rezistente (10–14). Bacteriofagii sunt virusuri capabile să distrugă bacteriile prin liza acestora după integrarea materialului genetic în genomul lor (15, 16). Fagii sunt omniprezenți în natură și în interacțiune permanentă cu bacteriile și cu populația umană (15, 17). Istoria bacteriofagilor este mai veche decât a antibioticelor, prima expunere cu privire la existența acestora anticipând descoperirea lui *Alexander Fleming* cu peste 30 de ani (5). De la prima lor utilizare de către d'Herelle pentru tratarea unui copil de 12 ani la Spitalul de Copii din Paris și până în prezent, bacteriofagii și-au demonstrat eficacitatea în tratamentul diverselor maladii în diverse țări: în Franța contra infecțiilor provocate de *S.aureus*, *P.aeruginosa* și *E.coli*; în SUA, Polonia și URSS pentru tratarea rănilor soldaților și bolilor de campanie (dizenteria și alte boli diareice) (5, 16, 18). După 50 de ani, terapia cu bacteriofagi revine în atenția cercetătorilor și a clinicienilor în două forme distincte posibile – preparate gata pentru utilizare contra agenților infecțioși identificați în mediu sau pentru tratamentul uman în cazul bolilor comune (răceală, laringită, boli diareice), sau ca preparate personalizate pentru tratamentul afecțiunilor pacientului infectat cu o tulpină specifică (prioritar, MDR sau PDR) (19).

Scopul acestei lucrări este de a realiza analiza narativă a oportunităților și a provocărilor pe care le aduce terapia cu bacteriofagi pentru medicina modernă prin realizarea analizei SWOT după cercetarea literaturii de specialitate.

MATERIAL ȘI METODE

Pentru realizarea studiului de sinteză a literaturii, a fost realizată o căutare avansată în bibliotecile electronice PubMed și SCOPUS utilizând cuvintele-cheie: „bacteriofagi”, „rezistența antimicrobiană”, „terapia cu fagi” și „sănătate umană” și

operatorii BOOLEAN „AND”, „OR” și „NOT”. Căutarea a generat 911 publicații – 644 în baza de date PubMed și 267 în baza de date SCOPUS. Dintre acestea, 28,21% (n=257) au fost dublicate. Articolele rămase au fost evaluate conform ghidurilor PRISMA (20). La prima etapa de cercetare a publicațiilor au fost verificate 654, din acestea, 74,9% (n=490) nu au corespuns scopului studiului. Testului de eligibilitate au fost supuse 164 de lucrări științifice, conform criteriilor de includere după cum urmează:

a) Articole publicate în perioada 2000-2023.

- b) Limbile de publicare – engleza și/sau româna.
- c) Publicații în acces deschis.
- d) Articole de sinteză a literaturii, articole de cercetare, metaanaliză.

Nu au fost incluse în cercetare articolele găsite publicate în limbile rusă, franceză, poloneză și chineză; articolele publicate între 1980 și 1999; scrisorile editoriale și corecțiile articolelor, precum și publicațiile cu acces restricționat (fig. 1). Pentru studiul final au fost selectate 40 de publicații.




Figura 1. Criteriile de selecție a publicațiilor conform Ghidului PRISMA 2020.

REZULTATE

Analiza SWOT a terapiei cu bacteriofagi ca metodă de combatere a rezistenței la antimicrobiene

A. Puncte forte

În cadrul cercetării publicațiilor selectate au fost identificate 13 puncte forte. Toate studiile au enunțat drept atu al terapiei cu bacteriofagi specificitatea înaltă a fagilor, care determină și alte puncte forte. Qadri H. et al. susțin că activitatea țintită asupra bacteriilor rezistente ar fi principalul argument în favoarea utilizării lor pentru că ar avea efect bactericid doar asupra agentului causal, fără a induce modificări ale microbiotei normale. De aceeași părere a fost și Mousavi, accentuând că anume această proprietate îi face siguri în utilizare și pentru pacienții cu malabsorbție, malnutriție și alte maladii ale tractului gastro-intestinal (4, 9, 19, 21-28). Al doilea cel mai frecvent punct forte identificat a fost toxicitatea scăzută. În susținerea acestui punct de vedere, autorii articolelor au citat concluzia raportului elaborat în 2020 de Grupul de Inițiativă pentru Rezistența la Antimicrobiene al Institutului Național pentru Alergii și Boli Infecțioase din SUA. De altfel, unii autori au considerat că toxicitatea minimă a fagilor se datorează compoziției acestora – materie organică care este ușor descompusă și asimilată, și nu are efecte negative asupra organelor cu funcție de detoxifiere (4, 11, 19, 23, 29).

Un alt punct forte important este capacitatea lor de a penetra și distruge biofilmele bacteriene. Formarea biofilmului este una din formele prin care agenții patogeni obțin rezistență față de factorii de mediu și agenții antimicrobieni care nu penetrează eficient clusterul bacterian. Schooley et al., Aranaga și coautorii au argumentat ideea de eficiență a fagilor contra biofilmelor prin capacitatea virusurilor de a produce enzime hidrolitice de tipul hidrolizinelor și depolimerazelor care pot distruge matricea biofilmului (11, 19, 23, 26, 28). Câteva din punctele forte se determină reciproc: bacteriofagii sunt microorganisme ubicuitare prezente permanent în orice mediu și rezistente la condițiile de mediu, de asemenea, sunt ușor de găsit și de izolat din probele biologice și de mediu (apă, sol, aer). Aceste proprietăți determină cost-eficiența înaltă a terapiei cu fagi (4, 9, 10, 17, 21, 22, 29).

O altă pereche de puncte forte identificate care se autodetermină au fost: capacitatea de autoreproducere și necesitatea unei singure doze pentru a asigura eficiența tratamentului. În 12,5% din studii, capacitatea de autodozare a bacteriofagilor a fost evidențiată ca punct forte în susținerea terapiei cu bacteriofagi contra RAM. Acest punct forte a fost argumentat din două poziții: (a) multiplicarea bacteriofagilor în organismul recipient reduce necesitatea unei doze repetate aproape la zero pentru că pacientul răspunde rapid la tratament (conform observațiilor lui d'Herelle de la începutul sec. XX și altor studii clinice din perioada postbelică și (b) o singură administrare reduce efectul toxic generalizat asupra organismului și riscul dezvoltării rezistenței (5, 19, 22, 23, 29, 30). Alte două puncte forte identificate sunt virulența minimă a bacteriofagilor și lipsa efectelor adverse. Studiul lui Qadri et al. a considerat virulența minimă un punct forte în legătură cu incapacitatea acestor virusuri să provoace o maladie de etiologie infecțioasă sau alte efecte adverse la oameni, animale sau alte organisme vii pe care le infectează (cu excepția bacteriilor-țintă). În baza studiilor efectuate, autorii au concluzionat că terapia cu fagi nu provoacă efecte adverse asupra macro-organismului, deci este sigură pentru utilizare la scară largă (11, 22, 26).

B. Puncte slabe

În urma analizei literaturii incluse în studiu, au fost determinate opt puncte slabe ale terapiei cu fagi. Cinci dintre acestea au fost dependente de proprietățile și comportamentul fagilor *in vivo*, două au fost determinate de politicile în sănătate, iar unul – de condițiile necesare pentru producerea fagilor pentru terapie. Printre cel mai des identificate puncte slabe ale terapiei cu bacteriofagi (în 17,5% din publicații) a fost imunogenitatea acestor virusuri. Șase din cele șapte studii au determinat că răspunsul imun, provocat la pătrunderea bacteriofagilor în organism, reduce doza infectantă și scade efectul lor bactericid până a ajunge la locul infecției. Brüssow H. a avut un alt argument, bazat pe memoria imunologică a celulelor care poate împiedica administrarea repetată a aceluiași bacteriofag la un pacient cu infecție reemergentă (9, 19, 21-23, 30, 31). Mutațiile spontane au fost considerate un punct slab din considerentul că bacteriofagul litic ar putea deveni temperat, astfel răspândind RAM în loc să o

combată. Deși rata de apariție a mutațiilor spontane în genomul bacteriofagului este de 1000 de ori mai scăzută decât în genomul bacterian, 10% din articolele analizate consideră mutațiile spontane un punct slab (10, 24, 25, 32).

Autorii au identificat și alte proprietăți ale bacteriofagilor care pot fi catalogate drept puncte slabe: sensibilitatea bacteriofagilor față de razele UV, de temperaturile înalte și de aciditatea sucului gastric au fost considerate de Adhikari et al și Cesta et al principalele neajunsuri care scad eficiența bacteriofagilor, deoarece scad concentrația lor din doza administrată (2, 33). Hibstu și Furfaro au considerat necesitatea unui contact direct cu bacteria-țintă un punct slab pentru că, în opinia lor, alte căi de administrare decât topic sau prin acces direct ar limita eficacitatea terapiei din cauza micșorării concentrației de fagi și extinderea timpului necesar ca bacteriofagii să ajungă la locul infecției (21, 34). Rahbarnia et al și Hatfull et al au considerat drept punct slab incapacitatea fagilor de a elimina agenții patogeni bacterieni strict intracelulari, reieșind din proprietatea fagilor de a nu afecta celulele și țesuturile umane (23, 35).

Politicile și regulamentele restrictive din domeniul sănătății reprezintă un alt punct slab atribuit terapiei cu bacteriofagi. Conform autorilor, există mai multe obstacole în aprobarea de către organismele internaționale din domeniu precum Food and Drug Administration (FDA, SUA) sau Agenția Europeană a Medicamentului (EMA, UE) a terapiei cu bacteriofagi pentru combaterea bacteriilor rezistente la antimicrobiene. Printre acestea pot fi enumerate: (a) bacteriofagii sunt organisme vii, cu o structură chimică și biologică instabilă, deci trebuie tratate ca GMO, produs biologic pentru utilizare medicală sau produs pentru terapie medicală avansată; (b) lipsesc date concludente, obținute din studiile clinice controlate, asupra siguranței și eficacității lor la utilizarea în tratamentul pacienților umani; (c) imposibilitatea de înregistrare a dreptului de proprietate intelectuală asupra bacteriofagilor care sunt ubicuitari și apar în mod natural în mediu (chiar și mutanți) (7, 10, 16, 21, 30, 34, 36, 37). Lipsa unui cadru legal standardizat, cel puțin la nivel regional, determină secundar accesibilitatea scăzută a pacienților la terapia cu bacteriofagi. Chiar dacă terapia are o istorie veche și este bine reglementată în diverse țări precum Polonia (începând cu 1996), Georgia, Federația Rusă și China (începând cu 1958), pacienții din

alte țări (Belgia, Canada, Japonia etc.) pot doar recurge la turism medical sau tratament experimental cu bacteriofagi pentru a se vindeca (36, 37, 38).

C. Oportunități

În cadrul acestui studiu am determinat nouă oportunități de utilizare a terapiei cu bacteriofagi în combaterea RAM. Șase studii (15%) au expus argumente în favoarea posibilității de utilizare a lizogenității bacteriofagilor ca mecanism și instrument pentru restabilirea sensibilității bacteriilor rezistente la antimicrobiene prin incorporarea genelor care să modifice structura capsulei bacteriene sau funcția pompelor de eflux (10, 19, 21, 28, 39, 40). Studiile lui Schooley RT și Suh GA. et al menționează că proprietatea bacteriofagilor de a penetra biofilmele bacteriene poate fi utilizată și în scop profilactic dacă dispozitivele implantabile (catetere, implanturi dentare, șuruburi și tije) ar fi prelucrate cu o soluție cu concentrație înaltă de bacteriofagi (11, 28). Posibilitățile medicinei moderne precum ingineria genetică, secvențierea întregului genom ar putea permite utilizarea produselor biologice ale bacteriofagilor (enzime, proteine) și a bacteriofagilor ca agenți antimicrobieni contra bacteriilor MDR și PDR, contra unui spectru mai larg de agenți patogeni și ca vehicul sau matrice în producerea vaccinurilor (5, 10, 18, 21, 33).

Tendențele medicinei moderne implică orientarea spre medicina personalizată și integrarea intervențiilor din sănătatea umană în conceptul „O singură sănătate”. Publicațiile cercetate au arătat că terapia cu bacteriofagi poate fi utilizată în aceste direcții prin intermediul ingineriei genetice atât în medicina umană, cât și veterinară. Șase studii (15%) au susținut utilizarea bacteriofagilor ca metodă de combatere a tulpinilor bacteriene MDR și PDR izolate de la pacienți. Bioingineria și secvențierea genomică ar fi, după părerea lor, instrumente de primă importanță și necesitate în tratamentul individualizat al pacientului purtător de bacterie rezistentă cu ADN unic, dar este necesară o bibliotecă genomică extinsă (7, 19, 41-44). Sulakvelidze A. a susținut în lucrarea sa că fagii pot fi folosiți ca metodă de prevenție sau de tratament al afecțiunilor tractului gastrointestinal apărute ca rezultat al antibioterapiei (16). Autorii a 12,5% din publicațiile incluse în studiu (n=5) s-au pronunțat în favoarea utilizării terapiei cu bacteriofagi pentru profilaxia bolilor în domeniile zooteh

nie, acvacultură cu înlocuirea parțială sau integrală a antibioticelor, susținând că bacteriofagii au sau ar avea în perspectivă capacitatea să reducă rata infecțiilor de origine zoonotică la oameni (5, 32, 42, 43, 44). Pe lângă aceste oportunități pe care le prezintă terapia cu bacteriofagi pentru sănătatea umană în vederea combaterii RAM, autorul unui articol a considerat drept oportunitate și potențialul terapiei cu bacteriofagi de a revitaliza industria farmaceutică, sectorul de bioinginerie și cel de afaceri. Poziția a fost argumentată prin cost-eficiența izolării și dezvoltării de noi fagi pentru terapie și rambursarea rapidă a investițiilor în caz de comercializare a produselor finite (38).

D. Amenințări

Au fost identificate șapte amenințări care ar putea diminua eficiența terapiei cu bacteriofagi. Transducția genică mediată de bacteriofagi a fost menționată drept cel mai mare obstacol (12,5% din studii) în utilizarea terapiei cu bacteriofagi. Această proprietate a virusurilor de a media transferul genelor ce codifică rezistența la antimicrobiene între două bacterii este motivul principal al întârzierii aprobării de către organizațiile internaționale de profil a terapiei cu fagi pentru combaterea RAM (11, 21, 24, 25, 45). Pe locul secund s-a clasat posibilitatea bacteriilor să dezvolte rezistență la fagi datorită adaptabilității rapide a acestora la condițiile nefavorabile de mediu. Această amenințare a fost determinată în 10% din studii (n=4) (11, 19, 26, 32).

Al treilea obstacol identificat a fost lizogenia, proprietatea bacteriofagilor de a-și integra materialul genetic în genomul bacterian fără a induce liza bacteriei. Autorii celor trei studii care au înaintat acest obstacol drept o provocare la adresa siguranței terapiei cu fagi pentru pacienți l-au argumentat prin faptul că materialul genetic viral poate altera ADN-ul bacteriei și induce hiperexprimarea factorilor de virulență, care, combinat cu RAM, devine o dublă amenințare pentru viața pacientului (21, 25, 45). La celălalt capăt, bacteriofagii litici cu eficacitate înaltă au fost considerați la fel de periculoși din cauza dezvoltării șocului septic la pacienți când detritul, produsele de metabolism și toxinele bacteriene ajung în circuitul sangvin în cantități ce depășesc norma admisă de protocoalele de tratament în vigoare (21, 34).

Alte două amenințări identificate au fost dilemele bioetice legate de tratamentul pacienților cu orga-

nisme vii, posibil modificate genetic și înalt mutagene, având în vedere că tratamentul administrat, chiar și experimental (în cadrul studiilor clinice) nu trebuie să dăuneze, iar pacientul are dreptul la autodeterminare dacă terapia este una experimentală (7) și perspectiva unui cost ridicat pentru tratamentul cu bacteriofagi dacă în costul pentru terapia personalizată vor fi incluse cheltuielile pentru producerea fagilor individualizați, e pentru spitalizare, pentru transportul soluției de fagi la patul pacientului (11) (fig. 2).

DISCUȚII

Analiza SWOT realizată pentru evaluarea terapiei cu bacteriofagi ca metodă de combatere a RAM a dat rezultate promițătoare. Punctele forte prevalează comparativ cu punctele slabe, cu un raport de 13:8, și există de 1,28 ori mai multe oportunități decât amenințări în perspectiva implementării terapiei cu bacteriofagi ca metodă de tratament. Unele puncte slabe sau obstacole listate de unii autori, sunt considerate oportunități în lumina inovațiilor în medicina moleculară și bioinginerie sau avantaje importante comparativ cu antibioterapia.

Cu precădere, capacitatea bacteriofagilor de a muta spontan și de a atenua sau de a pierde proprietățile litice au fost considerate de patru grupuri de autori drept un punct slab (10, 24, 25, 32), lizogenia și probabilitatea transducției genice – amenințări în cinci publicații (11, 21, 24, 25, 45), de cealaltă parte, 22,5% din studii consideră aceste proprietăți ale fagilor drept oportunități în contextul evoluției fulminante a RAM (5, 10, 18, 19, 21, 28, 33, 39, 40). Saha D. și coautorii consideră mutagenitatea fagilor un atu important în depășirea rezistenței bacteriei-țintă față de bacteriofagul specific, ceea ce minimizează pericolul pe care îl prezintă apariția rezistenței față de bacteriofagi în timpul tratamentului (29).

Lipsa cadrului legal standardizat la nivel regional, mai ales în spațiul european, aduce unele dificultăți în privința popularizării și implementării terapiei cu bacteriofagi în practica medicală. Este necesară realizarea unui studiu extins, multicentric și multidisciplinar care să cuprindă analiza comportamentului fagilor *in vitro*, în mediu, *in vivo* (pe modele animale) și în practica clinică. Astfel, ar fi depășit blocajul aprobării și adoptării terapiei cu fagi ca metodă de tratament și de combatere a fenomenului RAM. Studiile clinice con-




Figura 2. Terapia cu bacteriofagi prin prisma metodei de analiza SWOT.

trolate, considerate de EMA standardul de aur și unicul argument acceptabil la înregistrarea unei noi metode de tratament sau a unui nou preparat, ar fi una din metodele de cercetare ale aspectelor enumerate.

Caracteristicile fagilor precum ubicuitatea, toxicitatea redusă, specificitatea înaltă, neafectarea altor celule decât bacteriile-țintă, capacitatea de dezintegrare a biofilmelor bacteriene sunt argumente plauzibile în favoarea implementării terapiei cu bacteriofagi pe scară largă. Dilemele bioetice privind siguranța acestor virusuri pentru să-

nătatea umană se reduc considerabil dacă tratăm terapia cu bacteriofagi drept analog al administrării unui vaccin viu atenuat cum ar fi vaccinul BCG contra tuberculozei, vaccinul ROR sau Polio care sunt considerate sigure pentru utilizare. Acest punct de vedere a fost susținut și de Anomaly J. în publicația sa (46).

Așadar, terapia cu bacteriofagi este o alternativă plauzibilă pentru a suplini sau a înlocui terapia cu antimicrobiene în tratarea pacienților cu infecții cauzate de agenți patogeni MDR sau PDR (9, 23, 30, 33).

CONCLUZII

1. Rezistența la antimicrobiene este o problemă de sănătate publică care necesită intervenții rapide și eficiente. Terapia cu bacteriofagi este o alternativă plauzibilă care și-a demonstrat eficacitatea în cei peste 100 de ani de evoluție.
2. Punctele forte și oportunitățile care caracterizează terapia cu bacteriofagi depășesc riscurile utilizării acestei metode ca instrument de combatere a fenomenului RAM, cu un raport puncte forte/puncte slabe de 13:8 și oportunități/amenințări de 9:7.
3. Inovațiile în medicina moleculară și în ingineria genică transformă dezavantajele bacteriofagilor precum mutagenitatea înaltă, lizogenia și capacitatea de transducție genică în oportunități pentru dezvoltarea terapiei personalizate pentru combaterea RAM.
4. Autoritățile din domeniul sănătății publice ar trebui să promoveze și să întreprindă activități de cercetare în direcția implementării terapiei cu bacteriofagi atât în sănătatea umană, cât și în contextul abordării „O singură sănătate”.

CONFLICT DE INTERESE

Autorii declară lipsa conflictelor de interese în ceea ce privește studiul și acest articol.

MULȚUMIRI ȘI FINANȚARE

Studiul este realizat în cadrul proiectului JPIAMR „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters”; (*Phage*

Land), cifrul proiectului - 22.80013.8007.1M.

APROBARE ETICĂ

Protocolul cercetării a fost avizat pozitiv de către Comitetul de Etică a Cercetării al Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” nr. 7 din 09.01.2022 și Comitetul Național de Expertiză Etică a Studiului Clinic al Ministerului Sănătății nr. 1245 din 26.01.2022.

REFERINȚE

1. Gaynes R. The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Use. *Emerg Infect Dis.* 2017;23(5):849–53. PMID: PMC5403050. doi:10.3201/eid2305.161556.
2. Cesta N, Di Luca M, Corbellino M, Tavio M, Galli M, Andreoni M. Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases. *Infez Med.* 2020;28(3):322–331. Accesibil la: https://www.infezmed.it/media/journal/Vol_28_3_2020_5.pdf [Accesat: 27.12.2023].
3. Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran TB, Dhama K, Ripon MKH, Gajdacs M, Sahibzada MUK, Hossain MJ, Koirala N. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. *J Infect Public Health.* 2021;14(12):1750–1766. doi:10.1016/j.jiph.2021.10.020
4. Mousavi SM, Babakhani S, Moradi L, et al. Bacteriophage as a Novel Therapeutic Weapon for Killing Colistin-Resistant Multi-Drug-Resistant and Extensively Drug-Resistant Gram-Negative Bacteria. *Curr Microbiol.* 2021;78(12):4023–4036. doi:10.1007/s00284-021-02662-y
5. Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. *J Infect Dev Ctries.* 2014;8(2):129–36. doi:10.3855/jidc.3573. PMID: 24518621
6. WHO Departmental News: Vaccines could avert half a million deaths associated with anti-microbial resistance a year, published on 23rd of July 2023. Accesibil la <https://www.who.int/news/item/28-07-2023-vaccines-could-avert-half-a-million-deaths-associated-with-anti-microbial-resistance-a-year> [Accesat: 31 Decembrie 2023].
7. Verbeken G, Huys I, Pirnay JP, Jennes S, Chanishvili N, Scheres J, Górski A, De Vos D, Ceulemans C. Taking bacteriophage therapy seriously: a moral argument. *Biomed Res Int.* 2014;2014:621316. doi:10.1155/2014/621316
8. WHO publishes list of bacteria for which new antibiotics are urgently needed. Accesibil la <https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed> [Accesat: 01.01 2024].
9. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. *Int J Antimicrob Agents.* 2019;53(1):16–21. doi:10.1016/j.ijantimicag.2018.09.004
10. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, et al. Quality and safety requirements for sustainable phage therapy products. *Pharm Res.* 2015;32(7):2173–9. doi:10.1007/s11095-014-1617-7
11. Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, et al. Antibacterial Resistance Leadership Group. Considerations for the Use of Phage Therapy in Clinical Practice. *Antimicrob Agents Chemother.* 2022;66(3):e0207121. doi:10.1128/AAC.02071-21
12. Maimaiti Z, Li Z, Xu C, Chen J, Chai W. Global trends and hotspots of phage therapy for bacterial infection: A bibliometric visualized analysis from 2001 to 2021. *Front Microbiol.* 2023;13:1067803. doi:10.3389/fmicb.2022.106780
13. Rohde C, Wittmann J, Kutter E. Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria. *Surg Infect (Larchmt).* 2018;19(8):737–744. doi:10.1089/sur.2018.184
14. Ciobanu E, Croitoru C, Balan G, Bernic V, Burduniuc O, Ferdohleb A. Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters – a project launch in low-middle income countries of Eastern Europe. *One Health & Risk Management.* 2022;3(2S):28. doi:10.38045/ohrm.2022.2.05
15. Galben L, Bălan G. Utilizarea bacteriofagilor în practica medicală ca o alternativă la terapia antimicrobiană [The use of bacteriophages in medical practice as an alternative to antimicrobial therapy]. In: Ferdohleb A, Ciobanu E, Croitoru C. *Rezistența la antimicrobiene: amenințare globală pentru Sănătatea Publică* [Antimicrobial resistance: global public health threat]. Chișinău: Print-Caro, 2023, 144 p. Disponibil la <https://repository.usmf.md/handle/20.500.12710/26682> [Accesat: 10.01.2024].
16. Sulakvelidze A, Morris JG Jr. Bacteriophages as the-

- rapeutic agents. *Ann Med.* 2001;33(8):507-509. doi:10.3109/07853890108995959
17. Galben L, Neronova N, Bălan G. Utilizarea bacteriofagilor în practica medicală pentru diminuarea fenomenului de rezistență la antimicrobiene [The use of bacteriophages in medical practice to reduce the phenomenon of antimicrobial resistance]. *One Health & Risk Management.* 2023. Disponibil la <https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/523> [Accesat: 27.12.2023].
 18. Marga I, Paraschiv A. Bacteriofagii – potențiali înlocuitori pentru antibiotic [Bacteriophages – potential substitutes for antibiotics]. *One Health & Risk Management.* 2023(Dec.);23. Accesibil la: <https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/602> [Accesat: 28.12.2023].
 19. Aslam S, Schooley RT. What's Old Is New Again: Bacteriophage Therapy in the 21st Century. *Antimicrob Agents Chemother.* 2019;64(1): e01987-19. doi:10.1128/AAC.01987-19
 20. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines, Accesibil la http://prisma-statement.org/documents/PRISMA_2020_checklist.pdf [Accesat: 28.12.2023].
 21. Hibstu Z, Belew H, Akelew Y, Mengist HM. Phage Therapy: A Different Approach to Fight Bacterial Infections. *Biologics.* 2022;16:173-186. doi:10.2147/BTT.S381237
 22. Qadri H, Shah AH, Mir M. Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes. *Curr Drug Targets.* 2021;22(12): 1424-1436. doi:10.2174/1389450121666201228123212
 23. Rahbarnia L, Farajnia S, Naghili B, et al. Current trends in targeted therapy for drug-resistant infections. *Appl Microbiol Biotechnol.* 2019; 103(20):8301-8314. doi:10.1007/s00253-019-10028-5
 24. Fernández L, Duarte AC, Rodríguez A, García P. The relationship between the phageome and human health: are bacteriophages beneficial or harmful microbes?. *Benef Microbes.* 2021;12(2):107-120. doi:10.3920/BM2020.0132
 25. Khan AA, Manzoor KN, Sultan A, et al. Pulling the Brakes on Fast and Furious Multiple Drug-Resistant (MDR) Bacteria. *Int J Mol Sci.* 2021; 22(2):859. doi:10.3390/ijms22020859
 26. Aranaga C, Pantoja LD, Martínez EA, Falco A. Phage Therapy in the Era of Multidrug Resistance in Bacteria: A Systematic Review. *Int J Mol Sci.* 2022;23(9):4577. doi:10.3390/ijms23094577
 27. Huang Y, Wang W, Zhang Z, et al. Phage Products for Fighting Antimicrobial Resistance. *Microorganisms.* 2022;10(7):1324. doi:10.3390/microorganisms10071324
 28. Schooley RT. Exploring bacteriophage therapy for drug-resistant bacterial infections. *Top Antivir Med.* 2023;31(1):23-30. Accesibil la <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089292/> [Accesat: 27.12.2023].
 29. Saha D, Mukherjee R. Ameliorating the antimicrobial resistance crisis: phage therapy. *IUBMB Life.* 2019;71(7):781-790. doi:10.1002/iub.2010
 30. Brüssow H. What is needed for phage therapy to become a reality in Western medicine?. *Virology.* 2012;434(2):138-142. doi:10.1016/j.virol.2012.09.015
 31. Bosco K, Lynch S, Sandaradura I, Khatami A. Therapeutic Phage Monitoring: A Review. *Clin Infect Dis.* 2023;77(Supplement_5):S384-S394. doi:10.1093/cid/ciad497
 32. Pires DP, Costa AR, Pinto G, Meneses L, Azeredo J. Current challenges and future opportunities of phage therapy. *FEMS Microbiol Rev.* 2020; 44(6):684-700. doi:10.1093/femsre/fuaa017
 33. Adhikari N, Acharya KP. Effectiveness of Bacteriophage Therapy in Field Conditions and Possible Future Applications. *Curr Pharm Biotechnol.* 2020;21(5):364-373. doi:10.2174/1389201021666191217111156
 34. Furfaro LL, Payne MS, Chang BJ. Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles. *Front Cell Infect Microbiol.* 2018;8:376. doi:10.3389/fcimb.2018.00376
 35. Hatfull GF, Dedrick RM, Schooley RT. Phage Therapy for Antibiotic-Resistant Bacterial Infections. *Annu Rev Med.* 2022;73:197-211. doi:10.1146/annurev-med-080219-122208
 36. Jaglan AB, Anand T, Verma R, et al. Tracking the phage trends: A comprehensive review of applications in therapy and food production. *Front Microbiol.* 2022;13:993990. doi:10.3389/fmicb.2022.993990
 37. Yang Q, Le S, Zhu T, Wu N. Regulations of phage therapy across the world. *Front Microbiol.* 2023; 14:1250848. doi:10.3389/fmicb.2023.1250848
 38. Gordillo Altamirano FL, Barr JJ. Phage Therapy in the Postantibiotic Era. *Clin Microbiol Rev.* 2019; 32(2):e00066-18. doi:10.1128/CMR.00066-18
 39. Singh K, Biswas A, Chakrabarti AK, Dutta S. Phage Therapy as a Protective Tool Against Pathogenic Bacteria: How Far We Are?. *Curr Pharm Biotechnol.* 2023;24(10):1277-1290. doi:10.2174/1389201024666221207114047
 40. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World J Gastrointest Pharmacol Ther.* 2017;8(3):162-173. doi:10.4292/wjgpt.v8.i3.162
 41. Green SI, Clark JR, Santos HH, et al. A Retrospective, Observational Study of 12 Cases of Expanded- Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes. *Clin Infect Dis.*

- 2023;77(8):1079-1091. doi:10.1093/cid/ciad335
42. Ioannou P, Baliou S, Samonis G. Bacteriophages in Infectious Diseases and Beyond-A Narrative Review. *Antibiotics (Basel)*. 2023;12(6):1012. doi:10.3390/antibiotics12061012
43. Zagaliotis P, Michalik-Provasek J, Gill JJ, Walsh TJ. Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans. *Pathog Immun*. 2022;7(2):1-45. doi:10.20411/pai.v7i2.516
44. Ali Y, Inusa I, Sanghvi G, Mandaliya VB, Bishoyi AK. The current status of phage therapy and its advancement towards establishing standard antimicrobials for combating multi drug-resistant bacterial pathogens. *Microb Pathog*. 2023;181:106199. doi:10.1016/j.micpath.2023.106199
45. El Haddad L, Harb CP, Gebara MA, Stibich MA, Chermaly RF. A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans. *Clin Infect Dis*. 2019;69(1):167-178. doi:10.1093/cid/ciy947
46. Anomaly J. The Future of Phage: Ethical Challenges of Using Phage Therapy to Treat Bacterial Infections. *Public Health Ethics*. 2020;13(1):82-88. doi:10.1093/phe/phaa003

CUNOȘTINȚE, ATITUDINI ȘI PRACTICI PRIVIND REZISTENȚA LA ANTIMICROBIENE ÎN ȚĂRILE CU VENIT MIC ȘI MEDIU: SINTEZĂ NARATIVĂ

Livia ȚAPU^{1,2}, Alina FERDOHLEB¹, Larisa SPINEI¹, Carles M. BORREGO^{3,4}

¹Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

²Agencia Națională pentru Sănătate Publică, Chișinău, Republica Moldova

³Institutul Catalan pentru Cercetarea Apei (ICRA-CERCA), Girona, Spania

⁴Grupul de Ecologie Moleculară Microbiană, Institutul de Ecologie Acvatică, Universitatea din Girona, Girona, Spania

Autor corespondent: Livia Țapu, e-mail: liviatapu@gmail.com

Keywords: knowledge, attitudes, practices; antibiotic resistance; low- and middle-income countries.

KNOWLEDGE, ATTITUDES AND PRACTICES REGARDING ANTIMICROBIAL RESISTANCE IN LOW- AND MIDDLE-INCOME COUNTRIES - NARRATIVE SYNTHESIS

Introduction. Antimicrobial resistance (AMR) is an acute medico-social problem, and in order to minimize its effects, a comprehensive approach is needed at the individual level and in the formulation of public health policies.

Material and methods. A narrative synthesis of KAP studies results on AMR in LMICs was conducted. The search for sources was performed in public databases. After identifying articles and removing duplicates, 23 relevant ones were selected, of which 14 were fully analyzed.

Results. Studies have indicated that knowledge is generally deficient in LMICs. Negative or neutral attitudes and practices concerning antibiotic prescribing and administration prevail, with widespread self-medication. Determining factors are diverse, and addressing the AMR phenomenon necessitates a comprehensive approach, including policy-level initiatives aimed at raising awareness and educating the population.

Conclusions. The determinants of population KAP in LMICs are influenced by the economic situation and the health system. Clear objectives, correct sampling techniques, and standardization of research instruments are necessary for KAP studies to ensure the representativeness of the data.

Cuvinte-cheie: cunoștințe, atitudini, practici; rezistența la antibiotice; țări cu venit mic și mediu.

Introduction. Rezistența la antimicrobiene (RAM) este o problemă medico-socială stringentă, iar pentru minimizarea efectelor acesteia este necesară o abordare comprehensivă, la nivel individual, și formarea politicilor de sănătate publică.

Material și metode. A fost realizată o sinteză narativă a rezultatelor studiilor CAP (Cunoștințe, Atitudini și Practici) privind RAM în țările cu venit mic și mediu. Sursele au fost căutate în bazele de date publice. După identificarea articolelor și dedublare, au fost selectate 23 de surse relevante, dintre care 14 au fost analizate integral.

Rezultate. Studiile au arătat că în țările cu venit mic și mediu, cunoștințele cu privire la prescrierea și administrarea antibioticelor sunt, în general, slabe, atitudinile negative sau neutre, iar practicile necorespunzătoare, fiind pe larg răspândită automedicația. Creșterea nivelului de conștientizare și educarea populației cu privire la fenomenul RAM necesită o abordare complexă, inclusiv la nivel de politici.

Concluzii. Determinantele CAP ale populației în țările cu venit mic și mediu sunt influențate de situația economică și de sistemul de sănătate. Pentru studiul CAP, care asigură reprezentativitatea datelor, sunt necesare obiective clare, tehnici de eșantionare corecte și standardizarea instrumentelor de cercetare.

INTRODUCERE

Rezistența la antimicrobiene (RAM) este o amenințare globală pentru sănătate, cu impact semnificativ asupra sistemului de sănătate și a economiei (1). Utilizarea abuzivă și excesivă a antimicrobienele rămâne principala cauză a apariției agenților patogeni rezistenți la acțiunea acestora. Identificarea lacunelor în cunoștințe și planificarea intervențiilor care ar putea duce la utilizarea rațională a antimicrobienele sunt de o importanță decisivă pentru a reduce RAM (2). Minimizarea efectului rezistenței la antimicrobiene necesită un răspuns politic adecvat, care se bazează pe o bună guvernare și coordonare (3). Factorii sociali și comportamentali ai utilizării inadecvate a antibioticelor au fost identificați ca unul dintre factorii-cheie care contribuie la apariția RAM. Sondajele privind cunoștințele, atitudinile și practicile populației (CAP) fac parte din cadrul de monitorizare și de evaluare propus de Planul global de acțiune al OMS privind rezistența la antimicrobiene (4).

Scopul lucrării a fost identificarea caracteristicilor studiilor despre cunoștințele, atitudinile și practicile RAM, determinantele CAP ale populației privind fenomenul RAM în țările cu venit mic și mediu (LMIC).

MATERIAL ȘI METODE

A fost realizată o sinteză narativă care prezintă rezultatele a 14 studii CAP ale populației privind rezistența la antimicrobiene din cadrul țărilor cu venit mic și mediu (LMIC). Căutarea surselor de informații a fost realizată în bazele de date *PubMed*, *Google Scholar* și *Hinari* cu ajutorul următoarelor cuvinte-cheie: „antimicrobial resistance AND kap”, „antimicrobial resistance NEAR knowledge AND attitude AND practice”, „antimicrobial resistance NEAR knowledge attitude practice”.

Criteriile de includere a publicațiilor în studiu au fost: articol publicat în perioada ianuarie 2015 – ianuarie 2023; tipul de studiu – revii narrative, studii descriptive și observaționale despre CAP al populației privind rezistența la antimicrobiene, metodologie clară și explicită; articole scrise în limba engleză.

Criteriile de excludere a publicațiilor din studiu au fost: studii descriptive privind CAP ale studenților facultăților de medicină, lucrătorilor din do-

meniul medical sau veterinar, articolele care nu au metodologie sau aceasta este prezentată neexplicit.

Textul integral al studiilor a fost evaluat în baza variabilelor: scopul, metodologia, numărul cumulat de participanți/eșantionul și rezultatele.

Din informația colectată, au fost selectate evidențele privind cunoștințele, atitudinile și practicile populației în legătură cu rezistența la antimicrobiene care au fost interpretate și prezentate luând în considerare numărul, nivelul de evidență și calitatea studiilor. În *Google Academics* au fost identificate în total 1 760 de citări, în baza de date *PubMed* – 511, în *HINARI* – 523. După eliminarea înregistrărilor duplicate și screeningul abstractelor, au fost selectate 23 de articole, dintre acestea au fost excluse nouă care nu se refereau la țările cu venit mic și mediu, fiind revizuite integral 14 articole.

Studiul este realizat în cadrul Proiectului de cercetare „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters (PhageLand)” cifrul 22.80013.8007.1M și a fost aprobat la Comitetul de Etică a Cercetării al Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu”, proces-verbal nr. 7 din 9.01.2022 (5).

REZULTATE

După screeningul textului integral, au fost incluse în reviu integrativ 14 articole enumerate în tabelul 1, cu un număr cumulat de participanți la studiu de 9380 de persoane din populația generală.

Toate cele 14 studii incluse în analiză au avut obiective clare privind evaluarea nivelului de cunoștințe, atitudinii și practicii populației în legătură cu rezistența la antimicrobiene și consumul lor. Au fost folosite metodologii adecvate pentru studii transversale bazate pe populație în raport cu întrebările cercetate.

Studiile au demonstrat că în majoritatea țărilor LMIC populația are cunoștințe slabe privind utilizarea antibioticelor (6, 7, 8, 12, 13, 14, 16, 18, 19). În unele țări totuși există o tendință de îmbunătățire a cunoștințelor în acest domeniu datorită diferitor practici de creștere a gradului de conștientizare și de educare a populației (9, 11, 15, 17), îmbunătățirea factorilor socio-culturali (10).

Tabelul 1. Studii Cunoștințe, Atitudini și Practici ale populației cu privire la fenomenul de rezistență la antimicrobiene în țările cu venit mic și mediu.

Autorul	Țara	Anul	Scopul	Tipul studiului	Criteriile de eligibilitate	Eșantion	Sursa
Sa'ed H. Zyoud	Palestina	2012	Analiza cunoștințelor, atitudinilor și practicilor privind utilizarea antibioticelor în managementul infecțiilor tractului urinar la copii pe un eșantion mare de părinți	Studiu transversal	Studiu CAP organizat pe părinții copiilor cu infecții ale tractului respirator superior cu vârsta cuprinsă între 18 și 50 de ani.	385 părinți	(6)
Grace-Ange Elong Ekambi et. al.	Cameroon	2015	Acest studiu a fost conceput pentru a determina cunoștințele; atitudinile și practicile față de utilizarea antibioticelor într-o comunitate urbană și evaluează factorii asociați cu utilizarea antibioticelor	Studiu transversal și prospectiv	Studiu CAP organizat pentru comunitatea urbană, clienții farmaciilor, vârsta respondenților >15 ani	1192 respondenți	(7)
Inocência Mate et. al.	Maputo, Mozambic	2016	Obținerea datelor despre cunoștințele, atitudinile și practicile privind prescrierea și utilizarea antibioticelor în Africa subsahariană	Studiu transversal	Sudiu CAP pe populație adultă >18 ani, chestionar semistructurat	1019 participanți	(8)
Komal Raj Rijal	Nepal	2017	Explorarea cunoștințelor, atitudinea și practicile de utilizare a antibioticelor în rândul pacienților, lucrătorilor din domeniul sănătății, laboratoarelor, vânzătorilor de medicamente și fermierilor din Nepal	Studiu transversal	Sondaj față în față privind CAP, inclusiv pe pacienți cu vârsta preponderent (50%) între 26-50 de ani	516 participanți, dintre care 324 pacienți	(9)
Moyukh Chowdhury et. al.	Matlab, Bangladesh	2017 - 2019	Explorarea factorilor și a practicilor privind accesul și utilizarea antibioticelor, înțelegerea rezistenței antimicrobiene în comunitățile rurale din Bangladesh din perspectivă socio-culturală	Studiu calitativ, faza a doua a unui studiu multi-statal ABACUS	Studiu CAP organizat pe locuitorii din diferite categorii de vârstă din zone rurale, vârsta 16-60 de ani	59 informatori	(10)
Jane Mingjie Lim et. al.	Cambodgia	2018	Evaluarea cunoștințelor, atitudinilor și practicilor publice cu privire la antibiotice și rezistența la antibiotice în Cambodia, oferind informații de bază în funcție de care va fi monitorizat progresul intervențiilor viitoare	Studiu descriptiv	Sondaj CAP legat de utilizarea antibioticelor de către populația urbană și rurală din trei provincii canbodgeiene: Phnom Penh, Siem Reap și Prey Veng. Vârsta > 18 ani	2005 participanți	(11)
Hassan Waseem et. al.	Sialkot, Pakistan	2018 - 2019	Evaluarea cunoștințelor despre rezistența antimicrobiană și a atitudinii față de acest fenomen în rândul membrilor comunității, farmaciștilor/proprietari de farmacii și medicilor (Sialkot, Pakistan)	Studiu transversal	Studiu CAP bazat pe trei chestionare autoadministrate, destinate populației generale cu vârsta cuprinsă între 18 și 45 de ani, generală farmaciștilor și medicilor	473 participanți din po populația	(12)

Amit Khelgi et. al.	Mangaluru, India	2019	Evaluarea cunoștințelor privind utilizarea antibioticelor și rezistenței antimicrobiene în rândul populației rurale din Mangaluru. Determinarea atitudinilor oamenilor din mediul rural privind utilizarea antibioticelor. Analiza practicilor acestora în utilizarea antibioticelor	Studiu transversal	Studiu CAP bazat pe chestionar, destinat populației generale din mediul rural, vârsta 18-60 de ani	130 participanți	(13)
Emelda E. Chukwu	Nigeria	2020	Evaluarea nivelului actual de conștientizare și de cunoaștere a RAM de către publicul nigerian (Nord Central, Nord-Est, Nord-Vest, Sud-Est, Sud-Sud și Sud-Vest)	Studiu transversal	Studiu CAP, Chestionar pre-testat și validat pentru a obține informații de la publicul larg în șase zone geopolitice, vârsta 18-≥75 de ani	482 participanți	(14)
Calvin Sindato et. al.	Tanzania	2020	Determinarea cunoștințelor, atitudinilor și practicilor (CAP) cu privire la utilizarea antimicrobiene și RAM	Studiu transversal	Studiu CAP, Chestionar semi-structurat (Ilala, Kilosa și Kibaha, Tanzania), vârsta 29-54 de ani	828 participanți	(15)
Wudneh Simegn, Getachew Moges	Dessie, Etiopia de Nord	2021	Evaluarea nivelului de conștientizare și de cunoaștere a rezistenței antimicrobiene și a factorilor asociați în rândul adulților din Dessie, Etiopia	Studiu transversal	Studiu CAP bazat pe comunitate cu implicarea persoanelor adulte	407 adulți participanți	(16)
Matru-jyoti Pattnaik, Ashish Kumar Nayak, et. al.	Odisha, India	2021	Determinarea cunoștințelor, atitudinilor și practicilor (CAP) cu privire la utilizarea de antimicrobiene și AMR în rândul comunităților rurale din Tigris (Odisha), India	Studiu transversal	Studiu CAP bazat pe chestionar standardizat, folosind un dispozitiv electronic cu Open Data Kit., vârsta participanților 18 - > 60 de ani	1003 participanți	(17)
Haileyesus Dejene	Gondar, Etiopia de Nord	2021	Evaluarea cunoștințelor, atitudinilor și practicilor locuitorilor orașului Gondar cu privire la utilizarea și rezistența la antimicrobiene	Studiu transversal	Studiu CAP folosind un chestionar semistructurat pretestat, (orașul Gondar)	400 participanți	(18)
Zahraa N. Fakhreldain, Hayder CH. Assad	Iraq	2021 - 2022	Colectarea datelor despre nivelul cunoștințelor atitudinea și utilizarea antibioticelor, în comunități irakiene și explorarea factorilor predictivi ai pacientului asociați cu acestea	Studiu observațional transversal	Studiu CAP bazat pe chestionar autoadministrat validat, pretestat (orașul Al-AlSadar)	475 pacienți	(19)

În țările LMIC, pe lângă cunoștințele reduse ale populației cu privire la administrarea corectă a antibioticelor, persistă o atitudine negativă față de acest fenomen (6, 12, 13, 14, 16, 18) sau neutră (19). În alte țări, pe lângă nivelul mai înalt de cunoștințe, se observă și o atitudine conștientă, astfel populația cunoaște unii termeni referitori la antimicrobiene și rezistență la antibiotice. Majoritatea participanților au recunoscut că rezistența la antibiotice este o problemă (9, 11, 15, 17). Practicile populației în legătură cu rezistența la antibiotice sunt inadecvate (6, 7, 8, 12, 13, 14, 16) acolo unde este foarte răspândită automedicația și prescrierea inadecvată a antimicrobienelor (7, 8, 14, 16), unde lipsește accesul la facilități de asistență medicală (10). În general, practicile privind administrarea antibioticelor sunt corelate cu nivelul de cunoștințe al populației. Astfel, în unele cazuri s-au identificat practici corespunzătoare la populația anchetată, dar care totuși necesită îmbunătățire (9, 11, 15, 17, 19). Sunt binevenite unele campanii de conștientizare pentru a atenua utilizarea inadecvată a antibioticelor (9), precum și politicile referitoare la utilizarea corespunzătoare a antibioticelor, interzicerea comercializării acestora fără prescripție și abordarea *One Health* (9, 10, 16).

DISCUȚII

În urma analizei publicațiilor științifice au fost identificați determinanții principalelor compartimente. Nivelul redus de cunoaștere de către populație a fenomenul de RAM în LMIC este influen-

țat, în primul rând, de nivelul scăzut de educație al populației (8) și de accesul limitat la informații medicale (9), inclusiv cu privire la antibiotice și la administrarea corectă a acestora. Atitudinile negative ale populației privind fenomenul RAM sunt, în mare parte, agravate de nivelul redus de trai (13) și de atitudinea indiferentă față de problemele stringente din sănătatea publică (15, 18), lipsa de încredere în sistemul de sănătate (10), comunicare defectuoasă între medici și pacienți. Practicile slabe ale populației privind fenomenul RAM sunt determinate, în mare parte, de sărăcie și de situația conomică precară, de reutilizarea antibioticelor rămase (6, 14) și de automedicație (7, 9, 13, 17). Principalele motive invocate pentru practicarea automedicației în țările în curs de dezvoltare sunt lipsa accesului la asistență medicală aproape de populație, lipsa surselor financiare, ignoranța (7) și, cel mai important, lipsa sau controlul redus din partea autorităților cu privire la consumul de antibiotice, ceea ce duce inevitabil la agravarea situației privind RAM (9, 10, 12).

Studiile CAP pot ajuta factorii de decizii să planifice acțiuni și strategii de combatere a RAM și de atenuare a efectelor acestui fenomen (20). Pentru a maximiza efectele utilizării studiilor CAP este necesar suportul programelor de sănătate publică pentru a face progrese în rezolvarea problemelor RAM (21). Creșterea nivelului de conștientizare și educarea populației cu privire la rezistența la antibiotice are un rol important în prevenirea răspândirii acestui fenomen (22).

CONCLUZII

1. Această sinteză a identificat câteva caracteristici ale studiilor privind cunoștințele, atitudinile și practicile privind rezistența la antimicrobiene și consumul acestora.
2. Sunt necesare obiective foarte clare ale sondajului/studiului.
3. Pentru asigurarea reprezentativității datelor obținute sunt necesare tehnici de eșantionare corespunzătoare și corecte din punct de vedere științific.
4. Pentru a obține date credibile și comparabile sunt necesare teste de probă ale sondajelor și metode de implementare a chestionarelor, precum și standardizarea instrumentelor de cercetare.
5. În timpul elaborării chestionarului, trebuie luate în considerare caracteristicile sistemelor de sănătate, accesul la serviciile de sănătate.
6. Studiile CAP sunt un instrument de valoare mai ales dacă este asigurat suportul programelor de sănătate publică în scopul elaborării măsurilor de reducere a fenomenului de RAM.

CONFLICT DE INTERESE

Autorii declară lipsa conflictului de interese.

MULȚUMIRI ȘI FINANȚARE

Studiul este realizat în cadrul Proiectului de cercetare „Phage treatment and wetland technology as intervention strategy to prevent dissemination

of antibiotic resistance in surface waters (*Pha*

geLand)" cifrul 22.80013.8007.1M.

REFERINȚE

1. Spinei L, Raevschi E, Ferdohleb A, Ciobanu E, Croitoru C, et al. *Rezistența la antimicrobiene: amenințare globală pentru sănătatea publică* [Antimicrobial resistance: global threat to public health]. 2023. Available at: <https://repository.usmf.md/handle/20.500.12710/26682> [Accessed: January 10, 2024].
2. Rahbi FA, Salmi IA, Khamis F, et al. Physicians' attitudes, knowledge, and practices regarding antibiotic prescriptions. *J Glob Antimicrob Resist*. 2023;32:58-65. doi:10.1016/j.jgar.2022.12.005
3. Naing S, van Wijk M, Vila J, Ballesté-Delpierre C. Understanding Antimicrobial Resistance from the Perspective of Public Policy: A Multinational Knowledge, Attitude, and Perception Survey to Determine Global Awareness. *Antibiotics*. 2021;10(12):1486. doi:10.3390/antibiotics10121486
4. Hawkins O, Scott AM, Montgomery A, et al. Comparing public attitudes, knowledge, beliefs and behaviours towards antibiotics and antimicrobial resistance in Australia, United Kingdom, and Sweden (2010-2021): A systematic review, meta-analysis, and comparative policy analysis. *PLoS One*. 2022;17(1):e0261917. doi:10.1371/journal.pone.0261917
5. Ciobanu E, Croitoru C, Balan G, Bernic V, Burduniuc O, Ferdohleb A. „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters” - a project launch in low-middle income countries of Eastern Europe. *One Health & Risk Management*. 2022;3(2S):28-28. doi:10.38045/ohrm.2022.2.05
6. Zyoud SH, Abu Taha A, Araj KF, et al. Parental knowledge, attitudes and practices regarding antibiotic use for acute upper respiratory tract infections in children: a cross-sectional study in Palestine. *BMC Pediatr*. 2015;15:176. doi:10.1186/s12887-015-0494-5
7. Elong Ekambi GA, Okalla Ebongue C, Penda IC, Nnanga Nga E, Mpondo Mpondo E, Eboumbou Moukoko CE. Knowledge, practices and attitudes on antibiotics use in Cameroon: Self-medication and prescription survey among children, adolescents and adults in private pharmacies. *PLoS One*. 2019;14(2):e0212875. doi:10.1371/journal.pone.0212875
8. Mate I, Come CE, Gonçalves MP, Cliff J, Gudo ES. Knowledge, attitudes and practices regarding antibiotic use in Maputo City, Mozambique. Budhat-hoki SS, ed. *PLoS ONE*. 2019;14(8): e0221452. doi:10.1371/journal.pone.0221452
9. Rijal KR, Banjara MR, Dhungel B, et al. Use of antimicrobials and antimicrobial resistance in Nepal: a nationwide survey. *Sci Rep*. 2021; 11(1):11554. doi:10.1038/s41598-021-90812-4
10. Chowdhury M, Stewart Williams J, Wertheim H, Khan WA, Matin A, Kinsman J. Rural community perceptions of antibiotic access and understanding of antimicrobial resistance: qualitative evidence from the Health and Demographic Surveillance System site in Matlab, Bangladesh. *Glob Health Action*. 2019;12(sup1): 1824383. doi:10.1080/16549716.2020.1824383
11. Lim JM, Chhoun P, Tuot S, et al. Public knowledge, attitudes and practices surrounding antibiotic use and resistance in Cambodia. *JAC Antimicrob Resist*. 2021;3(1):dlaa115. doi:10.1093/jacamr/dlaa115
12. Waseem H, Ali J, Sarwar F, et al. Assessment of knowledge and attitude trends towards antimicrobial resistance (AMR) among the community members, pharmacists/pharmacy owners and physicians in district Sialkot, Pakistan. *Antimicrob Resist Infect Control*. 2019;8:67. doi:10.1186/s13756-019-0517-3
13. Khelgi A, Huchchannavar R, Mathew MM, Anandam S. Knowledge, attitude and practice regarding antibiotic use and antimicrobial resistance among the rural public in Mangaluru, India. *Journal of Preventive Epidemiology*. doi:10.34172/jpe.2022.26162
14. Chukwu EE, Oladele DA, Awoderu OB, et al. A national survey of public awareness of antimicrobial resistance in Nigeria. *Antimicrobial Resistance and Infection Control*. 2020;9(1):72. doi:10.1186/s13756-020-00739-0
15. Sindato C, Mboera LEG, Katale BZ, et al. Knowledge, attitudes and practices regarding antimicrobial use and resistance among communities of Ilala, Kilosa and Kibaha districts of Tanzania. *Antimicrob Resist Infect Control*. 2020;9(1):194. doi:10.1186/s13756-020-00862-y
16. Simegn W, Moges G. Awareness and knowledge of antimicrobial resistance and factors associated with knowledge among adults in Dessie City, Northeast Ethiopia: Community-based cross-sectional study. Aslam MS, ed. *PLoS ONE*. 2022;17(12): e0279342. doi:10.1371/journal.pone.0279342
17. Pattnaik M, Nayak AK, Karna S, et al. Perception and determinants leading to antimicrobial (mis)use: A knowledge, attitude, and practices study in the rural communities of Odisha, India. *Frontiers in public health*. 2022;10:1074154. doi:10.3389/fpubh.2022.1074154
18. Dejene H, Birhanu R, Tarekegn ZS. Knowledge, attitude and practices of residents toward antimicrobial usage and resistance in Gondar, Northwest

- Ethiopia. *One Health Outlook*. 2022;4(1). doi:10.1186/s42522-022-00066-x
19. Zahraa N. Fakhreldain, & Hayder CH. Assad. Factors Impacting Knowledge, Practice And Attitude About Antibacterial And Its Resistance By Cross Sectional Study In Iraq. *Journal of Pharmaceutical Negative Results*. 2022:562-571. doi:10.47750/pnr.2022.13.S01.68
 20. Pogurschi EN, Petcu CD, Mizeranschi AE, et al. Knowledge, Attitudes and Practices Regarding Antibiotic Use and Antibiotic Resistance: A Latent Class Analysis of a Romanian Population. *Int J Environ Res Public Health*. 2022;19(12):7263. doi:10.3390/ijerph19127263
 21. Kosiyaporn H, Chanvatic S, Issaramalai T, et al. Surveys of knowledge and awareness of antibiotic use and antimicrobial resistance in general population: A systematic review. *PLoS One*. 2020; 15(1):e0227973. doi:10.1371/journal.pone.0227973
 22. Spinei L, Ciobanu E, Balan G, Croitoru C, Tapu L, Ferdohleb A. The phenomenon of antibiotic resistance and people's knowledge. *One Health & Risk Management*. 2023:43-43. Available at: <https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/495> [Accessed: January 8, 2024].

MAPPING THE ANTIBIOTIC CONSUMPTION IN THE REPUBLIC OF MOLDOVA

Doina MACARI¹, Corina SCUTARI¹, Simona NEGRES², Mihail TODIRAS¹

¹Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

²Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Corresponding author: Doina Macari, e-mail: doina.macari@usmf.md

Keywords: mapping, antibiotic consumption, DDD, WHO, hospitals.

Introduction. Antibiotic consumption represents a crucial aspect of modern healthcare. Abuse and inappropriate use of antibacterial agents contribute to the phenomenon of bacterial resistance. The aim of the study was to determine antibiotic consumption in hospital conditions and map the results in order to highlight regions in the country with the highest levels of antibiotic consumption and the classes of antibiotics used.

Material and methods. Antibiotic consumption in hospitals (64 facilities) over a 4-year period (2018-2021) was determined using the defined daily dose (DDD) as the unit of measurement. The quantity of antibiotics consumed was expressed in DDD/1000 patient-days (hospitalization days), followed by mapping the results.

Results. A "very high" level of antibiotic consumption, expressed in DDD/1000 patient-days, was observed in the Falesti district, while a "medium" level of antibacterial agent consumption was observed in the Taraclia, Comrat, Ialoveni, Singerei, Glodeni, and Dondușeni districts. The total consumption per antibiotic class revealed an increased use of Cephalosporins, Imidazole derivatives, Macrolides, Tetracyclines, Fluoroquinolones, and Aminoglycosides.

Conclusions. Mapping antibiotic consumption is an efficient tool in highlighting administrative-territorial regions with high antibiotic consumption and identifying the most frequently used antibiotic classes. Providing this information is useful for developing policies aimed at optimizing antibiotic use and minimizing resistance.

Cuvinte-cheie: cartografiere, consum de antibiotice, DDD, OMS, spitale.

CARTOGRAFIEREA CONSUMULUI DE ANTIBIOTICE ÎN REPUBLICA MOLDOVA

Introducere. Consumul de antibiotice reprezintă un aspect crucial al asistenței medicale moderne. Abuzul și utilizarea necorespunzătoare a preparatelor antibacteriene favorizează fenomenul de rezistență bacteriană. Scopul studiului a fost determinarea consumului de antibiotice în condiții de staționar în Republica Moldova și cartografierea rezultatelor obținute.

Material și metode. În acest studiu a fost determinat consumul de antibiotice în condiții de staționar (64 de spitale), pe o perioadă de patru ani (2018-2021), folosind ca unitate de măsură doza zilnică definită (DDD). Cantitatea de antibiotice consumată a fost exprimată în DDD/1000 zile-pacient (zile de spitalizare), ulterior fiind efectuată cartografierea rezultatelor.

Rezultate. Rezultatele înregistrate atestă un nivel „foarte mare” de consum de antibiotice exprimat în DDD/1000 zile de spitalizare în raionul Fălești și un nivel „mediu” de consum de preparate antibacteriene în raioanele Taraclia, Comrat, Ialoveni, Singerei, Glodeni, Dondușeni. Consumul total per clase de antibiotice a scos în evidență un consum sporit de cefalosporine, de derivați de imidazol, de macrolide, de tetraciclone, de fluorochinolone și de aminoglicozide.

Concluzii. Cartografierea consumului de antibiotice reprezintă un instrument eficient de evidențiere a regiunilor administrativ-teritoriale în care consumul de antibiotice este ridicat, și a claselor de antibiotice cel mai frecvent utilizate. Aceste informații sunt utile pentru elaborarea de politici menite să optimizeze utilizarea antibioticelor și să minimizeze rezistența acestora.

INTRODUCTION

Antibiotics are crucial for treating infectious diseases, but bacterial resistance poses a rapidly increasing global threat. A key driver of resistance is antibiotic use (1). Monitoring antibiotic consumption patterns over time and across countries could inform policies aimed at optimizing antibiotic prescribing and minimizing antibiotic resistance. This may involve setting and enforcing per capita consumption targets or supporting investments in alternatives to antibiotics (2).

According to the European Centre for Disease Prevention and Control, hospital consumption represents only 9% of the overall European Union/European Economic Area (EU/EEA) total consumption of antibacterials for systemic use. The continued decline in consumption between 2020 and 2021 is not immediately apparent when hospital and community sectors are combined. The overall EU/EEA population-weighted mean consumption in the hospital sector decreased linearly by 0.04 DDD per 1,000 inhabitants per day between 2016 and 2019. The largest annual decrease occurred in 2020 (0.11 DDD per 1,000 inhabitants per day), followed by a reduction of 0.05 DDD per 1,000 inhabitants per day in 2021. At the country-level, eight countries experienced increases in hospital consumption between 2019 and 2020, and 11 had increases between 2020 and 2021. Five countries (Bulgaria, Croatia, Greece, Portugal, and Slovakia) had higher hospital consumption in 2021 than in 2019. The overall EU/EEA population-weighted proportion of Antimicrobial Medicines Consumption (AMC) from broad spectrum sub-groups also showed consecutive annual increases during the period 2019–2021. The largest annual increase in the past 10 years occurred between 2020 and 2021 (3).

In the Republic of Moldova, antibiotics constitute approximately 10% of the total number of medicines, with a prevalence of antibiotic consumption at 42.7%. National results, based on data regarding the antimicrobial resistance profile of microorganisms involved in systemic infections, indicate a high level of resistance. Isolates of *K. pneumoniae* show increased resistance to cephalosporins (>96%), fluoroquinolones (>50%), and aminoglycosides (>90%). For *A. baumannii*, the resistance profile to fluoroquinolones is 100%, carbapenems >90%, and aminoglycosides >95%. *E. coli* strains exhibit resistance rates of >80% to

penicillins, >65% to cephalosporins, and >55% to fluoroquinolones.

Currently, in the Republic of Moldova, 505 drugs are registered and classified according to the international code - ATC (Anatomical Therapeutic Chemical Classification) as systemic antibacterial agents. According to the Medicines and Medical Devices Agency (AMDM), there has been a constant increase in the number of antibiotics used in the last three years. In 2021, over 70 million packages were imported, representing a 10% increase compared to previous years, or over 20 boxes per capita within a year, which translates to almost two boxes per person per month (4, 5).

Therefore, there is a need to enhance the national surveillance system for antibacterial resistance and monitoring of antibiotic consumption both in hospital and outpatient settings. Studies on antibiotic consumption in hospital conditions in the Republic of Moldova are limited, which is why determining and mapping antibiotic consumption are crucial steps in preventing antibacterial resistance and promoting the rational use of antibiotics.

The aim of the study was to determine the consumption of antibiotics in hospitals in the Republic of Moldova and to map the results in order to highlight which regions of the country exhibit the highest levels of antibiotic consumption and the classes of antibiotics used.

MATERIAL AND METHODS

A comprehensive descriptive study was conducted to determine the consumption of antibacterial agents based on the geographical location of Public Health Institutions (IMSP) and the type of antibiotic delivered to IMSP.

The research utilized reports on the execution of public procurement contracts from the years 2018–2021, along with the number of hospitalization days of the healthcare units included in the study during the analyzed period.

The determination of antibacterial agent consumption was carried out in 64 IMSPs in the Republic of Moldova (the study did not include the Transnistrian region), using Defined Daily Dose (DDD) as the measurement unit recommended by the World Health Organization (WHO) for drug utilization studies (6).

The quantity of antibiotics consumed was expressed in DDD/1000 hospitalization days, with the DDD values from the 2022 version of the WHO's Anatomical Therapeutic Chemical Classification/Defined Daily Dose (ATC/DDD) system used for each antibiotic.

The practical calculation method of DDD/1000 patient days (hospitalization days) followed this algorithm:

Stage I: Examination of the antibacterial delivery report for each IMSP individually.

Stage II: Conversion of all concentrations into grams or million units (MU).

Stage III: Tabular insertion of columns: WHO DDD, and respective WHO DDD Unit.

Stage IV: Calculation of DDD.

Stage V: DDD calculation per 1000 hospitalization days.

Stage VI: Arrangement of antibacterial agents by classes.

Stage VII: The results obtained were entered into electronic databases and statistically processed using Microsoft Office Excel and IBM SPSS Statistics programs.

Based on the geographical location of IMSPs, the quantity of consumed antibiotics was centralized and distributed per district/municipality, followed by mapping the results.

Districts/municipalities were classified into 5 levels of antibiotic consumption based on the values obtained from the determination of DDD/1000 hospitalization days over the years 2018-2021.

Thus, the following levels were outlined: "very high" – 25.4-30 DDD/1000 hospitalization days, "high" – 20.7-25.4 DDD/1000 hospitalization days, "medium" – 16-20.7 DDD/1000 hospitalization days, "low" – 11.4-16 DDD/1000 hospitalization days, "very low" – 5-11.4 DDD/1000 hospitalization days.

RESULTS

After analyzing the distribution of districts/municipalities based on the level of antibiotic consumption, the research results revealed a "very low" level of antibacterial agent usage from 2018 to 2021 in the following districts of the Republic of Moldova (fig. 1): Cahul, Cimislia, Hincesti, Nisporeni, Straseni, Calarasi, Orhei, Telenesti, Rezina, Soldanesti, and in the Municipality of Balti.

The total antibiotic consumption in these districts

during the years 2018-2021 ranged between 5-11.4 DDD/1000 hospitalization days.

A "low" level of antibacterial agent consumption was recorded in the following districts: Cantemir, Leova, Basarabeasca, Stefan Voda, Causeni, Anenii Noi, Criuleni, Ungheni, Floresti, Soroca, Drochia, Edinet, Briceni, and in the Municipality of Chisinau.

The total antibiotic consumption in these districts during the years 2018-2021 ranged between 11.4-16 DDD/1000 hospitalization days.

A "medium" level of antibacterial agent consumption was recorded in the following districts: Taraclia, Comrat, Ialoveni, Singerei, Glodeni, and Donduseni.

The total antibiotic consumption in these districts during the years 2018-2021 ranged between 16-20.7 DDD/1000 hospitalization days.

Districts with a "high" level of antibiotic consumption, ranging between 20.7-25.4, were not identified.

A "very high" level of antibacterial agent consumption was recorded in Falesti district, where the total antibiotic consumption during the years 2018-2021 ranged between 25.4-30 DDD/1000 hospitalization days.

The trend of consumption for antibacterial preparations for the years 2018-2021 within the Public Health Institutions (IMSP) of the Republic of Moldova, as shown in Figure 2, is as follows:

- a) In 2018, the average total antibiotic consumption was 12.3 DDD/1000 hospitalization days.
- b) In 2019, the average total antibiotic consumption was 11 DDD/1000 hospitalization days.
- c) In 2020, the average total antibiotic consumption was 15.6 DDD/1000 hospitalization days.
- d) In 2021, the average total antibiotic consumption was 12.01 DDD/1000 hospitalization days.

Thus, there is an observed trend of increased antibiotic consumption in hospitals in the Republic of Moldova in 2020, a period associated with the COVID-19 pandemic. Additionally, in 2021, the trend of antibiotic preparations consumption is decreasing in the hospital sector, constituting 12.01 DDD/1000 hospitalization days.



Figure 1. Mapping the antibiotic consumption in the Republic of Moldova based on administrative-territorial zone for the years 2018-2021, Expressed in DDD/1000 hospitalization days.




Figure 2. The trend of antibiotic consumption for the years 2018-2021, expressed in DDD/1000 hospitalization days.

Thus, there is an observed trend of increased antibiotic consumption in hospitals in the Republic of Moldova in 2020, a period associated with the COVID-19 pandemic. Additionally, in 2021, the trend of antibiotic preparations consumption is decreasing in the hospital sector, constituting 12.01 DDD/1000 hospitalization days.

Regarding the classes of consumed antibacterial preparations, as shown in Figure 3, it is presented as follows:

a) In 2018, there was an increased consumption of antibiotics from the following classes: Cephalosporins (21.2 DDD/1000 hospitalization days), Imidazole derivatives (16.1 DDD/1000 hospitalization days), Quinolones (13.6 DDD/1000 hospitalization days), and Tetracyclines (14.4 DDD/1000 hospitalization days).

b) In 2019, there was an increased consumption of antibiotics from the following classes: Cephalosporins (18.4 DDD/1000 hospitalization days),

Tetracyclines (15.5 DDD/1000 hospitalization days), Imidazole derivatives (14.4 DDD/1000 hospitalization days), and Macrolides (10.4 DDD/1000 hospitalization days).

c) In 2020, there was an increased consumption of antibiotics from the following classes: Cephalosporins (25.6 DDD/1000 hospitalization days), Macrolides (21.7 DDD/1000 hospitalization days), Tetracyclines (19.7 DDD/1000 hospitalization days), and Imidazole derivatives (15 DDD/

1000 hospitalization days).

d) In 2021, there was an increased consumption of antibiotics from the following classes: Cephalosporins (17.4 DDD/1000 hospitalization days), Fluoroquinolones (15.4 DDD/1000 hospitalization days), Macrolides (12.9 DDD/1000 hospitalization days), Nitrofurantoin derivatives (9.9 DDD/1000 hospitalization days), and Aminoglycosides (9.5 DDD/1000 hospitalization days).




Figure 3. The consumption per class of antibiotics for the years 2018-2021, expressed in DDD/1000 hospitalization days.




Figure 4. The total consumption per class of antibiotics for the years 2018-2021, expressed in DDD/1000 hospitalization days.

Following the centralization of data for the years 2018-2021, the total consumption per class of antibiotics highlighted an increased consumption for the following antibiotic groups (fig. 4): Cephalosporins (20.5 DDD/1000 hospitalization days), Imidazole derivatives (14.1 DDD/1000 hospitalization days), Macrolides (13.8 DDD/1000 hospitalization days), Tetracyclines (13.2 DDD/1000 hospitalization days), Fluoroquinolones (11.2 DDD/1000 hospitalization days), and Aminoglycosides (9.4 DDD/1000 hospitalization days).

DISCUSSIONS

Providing reliable national data on the consumption of antibacterial agents is mandatory to understand the epidemiology of antibiotic resistance, as antibiotic misuse is a key factor promoting bacterial resistance (5). While the majority of antibiotics are used in outpatient settings, the administration of antibiotics in hospitals is a major driver for the spread of multidrug-resistant bacteria responsible for nosocomial infections.

Thus, the conducted study serves as an efficient tool in providing valuable information for the development of new policies to prevent and combat nosocomial infections. The determined consumption levels reflect the situation only in hospital conditions; for a more comprehensive overview,

it is necessary to assess antibiotic consumption in outpatient settings as well.

Regarding the antibiotic classes used in hospitals during the years 2018-2021, there is a predominant high consumption for antibiotics in the following classes: Cephalosporins, Imidazole derivatives, Macrolides, Tetracyclines, and Fluoroquinolones, and lower consumption for antibiotics in the classes: Amphenicols, Polymyxins, Carbapenems, Glycopeptides, and Lincosamides. The trend in antibiotic consumption is decreasing for the year 2021 by 23% compared to 2020.

Studies on antibiotic consumption are limited, as a major challenge in conducting these studies is the lack of data on antibiotic consumption in low- and middle-income countries (7). Strengthening national networks in the field of antimicrobial resistance and expanding subsequent participation in global and regional networks will enable the Republic of Moldova to adjust quality standards and operational procedures to international rigor and obtain comparable, standardized, and accurate data for evidence-based decision-making (4). Currently, monitoring of antimicrobial consumption relies on import data, and there is a clear need for the use of additional data sources, such as retail trade, including disaggregation by community and hospital sectors.

CONCLUSIONS

1. Mapping antibiotic consumption represents an efficient tool for highlighting the administrative-territorial regions with increased antibiotic use, contributing to the improvement of the national system for monitoring antimicrobial resistance and antibiotic consumption based on contemporary approaches. The study reveals a "very high" level of antibiotic consumption expressed in DDD/1000 hospitalization days in Falesti district and a "medium" level of antibacterial preparations consumption in the districts of Taraclia, Comrat, Ialoveni, Singerei, Glodeni, and Donduseni. Continuous monitoring of antibiotic consumption trends provides important information to competent authorities for implementing measures to reduce irrational antibiotic use, thereby decreasing the risk of resistant bacterial strains.
2. Determining the consumption of antibacterial preparations used in a hospital setting is an important step in estimating the costs associated with acquiring these preparations. It can signal the onset of bacterial resistance to certain classes of antibiotics and serve as an efficient tool to limit the misuse of drugs from a specific antibiotic class.

CONFLICT OF INTEREST

Authors have no conflict of interest to declare.

ETHICAL APPROVAL

Favorable opinion from the Research Ethics Committee No. 5 dated 12.07.2022, ref. no. 42 dated 26.05.2022, for the scientific research pro

ject titled: "Evaluation of antibiotic consumption and rational use of antibacterial preparations in hospitals."

ACKNOWLEDGMENTS

The authors would like to thank the Center for Centralized Public Procurement in Health for providing data on drug deliveries and to the

National Agency for Public Health for providing data on hospitalization days. The research was conducted within the multinational project *PhageLand*, "Phage treatment and wetland technology as an intervention strategy to prevent the dissemination of antibiotic resistance in surface

waters (*PhageLand*)," project code 22.80013.8007.1M.

The *PhageLand* project is funded through the Horizon Europe program under the JPI Antimicrobial Resistance mechanism.

REFERENCES

1. Versporten A, Gyssens IC, Pulcini C, Monnier AA, Schouten J, Milanič R, et al. Metrics to assess the quantity of antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. *J Antimicrob Chemother*. 2018;73(suppl_6):vi59-66. doi:10.1093/jac/dky119
2. Klein Eili Y, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. R. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015, *Proc Natl Acad Sci U S A*. 2018;115(15):E3463-E3470. doi:10.1073/pnas.1717295115
3. European Centre for Disease Prevention and Control. *Antimicrobial consumption in the EU/EEA (ESAC-Net) - Annual Epidemiological Report 2021*. Stockholm: ECDC; 2022. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/ESAC-Net_AER_2021_final-rev.pdf [Accessed January 7, 2024].
4. Programul național pentru supravegherea și combaterea rezistenței la antimicrobiene pe anii 2023-2027 [National Program for Surveillance and Control of Antimicrobial Resistance for 2023-2027]. Available at: https://gov.md/sites/default/files/document/attachments/subiect-09-nu-463-ms-2023_0.pdf [Accessed January 7, 2024].
5. Macari D, Scutari C, Todiraș M, Ferdohleb A. *Metodologia determinării formulei de calcul a consumului de antibiotice în spitale: Recomandări metodice* [Methodology for determining the formula for calculating antibiotic consumption in hospitals: Methodical recommendations]. Chișinău: "Print Caro", 2023. Available at: https://repository.usmf.md/bitstream/20.500.12710/25230/1/METODOLOGIA_DETERMINARII_DDD.pdf [Accessed January 7, 2024].
6. Negreș S, Zbârcea CE, Chiriță C, Ștefănescu E, Paul MD, Șeremet OC, et al. *Doza zilnică definită (DDD) unitate de măsură a consumului de medicamente în farmacia de spital și în farmacia de comunitate* [Defined daily dose (DDD) unit of measurement of drug consumption in hospital and community pharmacy]. Farmacia etică: istorie, realități și perspective. Chișinău, 2018. https://ibn.idsi.md/vizualizare_articol/124831 [Accessed January 7, 2024].
7. Browne AJ, Chipeta MG, Haines-Woodhouse G, Kumaran EPA, Hamadani BHK et al. Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study. *Lancet Planet Health*. 2021;5(12):e893-e904. doi:10.1016/S2542-5196(21)00280-1

RATIONAL USE OF ANTIBACTERIALS IN PLEURAL EMPYEMA

Nicolae BACINSCHI¹, Anastasia CARACAS¹, Svetlana LATUS¹, Eugenia VASILACHE^{1,2}

¹Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

²Gheorghe Paladi Municipal Clinical Hospital, Chisinau, Republic of Moldova

Corresponding author: Anastasia Caracas, e-mail: anastasia.caracas@usmf.md

Keywords: pleural empyema, antibacterial drugs, pathogenic flora, rational use.

Introduction. Pleural empyema remains a significant cause of morbidity and mortality globally. The rising incidence of this complex pathology necessitates an evaluation of diagnostic methods, surgical treatment, and antibiotic therapy strategies.

Material and methods. We selected and analyzed 50 observation records of patients with pleural empyema admitted to the thoracic surgical ward at Timofei Mosneaga Republican Clinical Hospital. A literature review was conducted to elucidate the rationale behind the administration of antibacterial treatment.

Results. Bacteriological examination of the pleural fluid revealed the presence of pathogenic flora, predominantly gram-negative (15 cases) - *P. aeruginosa*, *Acinetobacter*, *K. pneumoniae*, *E. aerogenes*, *S. marcescens*, *Corynebacterium*, *P. mirabilis*, and in 5 cases, a polymicrobial etiology was observed. Evaluation of microbial susceptibility allowed for a rational choice of antibacterial treatment. Beta-lactam antibiotics were most frequently administered, either in monotherapy or in combination. Other groups of antibacterials administered included fluoroquinolones, aminoglycosides, macrolides, polymyxins, nitroimidazole derivatives, and glycopeptides.

Conclusions. Effective and harmless antibacterial treatment can only be achieved by identifying the causative pathogens and their antimicrobial susceptibility, ensuring adequate concentrations in the pleural space, determining the routes of administration, the duration of therapy, and the rational combination of antimicrobials.

Cuvinte-cheie: empiem pleural, antibacteriene, floră patogenă, utilizare rațională.

UTILIZAREA RAȚIONALĂ A ANTIBACTERIENELOR ÎN EMPIEMUL PLEURAL

Introducere. Empiemul pleural continuă să fie o cauză importantă de morbiditate și de mortalitate în lume, iar creșterea incidenței acestei patologii complexe necesită o evaluare a metodelor de diagnostic, de tratament chirurgical și a strategiilor de antibioterapie.

Material și metode. Au fost selectate și analizate 50 de fișe de observație ale pacienților cu empiem pleural internați în Secția chirurgie toracică a IMSP SCR „Timofei Mosneaga”. Pentru elucidarea raționalității administrării tratamentului antibacterian a fost efectuat review-ul literaturii.

Rezultate. Examenul bacteriologic al lichidului pleural a permis depistarea florei patogene, preponderent floră gramnegativă (15 cazuri) - *P. aeruginosa*, *Acinetobacter* spp., *K. pneumoniae*, *E. aerogenes*, *S. marcescens*, *Corynebacterium* spp., *P. mirabilis*, iar în cinci cazuri - de etiologie polimicrobiană. Evaluarea sensibilității microorganismelor la antimicrobiene a permis alegerea rațională a tratamentului antibacterian. Cel mai frecvent, în monoterapie sau în combinație, au fost administrate antibioticele beta-lactamice. De asemenea au fost administrate antibacteriene din următoarele grupe: fluorochinolone, aminoglicozide, macrolide, polimixine, derivați de nitroimidazol, glicopeptide.

Concluzii. Tratamentul antibacterian eficient și inofensiv în emfizemul pleural poate fi realizat doar prin stabilirea agenților patogeni etiologici și a sensibilității lor la preparatele antimicrobiene, asigurarea unor concentrații adecvate în spațiul pleural, determinarea căilor de administrare, duratei curei de tratament, asocierea rațională de antimicrobiene.

INTRODUCTION

Pleural infections present a significant challenge for medical practice and public health, with a mortality rate of 10-20%, and even 35% in elderly and immunocompromised patients. Recent epidemiological data has indicated a global increase in the incidence of pleural infections, attributed to factors such as the growing elderly population with multiple chronic comorbidities, frequent use of immunosuppressive medications, evolution of pathogenic microbial flora and bacterial resistance, and improved accessibility of diagnostic methods, including in outpatient settings. The treatment of pleural infections is considered one of the most expensive among all lung infections. Various causes of pleural infections have been identified, including community-acquired and hospital-acquired pneumonia, lung abscess, chest injuries and trauma, bronchopleural fistula, esophageal perforation, post-surgical complications, bronchogenic cancer, immunocompromised conditions, post-operative infections, patients on hemodialysis, and those undergoing antitumor therapy. The subacute onset of the pathology leads to delayed admission of patients to specialized medical services and thus the therapeutic management of pleural empyema is associated with long duration of hospitalization, significant use of healthcare resources, long-term antibiotic therapy, chest tube drainage, and/or surgery. While mortality from pleural infections has decreased considerably in the antibiotic era, the increased use of antimicrobial preparations, including irrational use, has led to a rise in bacterial resistance, as evidenced by the epidemics and pandemics of the early 21st century (SARS CoV, MRES, Ebola, SARS CoV-2, etc.). In this context, it is imperative to adjust the antibacterial therapy of pleural infections by addressing several key questions, such as the selection of antibacterial preparations for empirical therapy, improvement of methods for detecting pathogens and their susceptibility to antimicrobial preparations, determination of optimal routes of antibiotic administration and duration of antibacterial treatment, rationality of stepwise antibacterial therapy, pharmacokinetic studies on drug penetration into the site of infection, ensuring sufficient inhibitory concentrations to combat pathogens, and advocating for combinations of antimicrobial preparations (1 - 4).

The aim of the study was to analyze the spectrum

of pathogens causing pleural empyema and their susceptibility to antimicrobial preparations, to characterize the groups of antibacterial preparations used, the duration of antibacterial treatment, and to justify the prescription of antimicrobial preparations based on pharmacokinetic data.

MATERIAL AND METHODS

The study was retrospective, involving the selection and analysis of 50 medical records of patients with pleural empyema as the primary (46 cases) or secondary (4 cases) clinical diagnosis, with or without fistulas, who were admitted to the thoracic surgery ward at the *Timofei Mosneaga* Republican Clinical Hospital. Bacteriological results from the medical records were analyzed to identify pathogens and their sensitivity to antibacterial preparations, and the prescription records were examined to analyze the antibiotics and synthetic chemotherapeutic agents used in the treatment. Additionally, relevant literature on antibacterial treatment for pleural infections was selected and analyzed in the PubMed database using keywords such as pleural infection, pleural empyema, pathogens, antibiotics, and bacterial resistance.

RESULTS

Based on the analysis of the medical records, it was found that the average age of the patients was 58 years (ranging from 31 to 77 years), with a predominance of male patients (41 males and 9 females). The duration of hospitalization ranged from 4 to 35 days, with an average of 12 days, and 8 patients required transfer to other wards, including intensive care. The causes of pleural empyema included pneumonia (29 cases), chest trauma (7 cases), pulmonary gangrene (4 cases), post-surgical infection (4 cases), lung abscess (2 cases), healthcare-associated empyema (2 cases), mesothelioma (1 case), and sepsis (1 case). The study was retrospective, and as a result, the data from observation records were not sufficient to differentiate between hospital-acquired and community-acquired etiologies.

The bacteriological examination of pleural fluid was conducted in all patients included in the study to identify the pathogen and antibacterial susceptibility. Our results indicate that bacterial growth was present in the pleural fluid in only

28 cases (56%). Among these, a single pathogen was identified in 23 cases (82.2%), while the etiology was polymicrobial in 5 cases (17.8%). Gram-positive flora (including *Staphylococcus aureus*-5, *Staphylococcus hominis*-1, *Staphylococcus epidermidis*-1, *Actinomyces odontolyticus*-1) was identified in 8 patients, and gram-negative flora (including *Pseudomonas aeruginosa*-8, *Acinetobacter*-1, *Klebsiella pneumoniae*-2, *Enterobacter*-1, *Serratia marcescens*-1, *Corynebacterium*-1, *Proteus mirabilis*-1) was found in 15 patients. The predominance of gram-negative agents and *Staphylococcus aureus* suggests that the pathogenic flora of the pleural infection was most likely acquired in a hospital setting.

The analysis of bacterial susceptibility results to antibacterial preparations revealed a high resistance of the identified agents. Specifically, *Staphylococcus aureus* MRSA was found to be pan-drug-resistant, *Pseudomonas aeruginosa* exhibited polyresistance, with sensitivity only to colistin or amikacin, *Enterococcus faecium* showed sensitivity to vancomycin, and *Corynebacterium* was sensitive to linezolid.

Antibacterial treatment was administered to 45 patients, with 17 receiving a single antimicrobial preparation and 28 receiving a combination of two or more antibacterials. Among these patients, bacterial growth was not observed in the pleural fluid of 3 individuals, and following surgery, their clinical condition improved, leading to a recommendation for continued antibacterial treatment at home. In 2 patients with detected pathogenic flora, no antibacterials were prescribed as the condition improved after pleural cavity drainage. The results of the bacteriological examination of pleural fluid prompted a modification of the drug regimen. The absence of bacterial growth in the pleural fluid may be attributed to the administered antibacterial treatment or to the presence of anaerobic agents, the identification of which is challenging using standard tests. Considering the advantageous nature of anaerobic infection growth in pleural fluid, the use of an antibacterial drug with a spectrum of action against anaerobic agents is essential. The study identified the use of metronidazole, meropenem, cefoperazone, ceftazidime, and piperacillin as monotherapy or combination therapy, providing coverage against anaerobic agents in 29 cases.

Based on the analysis of the prescription records,

the following medications were prescribed to patients with pleural empyema: beta-lactams (49); fluoroquinolones (9); aminoglycosides (11); polymyxins (4); macrolides (2); glycopeptides (1); and nitroimidazole derivatives (12). Among the beta-lactams, penicillins with beta-lactamase inhibitors were used in 16 cases (amoxicillin+clavulanic acid-9, piperacillin+tazobactam-7), second-generation cephalosporins (cefuroxime-4), and third-generation cephalosporins alone (ceftriaxone-4, cefotaxime-5) or in combination with beta-lactamase inhibitors (cefoperazone+sulbactam-14, ceftazidime+avibactam-5), as well as carbapenems (meropenem-3). Fluoroquinolones such as ciprofloxacin (7), levofloxacin (1), and moxifloxacin (1) were also used. Additionally, aminoglycosides like gentamicin (4) and amikacin (7), polymyxins specifically colistin (4), macrolides such as azithromycin (2), glycopeptides like vancomycin (1), and nitroimidazole derivatives like metronidazole (12) were prescribed.

In our study, the third generation of cephalosporins was the most frequently used beta-lactams (56% of cases). Their broad spectrum of action, which covers aerobic gram-positive, gram-negative (including anti-pseudomonas preparations such as cefoperazone and ceftazidime), and anaerobic bacteria, allows for effective coverage of the pathogenic flora commonly associated with pleural infections. Penicillins with beta-lactamase inhibitors were used in 15 cases either as monotherapy or in combination with other antibacterials. Amoxicillin+clavulanic acid, with its broad spectrum of action against predominantly aerobic bacteria, was frequently administered concomitantly with metronidazole to provide anti-anaerobic action. Patients showed negative bacteriological results, and the average duration of intravenous administration was 7 days. Piperacillin+tazobactam was used in 7 patients, either alone or in combination, for its anti-pseudomonas action as well as its anaerobic spectrum. An important issue is the increased resistance of *Pseudomonas aeruginosa*, *Enterobacteriaceae*, *Acinetobacter* spp, and *Klebsiella* spp, as detected in the bacteriological examination of pleural fluid in patients treated with beta-lactam antibiotics. Combining them with beta-lactamase inhibitors extends their spectrum and increases efficacy. Meropenem, with its ultra broad spectrum of action against both gram-positive and gram-negati-

ve aerobic and anaerobic bacteria, can therefore be used in polymicrobial pleural infections.

According to the results of the bacteriological examination of pleural fluid, aminoglycoside-sensitive pathogens were identified, including *Staphylococcus hominis*, *Staphylococcus epidermidis*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*, leading to the intravenous use of gentamicin or amikacin in 13 patients diagnosed with pyothorax. Gentamicin and particularly amikacin demonstrate activity against gram-negative aerobic flora and less activity against gram-positive flora, although this may be enhanced when combined with beta-lactams. Amikacin is considered to be an aminoglycoside with higher efficacy against *Pseudomonas aeruginosa*, attributed to its resistance to enzymes produced by microbes.

Vancomycin was administered in combination with amoxicillin/clavulanic acid to a patient whose pleural fluid showed growth of both *Enterococcus faecalis* (susceptible to amoxicillin/clavulanic acid, ampicillin, nitrofurantoin, ofloxacin, piperacillin/tazobactam, and vancomycin) and *Enterococcus faecium* (susceptible to linezolid, nitrofurantoin, and vancomycin). Creatinine values were monitored during treatment and showed insignificant variations. The patient was discharged with clinical improvement and recommended internal administration of ampicillin 500 mg twice daily (sources recommend administration every 6 hours-4 times daily).

Colistin was administered to 2 patients with polymicrobial pyothorax (*P. aeruginosa* with *Acinetobacter* and *P. aeruginosa*, *K. pneumoniae*, *P. mirabilis*, *S. saprophyticus*) and to 2 patients with *P. aeruginosa* in pleural fluid, susceptible to colistin. The disease progression in these patients was severe, requiring an average hospitalization period of 30 days, repeated surgical interventions for diagnostic and therapeutic purposes, and stays in 2 or 3 hospital wards during their hospitalization. Combined antibacterial therapies were ineffective, and colistin administration was the final treatment option. One patient received both inhaled and intravenous administration. The optimal dosing regimen is the administration of 9 million units per day, considering the severity of the pleural pathology.

Due to the diversity of causative pathogens and the presence of mixed flora (aerobic, anaerobic, fungal) in the treatment of pyothorax, it is recom-

mended to administer antibiotics with a spectrum of action against anaerobic agents, such as metronidazole. Metronidazole-resistant anaerobic bacteria (*Actinomyces odontolyticus*) and facultatively anaerobic bacteria (*Proteus mirabilis*, *Serratia marcescens*), which are not covered by the spectrum of action of metronidazole, were identified in the study. The dosing regimen, to ensure efficacy, involves administration of 500 mg internally or intravenously every 8 hours. In the study, metronidazole was administered intravenously in 10 cases, with a 100 ml of 5% solution twice daily, and internally in 2 cases, with 500 mg administered twice daily at 12-hour intervals.

DISCUSSIONS

The agents of community-acquired pleural infection included *Streptococcus viridans*, *Streptococcus pneumoniae*, methicillin-sensitive *Staphylococcus aureus* (MSSA), *Enterobacteriaceae*, *Klebsiella*, and *Pseudomonas*. Hospital-acquired infections involved methicillin-resistant *Staphylococcus aureus* (MRSA), *Enterobacteriaceae*, *Enterococcus*, *Streptococcus viridans*, *Pseudomonas*, and *Klebsiella*. Additionally, atypical flora (*Mycoplasma* spp., *Legionella* spp.) and fungal flora (*Candida*, *Aspergillus*) were rarely found, especially in immunocompromised patients. Anaerobic infections, which are difficult to detect, were thought to accompany pleural infection in about 25% of cases (1-5).

Pleural infection caused by resistant pathogens was found in 37% of isolates from community-acquired infections and 77% of isolates from hospital-acquired infections, which were resistant to at least one of the prescribed antibiotics for respiratory infections. The high rate of resistant bacteria limits therapeutic options, and in *vitro* susceptibility of pathogens does not always correlate with the therapeutic efficacy of antibacterials, given the importance of pharmacokinetic features (1, 2).

Prompt initiation of antimicrobial therapy is crucial for the treatment of pleural infection. The initial selection of antibacterials is empirical, based on the etiology of the pathology (community-acquired, hospital-acquired), the patient's condition, and clinical manifestations (2, 6).

For the selection of antibacterial therapy in a patient with pleural empyema, it is necessary to evaluate patient-dependent factors, pathology-

dependent factors, and the characteristics of the drug, which may influence the disease's progression and response to treatment. Among patient-dependent factors, it is essential to consider age, comorbidities, previous antibacterial treatment, and so on. Among pleural pathology-dependent factors, the stage of empyema, pleural effusion size, pleural thickening, degree of pleural inflammation, and duration of symptom onset to hospital admission are important. Significant characteristics of the antimicrobial preparation include its spectrum and mechanism of action, dose- and time-dependent antibacterial effect, duration of action and dosing regimen, pharmacokinetic properties, ability to penetrate pleural fluid, availability of parenteral and enteral forms, and adverse reactions (4).

In pleural infections, pleural effusions can rapidly progress from uncomplicated parapneumonic effusions to empyema. During the exudative stage of empyema, pleural fluid accumulates due to increased permeability of the visceral pleura. As the infection progresses, fibrin accumulation on the pleural membranes leads to pleural thickening and septum formation. When pyothorax develops, the pleural fluid becomes more acidic and purulent due to inflammation, and there is an increased flow of protein into the pleural space. Consequently, the penetration of antibiotics may be difficult due to the thickened pleura, with pleural fluid characteristics varying depending on the stage of pleural empyema. Mesothelial cells, which line the pleural cavity, play a crucial role in the filtration of pleural fluid, as it results from differences in hydrostatic and colloid-osmotic pressure between the pleural fluid and capillary blood. Furthermore, it has been suggested that mesothelial cells have the ability to reabsorb antibiotics (6, 7).

Cephalosporins are commonly prescribed and administered as first-line therapy for respiratory, urinary, and CNS infections, spanning from mild to severe, due to their broad spectrum of action, bactericidal effect, and low risk of adverse reactions. However, widespread use has led to the development of resistance to these drugs. The microorganisms mainly involved in conferring resistance to this antibiotic can be identified by the acronym *ESCKAPE*, which stands for *Enterococcus faecium*, *Staphylococcus aureus*, *Clostridium difficile*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacte*

riaceae. The rapid emergence of this resistance poses a serious threat to the continuous relevance of the antibiotic (8).

First-generation fluoroquinolones (such as ciprofloxacin) exhibit greater activity against gram-negative flora and moderate activity against atypical agents and gram-positive cocci. They also possess advantageous pharmacokinetic properties, allowing for effective penetration into body fluids and tissues, and maintenance of bactericidal concentrations for 12-24 hours. Moxifloxacin, on the other hand, demonstrates activity against both Gram-positive and Gram-negative bacilli, including anaerobes. In both animal and human studies, moxifloxacin has shown favorable pleural penetration and could be considered as a de-escalation option, particularly for internal administration (3, 9).

Polymyxins demonstrate significant activity against aerobic Gram-negative bacteria, including most pathogens of the *Enterobacteriaceae* family, such as *E. coli*, *Enterobacter*, *Klebsiella*, *Citrobacter*, *Salmonella*, and *Shigella*. They are also effective against common Gram-negative non-fermentative pathogens, including *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Gram-negative bacteria that are naturally resistant to polymyxins include *Pseudomonas mallei*, *Morganella morganii*, *Vibrio cholerae*, *Serratia marcescens*, *Proteus spp.*, *Providencia spp.*, *Burkholderia cepacia*, *Chromobacterium spp.*, *Edwardsiella spp.*, *Legionella*, *Brucella*, and *Campylobacter*. Polymyxins are not active against gram-negative cocci (*Neisseria spp.*), Gram-positive and anaerobic bacteria, parasites, or fungi. Orally administered polymyxins are used only for disinfection of the digestive tract due to poor absorption when taken internally. Additionally, polymyxins do not efficiently diffuse into tissues or penetrate the cerebrospinal fluid, pleural and peritoneal cavities. However, they are used systemically by intravenous administration for serious infections caused by pathogens resistant to other therapies. Carbapenem-resistant *Enterobacteriaceae*, *Pseudomonas aeruginosa*, and multidrug-resistant or pan-drug-resistant *Acinetobacter baumannii* pose major problems for antimicrobial therapy due to extremely limited treatment options. Polymyxins, along with fosfomycin, ceftazidime/avibactam, and the recently approved meropenem-vaborbactam, are among the last-resort antibiotics that are still effective against such pathogens (10, 11).

Along with aminoglycosides, polymyxins can be administered by inhalation. In ICU patients, pneumonia caused by carbapenem-resistant gram-negative bacteria is a frequent and serious complication. When treating lower respiratory tract infections, the pulmonary penetration of antimicrobials is considered an important factor that can affect their efficacy. For patients with pneumonia caused by multidrug-resistant bacteria, the intravenous administration of colistin combined with nebulized inhalation is more effective than intravenous infusion alone. However, the utility of polymyxins is currently facing increasing resistance worldwide, mainly due to the plasmid-encoded colistin resistance gene present in pathogens such as *Escherichia coli* and *Klebsiella pneumoniae* (10, 11).

Macrolides, including azithromycin, may be recommended for coverage of atypical microorganisms. They have a minor role in the etiology of pleural empyema, which is why they are rarely recommended as empirical therapy (4).

In community-acquired pleural infection, antibiotic regimens typically include either parenteral second or third-generation cephalosporins (e.g., ceftriaxone) combined with metronidazole for anaerobic coverage, or a β -lactam/ β -lactamase inhibitor combination (e.g., amoxicillin-clavulanic acid) in monotherapy. For patients with penicillin allergy, moxifloxacin used alone or a combination of levofloxacin and metronidazole are optimal therapeutic alternatives. In hospital-acquired pleural infection, antipseudomonal and anti-anaerobic antibiotics are required. Appropriate combinations include cefepime-metronidazole, piperacillin-tazobactam, or carbapenem. Additionally, coverage of *S. aureus* with vancomycin or linezolid should be considered (12, 13).

The therapeutic efficacy of antibacterials administered to patients with pleural empyema is determined by their ability to penetrate the pleural space and provide a concentration that reaches or exceeds the minimum inhibitory concentration (MIC) at the site of infection. Penetration of antibiotics into the lung follows various mechanisms, such as passive diffusion (β -lactams), permeation (macrolides), and active transport (quinolones, clindamycin). The differences in these mechanisms lead to variations in antimicrobial concentration between pulmonary sites and serum. For example, aminoglycosides are hydro-

philic, so they can enter cells very slowly via endocytosis and accumulate almost entirely in lysosomes. Macrolides enter the lungs through membrane penetration, and the rate is limited by the degree of lipid solubility. Quinolones and clindamycin penetrate cell membranes by active, energy-dependent transport and therefore can be saturated, leading to differences between serum and tissue levels. Another important pharmacokinetic parameter is the ability of antibiotics to penetrate pleural fluid. Studies recommend the use of β -lactams in the treatment of pleural empyema, demonstrating efficacy due to high penetration into pleural fluid (1, 3, 4, 14, 15).

It has been suggested that antibiotic levels in pleural fluid are lower than those in serum in patients with empyema, due to the lower permeability of the thickened pleura and the more acidic local environment. However, during acute infection characterized by inflammation, vasodilation, edema, and increased membrane permeability, the penetration of antimicrobial agents may be enhanced. In this context, for the assessment of antibiotic penetration into the pleural space, special and careful consideration should be given to the underlying pathophysiology and mechanisms of fluid formation. In empyema, during the exudative stage, pleural fluid accumulates in the pleural space due to inflammation and increased permeability of the visceral pleura. Progression of infection, bacterial invasion of the pleural space, fibrin deposition on pleural membranes, and the formation of septations cause thickening of the pleura and loss of elasticity. Regarding malignant effusions, an exudate predominantly forms due to the deregulation of pleural space drainage caused by the obstruction of blood and lymphatic vessels in the lungs and pleura. These features would determine the penetration of antimicrobial agents into the pleural fluid depending on the etiology and pathophysiological mechanisms. Based on the reported results, it was concluded that there is very little difference between chemically different antimicrobial agents in their degree of pleural penetration (16).

Most antibiotics exhibit good lung penetration. Blood concentrations of ampicillin and penicillin G were higher than those in lung sites. The pulmonary and blood concentration ratios of orally and intravenously administered amoxicillin and cefotaxime were greater than 1 at 5-6 hours after the last dose. Oral administration or intravenous in

fusion of linezolid and levofloxacin resulted in higher concentrations in pleural fluid than in serum. The higher concentration of the drug at the sites of infection compared to that in the blood may be associated with changes arising from the inflammatory process. Inflammatory conditions cause vasodilation of capillaries and loss of selectivity of penetration of large molecules through membrane cells. Increased membrane permeability facilitates the ability of antibiotics to penetrate the lung. The degree of expression of inflammation and the stage of empyema may influence lung penetration capacity, as demonstrated by the use of β -lactams, clindamycin, oleandomycin, and erythromycin. Lung penetration decreases with a reduction in the expression of the inflammatory process (14).

In pharmacokinetic studies, the penetration of antibiotics into the pleura is assessed by calculating the ratio of the total area under the curve (AUC) for the concentration of a given antibiotic in the pleural fluid to the serum concentration. In an experimental pleural empyema model in animals, penicillin exhibited the highest pleural fluid to serum AUC ratio (AUCLP/S), followed by metronidazole, ceftriaxone, and clindamycin. Most studies have indicated that aminoglycosides have poor pleural penetration and are inactivated by the acidic environment of the infected pleural space. Gentamicin had the lowest ratio in this study. Therefore, due to the low pleural penetration and the tendency of aminoglycosides to be inactivated in the acidic environment of the infected pleural space, this group is not recommended for the management of pleural infections. In a study of humans with parapneumonic effusions, ceftriaxone concentration remained above the minimum inhibitory concentration level for most susceptible organisms for 53 hours after a single parenteral dose. In patients with *Staphylococcus aureus* MRSA mediastinitis given linezolid, the drug had an AUCLP/S of 1.64, suggesting that it is a rational therapeutic option in resistant pleural infections (2, 4, 5, 13).

Fluoroquinolones, antimicrobial preparations with a large volume of distribution, exhibit extensive tissue penetration. The respiratory fluoroquinolones, moxifloxacin or levofloxacin, are recommended as initial empirical antibiotic therapy for patients with respiratory infections, including pleural effusion, due to their high activity against gram-positive and gram-negative bacteria, in-

cluding anaerobes. Several studies have investigated ciprofloxacin penetration into pleural fluid. Analysis of the structure of moxifloxacin, specifically the absence of the piperazinyl ring, revealed that the antimicrobial activity is not affected by acidic conditions. Thus, novel fluoroquinolones, including moxifloxacin, may be an attractive treatment option for pleural infections. The study determined inter-individual variability in moxifloxacin pharmacokinetics due to patient condition, concomitant drug administration, and competition for the same metabolic pathways. Examination of similar pharmacokinetic parameters (C_{max} , AUC) confirmed moxifloxacin's ability to penetrate tissue compartments independent of the degree of inflammation or pH reduction. Therefore, the empirical use of moxifloxacin in the treatment of parapneumonic effusion and empyema is supported by its sufficient penetration into the pleural space and a favorable pharmacokinetic profile, regardless of the origin of pleural fluid (15).

There are few reports describing vancomycin penetration into the pleural cavity, and the available data are inconclusive. In pleural empyema, the parietal pleura, which consists of the mesothelial cells lining the pleural cavity, may already be thickened, and the minimum inhibitory concentration (MIC) of vancomycin may not be sufficient for a bactericidal effect. However, other studies report the efficacy of vancomycin administration in patients with pleural empyema caused by sensitive gram-positive bacteria. In some countries, increasing cases of resistance have been observed, especially in enterococci, including multiresistant strains of *Enterococcus faecium* (7).

An important clinical issue is the duration of antibacterial treatment. The duration of antimicrobial therapy in pleural infection is an area lacking in evidence and is largely based on expert opinion and extrapolation from recommendations for the treatment of lung abscess. The recommended duration ranges from 2 to 6 weeks, and the authors suggest a minimum of 4 weeks (including both intravenous and oral treatment). Discontinuation of treatment (less than 2 weeks) increases the risk of recurrence. However, the duration should be guided by the response to therapy, improvement in clinical symptoms, positive dynamics and/or radiographic resolution, and improvement in laboratory markers of infection (2-4, 6, 13).

Another issue that needs to be assessed is the optimal time to switch from intravenous to oral antibiotics or to perform de-escalation therapy (stepwise). This could be done in the context of analyzing the clinical response and biochemical parameters and could coincide with the time of chest tube removal. Current guidelines recommend switching from intravenous to oral antibiotics when there has been clinical improvement

with normal body temperature, resolution of inflammation, and radiological improvement. A retrospective study showed that 3 weeks of antimicrobial therapy was usually adequate to prevent treatment failure. Treatment options with intrapleural enzyme therapies and surgery could serve as additional arguments for reducing the duration of antibiotic regimens (5, 13).

CONCLUSIONS

1. In patients with pleural empyema, gram-negative pathogens, commonly associated with hospital-acquired infections, were detected. Most of the bacterial isolates exhibited a high level of resistance to commonly prescribed empirical therapies.
2. Antibacterial preparations (beta-lactams, fluoroquinolones, polymyxins, glycopeptides, nitroimidazole derivatives) were carefully selected, taking into account their beneficial pharmacokinetic properties for penetration into pleural fluid and their activity against anaerobic flora.
3. The dosing regimen needs to be reviewed based on pharmacokinetic properties and the ability to penetrate the pleural space for patients with pleural infection.

CONFLICT OF INTEREST

Authors have no conflict of interest to declare.

ACKNOWLEDGMENT

There is no information.

ETHICAL APPROVAL

Since the article does not involve ethical risks, no research approval was required from the Ethics Committee.

REFERENCES

1. Atif M, Naseem M, Sarwar S, et al. Spectrum of Microorganisms, Antibiotic Resistance Pattern, and Treatment Outcomes Among Patients With Empyema Thoracis: A Descriptive Cross-Sectional Study From the Bahawal Victoria Hospital Bahawalpur, Punjab, Pakistan. *Front Med (Lausanne)*. 2021;8:665963. doi:10.3389/fmed.2021.665963
2. Avner BS, Ginosyan A, Le J, Mak J, Qiryaqoz Z, Huffman C. Analysis of antibiotic use and clinical outcomes in adults with known and suspected pleural empyema. *BMC Infect Dis*. 2022;22(1):783. doi:10.1186/s12879-022-07759-8
3. Bedawi EO, Ricciardi S, Hassan M, et al. ERS/ESTS statement on the management of pleural infection in adults. *Eur Respir J*. 2023;61(2):2201062. doi:10.1183/13993003.01062-2022
4. Foley SPF, Parrish JS. Pleural Space Infections. *Life (Basel)*. 2023;13(2):376. doi:10.3390/life13020376
5. Sundaralingam A, Banka R, Rahman NM. Management of Pleural Infection. *Pulm Ther*. 2021;7(1):59-74. doi:10.1007/s41030-020-00140-7
6. Calik M, Calik SG, Dagli M, Kesli R, Esme H. Pleural fluid penetration of moxifloxacin and doripenem: An experimental model of empyema. *North Clin Is-tanb*. 2019;7(2):99-105. doi:10.14744/nci.2019.05902
7. Lee S, Ahn HY, Kim K, Kim JH, Moon SY, Kim YD. Pharmacokinetics of Vancomycin Installation in Pleural Cavity—A Clinical Case with Animal Experiments. *Applied Sciences*. 2021;11(14):6456. doi:10.3390/app11146456
8. Adesoji AT, Onuh JP and Okunye OL. Bacteria Resistance to Cephalosporins and its Implication to Public Health. *J Bacteriol Mycol*. 2016;3(1):1021. Available at: https://www.researchgate.net/profile/Jude-Onuh-2/publication/332292430_Bacteria_Resistance_to_Cephalosporins_and_its_Implication_to_public_health/links/5cac8035a6fdccf47828f283/Bacteria-Resistance-to-Cephalosporins-and-its-Implication-to-public-health.pdf [Accessed 20.12.2023].
9. Bacinschi N, Pleşca C, Caracăş A, et al. Antibacterial therapy of community-acquired pneumonia. *Bulletin of the Academy of Sciences of Moldova. Medical Sciences*. 2021;1(69):116-120. doi:10.52692/1857-0011.2021.1-69.24
10. Ayoub Moubareck C. Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance. *Membranes (Basel)*. 2020;10(8):181. doi:10.3390/membranes10080181
11. Zhang B, Li X, Chen Y, et al. Determination of poly-

- myxin B in human plasma and epithelial lining fluid using LC-MS/MS and its clinical application in therapeutic drug monitoring. *J Pharm Biomed Anal.* 2023;227:115291. doi:10.1016/j.jpba.2023.115291
12. Arnold D, Read L, Noel A, et al. S13 Antibiotic penetration into the infected pleural space; a PK/PD study. *Thorax.* 2021;76:A13-A13. doi:10.1136/thorax-2021-BTSabstracts.19
 13. Hassan M, Patel S, Sadaka AS, Bedawi EO, Corcoran JP, Porcel JM. Recent Insights into the Management of Pleural Infection. *Int J Gen Med.* 2021;14:3415-3429. doi: 10.2147/IJGM.S292705
 14. Yang W, Zhang B, Zhang ZM. Infectious pleural effusion status and treatment progress. *J Thorac Dis.* 2017;9(11):4690-4699. doi:10.21037/jtd.2017.10.96
 15. Nguyen PTN, Le NV, Dinh HMN, Nguyen BQP, Nguyen TVA. Lung penetration and pneumococcal target binding of antibiotics in lower respiratory tract infection. *Curr Med Res Opin.* 2022;38(12):2085-2095. doi:10.1080/03007995.2022.2131304
 16. Chatzika K, Manika K, Kontou P, et al. Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. *Antimicrob Agents Chemother.* 2014;58(3):1315-9. doi:10.1128/AAC.02291-13

THE CONCEPT OF THE BIOBANK INFORMATION SYSTEM AT NICOLAE TESTEMITANU STATE UNIVERSITY OF MEDICINE AND PHARMACY, REPUBLIC OF MOLDOVA

Raisa PUIA, Galina BUTA, Alina FERDOHLEB, Mihail TODIRAS

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Raisa Puia, e-mail: raisa.puia@usmf.md

Keywords: Biospecimens, Biobank, research, database, donors.

Introduction. During the implementation of the Informational Record of Biospecimens within the Biobank project, the Register of Informational Record of Biospecimens within the Biobank software was developed and implemented.

Material and methods. A narrative synthesis on the informational aspect of bio-specimens within the Biobank at the international level was conducted. Sources were searched in public databases, and after identification and deduplication, 34 relevant sources were selected, out of which 15 were comprehensively analyzed. The Register of Informational Record of Biospecimens within the Biobank software fully captures the flow of information within the Biobank at the Nicolae Testemitanu State University of Medicine and Pharmacy and serves as a tool for managing the biospecimens stored in the Biobank. It offers various capabilities to ensure diverse and representative data regarding potential donors of biospecimens.

Results. The software enables rapid processing of biospecimens and their associated data, ensuring traceability with extensive management capabilities for diverse types of biospecimens at all stages throughout the Biobank circuit. The relevance of this data facilitates the improvement and acceleration of research and decision-making in the field of health, to the benefit of the donors. The software allows for the rapid registration and processing of biospecimens from donors in various research studies, adhering to the principles of research ethics and ensuring the anonymity of donors' personal data, as well as the biospecimen data and associated information.

Conclusions. The Register of Informational Record of Biospecimens within the Biobank software is relevant for initiating scientific research. Potential beneficiaries, including scientific researchers, collaborators in scientific laboratories, and the academic staff at Nicolae Testemitanu State University of Medicine and Pharmacy, will benefit from comprehensive informational support for biospecimen records within the Biobank and have opportunities to streamline research activities.

Cuvinte-cheie: biospecimene, biobancă, cercerare, bază de date, donatori.

CONCEPTUL SISTEMULUI INFORMAȚIONAL AL BIOBĂNCII UNIVERSITĂȚII DE STAT DE MEDICINĂ ȘI FARMACIE „NICOLAE TESTEMIȚANU” DIN REPUBLICA MOLDOVA

Introducere. În perioada realizării proiectului „Evidența informațională a biospecimenelor din cadrul Biobăncii” s-a elaborat și implementat softul „Registrul de evidență informațională a bio-specimenelor din cadrul Biobăncii”.

Material și metode. Softul „Registrul de evidență informațională a biospecimenelor din cadrul Biobăncii” reflectă pe deplin mișcarea fluxului informațional din cadrul Biobăncii USMF „Nicolae Testemițanu” și servește ca instrument de gestionare a biospecimenelor stocate în Biobancă și are o serie de posibilități pentru a asigura date diversificate și reprezentative privind potențialii donatori de biospecimene.

Rezultate. Softul permite prelucrarea rapidă a biospecimenelor și a datelor asociate acestora, și asigură trasabilitatea cu posibilități vaste de gestionare a biospecimenelor de natură diferită la toate etapele circuitului în Biobancă. Relevanța acestor date facilitează îmbunătățirea și accelerarea cercetării și luării de decizii în domeniul sănătății în beneficiul donatorilor. Softul permite înregistrarea și prelucrarea rapidă a biospecimenelor de la donatori în diverse studii de cercetare, respectând principiile eticii cercetării, și asigură anonimatul datelor personale ale donatorilor, precum și a datelor biospecimenelor și a informațiilor adiacente acestora.

Concluzii. Software-ul „Registrul informațional al biospecimenelor din cadrul Biobăncii” este relevant în inițierea cercetării științifice. Beneficiari potențiali, cercetători științifici, colaboratori ai laboratoarelor științifice și personalul didactico-științific al USMF „Nicolae Testemitanu”, vor beneficia de un suport informațional cuprinzător pentru evidența biospecimenelor din cadrul Biobăncii și vor avea posibilități de eficientizare a activității de cercetare.

INTRODUCTION

In the Republic of Moldova, the ongoing development of activities in the field of the human genome, technological innovations in cell processing, genetic research to study and describe the connections between genes, the physical and social environment, and people's lifestyles has led to the establishment of the national Biobank within the *Nicolae Testemitanu* State University of Medicine and Pharmacy (SUMPh), Republic of Moldova. Given the various types of Biobanks, it is essential to define the objectives of the Biobank at the outset of its formation.

The establishment of the Biobank requires accreditation and strict compliance with current quality standards. The Biobank at *Nicolae Testemitanu* SUMPh contains organized collections, storing human biological samples and associated data that are of great importance for research and personalized medicine. In other words, the Biobank serves as a repository of biological materials (biospecimens).

The purpose of the Biobank is to conduct the collection, reception, encoding/decoding, processing, storage, preservation, freezing, thawing, distribution, and/or destruction of biospecimens collected from patients involved in various research studies, along with their associated data, in order to support scientific investigations.

The individuals participating in the studies are assured of anonymity regarding their personal data after signing the consent form. Subsequently, samples are taken for the necessary biomaterial. The collected data are used exclusively for scientific and research purposes. During the biomaterial sampling and processing, personal data anonymization methods are employed, adhering to the limits established by the Personal Data Security Policy and the legal norms outlined in Law no. 133 of July 8, 2011, concerning the protection of personal data, as well as Law no. 71 of March 22, 2007, regarding registers. Ethical concerns surrounding biospecimens and the involvement of a number of people (operators) require special attention in information processing, with the incorporation of technological means. These factors constitute the critical components of the Biobank, with efforts made to ensure efficiency and safety in this aspect.

MATERIAL AND METHODS

A narrative synthesis was conducted on the infor-

mational subject of biospecimens within the Biobank at the international level. Simultaneously, data were systematized to fully reflect the movement of the information flow within the *Nicolae Testemitanu* SUMPh Biobank. Information sources were searched in PubMed, Google Scholar, and Hinari databases. The search strategies involved using keywords such as "biospecimens," "biobank," "database," "donors," and "data." The inclusion criteria for publications were articles published between January 2015 and January 2024. These publications were identified in databases such as Google Scholar, PubMed, HINARI, etc. After removing duplicate records and screening abstracts, 54 scientific sources were selected, of which 15 articles were fully reviewed.

The Biobank at *Nicolae Testemitanu* SUMPh features a specialized laboratory (scientific center) that enables the research, collection, processing, and storage of biospecimens obtained as a result of research projects. These biospecimens can be utilized in clinical trials or in prospective or retrospective studies (1). The increasing demand for tissues for translational studies is leading to a rise in the number of Biobanks (2).

RESULTS

The purpose of biobanks. To standardize the activities of the Biobank, it is necessary to implement standard operating procedures in all aspects, from acquisition, shipment, storage, and destruction to the safety of biospecimens (3). However, the development of these Biobank practices involves specialists to address potential ethical, legal, and social issues (4). The expanding field of biotechnology, which requires the establishment of an information system to monitor the collected biospecimens, highlights the increasing importance of financial support for Biobanks (5).

Biobanks serve as collections of biospecimens, which can later be used to elucidate medical diagnoses and personalized treatments (6). With this in mind, aliquoting will allow the use of biospecimens for both clinical and research purposes (7). To achieve this objective, the Biobank at *Nicolae Testemitanu* SUMPh collects, stores, and processes human biological materials, ensuring security in the collection of biospecimens intended for research or their use to guarantee a high level of

protection and promotion of human health. Various standard operating procedures and best practice protocols for biobanks are available, and the determination of which to use often depends on the specific needs of the clinic or study being conducted. The Best Practices for Operating Procedures, published by the Biospecimen Research Branch (NCI BBRB), can be accessed online (8).

Within the Biobank at *Nicolae Testemitanu* SUMPh, internationally standardized procedures, adjusted to the current legislation, have been implemented to assist researchers in making clinical decisions.

Screening the donor population can elucidate the specific alleles underlying a unique disease phenotype. By conducting such studies, it becomes possible to evaluate the environmental effects alongside the genetic ones, studying both monozygotic and dizygotic twins. This prospective approach can be employed in preventive medical programs and epidemiological studies (9).

The efficient management of biospecimens in the Biobank requires prompt and accurate collection, proper storage, and the recording of related information in an electronic system.

The information system allows for the accumulation and analysis of information related to biospecimens, including their storage in the Biobank and the monitoring of the flow of biospecimens from donors in various research studies. It ensures traceability with vast possibilities for managing biospecimens of different natures at all stages in the Biobank circuit.

The software contributes to the effectiveness and efficiency of personalized medicine processes, ensuring the qualitative management of information about research subjects. It serves as a strategic tool for the competitive clinical management of health services.

The information received from the medical institutions participating in the research projects is stored in the biospecimen record system using a standardized recording form. The data transmission procedure is outlined in a standardized instruction. The form encompasses primary patient data from various research studies, including passport information, epidemiological data, clinical details, paraclinical data, and more. These details are then presented to the operator responsible for records within the Biobank.

The Biobank operator accumulates and stores data in the *Register of Informational Record of Biospecimens within the Biobank* software, developed as part of the *Informational Record of Biospecimens within the Biobank* project, number 21.70086.37SD.

Collecting pertinent data on researched patients enables the assessment of management potential, efficiency options, and effectiveness in enhancing patients' quality of life while minimizing the impact on the health system.

Following the processing of all the data obtained at the Biobank level, information is obtained about the patients included in the research, with the elaboration of reports on the state of health regarding various medical conditions as well as their genealogy.

Donors' personal data, including biomaterial coding, are accessible to a limited number of people. Confidentiality regarding their identity and background is maintained throughout and after the completion of their studies.

Software requirements. Accreditation of a Biobank ensures that the laboratory (scientific center) controls and optimizes the use of biospecimens in accordance with good professional practice, as defined by internationally established standards. Accreditation requirements include the implementation of an operational quality management system and continuous control of the methods used for diagnostic purposes (10). Consequently, the Biobank is recognized for maintaining high-quality processes that produce reliable results. The accreditation process provides the Biobank with acknowledgment by ensuring consistency and standardization of practices.

Clinical research involving the Biobank requires approval from the Medical Ethics Committee (11). The cornerstone of bioethics is informed consent, which mandates providing patients and/or subjects with an overview of the study, a discussion of the protocol specifics, and disclosure of potential benefits and risks.

Equally important to a Biobank's role in acquiring and processing biospecimens is the management of clinical and research data relevant to each of those biospecimens. The *Nicolae Testemitanu* SUMPh Biobank's information record software has important capabilities that are recommended

in the practice guidelines and provides a secure environment that protects the data, includes a unique and unchangeable identifier for all biological samples, and the ability to continuously monitor the location and status of the evidence. The software system, with its implemented encryption component, operates 24/7, has a resilient infrastructure, and can effectively handle disasters and downtime. Moreover, it has the capability to recover stored data from regular backups using hard drives, external hard drives, USB sticks, and other portable memories, all properly encrypted to meet the latest information technology standards.

The biospecimen information record software within the Biobank satisfies the complete structure of the medical information of donors' samples. This adherence is in accordance with the sample collection form developed by the work team and provided to the Biobank at *Nicolae Testemitanu* SUMPh. It fully meets the needs for storage, processing, and validation of the obtained data. The software encompasses instruments enabling the accumulation and storage of information about the collected samples in the Biobank. It includes processing elements for primary donor data, diagnostic data, bio-specimen type, and more. It allows access to information about biospecimen donors from medical institutions, both separately by institution and in full, including donor data. The software facilitates the storage of sample information about donors through the software component created for the *Nicolae Testemitanu* SUMPh Biobank, which owns the database. Moreover, it grants access to collaborators at *Nicolae Testemitanu* SUMPh who are authorized to work with the IT system in question. The software enables the processing and analysis of results, such as the selection of samples based on criteria like nosology and those related to a specific period, on an institutional level. Additionally, it offers the capability to create reports through graphical representation and the use of statistical formulas. It is equipped with functionalities to analyze correlations between the data stored in the software from all medical institutions as a whole.

The software is equipped with interactive subsystems tailored to facilitate the tasks of operators. One group of operators focuses on collecting information from various medical institutions,

while another operator, situated within the Biobank at *Nicolae Testemitanu* SUMPh, processes the gathered data. Hence, the software, referred to as the *Register of Informational Record of Biospecimens within the Biobank*, is organized into modules, each comprising two primary components. The first component is designed to input information about donors and the details acquired during the collection of their samples from medical institutions. The second component is integrated within the Biobank at *Nicolae Testemitanu* SUMPh, and its role is to manage the collection and preservation of human biological material for scientific purposes.

Each system component encompasses functions such as input-output, data validation and control, and performing relevant calculations to ensure the provision of information flows based on various parameters (grouping criteria). This shared functionality across different system services enhances the efficiency and quality of information related to the collection of donor sample data.

The computer system can manage information collected at the time of receiving biospecimens, as well as details about previously stored samples (both current and stored over time). The software is equipped with a service and maintenance tool for the database. The system includes essential components for reporting statistical data (a set of standardized reports) about donor samples stored in the database. Diagnoses are recorded according to the international codes of ICD revision X.

The computer system, named *Register of Informational Record of Biospecimens within the Biobank*, implemented within the Biobank at *Nicolae Testemitanu* SUMPh, can group, adjust, and process information within an individual medical institution, as well as across all medical institutions whose donor samples are included in the register. It also has the capability to process data from any period within the stored records.

Taking into account the potential dangers that may arise when collecting donors' personal data as well as the real risks when storing and processing them, the software provides the possibility of anonymizing and encrypting personal data.

Within the computerized system of informational record of biospecimens within the Biobank, technical and organizational measures will be imple-

mented to prevent the destruction or unauthorized modification, processing, and access to the data in the system. The primary and traditional measure for protecting personal data is the obligation of the staff engaged in using the IT system to maintain the confidentiality of patients' medical data. Given the various potential biosecurity hazards involved in working with bio-specimens, it is crucial for all staff members to adopt appropriate security measures. The relevant Biobank staff will regularly review biosafety information documents for all materials used. These documents include Material Safety Data Sheets, providing information on health hazards associated with chemicals and infectious agents, as well as guidelines on how to use biosafety items (12).

To ensure the confidentiality of donor sample data and medical institutions, the software should restrict access to unauthorized individuals. Depending on the size, various types of staff may be required for proper Biobank operation (13, 14, 15). Therefore, when hiring staff for a Biobank, factors such as professional training, work ethic, promptness, intellectual capacity, teamwork, and communication skills must be taken into consideration. Additionally, employees should be enrolled in educational programs to obtain the required certifications. Biobank staff may have a range of responsibilities such as purchasing, processing, storing, and maintaining the database.

DISCUSSIONS

The system's integrity is assured by the proper functioning of the developed tools. Data processing for scientific medical research and statistical purposes must adhere to suitable safe guards. The computer system will provide regular

backups of data. The Biobank oversees the management and storage of data and generates electronic registers based on information authenticated and validated according to pre-established criteria.

The software developed for the Biobank provides data that will describe the biological material, its origin, and outcome. It facilitates information exchange with medical institutions through network traffic established between the Biobank and these institutions. Electronic records are created online, and the system encompasses various functionalities:

- Sample Collection Register - activates a screen with a table containing all the recorded samples;
- Project Log - opens a screen with a table containing all existing projects in the platform and related information;
- Donor register - opens a screen with a table containing the data of all the donors registered in the Biobank platform who have developed analyses, according to their agreement, for different scientific researches and projects;
- Results register - opens a screen with a table containing all the results of samples registered in the platform;
- Archived samples register - opens a screen with a table containing all the samples that have been destroyed, removed from research or have completed their research cycle.

The software implemented in the Biobank of the *Nicolae Testemitanu* SUMPh has an archiving system for sample records.

CONCLUSIONS

1. The development of the Biobank at *Nicolae Testemitanu* SUMPh adheres to the same requirements as other Biobanks for research. Emphasizing ethical considerations and respecting personal data through encryption are primary elements of the software development. This Biobank has the potential to offer unique research-based services to the scientific and medical community. Biospecimens are essential resources for research focused on human diseases. It is crucial for funding agencies, governments, and private entities to continue recognizing the importance of Biobanks in the ongoing development of human genome activities and genetic research.
2. Scientific researchers, collaborators of scientific laboratories, teaching and scientific staff at *Nicolae Testemitanu* SUMPh benefit from comprehensive informational support for recording biospecimens within the Biobank at *Nicolae Testemitanu* SUMPh, and they have the opportunity to enhance the efficiency of their research activities.

CONFIRMATION

This work was developed at *Nicolae Testemitanu* State University of Medicine and Pharmacy as part of the research project *Informational Evidence of Biospecimens within the Biobank* during the years 2021-2023, under the strategic direction of *Information Technology and Digital Development*. The project is registered in the State Register of projects in the field of science and innovation under the number 21.70105.37ŞD.

REFERENCES

1. Shabihkhani M, Lucey GM, Wei B, et al. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. *Clinical Biochemistry*. 2014;47(4-5):258-266. doi:10.1016/j.clinbiochem.2014.01.002
2. Krishnamurthy S. Biospecimen repositories and cytopathology. *Cancer Cytopathology*. 2014; 123(3):152-161. doi:10.1002/cncy.21505
3. Harati MD, Williams RR, Movassaghi M, Hojat A, Lucey GM, Yong WH. An introduction to starting a biobank. *Methods in molecular biology* (Clifton, NJ). 2019;1897:7-16. doi:10.1007/978-1-4939-8935-5_2
4. Vaught J, Lockhart NC. The evolution of biobanking best practices. *Clinica Chimica Acta*. 2012;413(19):1569-1575. doi:10.1016/j.cca.2012.04.030
5. Murphy J, Scott J, Kaufman D, Geller G, LeRoy L, Hudson K. Public Perspectives on Informed Consent for Biobanking. *American Journal of Public Health*. 2009;99(12):2128-2134. doi:10.2105/AJPH.2008.157099
6. De Souza YG. Sustainability of Biobanks in the Future. *Advances in Experimental Medicine and Biology*. 2015;864:29-35. doi:10.1007/978-3-319-20579-3_3
7. Martín Uranga A, Martín Arribas MC, Jaeger C, Posadas M. Outstanding ethical-legal issues on biobanks. An overview on the regulations of the Member States of the Eurobiobank project. *Revista De Derecho Y Genoma Humano = Law and the Human Genome Review*. 2005;(22):103-114. Available at: <https://pubmed.ncbi.nlm.nih.gov/16385793/> [Accessed: January 1, 2024].
8. Reznik ON, Kuzmin DO, Skvortsov AE, Reznik AO. Biobancile sunt un instrument esential pentru

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ETHICAL APPROVAL

The study was conducted and approved by the Ethics Committee no. 35/03.05.2022 of *Nicolae Testemitanu* State University of Medicine and Pharmacy of the Republic of Moldova.

- transplant. Istorie, stare actuală, perspective. *Jurnalul rus de transplantologie și organe artificiale*. 2017;18(4):123-132. doi:10.15825/1995-1191-2016-4-123-132
9. Krawetz SA, Casson PR, Diamond MP, et al. Establishing a biologic specimen's repository for reproductive clinical trials: technical aspects. *Systems Biology in Reproductive Medicine*. 2011;57(5): 222-227. doi:10.3109/19396368.2011.604819
10. Asslaber M, Zatloukal K. Biobanks: transnational, European and global networks. *Briefings in Functional Genomics and Proteomics*. 2007;6(3):193-201. doi:10.1093/bfpg/elm023
11. Lapić I, Rogić D, Ivić M, Tomičević M, Kardum Paro MM, Đerek L, Alpeza Viman I. Laboratory professionals' attitudes towards ISO 15189:2012 accreditation: an anonymous survey of three Croatian accredited medical laboratories. *Biochem Med (Zagreb)*. 2021;31(2):020712. doi:10.11613/BM.2021.020712
12. Kang B, Park J, Cho S, et al. Current Status, Challenges, Policies, and Bioethics of Biobanks. *Genomics & Informatics*. 2013;11(4):211. doi:10.5808/gi.2013.11.4.211
13. *Pathogen Safety Data (PSD) Guide*. 2016. Available at: https://tools.niehs.nih.gov/wetp/public/hasl_get_blob.cfm?ID=10823 [Accessed: January 1, 2024].
14. CDC. *National Healthcare Safety Network (NHSN) Patient Safety Component Manual*. 2023. Available at: https://www.cdc.gov/nhsn/pdfs/pscmanual/pscmanual_current.pdf [Accessed: January 1, 2024].
15. Hewitt RE. Biobanking: the foundation of personalized medicine. *Current Opinion in Oncology*. 2011;23(1):112-119. doi:10.1097/CCO.0b013e32834161b8

A NEW PROCEDURE FOR THE RAPID DETERMINATION OF *PSEUDOMONAS AERUGINOSA* BACTERIA IN MEDICATIONS

Nicolae PUSCAS

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Nicolae Puscas, e-mail: nicolae.puscas@usmf.md

Keywords: procedure, rapid determination, *Pseudomonas aeruginosa*, culture medium, medication.

Introduction. The microbiological quality of non-sterile products covers two relevant aspects: firstly, the assessment of microbial load, and secondly, the absence of pathogenic microorganisms. The absence of certain pathogenic microorganisms in a preparation depends on their route of administration. Oral pharmaceutical products require the absence of microorganisms such as *Salmonella* and coliform bacteria, such as *Escherichia coli*. On the other hand, topical products require the absence of species like *Staphylococcus aureus* and *Pseudomonas aeruginosa*. The methods commonly used for identifying microorganisms in medications are laborious and time-consuming. Considering these factors, the development of rapid methods for determining unacceptable microorganisms in medications is an urgent necessity.

Material and methods. This is an experimental study in which reference bacterial strains, medicinal preparations, components, ingredients, selectivity factors, and inhibition factors were utilized. For the preparation of the culture medium, high-purity reagents registered in the Republic of Moldova were used.

Results. Following the conducted studies, a rapid procedure has been developed for determining *P. aeruginosa* bacteria in medications. Detection of individual *P. aeruginosa* cells is possible after 9-12 hours of incubation, while results for concentrations of 10⁴-10⁵ CFU are obtained within 5-6 hours. The medium stands out for its high selectivity and specificity, predominantly for these bacteria, and is economical and straightforward to apply. The shelf life of the medium is two years (observation period).

Conclusions. The developed procedure is valuable for the rapid determination of *P. aeruginosa* bacteria, and the accuracy of the results will enable the timely implementation of microbiological monitoring strategies for large batches of medications.

Cuvinte-cheie: procedeu, determinare rapidă, *Pseudomonas aeruginosa*, mediu de cultură, medicament.

UN NOU PROCEDEU DE DETERMINARE RAPIDĂ A BACTERIILOR *PSEUDOMONAS AERUGINOSA* ÎN MEDICAMENTE

Introducere. Calitatea microbiologică a produselor nesterile acoperă două aspecte relevante: evaluarea încărcăturii microbiene și absența microorganismelor patogene. Absența unor microorganisme patogene într-un preparat este în funcție de calea lor de administrare. Astfel, în produsele farmaceutice de uz oral nu trebuie să existe microorganisme din genul *Salmonella* și bacterii coliforme, cum ar fi *Escherichia coli*, iar în produsele topice sunt inadmisibile speciile *Staphylococcus aureus* și *Pseudomonas aeruginosa*. Întrucât metodele actuale de identificare a microorganismelor în medicamente sunt laborioase și necesită mult timp, dezvoltarea de metode rapide este o necesitate stringentă.

Material și metode. În prezentul studiu experimental au fost utilizate tulpini bacteriene de referință, preparate medicamentoase, componente, ingrediente, factori de selectivitate și de inhibiție. Pentru prepararea mediului de cultură au fost utilizate reactivi de puritate înaltă înregistrate în Republica Moldova.

Rezultate. În urma studiilor efectuate s-a elaborat un procedeu rapid pentru determinarea bacteriilor *P. aeruginosa* în medicamente. Indicarea celulelor unice de *P. aeruginosa* este posibilă peste 9-12 ore de incubare, iar la concentrații de 10⁴-10⁵ UFC rezultatele se obțin timp de 5-6 ore. Mediul de cultură se distinge prin selectivitate și specificitate înaltă preponderent pentru această specie bacteriană, este economic și simplu în aplicare și are un termen de păstrare de doi ani (termen de observare).

Concluzii. Procedeu elaborat este util pentru determinarea rapidă a bacteriilor *P. aeruginosa* în medicamente, iar veridicitatea rezultatelor permite aplicarea în timp util a strategiilor de monitorizare microbiologică a loturilor mari de medicamente.

INTRODUCTION

The microbiological control of medication is one of the essential missions in ensuring the quality surveillance of human pharmaceuticals, in accordance with the provisions of the current analytical and normative documentation. Currently, medical practice and observations in the pharmaceutical field demonstrate that numerous pharmaceutical forms, often overlooked, may contain bacteria and/or fungi in significantly varied proportions and diverse species, mostly saprophytic. Their contamination with pathogenic, conditionally pathogenic, or even saprophytic microorganisms increasingly raises public, collective, or individual health concerns. These medications pose a significant risk, especially in the treatment of burns, wounds, and severe ulcerations on large denuded epidermal surfaces. Additionally, indigent intravenous medications prepared in hospitals, which carry a high risk of microbial contamination, have a short shelf life, leading to incidents that have resulted in fatalities (1, 2).

The increasing number of pharmaceutical recalls in recent years has once again made us aware of how crucial the microbiological quality of medications is. The presence of microorganisms in medications can become a source of infectious disease spread through them, especially when contaminated products are processed industrially in large batches (3).

The stability of a medication, alongside efficacy, purity, and safety, is a crucial factor in ensuring its quality. A medication considered stable maintains the quality characteristics imparted during preparation within the limits specified by official standards for a specified period. The medication should exhibit physical, chemical, and microbiological stability. Any change in the medication, whether apparent or not, as long as it falls outside the specifications provided by the manufacturer, can compromise its efficacy and safety. Medication incompatibilities may arise, and the presence of unacceptable microorganisms can introduce sources of contamination (1, 4).

In turn, the metabolic activity of microorganisms can induce physico-chemical instabilities, leading to the production of pyrogenic metabolites, a decrease in pharmacokinetic properties, and the nullification of therapeutic effects. This can instill doubt in the patient regarding the benefits offered by the medication.

In the treatment of various diseases, various pharmaceutical forms are used based on their content, mode of administration, and therapeutic action. These forms may be exposed to the unfavorable factors mentioned above. These preparations fulfil the indispensable conditions for the development of microorganisms; hence, a primary concern is to avoid microbial pollution from the technological preparation phase to the administration phase. The increasing number of pharmaceutical product recalls in recent years has once again made us aware of how crucial the microbiological quality of medications is (2, 4).

The *aim* of the study is to develop a procedure for the rapid detection and identification of unacceptable microorganisms in medications focusing on *P. aeruginosa*, which involves the culture medium for rapid multiplication and detection, as well as a minimal set of tests for swift identification.

MATERIAL AND METHODS

Bacterial strains

In this study, seven bacterial strains from the American Type Culture Collection (ATCC) and the National Collection of Strains from the United Kingdom were utilized, belonging to four species: *Pseudomonas aeruginosa* ATCC 27853, *Pseudomonas aeruginosa* ATCC 15442, *Pseudomonas aeruginosa* ATCC 49189, *Pseudomonas aeruginosa* NCTC 6750, *Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 25923, and *Staphylococcus epidermidis* ATCC 149990. Prior to the study, the strains were precultivated in Tryptic Soy Broth. All microbial strains were cultured on specific media for each species. The utilized media included Tryptic Soy Agar, Mannitol Salt Agar, MacConkey Agar, Blood Agar, Peptone Agar (BioMérieux, France), and MCS-Ps medium. The study also involved the use of medications labelled as "sterile," oral and topical preparations, components of formulations for micro-pellicle media, reagents, and chemical compounds for achieving selectivity, factors promoting multiplication, and inhibition factors obtained from official distributors.

A microbiological method was employed in the study, comparing known methods for the detection and identification of *Pseudomonas aeruginosa* with the proposed rapid determination proce-

cedure, the investigation of the selectivity of the concentrated micro-pellicle medium, the examination of the specificity of the rapid procedure, a comparative study of established identification means with the developed one, and the microbiological control of the medication regulated by the European Pharmacopoeia compared with the control of the medication using the proposed procedure and algorithm (5).

Development of the culture medium

The proposed procedure consists of the micro-pellicle culture medium, which includes in its composition casein hydrolysate, gelatin, sodium malonate, cetyltrimethylammonium bromide, sodium chloride, water-soluble bromothymol blue, monopotassium phosphate, and disodium phosphate. The research was conducted using materials and high-purity reagents from "Sigma-Aldrich".

For the preparation of the medium, stock solutions of phosphates are prepared in advance to obtain the phosphate buffer solution at pH 6.9-7.0, a 10% gelatin solution, and a 0.5% bromothymol blue solution.

The preparation of phosphate stock solutions takes place using the following method: monopotassium phosphate (KH_2PO_4) – 9.078 g is dissolved in 1000 ml of distilled water, and disodium phosphate (Na_2HPO_4) – 11.876 g in 1000 mL of distilled water until complete dissolution.

The 10% gelatin solution is prepared in a sterile tube by introducing 1.0 g of crystallized gelatin and 9.0 mL of distilled water. It is left for 45-50 minutes to swell, then heated in a water bath at a temperature of 85-90°C, stirring with a glass rod until completely dissolved.

For the preparation of the 0.5% bromothymol blue solution, in a sterile tube, 10.0 mL of sterile distilled water is poured, and 0.05 g of water-soluble bromothymol blue is added. The tube is then heated for 45 minutes in a water bath at a temperature of 85-90°C.

The preparation of the culture medium involves introducing casein hydrolysate, sodium malonate,

cetyltrimethylammonium bromide, sodium chloride, sterile distilled water, disodium phosphate, and monopotassium phosphate into a clean and sterile chemical retort. The mixture is stirred, and gelatin solution and bromothymol blue solution are added. The content is mixed to obtain a liquid culture medium, which is then dispensed in 0.2 ml portions into sterile bottles using a measured pipette. The bottles are dried at a temperature of +37°C for 24-48 hours and sterilized under the action of ultraviolet rays for 90-120 minutes. The tubes are sealed with sterile rubber stoppers and then with metal caps. Thus, the developed medium presents a sterile micro-pellicle fixed at the bottom of a 10.0 mL bottle.

RESULTS

For the determination of *P. aeruginosa* bacteria in the bottle with the medium, 2.0 ml of sterile distilled water and the strain of *P. aeruginosa* in a concentration of 10^1 10^9 are applied. The medium dissolves within 2-3 minutes, and then it is incubated in a thermostat at a temperature of 37°C for up to 9 hours.

In the presence of *P. aeruginosa* bacteria in the examined material, the color of the mixture in the bottle changes from green to blue. Meanwhile, in the control bottle, the color remains unchanged (remains green).

The time for the detection of *P. aeruginosa* bacteria depends on the initial concentration of the germs in one milliliter of the examined material. The detection of individual *P. aeruginosa* cells is possible after 9-24 hours of incubation, while the detection of concentrations of 10^4 - 10^5 CFU/mL takes 5-6 hours of incubation at a temperature of 37°C (tab. 1).

We determined the sensitivity and selectivity of the proposed medium. To assess the selectivity of the medium, we conducted a series of experiments with four batches of microorganisms in association, in 32 repetitions. When forming the associations, we selected the microorganisms deemed unacceptable in the majority of medications.

I. *P. aeruginosa* ATCC 27853 (10^2) + *S. aureus* ATCC 25923 (10^6); *P. aeruginosa* ATCC 27853 (10^2) + *E. coli* ATCC 25922 (10^6); *P. aeruginosa* ATCC 27853 (10^2) + *S. epidermidis* ATCC 149990 (10^6).

II. *P. aeruginosa* ATCC 27853 (10^3) + *S. aureus* ATCC 25923 (10^6); *P. aeruginosa* ATCC 27853 (10^3) + *E. coli* ATCC 25922 (10^6); *P. aeruginosa* ATCC 27853 (10^3) + *S. epidermidis* ATCC 149990 (10^6).

III. *P. aeruginosa* ATCC 27853 (10^4) + *S. aureus* ATCC 25923 (10^6); *P. aeruginosa* ATCC 27853 (10^4) + *E. coli* ATCC 25922 (10^6); *P. aeruginosa* ATCC 27853 (10^4) + *S. epidermidis* ATCC 14990 (10^6).

IV. *P. aeruginosa* ATCC 27853 (10^5) + *S. aureus* ATCC 25923 (10^6); *P. aeruginosa* ATCC 27853 (10^5) + *E. coli* ATCC 25922 (10^6); *P. aeruginosa* ATCC 27853 (10^5) + *S. epidermidis* ATCC 14990 (10^6) (tab. 2).

Table 1. The time of detection of *P. aeruginosa* based on their initial concentration (CFU/mL).

Microorganism concentration (CFU/mL)	Detection time, hours									
	1	2	3	4	5	6	7	8	9	24
10^1	-	-	-	-	-	-	-	+	++	++
10^2	-	-	-	-	-	-	-	+	++	++
10^3	-	-	-	-	-	-	-	++	++	++
10^4	-	-	-	-	-	+	++	++	++	++
10^5	-	-	-	-	+	++	++	++	++	++
10^6	-	-	+	++	++	++	++	++	++	++
10^7	-	+	+	++	++	++	++	++	++	++
10^8	-	-	+	++	++	++	++	++	++	++
10^9	-	+	++	++	++	++	++	++	++	++
>2 mld.	++	++	++	++	++	++	++	++	++	++

Note: „++” – pronounced positive reaction; „+” – positive reaction; „-” – negative reaction.

Table 2. The selectivity of the culture medium.

Microbial species	Exp. No.	Detection, hours				p	
		6	9	24	6.9	9.24	
<i>P. aeruginosa</i> (10^2) <i>S. aureus</i> (10^6)	32	0	90.6±1.9	96.9±2.1	-	<0.05	
<i>P. aeruginosa</i> (10^2) <i>E. coli</i> (10^6)	32	0	93.8±2.0	100±0.0	-	<0.05	
<i>P. aeruginosa</i> (10^2) <i>S. epidermidis</i> (10^6)	32	0	87.5±1.7	96.9±2.1	-	<0.05	
<i>P. aeruginosa</i> (10^3) <i>S. aureus</i> (10^6)	32	0	93.8±2.0	100±0.0	-	<0.05	
<i>P. aeruginosa</i> (10^3) <i>E. coli</i> (10^6)	32	0	96.9±2.1	96.9±2.1	-	<0.05	
<i>P. aeruginosa</i> (10^3) <i>S. epidermidis</i> (10^6)	32	0	100±0.0	100±0.0	-	-	
<i>P. aeruginosa</i> (10^4) <i>S. aureus</i> (10^6)	32	9.4±0.6	100±0.0	100±0.0	<0.001	-	
<i>P. aeruginosa</i> (10^4) <i>E. coli</i> (10^6)	32	6.2±0.4	96.9±2.1	96.9±2.1	<0.001	<0.05	
<i>P. aeruginosa</i> (10^4) <i>S. epidermidis</i> (10^6)	32	9.4±0.6	96.9±2.1	100±0.0	<0.001	<0.05	
<i>P. aeruginosa</i> (10^5) <i>S. aureus</i> (10^6)	32	28.1±1.1	96.9±2.1	100±0.0	<0.001	<0.05	
<i>P. aeruginosa</i> (10^5) <i>E. coli</i> (10^6)	32	31.3±1.2	100±0.0	100±0.0	<0.001	-	
<i>P. aeruginosa</i> (10^5) <i>S. epidermidis</i> (10^6)	32	28.1±1.1	96.9±2.1	100±0.0	<0.001	<0.05	

Based on the obtained results, we have determined that the medium exhibits selectivity towards *P. aeruginosa* bacteria, depending on the initial concentration of pseudomonads and the microorganisms in association.

To determine the sensitivity of the medium, we conducted a series of experiments with four reference strains of *P. aeruginosa* at two concentrations, 10^4 and 10^5 CFU/mL, in 14 repetitions. In parallel, we carried out the cultivation of bacteria on blood agar and peptone agar media (tab. 3).

Experimentally, we determined that the proposed medium is much more sensitive compared to blood agar and peptone agar media, allowing for the detection of *P. aeruginosa* bacteria within 6 hours.

The composition and optimal ratio of ingredients create a medium in the form of a micro-pellicle fixed at the bottom of a bottle, which serves as both a container for preserving the medium and, at the same time, for conducting the analysis. The storage term of the medium is 2 years (observation period).

Table 3. The sensitivity of the detection of *P. aeruginosa* bacteria.

Microbial species	Exp. No.	The concentration of microorganisms CFU/ml and their detection after 6 hours of incubation at 37°C					
		The micro-pellicle medium		Blood agar		Peptone agar	
		10^4	10^5	10^4	10^5	10^4	10^5
<i>P. aeruginosa</i> ATCC 27853	14	71.4±1.3	100±0.0	0	0	0	0
<i>P. aeruginosa</i> ATCC 15442	14	83.3±1.4	100±0.0	0	0	0	0
<i>P. aeruginosa</i> ATCC 49189	14	70.0±1.4	100±0.0	0	0	0	0
<i>P. aeruginosa</i> NCTC 6750	14	80.0±1.6	100±0.0	0	0	0	0

DISCUSSIONS

The control of “microbiological purity” carried out in support of pharmaceutical and biopharmaceutical production falls into three main categories: indication (qualitative), enumeration (quantitative), and characterization/identification. Traditional microbiological methods are listed in compendia and discussed using conventional techniques based on growth and multiplication, which are bulky and time-consuming. Generally, such tests require several days of incubation to determine microbial contamination, and therefore, managing them can lead to proactive corrective measures. Additionally, microbial growth is limited by the culture medium used and incubation conditions, influencing the sensitivity, specificity, and reproducibility of testing (6).

The most discussed topics revolve around the development of various technological platforms for rapid microbiological methods, and many have been readily adopted by microbiology laboratories and the pharmaceutical industry. Their use could enable drug companies to adapt to dead-

lines for manufacturing processes and product release. Some rapid methods also provide the possibility of real-time microbiological control, allowing management to respond to microbial contamination events over a more extended period and potentially offering cost savings and increased efficiency in quality control testing laboratories. Despite the numerous proven advantages in quality management and the initiatives of international associations to promote the use of analytical process technology, including rapid microbiological methods, the pharmaceutical and biopharmaceutical industry has been somewhat slow to embrace alternative microbiological control methodologies due to reported divergent results (6, 7).

The use of rapid methods is a dynamic field in applied microbiology that has garnered increased attention both nationally and internationally over time (8, 9, 10). This topic has been widely addressed in conferences and published documents worldwide. More recently, the use of alternative methods for microbiological quality control of

pharmaceutical products and materials used in pharmaceutical production has been extensively discussed in various guidelines and compendia in an attempt to facilitate the implementation of these technologies by pharmaceutical companies (6, 11).

Based on the above, the issue of developing procedures and means for the rapid detection and identification of bacteria from the *Pseudomonas* spp., *Staphylococcus*, *Candida*, and *Enterobacteriaceae* groups, as microorganisms unacceptable in medications, is current and aligns with the purpose of the proposed study.

The procedure pertains to culture media for the detection of *Pseudomonas aeruginosa* bacteria in various samples, environmental objects, including human pharmaceuticals. In technical essence, closer is the reagent for the detection of *P. aeruginosa* bacteria, which contains all optimal ingredients, with reference to the specific substrate of sodium citrate, used for rapid detection within 9 hours of incubation at a temperature of 37°C. The disadvantage of the known reagent is its lower specificity, as it allows the detection of other cit-

rate-positive microbial species.

The problem addressed by the proposed procedure lies in the development of a culture medium that allows a significant improvement in the specificity of detecting *Pseudomonas aeruginosa* bacteria.

A new culture medium is proposed that includes all optimal ingredients for the detection of *P. aeruginosa* bacteria, with sodium malonate as a specific substrate, water-soluble bromothymol blue as an indicator, sodium hydrogen phosphate, and potassium dihydrogen phosphate. The results of the conducted studies have shown an increase in the specificity of the medium by including sodium malonate as a specific substrate, which *P. aeruginosa* uses as the sole carbon source for multiplication. The other ingredients are included to promote and facilitate the multiplication of *P. aeruginosa*. Detection occurs under the pH conditions formed by sodium hydrogen phosphate and potassium dihydrogen phosphate, and the cleavage products of sodium malonate are indicated using bromothymolblue.

CONCLUSIONS

1. The use of the developed procedure allows for the rapid and specific isolation of *P. aeruginosa* strains and facilitates timely monitoring of pharmaceutical preparations and resources to limit contamination throughout the pharmaceutical manufacturing process.
2. The conducted studies indicate a clear increase in the sensitivity and speed of detection of *P. aeruginosa* bacteria in pure culture, mixed culture, or other research materials.
3. The described procedure is simple to implement, cost-effective, and can be used in microbiological laboratories of various levels.

REFERENCES

1. Salem N, Elbarrawy M, Azzam N. Microbiological quality of non-sterile pharmaceuticals in Egypt. *Beni-Suef Univ J Basic Appl Sci.* 2021;10:38. doi:10.1186/s43088-021-00127-6
2. Kumari B, Kumar S, Thota P, Pandey MK, Raghuvanshi RS, Teotia AK. Prevalence of Microbial Contaminants in Non-sterile Pharmaceutical Antacids. *Biomed J Sci & Tech Res.* 2023;50(3) 41696-41700. doi:10.26717/BJSTR.2023.50.007959
3. Rauf A, Erum A, Noreen S, Shujaat J, Ashraf MU, Afreen S. Microbiological quality control of some non-sterile preparations commonly used in Pakistan. *Pak J Pharm Sci.* 2018;31:1237–1242. Available online: <https://www.researchgate.net/profile/Alia-Erum/publication/326413775> [Accessed on 23 Dec.2023].
4. Miller MJ. Rapid Microbiological Methods. *Pharmaceutical Microbiological Quality Assurance and Control.* 2019: 429–458. doi:10.1002/9781119356196.ch13
5. European Pharmacopeia (11th Edn.). Microbiological examination of nonsterile products: microbial enumeration tests and Examination of non-sterile products: test for specified microorganisms. Available online: <https://www.edqm.eu/en/european-pharmacopoeia> [Accessed on 06 Sep.2023].
6. Nemati M, Hamidi A, Maleki Dizaj S, Javaherzadeh V, Lotfipour F. An Overview on Novel Microbial Determination Methods in Pharmaceutical and Food Quality Control. *Adv Pharm Bull.* 2016;6(3):301-308. doi:10.15171/apb.2016.042.
7. Moldenhauer J. Overview of Rapid Microbiological Methods. In: Zourob, M., Elwary, S., Turner, A. (eds.) *Principles of Bacterial Detection: Biosensors,*

- Recognition Receptors and Microsystems*. Springer, New York, 2008. doi:10.1007/978-0-387-75113-9_4
8. Pușcaș N, Balan G, Burduniuc O. Micro-test system for rapid isolation and identification of *Candida* species in urinary tract infections. *Anthropological Researches And Studies*. 2017;7:64-70. doi:10.26758/7.1.7
 9. Puscas N. Procedure for rapid determination of sterility of injectable solutions. *One Health and Risk Management*. 2023;2:78. Available online: https://ibn.idsi.md/sites/default/files/imag_file/78_23.pdf [Accessed on 11 Dec.2023].
 10. Balan G, Puscas N, Rudic V, Borta V, Timbalari E. Sistemul microtest pentru diagnosticul microbiologic rapid al vulvovaginitei candidozice. *Curierul medical*. 2014;57(1):86-90. Available online: <https://moldmedjournal.md/wp-content/uploads/2016/09/Cm-1-57-1.pdf> [Accessed on 11 Dec.2023].
 11. Louis M, Leblanc L, Montero Julian FA. Introduction to culture media in pharmaceutical microbiology for non-sterile products. *Pharmaceutical Microbiological Quality Assurance and Control*. 2019: 79-104. doi:10.1002/9781119356196.ch4

BACTERIAL NEUROLOGICAL DISEASES INFLUENCED BY GLOBAL WARMING

Catalina CROITORU, Ioana CALIGA

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Catalina Croitoru, e-mail: catalina.croitoru@usmf.md

Keywords: central nervous system, bacterial diseases, neuroinfections.

Introduction. In recent years, the incidence of infectious diseases affecting the central nervous system has increased. Among the reasons for the expansion of these diseases and the emergence of new neuropathogens are globalization, global warming, increased proximity between humans and wild animals due to human activities such as deforestation, the rising cases of antimicrobial resistance, etc.

Material and methods. A narrative synthesis of specialized bibliographic references was conducted, selecting sources from Google Scholar and ResearchGate using the keywords "bacterial diseases of the nervous system," "neuroinfections," and "global warming" in English. A total of 39 bibliographic sources were identified, excluding 3 abstracts and 4 duplicated articles. Additionally, 19 irrelevant articles were excluded, and 4 articles highlighting the topicality of the subject were added.

Results. Bacterial diseases affecting the nervous system tend to become increasingly severe due to the critical functions performed by the brain, spinal cord, peripheral nerves, and cranial nerves. Infections can occur in nervous tissue or in the meninges (covering membranes). Specialized literature mentions that there is no direct connection between neuroinfections and global warming. The development of neuroinfections is linked to exposure to bacterial agents in the environment and is associated with human behaviors. Although global warming can influence the distribution of disease vectors, there is a significant distance between this phenomenon and the direct transmission of neuroinfections. Global warming can impact human health in various ways, including the expansion of the range of vector-borne diseases or changes in the distribution of pathogens. However, these connections are complex and depend on numerous factors.

Conclusions. The effects of global warming can enhance the adverse impact of microorganisms on the nervous system.

Cuvinte-cheie: sistem nervos central, maladii bacteriene, neuroinfecții.

MALADII BACTERIENE NEUROLOGICE INFLUENȚATE DE ÎNCĂLZIREA GLOBALĂ

Introducere. În ultimii ani a crescut incidența bolilor infecțioase care afectează sistemul nervos central. Printre motivele expansiunii acestor boli și apariției de noi neuropatogeni se numără globalizarea, încălzirea globală, apropierea crescută dintre oameni și animalele sălbatice din cauza activităților umane precum defrișările, creșterea cazurilor de rezistență antimicrobiană etc.

Material și metode. A fost realizată o sinteză narativă a referințelor bibliografice de specialitate. Sursele au fost selectate în Google Scholar și ResearchGate folosind cuvintele-cheie „maladii bacteriene ale sistemului nervos”, „neuroinfecții” și „încălzire globală” în limba engleză. Astfel au fost identificate 39 de surse bibliografice, dintre care au fost excluse trei abstracte, patru articole dublate, 19 articole netematice și au fost adăugate patru articole ce reflectă actualitatea temei.

Rezultate. Bolile bacteriene, care afectează sistemul nervos, au tendință de a deveni tot mai grave din cauza funcțiilor critice pe care le îndeplinesc creierul, măduva spinării, nervii periferici și cranieni. Infecțiile pot apărea în țesutul nervos sau în meninge (membranele de acoperire ale creierului). În literatura de specialitate se menționează că nu există o conexiune directă între neuroinfecții și încălzirea globală. Dezvoltarea neuroinfecțiilor are legătură cu expunerea la agenții bacterieni din mediu și cu comportamentele umane. Deși încălzirea globală poate influența distribuția unor vectori ai bolilor, există o distanță semnificativă între acest fenomen și transmiterea directă a neuroinfecțiilor. Încălzirea globală poate afecta sănătatea umană într-o varietate de moduri, inclusiv prin extinderea ariei de răspândire a unor boli transmise de vectori sau prin schimbări în distribuția unor agenți patogeni, dar aceste legături sunt complexe și depind de numeroși factori.

Concluzii. Efectele încălzirii globale potențează acțiunea nefavorabilă a microorganismelor asupra sistemului nervos.

INTRODUCTION

The progress in human health and diseases has been substantial in today's world, with a growing emphasis on exploring the causal relationships between various illnesses and diverse causative factors, both internal and external. There is limited conclusive data or few pieces of evidence to suggest that climate change/global warming is responsible for altering disease patterns. However, extreme temperature fluctuations, such as heat-waves and cold spells, coupled with changes in precipitation levels leading to famine and floods, and the presence of airborne allergens with increased air pollution, impact human health at an individual level. Vector-borne diseases are directly affected by changes in temperature and precipitation levels. Water-related diseases arising from poor water quality, its quantity, and insufficient personal hygiene have complex associations. The loss of human lives, damage to health infrastructure, and public properties due to recent disasters like storms, cyclones, and hurricanes serve as a warning for the future world to address this situation now or never. On the other hand, the vulnerable population in low- or middle-income countries bears the brunt of the health burden related to global warming (1). Together, these factors will have adverse consequences on the health status of the population, including the health of the human brain (2).

Neurotropism, which affects the normal function of the brain, is characteristic of certain microorganisms such as prions, viruses, bacteria, fungi, and parasites (3). Bacterial infections of the central nervous system are significant causes of morbidity and mortality. Neuroinfections caused by these agents activate the immune response, inducing neuroinflammation, excitotoxicity, and neurodegeneration. Purinergic signaling is an evolutionarily conserved signaling pathway associated with these neuropathologies (4).

Global warming is a phenomenon of great concern, given the increasing temperature and frequency of extreme weather conditions directly impacting all life on Earth. The planet's temperature is rising at an unprecedented rate, leading to the loss of biodiversity. Biodiversity is a term that encompasses both macro and microenvironments. Altered biodiversity, the duration of pollination seasons and geography, coupled with the production of harmful gases, released toxic sub

stances, and chemicals, underscore the rise in disturbances related to the epithelial barrier (5, 6).

The incidence of infectious diseases affecting the central nervous system (CNS) has increased in recent years. Among the reasons for the expansion of these diseases and the emergence of new neuropathogens are globalization, global warming, and increased proximity between humans and wild animals due to human activities such as deforestation (4).

The anatomy of the brain and meninges determines the unique nature of infections of the central nervous system, often referred to as neuroinfections.

Many inflammatory conditions have been influenced by a disrupted epithelial barrier, best explained by the hypothesis of the epithelial barrier (6).

The increasingly frequent extreme weather events can synergistically damage the integrity of the epithelial barrier. A compromised epithelial barrier induces pro-inflammatory activation of epithelial cells. An "open" epithelial barrier contributes to the entry of the external exposome into and beneath the epithelium, triggering an expulsion response led by local inflammatory cells and chronic inflammation. These changes are associated with microbial dysbiosis with opportunistic pathogenic colonizers and decreased commensal presence. These cellular and molecular events are key mechanisms in the pathogenesis of numerous chronic inflammatory disorders (5, 7).

Thus, mitigating the impact on health should be tailored to regional health threats. Effective strategies need to be devised at all levels of the healthcare delivery system (1, 2).

The *aim* of the research was to analyze the issues related to bacterial diseases of the CNS in association with global warming.

MATERIAL AND METHODS

The research represents a narrative synthesis of specialized bibliographic references from both domestic and international sources. The synthesis relied on the theoretical evaluation of scholars' experiences regarding the addressed phenomenon. Sources were selected through the *Google Scholar* search engine and the *ResearchGate* social

network. The keywords “bacterial diseases of the nervous system,” “neuroinfections,” and “global warming” were used in English. The primary criterion for selecting bibliographic sources was the availability of full, free access to the articles.

The first stage of the work included selecting articles that contain two components of interest in the research: bacterial diseases of the nervous system and global warming. At this stage, 39 bib-

liographic sources were identified on *Google Scholar* and *ResearchGate*. In the *second stage*, 3 abstracts and 4 duplicated articles were excluded. After a detailed analysis of titles and abstracts (*third stage*), articles containing relevant information for the research topic with both requested components were selected. Thus, the final number for analysis consisted of 12 scientific articles, supplemented with 4 articles used in the introduction = 16 scientific articles (fig. 1).




Figure 1. Article selection algorithm.

RESULTS

Bacterial diseases of the nervous system are very rare but can be life-threatening.

Microbiology of the nervous system

Bacterial diseases of the CNS continue to increase in incidence due to conditions contributing to the emergence of pathogens, such as global travel, climate changes, and human encroachment into animal territories. The severity and complexity of these diseases are influenced by the diversity of etiological agents and their routes of neuroinvasion (8).

Among the bacterial diseases affecting the nervous system are: meningococcal meningitis, pneumococcal meningitis, listeriosis, Lyme disease, tuberculoid leprosy, lepromatous leprosy, tetanus, botulism, etc. (4, 9). Epidural abscesses remain localized, while subdural abscesses spread over one of the cerebral hemispheres. Infections in the subarachnoid space tend to spread over the brain and spinal cord (8, 10).

The major bacterial causes of central nervous system infections are *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Neisseria meningitidis* (9). Most of these agents invade through the bloodstream. In these infections, the number of bacteria rapidly increases in the cerebrospinal fluid. Brain abscesses often present a mixed flora of aerobic and anaerobic bacteria (4).

The bacterial world and global warming

Microorganisms provide long- and short-term feedback reactions to global warming and climate changes, which can be both positive and negative. Since they can recycle and modify fundamental elements such as carbon and nitrogen that make up cells, they play a significant role as producers or consumers of these gases in the environment. In unpopulated areas that were previously too cold for bacteria to survive, they have been able to spread and can cause fatal infections (11).

New infections could arise as the gap between ambient temperatures and human body temperature narrows. Floods and other natural disasters are more likely, driven by climate changes, leading to an increased risk of bacterial growth in people's homes. In this context, certain bacteria can lead to severe contamination of the lungs and brain (11).

The capacity of the medical system to treat bacterial diseases is compromised by antimicrobial resistance (a threat in which microorganisms, especially bacteria, become resistant to antibiotics and disinfectants, thereby complicating the ability to treat and prevent infections). Resistance is often developed through sub-inhibitory exposures to drugs and/or disinfectants but can also be caused by (often negative) environmental changes as a response mechanism to environmental conditions such as air temperature, water salinity, metals (potential toxic elements), and organic pollutants. Possible mechanisms through which climate change could affect the transfer of antimicrobial resistance genes between bacteria include:

- direct action, through changes in air temperature and/or precipitation,
- indirect impact, such as changes in human populations, disease vectors, agricultural processes, water availability, glacial and hydrological processes (1).

The impact of global warming on neurological diseases

Exposure to heat can lead to hyperthermia and heatstroke in extreme cases, which can be fatal. As global temperatures continue to rise, the incidence of hyperthermia and heatstroke is also inevitably expected to increase. Hyperthermia, along with atmospheric changes associated with global warming, is linked to an increased prevalence of migraines, seizures, stroke, and certain forms of dementia, including Alzheimer's disease. Prolonged exposure to heat can elevate levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α) and interleukin-1 (IL-1), and may induce gliosis and a decrease in synaptic density in the brain (2).

With global warming and the extremely hot summers witnessed worldwide in recent years, there is an increase in the incidence of fatal encephalitis caused by the so-called "brain-eating amoebas." (12).

The major cause of global warming is greenhouse gases that trap the thermal energy reflected by the Earth's surface. The main greenhouse gases include carbon dioxide, methane, nitrous oxide, and ozone. A new bacterium called *Methylokorus infernorum* has been discovered, which could help address the greenhouse gas issue. Found in geothermal areas with acidic and hot conditions, this bacterium utilizes methane gas. These bacteria can consume vast amounts of methane, approximately 11 kg/year, and could be useful in reducing ethane emissions from methane-producing facilities and landfills (13).

Bacteria can be involved in stopping global warming

Global warming has direct and indirect opposing effects on the structure and function of the microbial community in permafrost lake sediments.

Northern lakes disproportionately influence the global carbon cycle and may do so even more in the future, depending on how their microbial communities respond to global warming. Microbial communities can change due to the direct effects of global warming on their metabolism and the indirect effects of global warming on the connectivity of groundwater from permafrost thaw in the surrounding area (2).

Bacteria play a crucial role in the global carbon, nitrogen, and methane cycles. They capture carbon from non-living sources, making it available for living organisms through the process of carbon fixation. Bacteria can cycle carbon molecules under anaerobic conditions to produce energy through the fermentation process. Certain bacteria, such as *Thiobacillus ferrooxidans*, sulfur bacteria, and *Clostridium butyricum*, may participate in the carbon cycle (which describes the continuous movement of carbon atoms from the atmosphere to Earth and back to the atmosphere) (11, 14).

The main component of air, gaseous nitrogen (N₂), enters the biosphere through biological fixation. Bacteria exhibit specificity to certain plants. As a result of attaching to one of the plant's root hairs, the bacterium creates a hollow tube that leads into the root. Through this tube, bacteria develop and eventually form a nodule on the root. For bacteria, the plant provides food and energy, while nitrogen from the air is supplied in a form usable by the plant through fixation by the bacteria. *Rhizobium trifolium* contains the nitrogenase

enzyme, which fixes atmospheric nitrogen into a form of ammonium ions that is chemically advantageous for higher species. The plant transforms the fixed ammonium ion into nitrogen oxides and amino acids to create proteins and other compounds like alkaloids, as part of their symbiotic association. Bacteria contribute to the collection of energy or the accumulation of nitrogen in a form necessary for their growth and development. Bacteria that consume methane (CH_4), a greenhouse gas, are imperative for maintaining Earth's climate stability. Methane serves as an energy source for bacteria metabolism (11).

DISCUSSIONS

Neuroinfections begin nonspecifically, without signs of involvement of the nervous system.

Bacterial diseases affecting the nervous system tend to become more severe due to the critical functions performed by the brain, spinal cord, peripheral nerves, and cranial nerves. Infections can occur in nervous tissue or in the meninges (covering membranes).

Climate change is a global existential challenge that has introduced unprecedented pressures on the planet, already translating into significant consequences for human health.

The study conducted in Canada, sampling 19 lakes along a 1600 km latitudinal transect covering all major permafrost regions, assessed the potential impacts of global warming through spatial substitution over time. The direct effects of regional warming, such as temperatures and permafrost coverage extent, were compared with its indirect impacts on local groundwater connectivity and lake water chemistry. It was found that methanogens and metabolically diverse Euryarchaeota genes involved in all major pathways of methanogenesis responded particularly positively to the direct effects of regional global warming (15).

Some authors mention that increases in sequences representing methanogens and methanogenesis could be partially compensated by greater groundwater connectivity associated with warmer temperatures, as the abundance of these sequences has been negatively correlated with groundwater connectivity (16).

The opposing views among scientists on different aspects of global warming help explain why con-

siderable variation remains unexplained in methane emission predictions by Earth system models, even when microbial dynamics are considered. The potential methane production can be further enhanced in warmer locations due to the inadequate increase in its oxidation.

The specialized literature mentions that there is no direct connection between neuroinfections and global warming. The development of neuroinfections is linked to exposure to bacterial agents in the environment and is associated with human behavior. Although global warming can influence the distribution of disease vectors, there is a significant distance between this phenomenon and the direct transmission of neuroinfections. Global warming can impact human health in various ways, including expanding the range of vector-borne diseases or altering the distribution of pathogens, but these connections are complex and depend on numerous factors (6, 17).

Nevertheless, it is important to understand and address the consequences of global warming on human health, including potential public health risks and possible impacts on the distribution of infectious diseases. Studies in this field are ongoing to investigate these connections and to develop effective adaptation and mitigation strategies.

The increase in methanogenesis is supported by concurrent measurements of methane fluxes at the study sites. Together, the results provide a new understanding of why methane emissions are highly sensitive to rising temperatures in the study region. Future predictions of methane emissions could now be improved by considering how microbial dynamics vary with the direct and indirect effects of global warming associated with temperature and hydrology (14).

Environmental changes can create additional stress on microorganisms and the distribution of pathogens. Further research is needed to understand the microbiome, resistance, and environmental stress factors (such as temperature) that modify the impact, wastewater treatment, pathogens discharged into the environment, and the evolution and dissemination after exposure to ecological stress (1).

Diagnostic tests for neurological disorders often involve examining cerebrospinal fluid, and antibiotic therapy must use medications that can cross the blood-brain barrier.

CONCLUSIONS

1. Climate change represents a shift in balance, and the outcomes of the interaction between environmental factors and bacteria, the connections between these components, are complex and challenging to predict.
2. The effects of global warming enhance the unfavorable action of microorganisms on the nervous system.

CONFLICT OF INTEREST

Authors have no conflict of interest to declare.

ETHICAL APPROVAL

As the article does not involve ethical risks, approval from the Ethics Committee was not deemed necessary for the research.

REFERENCES

1. Lone SA, Malik A. *Microbiomes and the global climate change*. 2021. doi:10.1007/978-981-33-4508-9
2. Shabir BO. *The impact of climate change on brain health heat and the brain: dementia , stroke , migraine*. Available at: <https://www.news-medical.net/health/The-Impact-of-Climate-Change-on-Brain-Health.aspx> P [Accessed 16.11.2023].
3. Greenlee JE. *Introduction to brain infections*. 2022. Available at: <https://www.msdmanuals.com/professional/neurologic-disorders/brain-infections/introduction-to-brain-infections> [Accessed 11.11.2023].
4. Alves VS, Leite-Aguiar R, Silva JP, Coutinho-Silva R, Savio LEB. Purinergic signaling in infectious diseases of the central nervous system. *Brain Behav Immun*. 2020;89:480-490. doi:10.1016/j.bbi.2020.07.026
5. Ozdemir C, Kucuksezer UC, Ogulur I, et al. How does global warming contribute to disorders originating from an impaired epithelial barrier? *Ann Allergy, Asthma Immunol*. 2023;131. doi:10.1016/j.anai.2023.08.010
6. Ayeni EA, Aldossary AM, Ayejoto DA, et al. Neurodegenerative diseases: Implications of environmental and climatic influences on neurotransmitters and neuronal hormones activities. *Int J Environ Res Public Health*. 2022;19(19). doi:10.3390/ijerph191912495
7. Stefánsson MÖ. Vent microbes help predict thermal adaptation to climate change. *Res Sq*. 2023; preprint. doi:10.21203/rs.3.rs-3606419/v1
8. Cain MD, Salimi H, Diamond MS, Klein RS. Mechanisms of pathogen invasion into the central nervous system. *Neuron*. 2019;103(5):771-783. doi:10.1016/j.neuron.2019.07.015
9. Sekeyová Z, Danchenko M, Filipčík P, Fournier PE. Rickettsial infections of the central nervous system. *PLoS Negl Trop Dis*. 2019;13(8):1-18. doi:10.1371/journal.pntd.0007469
10. Roos KL. Bacterial infections of the central nervous system. *Contin Lifelong Learn Neurol*. 2015;21:1679-1691. doi:10.1212/CON.0000000000000242
11. Elshafei AM. General overview of climate change and global warming: Their effect on microorganisms. *Int J Environ Clim Chang*. 2022;(August 2022):1378-1387. doi:10.9734/ijecc/2022/v12i1131116
12. Mannan Baig A. Global warming favors pathogenicity of the brain-eating amoebae. *Anti-Infective Agents*. 2019;17:2-3. doi:10.2174/2211352516999181023142055
13. Gupta C, Prakash D, Gupta S. Role of microbes in combating global warming. *Int J Pharm Sci Lett*. 2014;4(2):359-363. Available at: https://www.researchgate.net/publication/264716464_Role_of_microbes_in_combating_global_warming [Accessed 09.12.2023].
14. Winder JC, Braga LPP, Kuhn MA, Thompson LM, Olefeldt D, Tanentzap AJ. Climate warming has direct and indirect effects on microbes associated with carbon cycling in northern lakes. *Glob Chang Biol*. 2023;29(11):3039-3053. doi:10.1111/gcb.16655
15. Walvoord MA, Kurylyk BL. Hydrologic impacts of thawing permafrost - A review. *Vadose Zo J*. 2016;15(6):1-20. doi:10.2136/vzj2016.01.0010
16. Ernakovich JG, Barbato RA, Rich VI, et al. Microbiome assembly in thawing permafrost and its feedbacks to climate. *Glob Chang Biol*. 2022;28(17):5007-5026. doi:10.1111/gcb.16231
17. Bedoya Cardona EY, Popa I, Morandi A, Montomoli C. Mental health during the COVID-19 quarantine in five countries. *One Health & Risc Management*. 2021;2(4):65-75. doi:10.38045/ohrm.2021.2(4)

CASE PRESENTATION – UNILATERAL DYSKINETIC CEREBRAL PALSY: TIME FOR A CHANGE IN CEREBRAL PALSY CLASSIFICATION?

Ecaterina GINCOTA¹, Ludmila MURZAC¹, Larisa SPINEI²

¹Republican Rehabilitation Center for Children, Chisinau, Republic of Moldova

²Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Ecaterina Gincota, e-mail: ecaterina.gincota@usmf.md

Keywords: dyskinesia, unilateral, case study, rehabilitation.

Introduction. Unilateral dyskinesia is a rare neurological disorder characterized by involuntary, abnormal movements on one side of the body. In children, understanding its clinical presentation and age-appropriate rehabilitation strategies is essential for the best outcome.

Material and methods. In this case-presentation, we conducted an in-depth examination of a 10-year-old boy with unilateral dyskinesia, previously diagnosed with bilateral spastic cerebral palsy. Extensive pediatric neurological assessments, including neuroimaging and child-friendly clinical evaluations, were performed to comprehensively document the patient's condition.

Results. Birth data: 39 weeks gestation, singleton, weight – 3950 g, length – 56 cm, head circumference – 36 cm, Apgar score at 5 minutes – 7, without birth-related complications. Para-clinical investigations revealed MRI-identified basal ganglia lesions in the putamen. Functional classifications indicated GMFCS II, MACS II, epilepsy, normal vision, normal hearing, EDACS level I, Viking speech scale III, and moderate intellectual disability. The pediatric patient exhibited pronounced dyskinesia limited to the right side of the body, which has progressively worsened over the past six years.

Conclusions. The results are in line with specific variables of dyskinetic CP. This study emphasizes the challenges in diagnosing pediatric patients with unilateral dyskinesia during the early stages. Clinical features are evident; therefore, rehabilitation strategies should be selected accordingly.

Cuvinte-cheie: dischinezie, unilaterale, studiu de caz, reabilitare.

STUDIU DE CAZ. PARALIZIA CEREBRALĂ (PC) DISCHINETICĂ UNILATERALĂ ÎMPUNE O SCHIMBARE A CLASIFICĂRII PC?

Introducere. Dischinezia unilaterală este o afecțiune neurologică rară, caracterizată prin mișcări involuntare, anormale pe o parte a corpului. La copii, înțelegerea prezentării sale clinice și a strategiilor de reabilitare adecvate vârstei este esențială pentru obținerea rezultatului scontat.

Material și metode. În prezentarea de caz, a fost efectuată o examinare aprofundată a unui băiat de 10 ani cu dischinezie unilaterală, diagnosticat anterior cu paralizie cerebrală spastică bilaterală. Pentru a documenta în mod cuprinzător starea pacientului, au fost efectuate evaluări neurologice, pediatrie extensive, inclusiv neuroimagistice, și evaluări clinice prietenoase pentru copii.

Rezultate. Date la naștere: 39 de săptămâni de gestație, greutate – 3950 g, talie – 56 cm, perimetrul cranian – 36 cm, scor Apgar la 5 min. – 7, fără complicații legate de naștere. Cu ajutorul RMN s-au evidențiat leziuni ale ganglionilor bazali în putamen. Clasificările funcționale au indicat GMFCS II, MACS II, epilepsie, vedere normală, auz normal, EDACS I, scara de vorbire Viking III și dizabilitate intelectuală moderată. Pacientul pediatric a prezentat dischinezie pronunțată, limitată la partea dreaptă a corpului care s-a agravat progresiv în ultimii șase ani.

Concluzii. Rezultatele sunt în concordanță cu specificul PC dischinetice. Acest studiu subliniază provocările în diagnosticarea pacienților pediatrici cu dischinezie unilaterală în stadiile incipiente. Caracteristicile clinice fiind evidente, strategiile de recuperare ar trebui selectate conform acestora.

INTRODUCTION

Dyskinetic cerebral palsy (CP), a subtype of cerebral palsy marked by uncontrolled, irregular movements, arises from damage to the extrapyramidal regions of the brain responsible for movement coordination. This particular form of CP is relatively uncommon, constituting between 6% and 17% of all cerebral palsy cases (1, 2). Unilateral dyskinesia, an unusual manifestation of this disorder, is characterized by involuntary movements on one side of the body and presents unique management challenges. Children with dyskinetic CP generally experience more severe motor impairments and are more likely to have associated disabilities compared to those with spastic CP (3, 4). Recognized risk factors for dyskinetic CP include sentinel events during childbirth, and characteristic lesions in the basal ganglia and thalamus are typically observed in neuroimaging (4, 5). Despite a general decline in the overall birth prevalence of CP in high-income countries (6) over the last two decades, data indicates an increase in the prevalence of dyskinetic CP in Europe from the 1970s to the 1990s (7 – 12). It's uncertain whether the observed decrease in dyskinetic CP prevalence from 2005 to 2010 represents a sustained trend or a temporary dip. The rise in dyskinetic CP's birth prevalence towards the late 20th century (7), concurrent with the stable prevalence of spastic quadriplegic CP despite significant advances in obstetric and perinatal care, suggests that these CP subtypes predominantly originate antenatally and are rarely preventable. This perspective was further supported in 1998 when an international consensus statement identified dyskinetic CP or spastic quadriplegic CP as key criteria for defining an acute intrapartum event (13). Understanding and preventing dyskinetic CP remains complex and challenging. Given its severity and resistance to treatment, a comprehensive, multi-disciplinary approach is essential for the effective management and support of individuals with this condition.

CASE PRESENTATION

In this study, we conducted an in-depth examination of a 10-year-old boy with unilateral dyskinesia, previously diagnosed with bilateral spastic CP. Extensive pediatric neurological assessments, including neuroimaging and child-friendly clinical evaluations, were performed to comprehensively document the patient's condition.

1. Birth data

Born in 2013 at a level II hospital, the pregnancy was the first, and it resulted in a single birth. The gestational age was 39 weeks, with a weight of 3980 g, length of 56 cm, head circumference of 36 cm, chest circumference of 34 cm, and abdomen circumference of 33 cm. The APGAR score was 4/7. The birth was through caesarean section due to hypoxia caused by a circular umbilical cord around the neck. The newborn was transferred to a tertiary level hospital on the same day and was hospitalized for 14 days in intensive care. The diagnosis at birth was moderate asphyxia and cerebral ischemia grade I-II, along with a convulsive syndrome. The child underwent repeated rehabilitation treatments and on 15.05.15, Botulinum Toxin Type A (Dysport) 200 IU was administered.

2. Clinical and paraclinical evaluations:

1. Cerebral Computed Tomography 2015 - cystiform dilatation of the cistern magna is determined. 2. Electroencephalography (EEG). During artifact-free periods, disorganized brain bioelectric activity is noted, without pathological interhemispheric asymmetry and epiphenomena. Functional probe reactivity attenuated. 3. M-Echo, 12.2023 structural averages are not deviated LS=LD=61mm Ventricle III=3 mm 4. Nuclear Magnetic Resonance (NMR), 2015 - Lesions of the basal ganglia in the putamen 5. Ophthalmologist consultation-07.2015 F.O. Moderate dilated veins, 03.2019 F.O. No changes.

3. Current functional assessments

3.1. Neurological status:

During the first year of life with a delay in motor development: the child was not sitting at 6-8 months, at 1.5 years he was not walking. At the age of 1 year, the diagnosis of Cerebral Palsy in the form of Spasticity was established. Since birth, he has had seizures, treated with Clonazepam. Last seizure 2 years ago. Last treatment in 12.2023. Hypertonic muscle tone, emphasis on the left. Bilateral muscle strength in upper limbs slightly diminished D=S=4p. In the bilateral lower limbs proximally 3 points; distal flexion 4 points; extension 2 points. ROT live superior D=S, inferior: patellar -exaggerated; Achilles-D=S; Babin-ski positive bilaterally, more pronounced on the left side. Unstable Romberg pose, the coordination tests performed with more pronounced inaccuracy on the right (when performing the index-

nose test, a tremor appears in the right hand).

3.2. Speech therapist evaluation

Dysarthria, global language disorders grade II. Viking speech scale III. EDACS (Eating and Drinking Ability Classification) level I.

3.3. Psycho-pedagogue evaluation

Purpose and objectives - training and development of attention. Conclusion - the cognitive level does not correspond to the chronological age, IQ=62.

3.4. Gross motor function evaluation

The patient is diagnosed with Cerebral Palsy, bilateral spastic form. After a more detailed analysis of the gross motor function and the biped movement pattern, the patient presents a mixed form - spatial form on the left side and dyskinetic - on the right. The patient experiences difficulties while moving, finding it hard to maintain balance with a swaying, inclined movement on the left side. While walking, the child stabilizes the right leg with the left upper limb. During movement with the legs, they go into more pronounced hyperextension on the right, and the patient has an asymmetrical posture with an inclination on the left side. Movement control is better in the left hemisphere. Gross Motor Function Level II (GMFCS II).

3.5. Assessment of fine motor function

While performing simple abduction and adduction movements, the patient demonstrates more concrete, coordinated, and precise movement with the left hand than with the right. The left side, being spastic, is better controlled by the patient than the right side, which is dyskinetic. When reaching for a fitball, the right hand is placed ahead of the left. When holding the ball, the left hand is placed below, the right above, and the head looks to the right. When holding an object with the left hand, the right hand goes into abduction, supination, and dorsiflexion, which demonstrates that the extrapyramidal system is damaged, and the brain eliminates the presence of the right hand. However, if asked to hold his hand close to his body, he struggles, and movements with his left hand become clumsier. With his right hand, he can only grasp and hold objects the size of a ping-pong ball and then throw it. The interdigital grip and the terminal opposition grip cannot be performed with the right hand. With the left hand, he performs prehension through terminal opposition only with the ring finger and the little

finger, and with the index and the medius only by sub-terminal opposition. When building a wall with blocks, he holds the pieces very tightly with his right hand due to the lack of co-contraction, while with his left hand he makes an effort to join the pieces. Fine movements of the hand and fingers are performed with difficulty and may be accompanied by intentional tremors. Manual Ability Classification (MACS) level II.

Lower limbs

Standing and walking are achieved with a large base of support. During the orthostatic position, support is performed only on the left leg, with the right leg initially lifted and then the heel lowered. The patient cannot maintain a standing position without movement for more than 3 seconds. Due to the lack of coordination of the activity of agonists, antagonists, and synergists, movements become uncontrolled and are carried out with high amplitude. This results in a "mowing gait" characterized by an abduction pattern along with dorsiflexion and eversion of the leg, and as compensation, hyperextension of the hip and knee. In activities of daily living (ADL), all actions are performed with the left hand, with the right hand not involved in the action. During dressing and undressing, the left hand engages and dresses the right hand, while the right hand is put aside, with the feet fixed on the floor. When putting on and taking off pants, socks, and shoes, coordinating the right leg is difficult. He manages, with difficulty, to fasten and unfasten buttons, and can easily unfasten and fasten zippers.

DISCUSSIONS

When conducting the rehabilitation process for dyskinetic cerebral palsy, whether it is unilateral or bilateral, it must be customized to fit each person's individual needs, abilities, and limitations. However, there are some general differences in the rehabilitation approach between the two types:

Unilateral Dyskinetic Cerebral Palsy: 1. Specific Focus: Rehabilitation will often be more focused on the part the affected body, which allows an intensive concentration on improving the function and coordination of that part. 2. Physical and Occupational Therapy: It will be aimed at improving strength, flexibility, and coordination of the affected body part. Exercises and activities are often designed to stimulate the use of the affected limb

and to encourage the development of fine and gross motor skills. 3. Use of Assistive Equipment: May be required on the affected side, such as orthotics or other support devices, to improve alignment and operation. 4. Compensatory Strategies: Patients can learn to use more effectively the unaffected side of the body to compensate and perform daily activities.

Bilateral Dyskinetic Cerebral Palsy: 1. Broad Approach: Rehabilitation requires a more global approach because both parts of the body are affected. This involves more coordination complex and careful planning to address the needs on both sides of the body. 2. Physical and Occupational Therapy: This will aim to improve motor control, strength, and coordination on both sides of the body. Therapists may use a variety of techniques, including whole-body exercises, activities involving both hands and feet, and relaxation techniques to control involuntary movements. 3. Extensive

Adaptations in Daily Life: Due to bilateral involvement, a wider range of assistive equipment and modifications of the home or school environment may be necessary to facilitate independence and safety. 4. Management of Involuntary Movements: Complex approaches may be required for managing uncontrolled movements, including medication, therapy with controlled movement, and in some cases, surgery.

Common Considerations: 1. Speech and Language Therapy: Both types can benefit from speech and language therapy, especially if facial muscle control is affected and coordination is needed for speech and eating. 2. Psychosocial Support: Emotional and psychological support is crucial in both cases, as cerebral palsy can have a significant impact on self-esteem, independence, and quality of life. 3. Multidisciplinary Approach: A multidisciplinary team involving doctors, therapists, educators, and other specialist services is essential to provide comprehensive care.

CONCLUSIONS

1. The results are in line with specific variables of dyskinetic CP. This study emphasizes the challenges in diagnosing and rehabilitating pediatric patients with unilateral dyskinesia during the early stages. In conclusion, although there are common basic principles in CP rehabilitation, the specific approaches and intensity of interventions may vary considerably between unilateral and bilateral cases.
2. An individualized assessment is essential for creating a personalized treatment plan to effectively address each person's needs and goals.

CONFLICT OF INTEREST

Authors have no conflict of interest to declare.

ACKNOWLEDGMENT

We have obtained permission from the parents to present this information.

REFERENCES

1. Shevell MI, Dagenais L, Hall N, Repacq C. The relationship of cerebral palsy subtype and functional motor impairment: a population-based study. *Dev Med Child Neurol.* 2009;51(11):872–7. doi:10.1111/j.1469-8749.2009.03269.x
2. Himmelmann K, Hagberg G, Uvebrant P. The changing panorama of cerebral palsy in Sweden. X. Prevalence and origin in the birth-year period 1999–2002. *Acta Paediatr.* 2010;99(9):1337–43. doi:10.1111/j.1651-2227.2010.01819.x
3. Pr  el M, Rackauskaite G, Larsen ML, Laursen B, Lorentzen J, Born AP, et al. Children with dyskinetic cerebral palsy are severely affected as compared to bilateral spastic cerebral palsy. *Acta Paediatr.* 2019;108(10):1850–6. doi:10.1111/apa.14806
4. Monbaliu E, Himmelmann K, Lin JP, Ortibus E, Bonouvrie L, Feys H, et al. Clinical presentation and management of dyskinetic cerebral palsy. *Lancet Neurol.* 2017;16(9):741–9. doi:10.1016/S1474-4422(17)30252-1
5. Kitai Y, Hirai S, Okuyama N, Hirotsune M, Nishimoto S, Hirano S, et al. Functional outcomes of children with dyskinetic cerebral palsy depend on etiology and gestational age. *Eur J Paediatr Neurol.* 2021;30:108–12. doi:10.1016/j.ejpn.2020.11.002
6. McIntyre S, Goldsmith S, Webb A, Ehlinger V, Holung S, Arnaud C, et al. Global prevalence of cerebral palsy: a systematic analysis. *Dev Med Child Neurol.* 2022. doi:10.1111/dmcn.15346
7. Himmelmann K, McManus V, Hagberg G, Uvebrant P, Kr  geloh-Mann I, Cans C. Dyskinetic cerebral palsy in Europe: trends in prevalence and severity.

- Arch Dis Child.* 2009;94(12):921–6.
doi:10.1136/adc.2008.144014
8. Himmelmann K, Uvebrant P. The panorama of cerebral palsy in Sweden part XII shows that patterns changed in the birth years 2007–2010. *Acta Paediatr.* 2018;107(3):462–8. doi:10.1111/apa.14147
 9. Hollung SJ, Vik T, Lydersen S, Bakken IJ, Andersen GL. Decreasing prevalence and severity of cerebral palsy in Norway among children born 1999 to 2010 concomitant with improvements in perinatal health. *Eur J Paediatr Neurol.* 2018;22(5):814–21. doi:10.1016/j.ejpn.2018.05.001
 10. Elkamil AI, Andersen GL, Salvesen KA, Skranes J, Irgens LM, Vik T. Induction of labor and cerebral palsy: a population-based study in Norway. *Acta Obstet Gynecol Scand.* 2011;90(1):83–91. doi:10.1111/j.1600-0412.2010.01022.x
 11. Gorter JW, Rosenbaum PL, Hanna SE, Palisano RJ, Bartlett DJ, Russell DJ, et al. Limb distribution, motor impairment, and functional classification of cerebral palsy. *Dev Med Child Neurol.* 2004; 46(7):461–7. doi:10.1017/s0012162204000763
 12. Himmelmann K, Horber V, De La Cruz J, Horridge K, Mejaski-Bosnjak V, Hollody K, et al. MRI classification system (MRICS) for children with cerebral palsy: development, reliability, and recommendations. *Dev Med Child Neurol.* 2017;59(1):57–64. doi:10.1111/dmcn.13166
 13. Surveillance of cerebral palsy in Europe (SCPE). Surveillance of cerebral palsy in Europe (SCPE): a collaboration of cerebral palsy surveys and registers. *Dev Med Child Neurol.* 2000;42:816–24. doi:10.1017/s0012162200001511

CHANGES IN YOUNG PEOPLE'S ATTITUDES TO THE PROBLEM OF COVID-19, FLU, AND OTHER UPPER RESPIRATORY INFECTIONS DURING THE WAR IN UKRAINE

Lyubov VLASYK¹, Natalia RYNHACH², Anastasiya SUKHOLOTYUK¹, Svitlana MARINOVA¹, Leonid VLASYK¹

¹Bukovinian State Medical University, Chernivtsi, Ukraine

²Institute for Demography and Life Quality Problems of the NAS of Ukraine, Kyiv, Ukraine

Corresponding author: Lyubov Vlasyk, e-mail: lyubov.vlasyk@gmail.com

Keywords:

COVID-19, pandemic, war, antiepidemic measures, Ukraine.

Introduction. The population of all countries of the world was affected by the COVID-19 pandemic, but the most severe consequences were for low- and middle-income countries (LMICs). Following Russia's invasion of Ukraine, there have been changes in people's attitudes to the challenges posed by the COVID-19 pandemic. The aim is to study the attitude of young people to the problem of COVID-19, influenza, and other upper respiratory infections (URI) during the war in Ukraine. **Material and methods.** The materials consist of the results of an online survey of young people in Chernivtsi and neighboring regions of the western part of Ukraine in 2023/2024 (N=269). The methods of sociological analysis, descriptive statistics, pair correlation, and logistic regression using PIVOT and SPSS were applied. **Results.** According to the results, 65.1% of respondents suffered from COVID-19, with 70.3% of them being vaccinated. During the pandemic, only 4.2% of respondents admitted that they did nothing to prevent infection. Since the beginning of the war, this percentage increased to 43.2%, with an additional 8.2% citing a lack of opportunity for prevention. At the end of the second year of the war, only 25.7% of respondents expressed concern about COVID-19, influenza, and other URIs. A direct correlation was found between this concern and the problem of restricting men's travel abroad during the pandemic ($r=0.239$), psychological issues ($r=0.198$), and financial problems ($r=0.224$) among females. Female anxiety was also influenced by job loss ($r=0.152$) and engagement in activities such as volunteering in aid delivery to the front ($r=0.288$) and cooking food for soldiers ($r=0.152$). Significance was established at the 95% CI, $p<0.05$. **Conclusions.** At the end of the second year of the war, the situation with COVID-19, influenza and other URIs was a concern of only one in four respondents (25.7%), which was also associated with vaccination (70%) and a transmitted disease (65%).

Cuvinte-cheie:

COVID-19, pandemie, război, măsuri antiepidemice, Ucraina.

SCHIMBĂRI ÎN ATITUDINEA TINERILOR FAȚĂ DE COVID-19, GRIPĂ ȘI ALTE INFECȚII ALE CĂILOR RESPIRATORII SUPERIOARE ÎN TIMPUL RĂZBOIULUI DIN UCRAINA

Introducere. Populația tuturor țărilor lumii a fost afectată de pandemia COVID-19, îndeosebi cea din țările cu venituri mici și mijlocii. Invazia Rusiei în Ucraina a indus schimbări în atitudinea oamenilor față de provocările pandemiei COVID-19. Scopul prezentului studiu constă în elucidarea atitudinii tinerilor față de COVID-19, gripă și alte infecții ale căilor respiratorii superioare în timpul războiului din Ucraina. **Material și metode.** Rezultatele unui sondaj online al tinerilor din Cernăuți și din regiunile învecinate din vestul Ucrainei din perioada 2023/2024 (N269) au fost analizate aplicând metode de sociologie, statistici descriptive, corelație de perechi, regresie logistică folosind PIVOT, SPSS. **Rezultate.** Sondajul a arătat că 65,1% dintre respondenți au suferit de COVID-19, dintre care 70,3% au fost vaccinați. În timpul pandemiei, doar 4,2% dintre respondenți au recunoscut că nu au făcut nimic pentru a nu se infecta, iar de la începutul războiului – 43,2%, 8,2% din respondenți motivând inactivitatea de prevenție prin faptul că „nu există posibilitate”. La sfârșitul celui de-al doilea an de război, situația privind COVID-19, gripa și alte URI-uri a provocat îngrijorare doar pentru 25,7% dintre respondenți. În cazul bărbaților, o corelație directă a fost stabilită între această preocupare și restricționarea călătoriilor bărbaților în străinătate în timpul pandemiei ($r=0,239$). Pentru femei mai acute sunt problemele psihologice ($r=0,198$) și financiare ($r=0,224$). Anxietatea femeilor a fost determinată și de pierderea locului de muncă ($r=0,152$), de livrarea de ajutoare pe front ($r=0,288$) și gătitul mâncării pentru soldați ($r=0,152$). Semnificația a fost aleasă la nivelul de 95% CI, $p<0,05$. **Concluzii.** La sfârșitul celui de-al doilea an de război, situația privind COVID-19, gripa și alte infecții ale căilor respiratorii superioare era o preocupare doar pentru unul din patru respondenți (25.7%), fapt determinat de vaccinare (70%) și de caracterul transmisibil al acestor afecțiuni (65%).

INTRODUCTION

Previously, it was believed that low- and middle-income countries (LMICs) faced a triple problem in healthcare, namely, major non-communicable diseases and road traffic accidents were added to the traditional infectious disease burden (1). However, the COVID-19 pandemic, against the background of the socio-economic crisis it caused, has made its own adjustments. It has deepened existing disparities between countries, posed challenges for management at various levels, and exacerbated the adverse effects of both communicable and non-communicable diseases (2, 3).

The WHO has emphasized that, although the COVID-19 pandemic has affected the populations of all countries around the world, the most severe consequences have been felt by those who were already in a vulnerable state, such as those with poorer health and less access to necessary quality healthcare. This group has suffered the most due to anti-epidemic restrictions, particularly in LMICs (4). Despite the fact that the COVID-19 pandemic is no longer considered a public health emergency of international concern, the disease continues to pose a serious threat to human health globally. With the pandemic now spanning four years, new strains of the virus are emerging, and WHO experts predict that it will persist for a significant period of time (5). The latest Human Development Report 2021/22 has highlighted the “stunning reality” of a two-year decline in the global Human Development Index (HDI) due to the COVID-19 pandemic, which has led to an unprecedented synchronized multidimensional crisis (6). Ukraine, despite belonging to the LMICs in terms of per capita income, has demonstrated an almost steady increase in the HDI since 1996. However, in 2020, progress gave way to regression, with the main factor being a reduction in life expectancy, primarily as a result of the pandemic (7).

The situation in the country worsened significantly when, amidst the COVID-19 pandemic, the Russian armed forces launched a large-scale invasion of Ukraine on February 24, 2022. Civilian casualties increased, and large areas came under occupation. More than 15 million civilians were displaced within Ukraine or abroad (8). Military shelling of civilian objects continues in Ukraine. The humanitarian and psychological crises in areas near and far from the war zone worsened during the winter of 2023 due to repeated bombard-

ments of civilian infrastructure (9).

Against the backdrop of military operations, the public's attitude toward disease prevention, compliance with anti-epidemic measures, and their implementation face significant challenges. *The purpose* of our study was to examine the attitudes of young people toward COVID-19, influenza, and other upper respiratory infections (URIs) during the period of martial law in Ukraine.

MATERIAL AND METHODS

The materials were based on the results of an online survey of young people in Chernivtsi and nearby regions of the western part of Ukraine. The participants included students (3-6 years), graduates of Bukovinian State Medical University (BSMU), and individuals from other educational institutions. The survey, titled “Let’s summarize,” was conducted through a Google form from December 20, 2023, to January 03, 2024, and involved 269 respondents, comprising 68 males and 201 females. For comparative analysis, the results of an online survey conducted by the Ptukha Institute of Demography and Social Studies of the National Academy of Sciences of Ukraine in May 2022 were utilized. This survey encompassed 523 respondents (130 males and 393 females) from 16 educational institutions across various regions of Ukraine, aiming to investigate the impact of the COVID-19 pandemic and the Russo-Ukrainian war on the lives and health of students. The specifically designed “Let’s summarize” questionnaire included questions about the most significant challenges young people encountered during the COVID-19 pandemic (2020/21), the full-scale invasion (from 02/24/2022), and at the end of the second year of the war (2023/24). A separate section addressed whether the current situation with COVID-19, influenza, and other upper respiratory infections as of early 2024 is a cause for concern. Respondents could choose multiple answers, and open-ended questions were also included. The research employed sociological methods, descriptive statistics using PIVOT, as well as the method of pairwise correlation, logistic regression, with the determination of the probability of an event (P) using the SPSS statistical program. Reliability was set at the 95% confidence interval with $p < 0.05$. To compare the frequency of individual responses among males and females, the *Student's t-test* was used for relative values.

RESULTS

The respondents were requested to outline their individual challenges over the past 4 years in light of the COVID-19 pandemic and Russia's full-scale invasion with the outbreak of hostilities in Ukraine. The socio-demographic characteristics of the respondents and significant events that occurred in their lives during the war are detailed in Table 1. A majority of the respondents, constituting 92.2%, were young. Changes in the educational process (start/completion) were reported by 28.3% of respondents, while changes in employment were noted by 42.5%. Among those who found employment, 18.8% either lost their jobs or changed their field of activity. Additionally, one in ten respondents initiated a family, and 7.5% of female respondents gave birth to a child. According to the survey, a significant proportion of young people, up to 65.1% (64.7% males, 65.2% females) had contracted COVID-19, as confirmed by testing and clinical examination. For comparison purposes, in the 2022 survey, 36.3% (37.7% of males, 35.9% of females) reported having had the disease, confirmed by testing. At the time of the survey, 70.3% of respondents were vaccinated against COVID-19.

In addition to health problems, the pandemic has also caused financial difficulties, as indicated by more than a quarter of respondents in both the 2023/24 survey, with 25.3% (20.6% males;

26.9% females), and in the 2022 survey with 25.8% (23.1% males, 26.7% females). Financial problems associated with the spread of coronavirus disease were found to be less significant than the same problems caused by the war, as reported by 49.5% and 35.7% of respondents, respectively. A correlation was found between financial problems during the pandemic (2020-2021) and feelings of anxiety about the situation with COVID-19, influenza, and other URIs in early 2024 among females ($r=0.224$, $p<0.01$).

A correlation was observed between the presence of psychological health complaints, encompassing mood swings, stress, and depression, at the time of the survey and the financial problems that existed at the beginning of the war among males ($r=0.286$, $p<0.05$) and females ($r=0.174$, $p<0.05$). Financial problems during the 2020-2021 pandemic were found to be important for females' psychological health ($r=0.289$, $p<0.01$).

According to the results of the 2023/24 survey, 82.5% of respondents reported significant problems during the COVID-19 pandemic (2020-2021). The structure of these problems was predominantly associated with the restriction of usual communications, movement within the country, and foreign travel, accounting for 47.7% in total. A slightly smaller share (40.8%) was attributed to psychological problems, including fear of death, safety, and the health of relatives (fig. 1).




Figure 1. The structure of problems that occurred during the COVID-19 pandemic (2020-2021) according to respondents (survey 2023/24).

Psychological problems during the war were more relevant than during the pandemic and accounted for 58.5% of the structure. At the same time, the share of problems related to the restri-

ction of usual communications and movement decreased from the beginning of the pandemic to 29.2% during the war (fig. 2).

Table 1. Socio-demographic characteristics of respondents.

Determinants		Quantity	Percentage (%)
Total		269	100
Males		68	25.3
Females		201	74.7
Age	18-24	209	77.7
	25-44	39	14.5
	45 and older	21	7.8
Education	Higher	85	31.6
	Incomplete higher	126	46.8
	Secondary specialized	32	11.9
	Secondary	26	9.67
Studying	Total	211	78.4
	Males	52	26.5
	Females	159	79.1
Working	Total	133	49.4
	Males	40	58.8
	Females	93	46.3
Working with those who are studying	Total	88	41.7
	Males	25	48.1
	Females	63	39.6
During the period of martial law	Total	46	17.1
	Males	6	8.8
	Females	40	19.9
Completed studying	Total	30	11.2
	Males	4	5.9
	Females	26	12.9
Started a family	Total	28	10.4
	Males	5	7.4
	Females	23	11.4
Found employment	Total	69	25.7
	Males	16	23.5
	Females	53	26.4
Lost a job	Total	19	7.1
	Males	6	8.8
	Females	13	6.5
Changed their field of activity	Total	26	9.7
	Males	10	14.7
	Females	16	8.0

Financial problems had almost the same share in the structure of complaints – 11.5% during the pandemic and 12.3% at the beginning of the war, with no statistically significant difference between males and females.

Among all COVID problems (593), each respondent named an average of two (2.2), while since the beginning of the war, 780 have been named, with an average of three (2.9).

The frequency of psychological problems differed

significantly. During the war, they were reported more often than during the 2020-21 pandemic, with more than twice as many females (77.1% vs. 34.8%) and three times as many males (52.9% vs. 17.6%). The concern for the safety and mental health of relatives during the war was also twice as significant to respondents (51.7% vs. 26.4%) compared to during the pandemic. During the pandemic, psychological problems in various manifestations, including the fear of death, safety, and mental health of relatives, affected the vast

majority of respondents (59.5%, comprising 42.6% males and 65.2% females), but the impact

of the war surpassed this, affecting 84.8% of respondents (66.2% males and 91.0% females).




Figure 2. The structure of problems that occurred during the full-scale Russian invasion (from 02/24/2022) according to respondents (survey 2023/24).

According to a survey of students in higher education institutions in Ukraine at the beginning of the war in 2022, the vaccination rate was 69.6% (with 70% among males and 69.5% among females). Trust in vaccines and vaccination was observed in 51.6% of respondents, with an additional 18.0% being immunized on demand. Prior to the war, students were meticulous in following anti-epidemic measures against COVID-19: 89.1% (87.7% males, 89.6% females) used masks in public places, 73.4% (68.5% males, 75.1% females) frequently and thoroughly washed their hands or regularly disinfected them, 36.5% (35.4% males, 36.9% females) limited their movements and avoided unnecessary outings. Students often ventilated the room they were in for an extended period (44.7%, with 36.9% males and 47.3% females), maintained social distance (49.3%, with 44.6% males and 50.9% females), avoided crowds and public events (55.3%, with 55.4% males and 55.2% females), and did not use public transport, preferring to walk when possible (40.0%, with 40.0% males and 39.9% females). Only 4.2% of respondents (4.6% males, 4.1% females) admitted to doing nothing to prevent infection.

With the outbreak of war, the attitude towards the implementation of anti-epidemic measures has changed: 43.2% (44.6% males, 42.7% females) answered “no action.” Another 8.2% (10.8% males, 7.4% females) added “no possibility.” Partial measures could be taken by 35.0% of respondents, with fewer males (22.3%) than fe-

males (39.2%) ($t=3.84$, $p<0.001$). However, 13.2% of respondents did not change their infection prevention actions since the beginning of the war, with more males (22.3%) than females (10.2%) ($t=3.06$, $p<0.01$).

As a result, at the end of the second year of the war (1 year and 10 months), the situation with COVID-19, influenza, and other URIs was a concern for only one in four respondents (25.7%), with females (27.9%) expressing this concern more often than males (19.1%) ($t=2.13$, $p<0.05$). A direct correlation was found between male anxiety about the situation with COVID-19, influenza, and URIs and the problem of restricting travel abroad during the 2020/21 pandemic ($r=0.239$, $p<0.05$) and an inverse correlation with continuing education during this period ($r=-0.259$, $p<0.05$). Male anxiety was also influenced by the reassessment of the importance of preserving their own health and that of their loved ones during the war ($r=0.238$), with an error probability of 5.1%.

There was a correlation between female anxiety about the situation with COVID-19, influenza, and other URI and psychological problems that arose during the 2020/21 pandemic ($r=0.198$, $p<0.01$), except for financial problems, which have already been discussed. Female anxiety was also influenced by job loss ($r=0.152$, $p<0.05$), volunteering in the form of participation in the delivery of aid to the front ($r=0.288$, $p<0.01$), and cooking ($r=0.152$, $p<0.01$). A correlation was found bet-

ween the presence of psychological complaints in females at the time of the survey and anxiety about COVID-19, influenza, and other upper respiratory infections ($r=0.163$, $p<0.05$). When applying logistic regression, a statistically significant inverse characteristic was found to be mastery of first aid skills. Thus, with a high probability ($P=0.99\%$), the concerns of female respondents about the current situation can be described as follows: $Z = -8.220 + 1.21a - 0.728b + 2.030c$, where a - financial problems during the 2020/21 pandemic; b - mastering first aid; c - participation in the delivery of aid to the front line.

DISCUSSIONS

The online survey of young people in Chernivtsi and nearby regions of the western part of Ukraine successfully complements the previous 2022 study of students studying at higher education institutions in various regions of Ukraine. The aim is to explore the most significant challenges faced by young people during the COVID-19 pandemic (2020/21) and Russia's full-scale invasion of Ukraine. This study aligns with a survey conducted by the independent think tank Cedos in Ukraine among the civilian population (10, 11, 12).

The research results revealed that in Ukraine (across most of its regions), unlike other LMICs, challenges arising from the war distort commonly accepted strategies for combating infectious diseases. The population, particularly young people, struggle to adhere fully to anti-epidemic measures across all territories. During the war, psychological concerns displaced fears of the pandemic. Psychological issues during the pandemic may lose their relevance in retrospect, potentially impacting the survey results in late 2023 and early 2024. Challenges related to communication

and transportation decreased to 29.2% due to adaptation to the current situation. The smaller proportion of financial issues in the survey conducted among students and graduates of BSMU was attributed to the survey being conducted in the relatively less war-affected territory of Bukovyna.

At the time of the survey, 70.3% of respondents were vaccinated against COVID-19, which could have reduced the fear of getting sick, but was not statistically significant. This may be due to the fact that a significant number of students had already had these infections at the time of the survey. For example, the inverse correlation showed that male students were less likely to be concerned about the situation with COVID-19, influenza, and other URI. Young people seemed to have moved on from COVID-19 as an experience. In the comments to the questionnaire, we read: "Why ask about COVID-19? Are you looking to resume it?" Female anxiety regarding the situation with COVID-19, influenza, and Upper Respiratory Infections (URI) was influenced by job loss (effectively a financial problem) and volunteering, manifested through participating in delivering aid to the front lines and cooking (effectively demonstrating concern for the health and safety of soldiers). Studies among Czech university students [12] associated the female gender with higher levels of anxiety and depressive symptoms. Logistic regression identified an additional stress reduction factor: mastering first aid skills. Among males, this supportive component could be characterized as a reassessment during the war of the importance of preserving their own health and that of their loved ones. Consequently, more males (22.3%) than females (10.2%) did not alter their actions to prevent COVID-19 since the beginning of the war ($p<0.01$).

CONCLUSIONS

1. At the end of the second year of the war, the situation with COVID-19, influenza, and other URIs concerned only one in four respondents (25.7%), and no statistically significant relationship was found between experiences and vaccination (70%) or past illnesses (65%).
2. The psychological challenges faced by young people in Ukraine during the war (84.8%) overshadowed those caused by the pandemic (59.5%), leading to adverse changes in compliance with COVID-19 anti-epidemic measures in the initial months of the war. Notably, 43.2% of respondents reported engaging in no preventive activities.
3. A weak direct correlation was observed between the concerns of males about the situation with COVID-19, influenza, and URIs during the war (2023/24 survey) and the problem of restricting travel abroad during the 2020/21 pandemic ($r=0.239$, $p<0.05$). Additionally, there was an inverse

correlation with the pursuit of continuing education during the survey period.

4. There is a weak direct correlation between females' concerns about the situation with COVID-19, influenza, and other URIs and various factors, which include psychological issues ($r=0.198$, $p<0.01$), financial problems ($r=0.224$, $p<0.01$) arising during the 2020/21 pandemic, job loss ($r=0.152$, $p<0.05$), volunteering in the form of participation in the delivery of aid to the front ($r=0.288$, $p<0.01$), cooking ($r=0.152$, $p<0.01$), and the presence of psychological complaints at the time of the survey ($r=0.163$, $p<0.05$).

CONFLICT OF INTEREST

The authors declare no conflict of interest regarding the study and this paper.

ETHICAL APPROVAL

The study was approved by the Ethics Committee of Bukovinian State Medical University (approval

number 4 from 21.12.2023).

ACKNOWLEDGEMENT

I express my sincere gratitude to the students who responded and involved their friends in filling out the "Let's summarize" survey at the beginning of 2024.

REFERENCES

1. Haileamlak A. The Triple Challenges of Low and Middle-Income Countries. *Ethiop J Health Sci*. 2018;28(1):1-2. doi:10.4314/ejhs.v28i1.1
2. Horton R. Offline: COVID-19 is not a pandemic. *Lancet*. 2020;396:874. doi:10.1016/S0140-6736(20)32000-6
3. Spinei L, Ferdohleb A, Globa N, Nicov I. The COVID-19 pandemic worldwide management – strategies of the World Health Organization and some Countries: a narrative review. *MJHS*, 2020;23 (1): 158-76. Available at: <https://cercetare.usmf.md/ro/revista-mjhs/Arhiva-MJHS/revista-de-stiinte-ale-sanatatii-din-moldova-nr-1-2020-editie-speciala> [Accessed: December 19, 2023].
4. World Health Organization. Health equity and its determinants. World Health Day 2021: It's time to build a fairer, healthier world for everyone, everywhere. Available at: <https://cdn.who.int/media/docs/default-source/world-health-day-2021/health-equity-and-its-determinants.pdf> [Accessed: December 19, 2023].
5. World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. Available at: [https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-coronavirus-disease-\(covid-19\)-pandemic](https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic) [Accessed: December 19, 2023].
6. United Nations Development Programme. Human Development Report 2021-22. Uncertain Times, Unsettled Lives: Shaping our Future in a Transforming World. Available at: https://hdr.undp.org/system/files/documents/global-report-document/hdr2021-22pdf_1.pdf [Accessed: December 19, 2023].
7. United Nations Development Programme and Oxford Poverty and Human Development Initiative. Global Multidimensional Poverty Index 2023 Unstacking global poverty: Data for high impact action. Available at: <https://hdr.undp.org/system/files/documents/hdp-document/2023mpireportenpdf.pdf> [Accessed: December 19, 2023].
8. Haydabrus A, Santana-Santana M, Lazarenko Y, Giménez-Llort L. Current War in Ukraine: Lessons from the Impact of War on Combatants' Mental Health during the Last Decade. *Int J Environ Res Public Health*. 2022;19(17):10536. doi:10.3390/ijerph191710536
9. Hino M, Kunii Y, Gerashchenko BI, Hamaie Y, Egawa S, Kuriyama S, et al. On the Mental Health Needs Under the Russian Invasion in Ternopil, Ukraine: A Preliminary Report on the Provision of Mental Health Service. *Annals of Global Health*. 2023;89(1):41,1-6. doi:10.5334/aogh.4076
10. Bobrova A, Lazarenko V, Khassai Y, Filipchuk L, Syrbu O, Lomonosova N, et al. The First Days of Full-Scale War in Ukraine: Thoughts, Feelings, Actions. Initial research results. *Cedos*. 2022;36. Available at: <https://cedos.org.ua/wp-content/uploads/the-first-days-of-full-scale-war-in-ukraine-4.pdf> [Accessed: December 19, 2023].
11. Khelashvili A, Bobrova A, Khassai Y, Syrbu O, Lomonosova N, Nazarenko Y. A year of full-scale war in Ukraine: thoughts, feelings, actions. *Cedos*. 2023; 86. Available at: <https://cedos.org.ua/wp-content/uploads/layout-one-year-eng.pdf> [Accessed: December 19, 2023].
12. Riad A, Drobov A, Krobot M, et al. Mental Health Burden of the Russian-Ukrainian War 2022 (RUW-22): Anxiety and Depression Levels among Young Adults in Central Europe. *Int J Environ Res Public Health*. 2022;19(14):8418. doi:10.3390/ijerph19148418

SYNERGISTIC ACTION OF CHEMICAL COMPOUNDS AND SPIRULINA EXTRACTS

Dmitri IUNAC, Greta BALAN

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Dmitri Iunac, e-mail: dmitri.iunac@usmf.md

Keywords: chemical compounds, biological compounds, synergistic action, antimicrobial action.

Introduction. Antimicrobial resistance is a critical global issue, and the demand for new drugs is urgent. The current model of antimicrobial discovery is not providing sufficient new agents to address current levels of antimicrobial resistance. In this study, we aim to assess the antimicrobial activity of recently synthesized chemical compounds and spirulina extracts, along with their associative effects.

Material and methods. It is an experimental study, which includes seven newly synthesized chemical compounds and three extracts from *Spirulina platensis*.

Results. The *in vitro* results of the present study determined the MIC values of chemical compounds and spirulina extracts against gram-negative, gram-positive microorganisms, and fungi of the genus *Candida*. The optimal combination of two compounds can enhance benefits over time and minimize side effects. The synergistic or partially synergistic effects of biological compounds in conjunction with chemical compounds strongly corroborated this assertion. Time-kill curves and FICI scores confirmed the ability of the compounds to synergistically reduce the microbial count below the lowest detectable limit within 24 hours.

Conclusions. Our study offers a potential therapeutic option for antibiotic-resistant microbial agents by combining natural extracts with a variety of chemical compounds from different classes. The results of the present study are promising, and this knowledge holds potential utility for the development of future therapeutic strategies.

Keywords: chemical compounds, biological compounds, synergistic action, antimicrobial action.

Cuvinte-cheie: compuși chimici, compuși biologici, acțiune sinergică, acțiune antimicrobiană.

ACȚIUNEA SINERGICĂ A COMPUȘILOR CHIMICI ȘI A EXTRACTELOR DIN SPIRULINĂ

Introducere. Rezistența la antimicrobiene reprezintă o problemă globală gravă, de aceea obținerea unor noi remedii cu acțiune antimicrobiană este o urgență. Modelul actual de descoperire a antimicrobienei nu furnizează agenți noi, suficienți pentru combaterea nivelurilor actuale de rezistență la antimicrobiene. În acest studiu ne-am propus să evaluăm activitatea antimicrobiană a unor compuși chimici noi sintetizați și a extractelor din spirulină, precum și efectele asociative ale acestora.

Material și metode. În prezentul studiu experimental au fost testați șapte compuși chimici noi sintetizați și trei extracte din *Spirulina platensis*.

Rezultate. *In vitro* au fost determinate valorile CMI ale celor șapte compuși chimici noi sintetizați și a trei extracte din spirulină împotriva microorganismelor gramnegative, grampozitive și a micetelor din genul *Candida*. Combinația adecvată a doi compuși poate mări beneficiile în timp și minimaliza reacțiile adverse. Efectele sinergice sau parțial sinergice ale compușilor biologici în combinație cu compușii chimici au susținut acest efect. Curbele de omorâre în timp și scorurile FICI au confirmat capacitatea compușilor testați de a reduce sinergic numărul de microorganisme sub cea mai mică limită detectabilă în 24 de ore.

Concluzii. Studiul oferă o opțiune terapeutică potențială pentru agenții microbieni rezistenți la antibiotice prin combinarea extractelor naturale și a compușilor chimici din diferite clase. Rezultatele obținute sunt promițătoare și pot fi utile pentru dezvoltarea viitoarelor strategii terapeutice.

INTRODUCTION

Bacterial resistance to conventional antimicrobials has become a significant and life-threatening issue worldwide, imposing a substantial economic burden on healthcare systems.

Over the recent decades, the number of antimicrobial-resistant bacteria has increased dramatically due to the widespread use of antibiotics (1, 2). Despite the emergence of new antibiotics with different mechanisms of action, the process of drug discovery and development typically spans between 10 and 17 years, with a success rate below 10% (3). Furthermore, while new single-target antimicrobials are widely used, new antibiotic-resistant strains will inevitably arise.

This ever-growing challenge makes the discovery of new antibiotics inevitable, as well as the development of new alternative approaches. Increased attention among these alternative approaches has been given to antimicrobials combined with plant extracts. The latter approach, namely, the combination therapy or synergistic therapy used in combating resistant microorganisms can lead to new ways of treating infectious diseases, which is likely to outline a potential area for future investigations. Combination therapy is also efficient in patients with severe infections caused by antibiotic-resistant pathogens. Synergism consists of intensifying the pharmacodynamic effects of two or more associated compounds (4).

Combination therapy is the most common empirical treatment recommended in cases of bacterial infections within intensive care units, where monotherapy may not be effective against all the potential disease-causing pathogens. Moreover, combination therapy may reduce the drug dosage and thus minimize the side effects, which might result in overcoming the toxicity problem and the spread of resistant microbial strains (5).

MATERIAL AND METHODS

Chemical compounds

The study included the following chemical compounds, which were synthesized at the Department of Inorganic Chemistry, Department of Chemistry, at State University of Moldova: C1 ($C_{14}H_{19}CuN_7O_4S$), C2 ($C_{13}H_{16}Br_2CuN_4S$), C3 ($C_{10}H_{14}CuN_4O_5S_2$), C4 ($C_{13}H_{17}ClCuN_4S$), C5 ($C_{18}H_{20}CuN_4O_2S$), C6 ($C_{14}H_{20}N_4S$) and C7 ($C_{14}H_{19}ClCuN_4S$).

ES1, ES2 and ES3 *Spirulina* extracts

The biologically active complexes *ES1*, *ES2* and *ES3* extracts were obtained through a biotechnological process from the cyanobacterial strain of *Spirulina platensis* CNMN CB-02 (*Spirulina*), stored within the National Collection of Non-Pathogenic Microorganisms, at the Institute of Microbiology and Biotechnology.

Spirulina biomass was obtained from a cyanobacterial growth culture and through controlled synthesis of its biologically active compounds. Biologically active complexes, encompassing free amino acids, oligopeptides, proteins, sulphated polysaccharides, and phospholipids, were extracted from the *Spirulina* biomass. These extracts were successively fractionated and purified by using benign solvents and techniques. Relevant formulas were developed and standardized for complex compositions of extracts, based on biologically active complexes derived from *Spirulina* biomass. All extracts were natural and devoid of herbicides, toxins, or preservatives.

ES1 spirulina extract is an amino acid/oligopeptide complex, which contains non-essential (glycine, alanine, serine, cysteine, tyrosine, aspartic acid, glutamic acid, and proline) and essential amino acids (arginine, phenylalanine, histidine, isoleucine, leucine, lysine, threonine, tryptophan, and valine), being in their free state or combined in oligopeptides (up to 10kDa), as well as biologically functionalized macro- and microelements.

In vitro tests were used for *ES1 form*, which is an alcoholic solution, having 10mg/ml of extract concentration and 50% of alcohol concentration.

ES2 spirulina extract is a synergistic combination of amino acid/oligopeptide complex, sulfated polysaccharides, proteins, and biologically functionalized macro- and microelements derived from *spirulina*. For the *ES2 form*, *in vitro* tests were conducted using an alcoholic solution with a concentration of 20 mg/ml of extract and 45% alcohol concentration.

ES3 spirulina extract is a glycosidic carotenoid. *In vitro* tests were conducted using an 80% aqueous-ethanol solution.

Microbial strains

Microbial strains of *Staphylococcus aureus* ATCC 25923, *Bacillus subtilis* ATCC 6633, *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC

27853, *Acinetobacter baumannii* ATCC BAA-747, and *Candida albicans* ATCC 10231 were used in the study. The microbial strains were cultured on appropriate nutrient media at their optimum growth temperature. Overnight cultures of the bacterial strains were used for further investigations.

Antimicrobial activity

Serial culture dilutions were used to determine the antibacterial activity of the plant, allowing for the assessment of the minimum inhibitory concentration (MIC) and the minimum bactericidal/fungicidal concentration (MBC/MFC). MIC and MBC/MFC were determined using a discontinuous gradient of extract concentrations tested in Muller-Hinton broth, followed by the addition of 100 µL of bacterial suspension according to the 0.5 McFarland turbidity standard. The tubes were then incubated at 35-37°C for 18-24 hours, and the MIC value was determined by macroscopic analysis of the tubes, based on the presence or absence of bacterial growth. MBC/MFC was determined by replicates of Muller-Hinton agar dilution. The MBC/MFC value represented the lowest concentration of extract that reduced the number of microbial colonies by up to 99.9% (6, 7).

The negative control sample consisted of Muller-Hinton broth containing the studied extracts, while the positive control sample involved Muller-Hinton broth inoculated with the studied microorganisms. All experiments were conducted in triplicate.

Methods of synergy testing

The combined antibacterial effects of two preparations were assessed using the checkerboard method, followed by the determination of the FIC index (Fractional Inhibitory Concentration). Stock solutions and double dilutions of each compound were prepared in accordance with EUCAST recommendations immediately before testing (6). The assays were conducted in multiwell plates, with 50 µL of Mueller-Hinton broth added per well. The first combined compound was serially diluted along the y-axis (y), while the second compound was diluted along the abscissa axis (x). A suspension corresponding to the McFarland 0.5 turbidity standard was prepared from the tested strain, and subsequently, 100 µL of microbial suspension (5×10^5 CFU / ml) was added to each well. The plates were incubated at 35°C for 24 hours aerobically.

Fractional inhibitory concentration was calculated using the MIC of the combined compounds, as well as the MIC of each compound obtained through parallel testing, according to the following formula:

where,

$$\Sigma FIC = FIC (A) + FIC (B)$$

$$FIC (A) = \frac{MIC (A) \text{ combination}}{MIC (A) \text{ alone}}$$

and

$$FIC (B) = \frac{MIC (B) \text{ combination}}{MIC (B) \text{ alone}}$$

The ΣFIC values were interpreted as follows: $\Sigma FIC \leq 0,5$ = Synergistic; $0,5 < \Sigma FIC \leq 1$ = Additive; $1 < \Sigma FIC \leq 4$ = Indifferent; $\Sigma FIC > 4,0$ = Antagonistic.

Time-Kill Assay

Time-Kill Assay enables the measurement of changes in the population of aerobic microorganisms over a defined period in the presence of antimicrobial agents. The assay was conducted on *S.aureus*, *E.coli* and *C.albicans* strains, based on the aforementioned method with minor modifications (8). A saline suspension was prepared from an 18-24 hour microbial culture, by finally obtaining an inoculum of 1×10^6 CFU/mL. This suspension was evenly distributed into four tubes: I tube (culture control sample) - Mueller Hinton broth; II tube - Mueller Hinton broth + 0.5×CMI extract; III tube - Mueller Hinton broth + 1×CMI extract; IV tube - Mueller Hinton broth + 2×CMI extract. The tubes were incubated at 35°C for 24 hours. 100 µL from each tube was replicated on the plate medium at specific intervals. Afterwards, the plates were incubated at 37°C for 24 hours and the CFU/plate was measured, followed by CFU/mL (the mean number of colonies multiplied by dilution). The tests were performed in triplicate (three independent experiments).

Time-Kill curves were graphically represented by $\log_{10}$ CFU mL⁻¹ versus the 24-hour time period. Bactericidal activity (99.9% of killing) was defined as a ≥ 3 - $\log_{10}$ CFU mL⁻¹ reduction in the number of colonies from the initial inoculum.

Statistical analysis

Data are expressed as mean standard deviation. Statistical analysis involved a one-way analysis of variance (ANOVA). $P < 0.001$ was considered to indicate a statistically significant difference.

RESULTS

The antimicrobial effect of chemical compounds and biologically active complex extracts derived from the cyanobacterium *Spirulina platensis*, namely *ES1*, *ES2*, and *ES3*, were observed during the initial stage of the present research.

Based on this, we conducted in vitro assays to assess the bactericidal and antifungal effects of

seven new chemical compounds on gram-positive bacteria, gram-negative bacteria, and fungi of the genus *Candida*. The tests demonstrated that all chemical compounds exhibited superior bactericidal and bacteriostatic actions against gram-positive bacteria. In comparison to control drug preparations (Furacillin and Miconazole), most compounds were effective at lower doses (tab. 1).

Table 1. The antibacterial activity of chemical compounds against some microbial strains (µg/mL).

Chemical compounds		<i>S. aureus</i>	<i>B. subtilis</i>	<i>A. baumannii</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>C. albicans</i>
C1	MIC	0.976	0.976	0.976	7.812	250	15.62
	MBC	1.953	0.976	1.953	15.62	500	31.25
C2	MIC	0.976	0.976	15.62	15.62	125	3.906
	MBC	1.953	1.953	31.25	31.25	250	7.812
C3	MIC	0.122	0.122	1.953	3.906	15.62	31.25
	MBC	0.244	0.244	3.906	7.812	31.25	62.5
C4	MIC	0.488	0.122	7.812	15.62	>500	1.953
	MBC	1.953	0.122	15.62	31.25	>500	31.25
C5	MIC	0.488	0.244	3.906	7.81	125	7.81
	MBC	0.976	0.488	7.812	15.62	250	15.62
C6	MIC	0.061	1.953	0.25	>500	>500	0.976
	MBC	0.244	3.906	0.50	>500	>500	1.953
C7	MIC	0.976	0.488	62.50	31.25	>500	7.812
	MBC	1.953	0.976	125	62.50	>500	15.62
Furacillinum	CMI	4.67	4.67	4.67	4.67	4.67	-
	MBC	4.67	4.67	9.35	4.67	9.35	-
Miconazole	MIC	-	-	-	-	-	16.0
	MFC	-	-	-	-	-	32.0

Note: *S. aureus* (*Staphylococcus aureus* ATCC 25923); *B. subtilis* (*Bacillus subtilis* ATCC 6633); *A. baumannii* (*Acinetobacter baumannii* BAA-747); *E. coli* (*Escherichia coli* ATCC 25922); *P. aeruginosa* (*Pseudomonas aeruginosa* ATCC 27853); *C. albicans* (*Candida albicans* ATCC 10231). MIC – minimum inhibitory concentration; MBC – minimum bactericidal concentration; MFC – minimum fungicidal concentration.

C6 (*S. aureus* MIC 0.061 µg/mL), C4 and C5 (*S. aureus* MIC 0.488 µg/mL) were identified as the most active compounds against gram-positive strains. Compounds C6 (*A. baumannii* MIC 0.25 µg/mL) and C1 (*A. baumannii* MIC 0.976) exhibited a higher activity on gram-negative strains. Only four compounds were active against *P. aeruginosa* strains, the most active being C3 (MIC 15.62).

C. albicans strain demonstrated sensitivity to all tested compounds, whereas C6 (MIC 0.976) and C4 (MIC 1.953) compounds showed a higher low-dose activity.

The experimental testing of the biological com-

pounds showed that all extracts of *S. platensis* exhibited promising antimicrobial activity against both gram-positive and gram-negative bacterial strains used in the present research (tab. 2).

The *ES3* extract exhibited a high antibacterial and antifungal activity compared to *ES1* and *ES2* extracts. The highest activity of *ES3* extract was recorded against *B. subtilis* strains (MIC 0.004 mg/mL) and *C. albicans* strains (0.004 mg/mL), as well as against gram-negative bacillus strains, being active at MIC 0.009 mg/mL. The *ES2* extract displayed bacteriostatic activity against all tested species at higher concentrations, compared to *ES1* and *ES3* extracts.

Table 2. The action of biologically active complex extracts of *Spirulina platensis* against some bacterial strains.

Species	ES1		ES2		ES3		Ampicillin
	MIC mg/mL	MBC mg/mL	MIC mg/mL	MBC mg/mL	MIC mg/mL	MBC mg/mL	MIC µg/mL
Gram-positive bacteria							
<i>S. aureus</i> ATCC 25923	0.625	1.25	2.5	5.0	0.018	0.037	0.08
<i>B. subtilis</i> ATCC 6633	0.156	0.156	2.5	5.0	0.004	0.004	0.078
Gram-negative bacteria							
<i>P. aeruginosa</i> ATCC 27853	0.625	1.25	1.25	2.5	0.009	0.018	0.012
<i>E. coli</i> ATCC 25922	0.625	1.25	2.5	5.0	0.009	0.018	0.025
<i>A. baumannii</i> BAA-747	0.625	1.25	1.25	2.5	0.009	0.018	0.25
Yeast	MIC mg/mL	MFC mg/mL	MIC mg/mL	MFC mg/mL	MIC mg/mL	MFC mg/mL	Miconazole MIC µg/ml
<i>C. albicans</i> ATCC 10231	0.625	1.25	1.25	2.5	0.004	0.009	16.0

Subsequently, the synergistic action of the chemical compounds combined with the biological compounds was assayed on six reference strains. The determination of the Fractional Inhibitory Concentration Index revealed synergistic actions in 87.2% of cases, additive actions in 6.8%, and indifferent actions in 6.0%. The tested compounds did not show any antagonistic relationship (FICI > 4) (ta. 3).

The testing of the chemical compound C1 combined with three biological compounds revealed the synergism phenomenon in most cases, except for *P. aeruginosa* bacteria, where the additive and indifferent phenomenon were registered in combinations with ES1 and ES2, respectively.

The C2 compound showed synergism against the tested bacteria in all combinations, with the exception of its combination with the ES2 compound. In this particular case, an indifferent action (FICI-1.56) was observed against the *P. aeruginosa* strain.

The C3 compound, in combination with biological compounds, exhibited synergistic action in 72.2% of cases, additive action in 22.2% of cases, and indifferent action in 5.6% of cases against the tested strains, whereas the C4 compound showed predominantly synergistic action (94.4%) and additive action in only 5.6% of cases.

The C5 compound, when combined with ES2, showed indifferent action against *E. coli* and *P. aeruginosa* strains. Additionally, when combined with ES1, it showed indifference against *P. aeruginosa* strains only.

C6 exhibited indifferent action against *A. baumannii* strain when combined with ES2 and showed additive action in combination with ES1. On the other hand, the C7 compound, when combined with ES2, revealed an additive effect against *E. coli* strains.

The chemical compounds combined with the biological compound ES3 showed a synergistic action against all tested bacterial species, except for C3 that showed additive effects (FICI 0.56) against *P. aeruginosa* strains.

The minimum inhibition concentrations for the combined chemical and biological compounds resulted in a 4 to 32-fold decrease in the MIC of the parent compound (tab. 4). The additive and indifferent actions were particularly recorded against gram-negative bacilli and fungi of the *Candida* genus.

To determine the synergistic activity of the chemical compounds in combination with the biological compounds, along with the treatment duration and efficiency on the viability of microbial cells, the time-kill behavior was assessed.

Table 3. Interaction between chemical compounds and biological compounds expressed by FICI.

Tested compounds	<i>S. aureus</i> ATCC 25923	<i>B. subtilis</i> ATCC 6633	<i>A. baumannii</i> BAA-747	<i>E. coli</i> ATCC 25922	<i>P. aeruginosa</i> ATCC27853	<i>C. albicans</i> ATCC 10231
C1	ES1	0.35 (S)	0.12 (S)	0.5 (S)	0.32 (S)	0.61 (Ad)
	ES2	0.32 (S)	0.35 (S)	0.5 (S)	0.37 (S)	1.37 (I)
	ES3	0.35 (S)	0.12 (S)	0.40 (S)	0.32 (S)	0.5 (S)
C2	ES1	0.32 (S)	0.35 (S)	0.30 (S)	0.35 (S)	0.5 (S)
	ES2	0.35 (S)	0.35 (S)	0.30 (S)	0.35 (S)	1.56 (I)
	ES3	0.12 (S)	0.12 (S)	0.32 (S)	0.35 (S)	0.44 (S)
C3	ES1	0.37 (S)	0.35 (S)	0.32 (S)	0.32 (S)	0.75 (Ad)
	ES2	0.44 (S)	0.32 (S)	0.44 (S)	0.56 (Ad)	1.23 (I)
	ES3	0.32 (S)	0.12 (S)	0.25 (S)	0.32 (S)	0.56 (Ad)
C4	ES1	0.32 (S)	0.35 (S)	0.5 (S)	0.44 (S)	0.5 (S)
	ES2	0.37 (S)	0.32 (S)	0.5 (S)	0.5 (S)	0.84 (Ad)
	ES3	0.32 (S)	0.32 (S)	0.44 (S)	0.44 (S)	0.44 (S)
C5	ES1	0.32 (S)	0.25 (S)	0.32 (S)	0.5 (S)	1.23 (I)
	ES2	0.32 (S)	0.32 (S)	0.37 (S)	1.24 (I)	1.42 (I)
	ES3	0.30 (S)	0.35 (S)	0.25 (S)	0.44 (S)	0.5 (S)
C6	ES1	0.35 (S)	0.37 (S)	0.56 (Ad)	NT	NT
	ES2	0.32 (S)	0.44 (S)	1.07 (I)	NT	NT
	ES3	0.12 (S)	0.32 (S)	0.5 (S)	NT	NT
C7	ES1	0.35 (S)	0.25 (S)	0.44 (S)	0.5 (S)	NT
	ES2	0.32 (S)	0.32 (S)	0.5 (S)	0.84 (Ad)	NT
	ES3	0.32 (S)	0.25 (S)	0.37 (S)	0.44 (S)	NT

Note: Synergistic (S) actions- $FICI \leq 0.5$; Additive (Ad) actions - $0.5 < FICI \leq 1$; Indifferent actions (I) - $1 < FICI \leq 4$; Antagonistic actions (An) $FICI > 4$; NT – not tested.

Distinct time-kill profiles were recorded for each bacterial strain within 24 hours after inoculation. The results indicated no increase in the microbial strains tested in the first 30 minutes after inoculation. However, variations in antimicrobial activity among the tested compounds or bacterial strains were observed over the subsequent 90 minutes of incubation. No decrease in the number of CFUs was noted in the control tubes, and the use of chemical or biological compounds alone at a concentration of 0.5MIC did not induce bacterial death unless observed over 24 hours.

The combined chemical and biological compounds showed a significant reduction in the number of microorganisms. The combination of chemical compounds with ES3 exhibited the best results on the tested species, as the microorganisms were killed over 8, 12, 16 and 20 hours. The combinations of 0.25MIC C1 + 0.25×MIC ES3 and 0.25×MIC C2 + 0.25×MIC ES3 completely inhibited the growth of *S. aureus* strains over 8 hours.

The combinations of chemical compounds with the ES2 biological compound showed bactericidal action for 16 and 20 hours. Notably, only the combination of ES3 with C2 displayed a bactericidal action against *S. aureus* strains over 8 hours.

DISCUSSIONS

Arthrospira platensis (also called *Spirulina platensis*), one of the most well-known cyanobacteria produced on an industrial scale, has attracted the attention of researchers as a natural compound with therapeutic properties and potential antimicrobial effect (antibacterial, antifungal, and antiviral). During the investigation of *Arthrospira platensis* as a source of proteins, vitamins (such as vitamin B12 and provitamin A), and essential fatty acids such as γ -linolenic acid, biologically active compounds with antimicrobial activity against some species of microorganisms were obtained. Therefore, commercial production of spirulina has gained importance worldwide due to

its multiple benefits. Spirulina can suppress the growth of several microorganisms due to its rich content of bioactive ingredients with antimicrobial activity. The effectiveness of spirulina extracts on microorganisms with multiple resistance to antimicrobials was experimentally demonstrated. Their antimicrobial activity is attributed to the presence of carbohydrates, phenolic compounds, flavonoids, and tannins in their

composition. One objective of this study was to investigate the antimicrobial activity of spirulina, and the results indicated that spirulina extracts have a greater potential to inhibit the growth of gram-positive bacteria compared to gram-negative bacteria. This effect can be attributed to the complicated structure of the cell wall (outer membrane) of gram-negative bacteria (9, 10, 11).

Table 4. The synergistic antimicrobial effects of chemical and biological compounds against the reference strains.

Tested com- pounds	<i>S. aureus</i> ATCC 25923	<i>B. subtilis</i> ATCC 6633	<i>A. baumannii</i> BAA-747	<i>E. coli</i> ATCC 25922	<i>P. aeruginosa</i> ATCC27853	<i>C. albicans</i> ATCC 10231	
C1	ES1	1/32 _C + 1/16 _B	1/32 _C +1/32 _B	1/4 _C + 1/4 _B	1/16 _C + 1/8 _B	-	1/16 _C + 1/8 _B
	ES2	1/16 _C + 1/8 _B	1/32 _C +1/16 _B	1/4 _C + 1/4 _B	1/8 _C + 1/8 _B	-	1/16 _C + 1/32 _B
	ES3	1/32 _C + 1/16 _B	1/32 _C + /32 _B	1/16 _C + 1/4 _B	1/8 _C + 1/16 _B	1/4 _C + 1/4 _B	1/16 _C + 1/8 _B
C2	ES1	1/8 _C + 1/16 _B	1/32 _C +1/16 _B	1/8 _C + 1/32 _B	1/32 _C + 1/16 _B	1/4 _C + 1/4 _B	1/8 _C + 1/4 _B
	ES2	1/16 _C + 1/32 _B	1/32 _C +1/16 _B	1/8 _C + 1/32 _B	1/16 _C + 1/32 _B	-	1/4 _C + 1/8 _B
	ES3	1/32 _C + 1/32 _B	1/32 _C +1/32 _B	1/16 _C + 1/8 _B	1/32 _C + 1/16 _B	1/4 _C + 1/4 _B	1/8 _C + 1/8 _B
C3	ES1	1/8 _C + 1/8 _B	1/32 _C +1/16 _B	1/16 _C + 1/8 _B	1/16 _C + 1/8 _B	-	1/4 _C + 1/4 _B
	ES2	1/8 _C + 1/4 _B	1/16 _C + 1/8 _B	1/4 _C + 1/8 _B	-	-	-
	ES3	1/16 _C + 1/8 _B	1/32 _C +1/32 _B	1/16 _C +1/16 _B	1/16 _C + 1/8 _B	-	1/4 _C + 1/8 _B
C4	ES1	1/16 _C + 1/8 _B	1/32 _C +1/16 _B	1/4 _C + 1/4 _B	1/4 _C + 1/8 _B	1/4 _C + 1/4 _B	1/8 _C + 1/8 _B
	ES2	1/8 _C + 1/8 _B	1/16 _C + 1/8 _B	1/4 _C + 1/4 _B	1/4 _C + 1/4 _B	-	1/8 _C + 1/4 _B
	ES3	1/8 _C + 1/16 _B	1/8 _C + 1/16 _B	1/8 _C + 1/4 _B	1/8 _C + 1/4 _B	1/8 _C + 1/4 _B	1/16 _C + 1/8 _B
C5	ES1	1/16 _C + 1/8 _B	1/16 _C +1/16 _B	1/16 _C + 1/8 _B	1/4 _C + 1/4 _B	-	1/8 _C + 1/4 _B
	ES2	1/8 _C + 1/16 _B	1/8 _C + 1/16 _B	1/8 _C + 1/8 _B	-	-	1/4 _C + 1/4 _B
	ES3	1/32 _C + 1/8 _B	1/32 _C +1/16 _B	1/16 _C + 1/8 _B	1/8 _C + 1/4 _B	1/4 _C + 1/4 _B	1/8 _C + 1/8 _B
C6	ES1	1/32 _C + 1/16 _B	1/8 _C + 1/8 _B	-	NT	NT	1/16 _C + 1/8 _B
	ES2	1/16 _C + 1/8 _B	1/8 _C + 1/4 _B	-	NT	NT	1/8 _C + 1/8 _B
	ES3	1/32 _C + 1/32 _B	1/16 _C + 1/8 _B	1/4 _C + 1/4 _B	NT	NT	1/32 _C + 1/16 _B
C7	ES1	1/32 _C + 1/16 _B	1/16 _C +1/16 _B	1/8 _C + 1/4 _B	1/4 _C + 1/4 _B	NT	1/4 _C + 1/16 _B
	ES2	1/8 _C + 1/16 _B	1/8 _C + 1/16 _B	1/4 _C + 1/4 _B	-	NT	1/4 _C + 1/8 _B
	ES3	1/8 _C + 1/16 _B	1/16 _C +1/16 _B	1/8 _C + 1/8 _B	1/8 _C + 1/4 _B	NT	1/16 _C + 1/32 _B

In recent years, the number of works dedicated to the research of coordination complexes has increased significantly, which indicates the increased interest of researchers in these chemical compounds. The main advantages of these compounds are their homogeneity, stability, the possibility of exact dosing, the ease of assessing metabolic processes, as well as the strict observance of technological operations. Most of the studies emphasize the potential for controlling the properties and biological effects of these compounds (12, 13).

Coordination chemistry remains one of the most important and current areas of inorganic chemis

try. Of particular interest is the synthesis and study of the physico-chemical properties of coordination complexes formed by transition metals with organic ligands. Ligands with a high coordination tendency form compounds with diverse compositions, structures, and properties. Due to their valuable biological activity, these compounds are used in medical practice. Among them are heterocyclic thiosemicarbazones with antibacterial, antifungal, antimalarial, and antiviral properties (14, 15).

In recent decades, the development of new antimicrobial drugs has been based on combining traditional antimicrobials with various coordinating

compounds. The remarkable results of these studies have been confirmed by the intensification of activity and broadening of the spectrum of action when using compounds with both synergistic and cumulative effects, as well as the prevention of antimicrobial resistance. This approach also allows for the reduction of treatment doses, costs, and toxic side effects (16).

The research of recent years has not only highlighted a new alternative in combating multiresistant microorganisms but has also suggested the possibility of restoring the antimicrobial effect of some antimicrobials previously categorized as ineffective. Promising results have also been observed when natural compounds with antimicrobial action were combined with synthetic antimicrobials. The combined use of natural and synthetic antimicrobial compounds in the treatment of infectious diseases potentiates the antimicrobial spectrum, reduces the toxicity of some antimicrobials, and prevents the development of antimicrobial resistance (17, 18).

Combination therapy is more effective in polymicrobial infections compared to monotherapy. Antimicrobial remedies of natural origin, when used

in combination with synthetic medicines, have shown a series of effective interactions, including the synergistic amplification of antimicrobial potential and reduction of the adverse effects of synthetic medicines. These synergistic effects of combined medicines reduce therapeutic failures, increase efficacy, and shorten hospital stays (19, 20).

The synergy of natural medicines combined with antimicrobials, particularly against microorganisms prone to developing resistance, has been investigated by several researchers. Some have observed that *Berberis aetnensis* leaf extracts significantly reduce the minimum inhibitory concentration of ciprofloxacin, thereby restoring its efficacy in the therapy of *S. aureus*, *E. coli* and *P. aeruginosa* infections. In another study, a significant increase in antimicrobial activity against multiresistant *P. aeruginosa* strains was demonstrated when antibiotics were combined with clove, jambolan, pomegranate, and thyme extracts. The use of clove-ampicillin and clove-tetracycline combinations resulted in increased antimicrobial activity against *K. pneumoniae* and *Proteus* spp. strains (20).

CONCLUSIONS

1. All chemical and biological compounds included in the study have exhibited antibacterial and antifungal activity at various concentrations.
2. 87.2% of the combinations of chemical compounds with biological ones exhibited synergistic actions, while only 6.8% showed additive actions, and 6.0% were indifferent. Additive and indifferent effects were particularly observed on gram-negative bacilli and yeast-like fungi. No antagonistic actions were recorded when combining chemical compounds with biological ones. In combinations, the MIC for chemical and biological compounds decreased from four to 32 times compared to the MIC of individual compounds.
3. When using chemical and biological compounds at a concentration of 0.25 times the MIC, in most cases, there was no recorded reduction in the number of microbial cells. However, when these compounds were combined, the microorganisms were killed within 8-24 hours. The shortest time for microbial destruction (8-20 hours) was observed when combining chemical compounds with the biological compound ES3.
4. This study presents a potential therapeutic option for antibiotic-resistant microorganisms by combining natural extracts with a range of different classes of chemical compounds. The most effective approach to developing antimicrobials with minimal toxic or adverse side effects is through the use of natural products.

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ETHICAL APPROVAL

The study was conducted and approved by the Ethics Committee no. 3/14.04.2023 of *Nicolae Testemitanu* State University of Medicine and Pharmacy of the Republic of Moldova.

REFERENCES

- Balan G. Antibiotic susceptibility and factors involved in virulence and persistence of *Acinetobacter baumannii* strains. *The Moldovan Medical Journal*. 2021;64(1):5-9. doi:10.5281/zenodo.4527024
- Balan G. Rezistența la antibiotice și formarea biofilmelor de către tulpinile de *Staphylococcus aureus* izolate din ulcere trofice [Antibiotic resistance and biofilm formation by *Staphylococcus aureus* strains isolated from trophic ulcers]. *Sănătate Publică, Economie și Management în Medicină*. 2020; 1(83):48-52. Available online: https://repository.usmf.md/bitstream/20.500.12710/9075/1/BALAN_Greta_REZISTENTA.pdf [Accessed on 16 Dec.2023].
- Almaaytah A, Alnaamneh A, Abualhaijaa A, Alshari N, Al-Balas Q. *In vitro* synergistic activities of the hybrid antimicrobial peptide melitap-27 in combination with conventional antibiotics against planktonic and biofilm forming bacteria. *Int. J. Pept. Res. Ther.* 2016;22, 497–504. doi:10.1007/s10989-016-9530-z
- Cheesman MJ, Ilanko A, Blonk B, Cock IE. Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution? *Pharmacogn Rev.* 2017;11(22):57-72. doi:10.4103/phrev.phrev.21_17
- Soren O, Brinch KS, Patel D, Liu Y, Liu A, Coates A, et al. Antimicrobial peptide novicidin synergizes with rifampin, ceftriaxone, and ceftazidime against antibiotic-resistant *Enterobacteriaceae* *in vitro*. *Antimicrob. Agents Chemother.* 2015;59: 6233–6240. doi:10.1128/AAC.01245-15
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters Version 8.1. Available online: http://www.eucast.org/clinical_breakpoints [Accessed on 12 Dec.2023].
- CLSI, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, 2nd ed., NCCLS document M27-A2. CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA, 2002. Available online: https://clsi.org/media/1461/m27a3_sample.pdf [Accessed on 02 Dec.2023].
- Petersen PJ, Labthavikul P, Jones CH, Bradford PA. *In vitro* antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. *J Antimicrob Chemother.* 2006;57(3): 573–6. doi:10.1093/jac/dki477
- Behta E, Burduniuc O, Bucova V, Craciun O, Bivol M, Burduniuc A, Brinza O, Grumeza M, Balan G. Antimicrobial discovery – impact of the natural sources. *Studia Universitatis Moldaviae*. 2020; 4(131);263-278. doi:10.5281/zenodo.4431529
- Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. *Molecules*. 2020;16;25(6):1340. doi:10.3390/molecules25061340
- Burduniuc O, Djur S, Chiriac T, Rudic V, Balan G. In vitro evaluation of antimicrobial and biofilm inhibitory activity of *Spirulina platensis* extracts. *Health of Society*. 2021;9(3):118-123. doi:10.22141/2306-2436.9.3.2020.219242
- Gulea A, Usataia I, Graur V, et al. Synthesis, Structure and Biological Activity of Coordination Compounds of Copper, Nickel, Cobalt, and Iron with Ethyl N'-(2-Hydroxybenzylidene)-N-prop-2-en-1-ylcarbamohydrazonothioate. *Russ J Gen Chem*. 2020;90:630-639. doi:10.1134/S107036322004012X
- Lozan-Tirsu C, Zariciuc E. Biochemical Composition Changes of Gram-Negative Microorganisms under the Action of New Chemical Compounds". *One Health & Risk Management*. 2021;3(2):55-60. doi:10.38045/ohrm.2021.3.09
- Gulea A, Graur V, Diurici E, Ulchina Iu, Bourosh P, Balan G, Burduniuc O, Tsapkov V, Rudic V. Synthesis, Structure, and Biological Activity of Copper (II), Nickel (II), Cobalt (III), and Iron (III) Coordination Compounds with 2-[2-[(Prop-2-en-1-yl) carbamothioyl] hydrazinylidene] propanoic Acid. *Russian Journal of General Chemistry*. 2020;9(11): 2120-2127. doi:10.1134/S107036322011016X
- Gulea A, Mitkevich N, Chumakov Y, Petrenko P, Balan G, Burduniuc O, Tsapkov V. Synthesis, Structure, and Biological Activity of Coordination Compounds of Cobalt (II), Nickel (II), and Copper (II) with N-(Methoxyphenyl)-2-[(5-nitrofuryl) methylene] hydrazine Carbothioamides. *Russian Journal of General Chemistry*. 2019;89:1415-1423. doi:10.1134/S1070363219070119
- Claudel M, Schwarte J, Fromm K. New Antimicrobial Strategies Based on Metal Complexes. *Chemistry*. 2020;2(4):849-899. doi:10.3390/chemistry2040056
- Kragh K, Gijón D, Maruri A, Antonelli A, Coppi M, Kolpen M, Crone S, Tellapragada C, Hasan B, Radmer S, et al. Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening. *Journal of Antimicrobial Chemotherapy*. 2021;76(4):1001-1009. doi:10.1093/jac/dkaa543
- Saqib S, Alqahtani N, Ahmad I, Kader M, Al Shahrani S, Asiri E. Evaluation and Comparison of Antibacterial Efficacy of Herbal Extracts in Combination with Antibiotics on Periodontal pathobionts: An *in vitro* Microbiological Study. *Antibiotics*. 2019;8(3):89-101. doi:10.3390/antibiotics8030089
- Sheard D, O'Brien-Simpson N, Wade J, Separovic F.

20. Combating bacterial resistance by combination of antibiotics with antimicrobial peptides. *Pure and Applied Chemistry*. 2019;91(2):199-209. doi:10.1515/pac-2018-0707
21. Silva D, Costa P, Ribon A, Purgato G, Diaz G, Diaz M. Plant Extracts Display Synergism with Different Classes of Antibiotics. *An Acad Bras Cienc*. 2019; 91(2):e20180117. doi:10.1590/0001-3765201920180117

METHODS FOR STIMULATING COGNITIVE ABILITIES USED BY STUDENTS

Mariana CERNITANU

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Mariana Cernitanu, e-mail: mariana.cernitanu@usmf.md

Keywords: cognitive ability, learning activity, stimulation, students.

Introduction. The modern workplace requires workers to have broad cognitive and affective abilities. For continuous progress and societal improvement, students' education plays a crucial role, and for this, students need a high level of cognitive abilities to apply in their learning activities, reflecting in their academic performance. There are several methods to stimulate cognitive abilities, which can be healthy, unhealthy, or a combination of both. The aim of the research is to identify and describe the methods used by students to stimulate cognitive abilities in their learning activities.

Material and methods. Google Drive questionnaire. Sample -212 of respondents.

Results. It was found that students prefer physical activities to stimulate their cognitive abilities. The most common method is walking (45.7%), followed by workout (17.10%), and meditation (15.2%). They also engage in other activities such as swimming, outdoor games, practicing yoga, drawing, cooking, etc. At the same time, students have a high rate of consuming caffeinated beverages, with 30.50% drinking them systematically, 37.10% occasionally, and 19% rarely. One-third of the respondents (30.5%) occasionally consume energy drinks, and 11.4% rarely do so.

Conclusions. Alongside healthy methods, students use many other quick and efficient ways to stimulate their cognitive abilities. The study results raise concerns about the students' risk behavior, as some prefer unhealthy methods to stimulate their cognitive abilities in their learning activities.

Cuvinte-cheie: capacitate cognitivă, activitate de învățare, stimulare, elevi.

METODE DE STIMULARE A ABILITĂȚILOR COGNITIVE UTILIZATE DE ELEVI

Introducere. Pentru obținerea de performanțe academice, elevii au nevoie de un nivel ridicat de abilități cognitive pe care să le utilizeze în activitățile lor de învățare. Există mai multe metode de stimulare a abilităților cognitive ale elevilor care pot fi sănătoase sau nesănătoase.

Scopul cercetării. Identificarea și descrierea metodelor de stimulare a abilităților cognitive utilizate de elevi în activitatea de învățare.

Material și metode. Chestionarul Google Drive a fost completat de 212 respondenți.

Rezultate. În urma analizei răspunsurilor din chestionare s-a constatat că elevii preferă activitățile fizice pentru a-și stimula abilitățile cognitive, cele mai aplicate fiind mersul pe jos (45,7%), antrenamentul (17,10%) și meditația (15,2%). Urmează, în ordinea descreșterii preferințelor, înotul, jocurile în aer liber, practicarea yoga, desenul, gătitul etc. Printre preferințele elevilor se numără și băuturile cofeinizate, care sunt consumate sistematic (30,50%), uneori (37,10%) sau ocazional (19%). O treime dintre respondenți (30,5%) consumă băuturi energizante ocazional, iar 11,4% – rar.

Concluzii. Pe lângă metode sănătoase, elevii folosesc multe alte modalități mai puțin sănătoase, dar rapide și eficiente de a-și stimula abilitățile cognitive. Rezultatele studiului ridică un motiv de îngrijorare cu privire la comportamentul de risc al elevilor care preferă metode nesănătoase de stimulare a abilităților cognitive în activitatea de învățare.

INTRODUCTION

High cognitive abilities are becoming increasingly relevant in our highly competitive world. Often referred to as “21st century skills,” these abilities include being able to solve complex problems, think critically, communicate effectively across diverse cultures and using various techniques, work in collaboration with others, adapt to rapidly changing environments and conditions for performing tasks, effectively manage one’s work, and autonomously acquire new skills and information (1). Both psychological and pedagogical theory and practice prove that extracting, structuring, and organizing knowledge, along with developing skills to find solutions to problems by students, are possible only as a result of their intensive cognitive activity. Common examples of cognitive activities are reasoning, thinking, perceiving, listening, observing, etc. High-level cognitive activities usually include problem-solving, decision-making, and sense-making that involve using and working with information (2). Cognitive ability is closely associated with educational attainment, occupation, and health outcomes (3).

The level of education directly influences cognitive function by enhancing brain function, and indirectly by encouraging individuals with higher education to engage in intellectually stimulating activities, thus preserving cognitive ability. Many efforts to enhance cognition are of a rather commonplace nature, with some practices dating back thousands of years. Education and training, for example, aim not only to impart specific skills or information but also to improve general mental faculties such as concentration, memory, and critical thinking. Various forms of mental training, including yoga, martial arts, meditation, and creativity courses, are also commonly employed. Caffeine is widely used to improve alertness, and herbal extracts believed to improve memory, like Ginkgo Biloba, enjoy significant popularity, with sales amounting to several hundred million dollars annually in the U.S.A. In an ordinary supermarket, numerous energy drinks are on display, appealing to consumers seeking to turbo-charge their brains (4).

According to some authors (Chrisantus O. Brumboiu I, Porrovecchio A, Peze T, Hurdziel R, Cazacu I, Mogosan C, Ladner J, Tavolacci P.M.), students use various methods to stimulate cognitive ability in their learning activities, such as the kinesiology

method, meditation method, maintaining proper sleep, keeping a healthy and balanced diet, use of prescription drugs (beta-blockers, modafinil, and methylphenidate), use of “soft enhancers” (caffeinated products, food supplements, and energy drinks), and use of “drugs of abuse” (alcohol, cannabis, cocaine, and amphetamines) (5, 6).

As the discussion about stimulating cognitive abilities is widely covered in the literature, it has sparked empirical curiosity to know which specific methods students from our university use. Therefore, *the aim of the study* is to identify and describe the most common methods for stimulating cognitive abilities used by students in their learning activities.

MATERIAL AND METHODS

The study represents a descriptive, cross-sectional research based on the collection, interpretation, and evaluation of data. Research methods include bibliographic, statistical, and sociological approaches. A study was conducted among university students aged 18 and above from the Republic of Moldova. University students were invited by email to complete an online anonymous 20-minute Google Drive questionnaire consisting of 15 questions. Respondents’ confidentiality was fully respected, as the Google Drive questionnaire did not collect emails. The criteria for respondent selection included student status, age above 18, and their agreement to respond to the questions. A total of 246 students responded to the questionnaire, but only 212 responses met the age criteria for inclusion in the research. Data about different methods for stimulating cognitive abilities (healthy or less healthy) were collected. All questions adhered to non-discriminatory and non-harm principles. The data were analyzed through an Excel database, and conclusions were formulated.

RESULTS

Students from various academic years participated in the survey, with the majority (75.5%) belonging to the second and third years of study. Out of the 212 respondents, 91.4% fell within the age range of 19 to 24, while 6.7% were older than 25, and the remaining were under 19. When queried about the time allocated to their learning activities, 46.7% of students reported spending

3-4 hours on learning, 32.40% dedicated less than 3 hours, and 21% spent more than 4 hours on learning.

Out of 212 respondents, when asked about methods to stimulate or reinforce their cognitive abilities in learning activities, 45.70% of students pre-

fer walking, 15.2% prefer meditation, 17.1% prefer workouts, 2.90% of the students prefer swimming as well as physical exercises, 7.60% of respondents prefer outdoor games and activities, and 9.10% prefer to sleep or engage in other activities such as drawing, cooking, or playing musical instruments (fig. 1).




Figure 1. Students' preferred physical activities for stimulating cognitive abilities.

An important factor for stimulating cognitive abilities is sleep. Despite unanimous agreement among all respondents about the significant impact of sleep, 53.3% of students sleep less than 7 hours, 45.70% sleep for 7-9 hours, and only 1% of students reported sleeping for more than 9 hours.

When asked about their consumption of caffeinated drinks while studying, students provided varied responses. Among respondents, 37.10% and 30.50% of students drink caffeinated drinks sometimes and systematically, respectively. Additionally, 19% of students prefer only occasional consumption, and 13.30% do not consume caffeinated drinks (fig. 2).

When asked about the healthiness of their meals, more than half of the respondents (62.90%) perceive their eating habits as average in terms of healthiness. Meanwhile, 23.80% of them acknowledge following a poor healthiness of eating habit, and only 13.30% of students believe they have a good level of healthiness in their eating habits.

Among the 212 respondents, 48% of students never used energy drinks, while 38% of students drink them occasionally, and 12% use them seldom. Only 2% of the respondents use energy drinks regularly (fig. 3).




Figure 2. Consumption of caffeinated drinks while studying.

When asked about the use of drugs like Ritalin, Dexedrine, and Adderall without a doctor's prescription, all respondents (100% of the students) reported never using them. Regarding the use of psychoactive drugs such as marijuana, crack, cocaine, MDMA, codeine, morphine, dermol, and

others without a doctor's prescription, the majority of the 212 respondents, 95%, reported never using them. Only a very few respondents (4%) indicated using them occasionally or trying them once or twice, and no one reported using them regularly (fig. 4).




Figure 3. Energy drink consumption.




Figure 4. Use of psychoactive drugs (without doctor's prescription).

DISCUSSIONS

In this study, one of the main aspects investigated was the time spent on learning activities, and the findings reveal that a majority (46.7%) of students dedicate around 3-4 hours to studying. Additionally, 21% of students invest more than 4 hours in learning, indicating a high motivation to enhance their cognitive abilities and achieve aca-

demic success. The study also highlights that students prefer engaging in physical activities to stimulate their cognitive abilities. The most favored methods include walking (45.7%), followed by workout (17.10%), and meditation (15.2%). Furthermore, students express a preference for various other activities such as swim-

ming, playing outdoor games, practicing yoga, drawing, cooking, etc. These activities are not only essential for cognitive stimulation but also contribute to maintaining the mental and physical well-being of students.

According to the study data, students exhibit a high rate of caffeinated drink consumption, with 30.50% drinking them systematically, 37.10% sometimes, and 19% occasionally. Caffeinated beverages, such as coffee, tea, and cola, are generally socially acceptable and serve as coping strategies for students to enhance cognitive function and manage stressful academic situations. However, the misuse of caffeinated drinks, especially among systematic users, can lead to various adverse effects. Similar to caffeinated beverages, 30.5% of students use energy drinks occasionally, and 11.4% use them seldom. It is crucial to be

mindful of the dosing of energy drinks, as increased consumption poses potential risks.

The study indicates that the majority of students (62.90%) maintain an average level of healthiness in their eating habits, while 23.80% follow poor dietary practices. Regarding the use of drugs like Ritalin, Dexedrine, and Adderall without a doctor's prescription, all respondents (100%) reported never using them. Additionally, the consumption of drugs of abuse for neuroenhancement, such as marijuana, cocaine, MDMA, crack, morphine, etc., is very low (4-5%), with the majority (95%) of students reporting never using them. While the data suggests a healthy and positive approach, it's important to note that in reality, many students may not disclose the use of unhealthy methods for neuroenhancement.

CONCLUSIONS

1. The information derived from specialized literature sources highlights the correlation between cognitive abilities and learning activities. The enhancement of students' education is pivotal for societal improvement, and achieving a high level of cognitive abilities is essential for students to excel in their learning activities, thereby positively influencing their academic performance.
2. Research reveals that the majority of students favor healthy methods to stimulate their cognitive abilities, such as physical exercise, walking, and meditation. These practices contribute to increased attention during learning activities. However, some students opt for a combination of both healthy and unhealthy methods. They may engage in healthy activities while also resorting to less advisable practices like smoking or using psychoactive drugs without a doctor's prescription. It appears that students utilizing systematic methods for cognitive stimulation may prioritize approaches with immediate effects. Notably, only a very small percentage of students choose to rely solely on unhealthy methods to enhance their cognitive abilities during learning activities.
3. The study results highlight a concern regarding the risk behavior of students who opt for unhealthy methods to stimulate cognitive abilities during learning activities. It emphasizes the need for educational programs and other measures aimed at increasing awareness among students about the potential consequences associated with unhealthy methods of cognitive enhancement during learning activities.

CONFLICT OF INTEREST

Authors have no conflict of interest to declare.

ETHICAL APPROVAL

Not applicable to this research.

REFERENCES

1. Assessing 21st Century Skills: Summary of a Workshop. National Research Council (US) Committee on the Assessment of 21st Century Skills. Washington (DC). Available at: <https://www.ncbi.nlm.nih.gov/books/NBK84221> [Accessed: January 05th 2024].
2. Deryabina N, Sergeichik T. The Development of University Students' Cognitive Activity as a Part of Human Capital Growth in Kuzbass Mining, Kemerovo State University, Kemerovo, Russia, Vth International Innovative Mining Symposium. *E3S Web of Conferences*. 2020. doi:10.1051/e3sconf/202017404034
3. Susan du Plessis. 16 Cognitive Skills: What They Are, Why They Matter, How to Improve, cognitive skills and study method. *Edublox Research*. Available at: <https://www.edubloxtutor.com/cognitive-skills/> [Accessed: December 27, 2023].

4. Bostrom N, Sandberg A. Cognitive Enhancement: Methods, Ethics, Regulatory Challenges. doi:10.1007/s11948-009-9142-5
5. Chrisantus O. The effects of drug abuse on students academic performance. Available at: <https://www.projecttopics.org/effects-drug-abuse-students-academic-performance.html> [Accessed December 22, 2023].
6. Brumboiu I, Porrovecchio A, Peze T, Hurdziel R, Cazacu I, Mogosan C, Ladner J, Tavalacci P.M. Neuroenhancement in French and Romanian University Students, Motivations and Associated Factors. *International Journal of Environmental Research and Public Health*. 2021;18(8):3880. doi:10.3390/ijerph18083880

USE OF MICROMOLECULAR COPPER COMPLEXES OF THIOSEMICARBAZIDES AS AN ENDOGENOUS CATALASE INDUCER/ACTIVATOR

Lilia ANDRONACHE¹, Valeriana PANTEA¹, Aurelian GULEA², Olga TAGADIUC¹, Valerii MATCOVSCHI³, Valentin GUDUMAC¹

¹Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

²Moldova State University, Chisinau, Republic of Moldova

³Diomid Gherman Institute of Neurology and Neurosurgery, Chisinau, Republic of Moldova

Corresponding author: Lilia Andronache, e-mail: lilia.andronache @usmf.md

Keywords: copper coordinating compound, thiosemicarbazide derivatives, production or activation of CAT, multifactorial diseases.

Introduction. Oxidative stress is a major mechanism in the pathogenesis of many diseases, including severe multifactorial ones. Catalase (CAT), along with superoxide dismutase, is one of the first-line antioxidant defense enzymes. The development of methods/compounds that can increase/induce CAT will provide new possibilities to strengthen antioxidant protection and prevent oxidative damage to cells and tissues.

Material and methods. The ability of three copper coordination compounds from the class of transition metal thiosemicarbazides to enhance/induce CAT in erythrocytes of healthy white laboratory rats has been studied.

Results. Dichloro-(methyl-N-(prop-2n-1-yl)-2-(pyridin-2-ylmethylidene)hydrazine-carbimido-thioate)copper was found to show the highest induction and/or activation of CAT, exceeding 2.71 times the values of the control group and 1.80 times the values produced by vitamin D3. This reveals increased synthesis of CAT after exposure to this compound, a phenomenon that we have established for the first time.

Conclusions. The compound can be used as a therapeutic agent, which, by activating the production of CAT in the body, can prevent and/or reduce the occurrence of multifactorial diseases, due to prevention of the damage of cells associated with excessive accumulation of hydrogen peroxide. The obtained data open perspectives for the research of biologically active synthetic compounds, which will diversify the arsenal of effective tools for preventing/treating various diseases.

Cuvinte-cheie: complex coordonativ al cuprului, derivați de tiosemicarbazidă, producerea sau activarea CAT, boli multifactoriale.

UTILIZAREA COMPLEXELOR MICROMOLECULARE DE CUPRU ALE TIOSEMICARBAZIDELOR CA INDUCTORI/ACTIVATORI ENDOGENI AI CATALAZEI

Introducere. Stresul oxidativ este un mecanism major în patogeneza multor boli, inclusiv a celor multifactoriale severe. Catalaza (CAT), împreună cu superoxid dismutaza, este una dintre enzimele de apărare antioxidantă de primă linie. Dezvoltarea de metode/compuși care pot crește/induce CAT va oferi noi posibilități de a spori protecția antioxidantă și de a preveni deteriorarea oxidativă a celulelor și a țesuturilor.

Material și metode. A fost studiată capacitatea a trei compuși de coordonare a cuprului din clasa tiosemicarbazidelor metalelor de tranziție de a crește/induce CAT în eritrocitele șobolanilor albi de laborator sănătoși.

Rezultate. S-a constatat că dicloro-(metil-N-(prop-2n-1-il)-2-(piridin-2-ilmetiliden)hidrazin-carbimido-tioat)cuprul exercită cea mai potentă inducție și/sau activare a CAT, depășind de 2,71 ori valorile lotului martor și de 1,80 ori valorile produse de vitamina D3. Aceste date relevă sinteza endogenă crescută a CAT după expunerea la acest compus, fenomen care a fost stabilit pentru prima dată.

Concluzii. Compusul poate fi utilizat în medicină ca agent terapeutic care, prin activarea/inducerea CAT în organism, poate preveni și/sau reduce apariția bolilor multifactoriale cauzate de deteriorarea celulelor și a țesuturilor, asociate cu acumularea excesivă de peroxid de hidrogen. Datele obținute deschid noi perspective pentru cercetarea compușilor sintetici biologic activi care vor diversifica arsenalul de instrumente eficiente pentru prevenirea sau tratarea diferitor boli.

INTRODUCTION

CAT plays a central role in the detoxification of oxygen peroxide (H_2O_2), which is crucial in defending cells against oxidative damage caused by H_2O_2 . Hydrogen peroxide is toxic due to its ability to form other reactive oxygen species (ROS), such as the hydroxyl radical in the Fenton reaction. Additionally, H_2O_2 can act as an important signalling molecule, being involved in multiple physiological and pathological processes (1). CAT can also act as a peroxidase, thus contributing to the metabolism of micromolecular substrates such as methanol, ethanol, azide, and hydroperoxides. In the case of ethanol, the enzyme is able to oxidize it to acetaldehyde, contributing to its metabolism in the liver. Thus, CAT may have additional roles, such as detoxification or activation of toxic and antitumor compounds.

However, the molecular mechanisms regulating the expression of CAT, the oldest known antioxidant enzyme, have not yet been fully elucidated. Identifying these mechanisms will allow us to find new approaches to modulate antioxidant status in a variety of pathological conditions (2, 3).

Deficiency or impaired functioning of CAT is linked to the pathogenesis of a number of age-related diseases, such as diabetes mellitus, hypertension, anemia, vitiligo, Alzheimer's disease, Parkinson's disease, bipolar disorder, cancer, and schizophrenia (4).

Several known compounds have been identified to increase CAT activity in tissues during various pathological processes. Notable examples include the elevation of CAT activity in erythrocytes of patients with type II diabetes through metformin treatment (5). Additionally, CAT production and/or activity in the mouse macrophage-like cell line RAW264 is increased by treatment with sodium nitroprusside (SNP) and 1-hydroxy-2-oxo-3,3-bis-(2-aminoethyl)-1-triazene (NOC18). At the maximum concentration of 300 $\mu\text{mol/L}$, NOC18 statistically and conclusively increases CAT activity by up to 50%, thereby protecting macrophages from apoptosis induced by H_2O_2 (6). Furthermore, adding coffee to the feed of animals with liver cancer increases CAT activity almost to the values specific to healthy animals (7). Melatonin has been shown to increase CAT activity in peripheral blood mononuclear cells (PBMC) by 80% compared to untreated cells (8), while Fulleranol (C60(OH)36) increases it in red blood cells by

24% ($p < 0.05$) compared to untreated ones (9). However, these methods have the disadvantage of being ineffective, as they do not provide stable, sufficiently high induction and/or activation of CAT.

The method closest in technical essence and result to increasing the production or activity of CAT in the body is based on the administration of vitamin D3 or its derivatives (10). However, this method has several disadvantages, namely that it does not provide sufficient stimulation of the production and/or activity of CAT, and the simultaneous use of vitamin D3 with its analogues increases the risk of developing hypervitaminosis D and its toxic effects.

The problem that our method solves is the generation of new copper coordination compounds from the class of thiosemicarbazides, thereby expanding the range of synthetic compounds with high CAT induction/activation potential.

MATERIAL AND METHODS

Three new local copper coordinating compounds (CC), derivatives of thiosemicarbazide, were included in the study:

- 1) Acetato-2-(((metilsulfanil)((prop-2-en-1-il)amino)metiliden}hidraziniliden) metil) fenolatoaquacupru (coded (Cu(OAc)2);
- 2) Bromo-2-{{2-(prop-2-en-1-ylcarbamothi-oyl)-hydrazinylidene) methyl}phenolatocopper, coded (Cu(HL)Br);
- 3) Dichloro-(methyl-N-(prop-2-en-1-yl)-2-(pyridin-2-ylmethylidene)hydrazine-carbimidothioate)copper, coded (Cu(L-H)Cl2).

These compounds were synthesized at Moldova State University in the "Advanced Materials in Biopharmaceutics and Technology" Laboratory, by the team of professor Aurelian Gulea, PhD, academician (11, 12, 13).

The effect of the local CC on erythrocyte CAT was evaluated in experiments on *Rattus norvegicus domestica albino*. The experiments were conducted in accordance with contemporary principles in the biological standardization of experiments and the Helsinki Declaration with subsequent amendments (Somerset West Amendment, 1996). The study was approved by the Research Ethics Board of Nicolae Testemitanu State University of Medicine and Pharmacy (approval no. 81 of 19.09.2020).

The experiments involved 50 rats weighing 180-230 g, divided into 5 groups of 10 animals each. The first group, the control, consisted of animals kept on a regular vivarium diet and injected with physiological saline 3 times a week for 30 days. CC were administered in a dose of 1.0 $\mu\text{M/kg}$, 3 times a week for 30 days in the following way: group 2 – $(\text{Cu}(\text{OAc})_2)$, group 3 – $(\text{Cu}(\text{HL})\text{Br})$, group 4 – $(\text{Cu}(\text{L-H})\text{Cl}_2)$. The rats in group 5 (prototype) were administered vitamin D3 in a dose of 20.0 $\mu\text{M/kg}$ in the same way as CC. After 24 hours from the last administration of the tested compounds, the blood was collected for the evaluation of CAT. The erythrocyte mass, obtained after decanting the blood serum, was washed 3 times with physiological saline.

CAT activity was determined according to the method described by Korolyuk M.A. et al. (1988) (14) with modifications (15). Briefly, 0.01 mL of the erythrocyte mass diluted 1000 times with distilled water was pipetted into the 96-well photometric microplates, and 0.18 mL of 0.03% H_2O_2 was added. In the control samples, instead of H_2O_2 , the same amount of distilled water was added. Three parallel reference samples, which contain only H_2O_2 and distilled water, were prepared. The samples were incubated for 10 minutes at 37°C, and afterwards, 0.10 mL of 4% ammonium molybdate solution was added. The solution was shaken, and its absorbance was measured at 410 nm. The difference between the absorbance of the reference sample and the ex-

perimental sample was calculated. Enzyme activity was expressed in $\mu\text{mol per s per 1 g Hb}$ ($\mu\text{mol/s}\cdot\text{g Hb}$).

The spectrophotometric method was used to assess the levels of vitamin D in the research samples (16).

The statistical evaluation of the obtained data was conducted using StatsDirect Statistical Analysis Software (StatsDirect Ltd, UK). Mean $\pm$ standard deviation ($X\pm S$) was calculated. To test the significant difference between the studied markers of the compared groups, the non-parametric "U" Mann-Whitney statistical test and the significance threshold "p" ($p<0.05$) were employed.

RESULTS

The results of the assessment of the changes in the CAT activity of erythrocytes due to the administration of certain local CC are presented in the statistical data in Table 1.

Based on the experimental data presented in Table 1, it is evident that the mentioned compounds induce a greater activation of CAT than that produced by vitamin D3, used as a prototype. The studied thiosemicarbazone derivatives increased erythrocyte CAT activity by 1.9-2.7 times compared to the control values and by 1.8 times compared to the values produced by the prototype (vit. D3). Compound $\text{Cu}(\text{L-H})\text{Cl}_2$ was found to exhibit the highest CAT induction/activation activity, exceeding the control values by 2.72 times and the prototype values by 1.8 times.

Table 1. The impact of local CC, derivatives of thiosemicarbazide, on erythrocyte CAT activity.

Study groups	CAT, $\mu\text{M/s}\cdot\text{g Hb}$ ($X\pm S$)
Control group	18.80 $\pm$ 4.02 (100%)
Acetato-2-(((metilsulfanil)((prop-2-en-1-il)amino)metiliden}hidraziniliden)metil) fenolatoaquacupru (0,1 $\mu\text{M/kg}$) (coded $(\text{Cu}(\text{OAc})_2)$)	35.7 $\pm$ 5.61 *** (190%)
Bromo-2-((2-(prop-2-en-1-ylcarbamoithioyl)-hydrazinylidene)methyl)phe-nolato copper (0,1 $\mu\text{M/kg}$), coded $(\text{Cu}(\text{HL})\text{Br})$	50.8 $\pm$ 5.66 *** (270%) ## (178%)
Dichloro-(methyl-N-(prop-2n-1-yl)-2-(pyridin-2-ylmethylidene)hydrazine-car-bimido-thioate)copper (0,1 $\mu\text{M/kg}$), coded $(\text{Cu}(\text{L-H})\text{Cl}_2)$	51.2 $\pm$ 7.98 *** (272%) ## (179%)
Vitamina D3 (prototip) (20 $\mu\text{M/kg}$)	28.6 $\pm$ 4.26 ** (152%)

Note: statistically significant difference with the control group *- $p<0.05$; ** - $p<0.01$; *** - $p<0.001$; statistically significant difference with the prototype (vitamin D3) - # $p<0.05$; ## - $p<0.01$.

DISCUSSIONS

The established properties of the studied CC are of interest for medicine in terms of expanding the range of synthetic inducers/activators of CAT. Enzyme induction is a process in which a molecule (e.g., a drug) induces an increase in the metabolic activity of an enzyme either by binding to the enzyme and activating it, or by increasing the expression of the gene encoding the enzyme (17, 18). Enzyme induction occurs when the molecule (called an inducer) facilitates gene expression. The specifics of how this occurs depend on control mechanisms as well as on differences between prokaryotic and eukaryotic cells (18).

CAT is one of the most important antioxidant enzymes, present in almost all aerobic organisms. In 1937, CAT was first crystallized from bovine liver in the laboratory of Sumner and Dounce. The gene encoding CAT in humans is located on chromosome 11 (19).

The significance and importance of the CAT induction phenomenon by CC, derivatives of thiosemicarbazide, stem from the broad range of practical applications of these inducers.

These inducers could potentially be used as agents for the treatment and prevention of renal fibrosis caused by CAT deficiency (20), or for the treatment of some forms of infertility, since CAT is found in mouse oocytes and likely plays a role in genomic protection from oxidative damage during meiotic maturation (21). It has been established that CAT expression is also altered in cancer cells, which favors cell proliferation by inducing genetic instability and activating oncogenes. Regulation of CAT expression is likely controlled mainly at transcriptional levels, although other mechanisms may be involved. In addition to transcription factors such as Sp1 and NF- κ B, the transcription factors JunB and RAR α are crucial regulators in breast cancer cells by recruiting proteins involved in transcriptional complexes and chromatin remodeling. Therefore, CAT may be an attractive therapeutic target in the context of cancer (22).

CAT was found to significantly decrease chromosomal aberrations and to delay or prevent spontaneous neoplastic transformation in mice fibroblasts and epidermal keratinocytes (23). Similarly, liver CAT activity decreases in the presence of a growing tumor, and after the tumor is remo-

ved, this activity returns to normal, demonstrating the importance of this antioxidant enzyme in tumorigenesis (24).

The methods for inducing CAT expression or activity are important for treating retinal oxidative stress associated with diabetic retinopathy (25).

Due to the ability of thiosemicarbazone derivatives to easily penetrate the blood-brain barrier (26) and their stability in the bloodstream, these compounds could be used to develop new effective methods for the early diagnosis of severe brain diseases, such as brain tumors and their metastases, as well as for the visualization of A β plaques in Alzheimer's disease.

CAT could be extremely useful for the development of effective therapies for brain and neurological dysfunctions. This is based on the fact that brain CAT activity is extremely low compared to other tissues and organs, such as the liver and kidney. The results of some studies reveal the importance of transient receptor potential (TRP) channels as a key component of the neurological Ca²⁺ ion entry pathway in response to the harmful action of reactive oxygen species (ROS). Exploratory data suggest that CAT may act effectively by suppressing the TRP channel activated by oxidative stress, exhibiting protective effects on neuronal mitochondrial function and neuronal survival (27). In the future, CAT could be extremely useful for the development of effective therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as well as sensory pain, because the decrease of CAT activity due to oxidative stress plays an important role in the pathogenesis of the aforementioned diseases (28).

One of the most severe multifactorial diseases is sepsis, a systemic inflammatory syndrome caused by infections that can lead to organ dysfunction with a high mortality rate (over 25%). Considering that the most susceptible to sepsis are children, people aged over 65 years, as well as patients with immunodeficiency, autoimmune diseases, tumors, kidney, and lung diseases (29), developing treatments using CAT inducers and/or activators would be a desirable and effective option. Septic shock is also one of the frequent complications of COVID-19 (30); therefore, CAT inducers could be an attractive therapeutic target

for the prevention of complications and treatment of SARS-CoV-2 infection. CAT helps regulate cytokine production, protect against oxidative damage, and suppress SARS-CoV-2 replication, as

shown in human leukocytes, alveolar epithelial cells, and rhesus macaques, without noticeable toxicity (31, 32).

CONCLUSIONS

1. An effective method of inducing/activating CAT in the body has been developed using biologically active copper coordination compounds from the class of transition metal thiosemicarbazides. These compounds can prevent and/or reduce the occurrence of a variety of multifactorial diseases and the development of cell and tissue damage related to the excessive accumulation of hydrogen peroxide.
2. Therefore, the data obtained mark the beginning, opening up prospects for the development and research of new CCs, which will diversify the arsenal of means to combat various severe pathological processes. Further studies are needed to confirm the therapeutic utility of these bioactive compounds.

AUTHORS' CONTRIBUTION

The authors declare that their authorship complies with the international ICMJE criteria. All authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published, and agree to be accountable for all aspects of the work.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest regarding the publication of this paper.

ETHICAL APPROVAL

The research was approved by the Research Ethics Boar of *Nicolae Testemițanu* State University of Medicine and Pharmacy (approval no. 73 of April 26, 2017).

ACKNOWLEDGMENTS

The authors would like to thank the Government of the Republic of Moldova for supporting this research by funding the Institutional fundamental research grant 15.817.04.05F (2015-2020) and the State Program research grant No. 20.80009.5007.10 (2020-2023).

REFERENCES

1. Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. *Redox Biol.* 2017; 11:613-619. doi:10.1016/j.redox.2016.12.035
2. Cullen JJ, Mitros FA, Oberley LW. Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer. *Pancreas.* 2003;26(1):23-27. doi:10.1097/00006676-200301000-00005
3. Kwei KA, Finch JS, Thompson EJ, Bowden GT. Transcriptional repression of catalase in mouse skin tumor progression. *Neoplasia.* 2004;6(5):440-448. doi:10.1593/neo.04127
4. Nandi A, Yan LJ, Jana CK, Das N. Role of Catalase in Oxidative Stress- and Age-Associated Degenerative Diseases. *Oxid Med Cell Longev.* 2019;2019:9613090. doi:10.1155/2019/9613090
5. Pavlović D, Kocić R, Kocić G, et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. *Diabetes Obes Metab.* 2000;2(4):251-256. doi:10.1046/j.1463-1326.2000.00089.x
6. Yoshioka Y, Kitao T, Kishino T, Yamamuro A, Maeda S. Nitric oxide protects macrophages from hydrogen peroxide-induced apoptosis by inducing the formation of catalase. *J Immunol.* 2006;176(8):4675-4681. doi:10.4049/jimmunol.176.8.4675
7. Schmidt de Magalhães C, Takarada JE, Costa Carvalho N, et al. The Coffee Protective Effect on CAT System in the Preneoplastic Induced Rat Liver. *Journal of Chemistry.* 2016;9. doi:10.1155/2016/8570321
8. Emamgholipour S, Hossein-Nezhad A, Ansari M. Can Melatonin Act as an Antioxidant in Hydrogen Peroxide-Induced Oxidative Stress Model in Human Peripheral Blood Mononu

- clear Cells?. *Biochem Res Int.* 2016; 2016: 5857940. doi:10.1155/2016/5857940
9. Grebowski J, Kazmierska-Grebowska P, Cichon N, Piotrowski P, Litwinienko G. The Effect of Fullerenol C₆₀(OH)₃₆ on the Antioxidant Defense System in Erythrocytes. *Int J Mol Sci.* 2021;23(1):119. doi:10.3390/ijms23010119
 10. Sposoby Uvelicheniya Vyrabotki ili Aktivnosti Katalazy RU 2012 157 084 A/ Ways to Increase CAT Production or Activity/ RU 2012 157 084 A. Available at: <https://patentimages.storage.googleapis.com/84/19/c2/1cac8eae8c6236/RU2012157314A.pdf> [Accessed: 07.01.2024].
 11. Gulea A, Zariciuc E, Graur V, Tsapkov V, Rudic V. The study of antimicrobial and antitumor activity of biometal coordination compounds of substituted salicylaldehyde 4-allylthiosemi carbazones. In: *International Scientific Conference on Microbial Biotechnology. 3rd edition.* Chişinău. Moldova. October 12-13, 2016;67-68. Available at: https://ibn.idsi.md/ro/visualizare_articol/73883 [Accessed: 07.01.2024].
 12. Pahontu E, Usataia I, Graur V, et al. Synthesis, characterization, crystal structure of novel Cu (II), Co (III), Fe (III) and Cr (III) complexes with 2-hydroxybenzaldehyde-4-allyl-S-methylisothiosemicarbazone: Antimicrobial, antioxidant and in vitro antiproliferative activity. *Appl Organometal Chem.* 2018; 32:e4544. doi:10.1002/aoc.4544
 13. Graur V. *Designul şi sinteza compuşilor biologic activi ai metalelor 3d cu 4-alilchalconsemicarbazone şi derivaţii lor.* Autoreferat al tezei de doctor în ştiinţe chimice [The design and synthesis of biologically active compounds of 3d metals with 4-allylchalconsemicarbazones and their derivatives. Synopsis of the doctoral thesis in chemical sciences]. Chişinău 2017. Available at: <http://www.cnaa.md/thesis/51500/> [Accessed: 07.01.2024].
 14. Koroliuk MA, Ivanova LI, Maïorova IG, Tokarev VE. Metod opredeleniia aktivnosti katalazy [A method of determining catalase activity]. *Lab Delo.* 1988;(1):16-19. Available at: <https://pubmed.ncbi.nlm.nih.gov/2451064/> [Accessed: 06.01.2024].
 15. Gudumac V, Rîvneac V, Tagadiuc O, Sardari V, Rîvneac E, Andronache L, Ştirba O, Pantea V, Popa V. *Metode de cercetare a metabolismului hepatic.* Elaborare metodică [Research methods of liver metabolism. Methodical elaboration]. Chisinau, 2012.
 16. Rahman A, Rahman MM, Hossain MS, et al. A Simple and Alternative UV Spectrometric Method for the Estimation of Vitamin D3. *Microbial Bioactives.* 2019;2(1):098-105. doi:10.25163/microbbioacts.212086A2127261219
 17. Stanbury PF, Whitaker A, Hall SJ. *Principles of Fermentation Technology* (2nd ed.). 1995. Elsevier. Available at: https://books.google.md/books?id=CW8vBQAAQBAJ&redir_esc=y [Accessed: 06.01.2024].
 18. Nestler EJ. Epigenetic mechanisms of drug addiction. *Neuropharmacology.* 2014;76 Pt B(00):259-268. doi:10.1016/j.neuropharm.2013.04.004
 19. Sumner JB, Dounce AL. Crystalline catalase. *Science.* 1937;85(2206):366-367. doi:10.1126/science.85.2206.366
 20. Kobayashi M, Sugiyama H, Wang DH, et al. Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. *Kidney Int.* 2005; 68(3):1018-1031. doi:10.1111/j.1523-1755.2005.00494.x
 21. Park YS, You SY, Cho S, et al. Eccentric localization of catalase to protect chromosomes from oxidative damages during meiotic maturation in mouse oocytes. *Histochem Cell Biol.* 2016;146(3):281-288. doi:10.1007/s00418-016-1446-3
 22. Glorieux C, Calderon PB. Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach. *Biol Chem.* 2017;398(10):1095-1108. doi:10.1515/hsz-2017-0131
 23. Jones GM, Sanford KK, Parshad R, Gantt R, Price FM, Tarone RE. Influence of added catalase on chromosome stability and neoplastic transformation of mouse cells in culture. *Br J Cancer.* 1985;52(4):583-590. doi:10.1038/bjc.1985.230
 24. Asaduzzaman Khan M, Tania M, Zhang Dz, et al. Antioxidant enzymes and cancer. *Chin. J. Cancer Res.* 2010;22:87-92. doi:10.1007/s11670-010-0087-7
 25. Giordano CR, Roberts R, Krentz KA, et al. Catalase therapy corrects oxidative stress-induced pathophysiology in incipient diabetic retinopathy. *Invest Ophthalmol Vis Sci.* 2015; 56(5):3095-3102.

- doi:10.1167/iov.14-16194
26. Fu X, Zhang Y, Jiang W, Monnot AD, Bates CA, Zheng W. Regulation of copper transport crossing brain barrier systems by Cu-ATPases: effect of manganese exposure. *Toxicol Sci.* 2014;139(2):432-451.
doi:10.1093/toxsci/kfu048
 27. Nazıroğlu M. Molecular role of catalase on oxidative stress-induced Ca(2+) signaling and TRP cation channel activation in nervous system. *J Recept Signal Transduct Res.* 2012;32(3):134-141.
doi:10.3109/10799893.2012.672994
 28. Gáspár T, Domoki F, Lenti L, et al. Neuroprotective effect of adenoviral catalase gene transfer in cortical neuronal cultures. *Brain Res.* 2009;1270:1-9.
doi:10.1016/j.brainres.2009.03.006
 29. Li F, Yan R, Wu J, et al. An Antioxidant Enzyme Therapeutic for Sepsis. *Front Bioeng Biotechnol.* 2021;9:800684.
doi:10.3389/fbioe.2021.800684
 30. Chen S, Gao Z, Hu L, et al. Association of Septic Shock with Mortality in Hospitalized COVID-19 Patients in Wuhan, China. *Adv Virol.* 2022;2022:3178283.
doi:10.1155/2022/3178283
 31. Cárdenas-Rodríguez N, Bandala C, Vanoye-Carlo A, et al. Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19. *Antioxidants (Basel).* 2021;10(6):971.
doi:10.3390/antiox10060971
 32. Qin M, Cao Z, Wen J, et al. An Antioxidant Enzyme Therapeutic for COVID-19. *Adv Mater.* 2020;32(43):e2004901.
doi:10.1002/adma.202004901

UTILIZAREA POTENȚIALĂ A BACTERIOFAGILOR LA BIOAUGMENTAREA PROCESELOR BIOLOGICE DE EPURARE A APELOR UZATE

Lucia GALBEN, Oana-Simina IACONI, Greta BĂLAN

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Lucia Galben, e-mail: galben luciagalben@mail.ru

Cuvinte-cheie:

bacteriofagi, tratare biologică, ape uzate, stație de epurare, rezistența la antimicrobiene.

Introducere. În ultimii ani, calitatea apei a scăzut considerabil ca urmare a creșterii populației și a dezvoltării industriale. Stațiile de epurare a apelor uzate primesc tone de apă uzată provenită din diverse surse, cum ar fi spitale, abatoare, ferme, unități farmaceutice și canalizare menajeră. Aceste stații adăpostesc o diversitate mare de bacterii și resturi de preparate antimicrobiene, ceea ce facilitează interacțiunea dintre diverse microorganisme și antimicrobiene, simplificând dezvoltarea mecanismelor de rezistență la antimicrobiene, precum și transmiterea genelor de rezistență de la o celulă la alta. Prin urmare, utilizarea metodelor eficiente de tratarea a apelor uzate are o importanță majoră în eliminarea microorganismelor rezistente la antimicrobiene.

Scop. Evaluarea utilizării bacteriofagilor la bioaugmentarea proceselor de tratare biologică a apelor uzate.

Material și metode. Am realizat un studiu secundar-sinteză narativă a literaturii. Informația a fost obținută din bazele de date electronice internaționale folosind următoarele cuvinte-cheie „ape uzate”, „stația de epurare”, „rezistența la antimicrobiene”, „utilizarea bacteriofagilor”, „tratare biologică” în diferite combinații. Din numărul total de articole găsite (49), au fost selectate și analizate 25.

Rezultate. Multiple studii au raportat că în pofida utilizării diverselor procese de tratare biologică și/sau chimică, stațiile de epurare a apelor uzate nu sunt pe deplin eficiente în îndepărtarea agenților patogeni. Higgins și colab. (2018) menționează că agentul patogen oportunist *Acinetobacter baumannii* a fost depistat la toate etapele de epurare, fiind ulterior eliberat în mediu. Oliveira și colab. (2021) au constatat ineficiența proceselor convenționale de tratare a apelor uzate în eliminarea agenților patogeni rezistenți la carbapeneme. Bioreactoarele cu membrană sunt strategii avansate de tratare a apelor uzate, apreciate pentru capacitatea lor înaltă de eliminare a microorganismelor, însă formarea biofilmelor pe membrane împiedică funcționarea adecvată a acestora. O alternativă promițătoare este tratarea apelor uzate cu bacteriofagi ce oferă un remediu ecologic și rentabil în eliminarea microorganismelor din apele uzate. Bacteriofagii afectează gazda prin două moduri, fie prin modificarea procesului metabolic, adaptării și potențialului de supraviețuire al gazdelor, fie prin distrugerea directă a celulelor-gazdă. Printre proprietățile bacteriofagilor care îi fac atrăgători ca agenți terapeutici sau în calitate de biocontrol se numără liza doar a bacteriilor specifice acestora prin receptori specifici, creșterea ca număr în funcție de densitatea agenților patogeni și adaptarea ușoară la condițiile de mediu. Bacteriofagii au rol și în îndepărtarea biofilmelor bacteriene.

Concluzii. Creșterea semnificativă a rezistenței la antimicrobiene a adus în prim-plan terapia cu bacteriofagi, care are o istorie de peste 100 de ani. Aplicarea bacteriofagilor la stațiile de epurare influențează semnificativ capacitatea procesului de tratare, deci și calitatea apei uzate, precum și eliminarea agenților patogeni din biofilme și din nămol.

A REVIEW ON PREVALENCE AND ANTIMICROBIAL RESISTANCE OF *SALMONELLA* SPP. AND *CAMPYLOBACTER* SPP: ONE HEALTH PERSPECTIVE

Valentina CRETU¹, Olga BURDUNIUC², NICOLAE STARCHIUC¹

¹Technical University of Moldova, Chisinau, Republic of Moldova

²National Agency for Public Health, Chisinau, Republic of Moldova

Corresponding author: Valentina Cretu, e-mail: valentinaa.cretu@gmail.com

Keywords: carcasses, incidence, *Salmonella* spp., *Campylobacter* spp. AMR, poultry.

Introduction. Conducting an updated review of the antimicrobial resistance phenomenon and associated factors, as well the mechanisms and current perspectives on the “One Health” approach, including the Republic of Moldova’s position in response to the World Health Organization’s call, are priority directions for both human and veterinary medical services. Systematic review and gathering scientific information on the spread, incidence, resistance, and serotyping of bacteria from the genera *Salmonella* spp. and *Campylobacter* spp. remain crucial priorities worldwide.

The aim. The study focuses on analysing and assessing data regarding the incidence of infections with microorganisms from the *Campylobacter* spp. and *Salmonella* spp. genera in humans and in products of animal origins.

Material and methods. The study was conducted by analysing specialized literature from various databases, selecting relevant articles published between 2018 and 2023. The keywords used included prevalence, distribution of serotypes, antimicrobial resistance phenotypes, and genotypes of *Salmonella* spp. and *Campylobacter* spp. strains in humans and animal products. The *One Health* approach was employed. In total, 93 bibliographic sources were examined; utilizing databases such as *Embase*, *PubMed*, *Hinari*, *Google Scholar*, and data published by ECDC and WHO.

Results. The results regarding the proposed subjects were analysed. This was carried out within an integrative approach to the current situation in the field of human health, animal health, and the environment, as well as the position of the Republic of Moldova in combating the phenomenon of AMR. The obtained data confirmed that the highest prevalence of *Campylobacter* spp. among all types of samples investigated was found in poultry carcasses, with an average prevalence of 57% (44 out of 77 carcasses tested positive for *Campylobacter*). In comparison, based on surveillance data, on average, 38% of samples from fresh poultry meat in 22 European countries tested positive for *Campylobacter* (as of 2018).

The prevalence of pathogens in the carcasses of free-range broilers may result from the dissemination of bacteria from the genera *Salmonella* spp. and *Campylobacter* spp. in small-scale poultry farms, potentially affecting food safety.

Conclusions. The results regarding the incidence of *Salmonella* spp. and *Campylobacter* spp. argue for the importance and necessity of applying new techniques to assess the impact of zoonotic bacteria on public health. Systematic monitoring of the “environment-animal-human” components is an activity that will determine the level of quality of life. Bacteria from the genera *Salmonella* spp. and *Campylobacter* spp. are most frequently involved in foodborne infections in humans, underscoring the need for a revision of monitoring programs and mitigation strategies to reduce their impact on public health.

REZISTENȚA LA ANTIMICROBIENE ȘI FACTORII DE PATOGENITATE AI TULPINILOR CLINICE DE *STAPHYLOCOCCUS* SPP.

Mihail RULEVSCHI, Dmitri IUNAC, Greta BĂLAN

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Mihail Rulevski, e-mail: rulevskimihai90@gmail.com

Cuvinte-cheie:*Staphylococcus* spp., rezistența la antimicrobiene, factori de patogenitate.

Introducere. Tulpinile de *Staphylococcus* spp. izolate din secțiile de terapie intensivă și din hemocultură sunt din ce în ce mai rezistente la un număr mare de agenți antimicrobieni. În mod inevitabil, acest fenomen a dus la ineficiența mai multor antimicrobiene, ceea ce pune viața pacienților în pericol. *S. aureus* este agentul patogen care trezește cele mai mari îngrijorări din cauza virulenței intrinseci, a capacității de a provoca o gamă variată de infecții și de a se adapta la diferite condiții de mediu. Mortalitatea prin bacteriemie cu *S. aureus* este în jur de 20–40%, în ciuda disponibilității antimicrobiene eficiente. Persistența microorganismelor este determinată de mulți factori care inactivează mecanismele antimicrobiene ale sistemului imun. De aceea, este binevenită studierea factorilor de patogenitate ai microorganismelor, de a căror manifestare depinde rata de eliminare a acestora din focar și prognosticul bolii.

Scop. Evaluarea rezistenței la antimicrobiene și a factorilor de patogenitate ai tulpinilor clinice de *Staphylococcus* spp.

Material și metode. Studiul a fost efectuat pe 102 tulpini de *Staphylococcus* spp. izolate din infecții invazive în culturi pure și ulterior identificate prin metode microbiologice clasice și sistemul Vitek2 Compact (BioMerieux). Testarea sensibilității la antimicrobiene și a capacității de formare a biofilmului a fost efectuată cu ajutorul metodei discdifuzimetrică Kirby-Bauer și, respectiv, a testului cantitativ de aderență. Activitatea antilizozim a fost determinată după metoda descrisă de Gordina E. și coaut, iar activitatea anticomplementară – după metoda descrisă de Bukharin O. și coaut.

Rezultate. 74 (72,5%) de tulpini de *Staphylococcus* spp. izolate din infecțiile invazive au fost polirezistente la antibiotice, 41 (40,2%) – metilicin rezistente (MRS), 19 (15,8%) – pozitive prin testul D, iar 76 (75,5%) au produs biofilme. Tulpinile de stafilococi au prezentat sensibilitate mai înaltă la vancomicină (100%) și la linezolid (90,6%). Rată mai mare de rezistență inductibilă la clindamicină a fost observată printre tulpinile MRS, în comparație cu cele sensibile la metilicină. Similar, rate mai mari de polirezistență și rezistență la metilicină au fost înregistrate printre tulpinile producătoare de biofilm, în comparație cu tulpinile care nu produc biofilm. Activitatea antilizozim și anticomplementară a fost pusă în evidență la 83,3% dintre tulpini și la 69,6%, respectiv.

Concluzii. Pentru un management eficient al infecțiilor provocate de stafilococi este important de a include în diagnosticul de laborator de rutină testul D pentru detectarea rezistenței inductibile la clindamicină. Vancomicina și linezolidul pot fi indicate în tratamentul empiric al infecțiilor severe cauzate de *Staphylococcus* spp. Cunoașterea factorilor de persistență a *Staphylococcus* spp va permite utilizarea lor în calitate de țintă de atac la selectarea preparatelor antimicrobiene.

Studiul este realizat în cadrul proiectului JPIAMR „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters”; (PhageLand), cifrul proiectului 22.80013.8007.1M.

EVALUAREA PRACTICILOR DE UTILIZARE A ANTIBACTERIENELOR DE CĂTRE MEDICII VETERINARI DIN REPUBLICA MOLDOVA

Cristina SÎRBU¹, Nicolae STARCIUC¹, Olga BURDUNIUC²

¹Universitatea Tehnică din Moldova, Chișinău, Republica Moldova

²Agencia Națională pentru Sănătate Publică, Chișinău, Republica Moldova

Autor corespondent: Cristina Sîrbu, e-mail: kristina.sirbu1985@gmail.com

Cuvinte-cheie:

medic veterinar, RAM, antimicrobiene, sensibilitate, prescripție.

Introducere. Problema utilizării excesive și incorecte a preparatelor antimicrobiene la creșterea animalelor rămâne a fi una acută. Prezentul studiu prevede analiza corectitudinii utilizării antimicrobiene, în contextul rezistenței la antimicrobiene (RAM), în tratamentul și profilaxia bolilor bacteriene la animale. Stabilirea cauzelor RAM și reducerea impactului acesteia rămâne o prioritate în contextul abordării unei singure sănătăți.

Scop. Evaluarea practicilor de utilizare a antimicrobienelelor de către medicii veterinari în Republica Moldova.

Material și metode. Studiul a fost bazat pe datele unui chestionar standardizat autoadministrat îndeplinit de către medicii/felcerii veterinari care activează în circumscripțiile teritoriale sanitar-veterinare ale Agenției Naționale pentru Siguranța Alimentelor din 35 de raioane ale țării, în perioada 20-27 septembrie 2023, pe un eșantion de 150 de respondenți.

Rezultate. La studiu au participat 123 de respondenți (82%), dintre care 32% t medici veterinari, iar restul 68%) – felceri veterinari. Vechimea medie în muncă a respondenților a fost de 27 de ani. 3% (4) dintre medicii veterinari consideră că problema RAM este importantă doar pentru sănătatea publică, 7% o consideră problemă de ordin național, iar 88% – de nivel global. Dintre medicii veterinari chestionați, 92% prescriu antibiotice diferitor specii de animale de rentă, iar 36% folosesc antibiotice pentru a trata bolile neinfecțioase atât la animale adulte, cât și la tineret. În 80% din cazuri, prescrierea antibioticelor de către medicii veterinari are la bază examinarea clinică a animalelor de rentă bolnave. Nici unul dintre medicii veterinari chestionați nu efectuează teste de sensibilitate la antibiotice, utilizând antibiotice cu spectru larg de acțiune. Recurg la serviciile de laborator atunci când prescriu antibiotice patru (3%) medici veterinari și doar în trei (67%) cazuri motivul utilizării serviciilor de laborator a fost determinarea sensibilității la antibiotice. În 76% din cazuri, medicii veterinari nu efectuează teste de laborator înainte de a prescrie antibiotice din cauza lipsei unui laborator în apropiere, iar cinci respondenți consideră că testele de laborator nu sunt necesare.

Concluzii. (1) Chestionarea medicilor veterinari responsabili de utilizarea antimicrobienelelor în creșterea animalelor reprezintă o măsură periodică obligatorie care poate contribui semnificativ la ajustarea metodelor de diminuare a fenomenului RAM. (2) Rezultatele anchetei au demonstrat principalele cauze ale neaprecierii sensibilității florei bacteriene la antimicrobiene o constituie accesul limitat la serviciile diagnosticului de laborator din cauza plasamentului la distanțe mari a laboratoarelor, obținerea tardivă a rezultatelor și costurile mari ale testelor de laborator. (3) Una din măsurile importante, care ar contribui eficient la reducerea RAM, este utilizarea antimicrobienelelor în baza prescripției veterinare care rămâne o problemă prioritară la nivel național.

SPECTRUL ȘI REZISTENȚA LA ANTIMICROBIENE ALE INFECȚIILOR TRACTULUI URINAR ASOCIATE CATETERIZĂRII

Lucia GALBEN, Eugeniu CHEPTENE, Alexandru FERDOHLEB

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Lucia Galben, e-mail: galben luciagalben@mail.ru

Cuvinte-cheie:

spectrul microbian, rezistență la antimicrobiene, infecții urinare asociate cateterizării.

Introducere. Infecțiile tractului urinar reprezintă cca 40% din totalul infecțiilor asociate asistenței medicale, majoritatea cazurilor fiind determinate de cateterizare. La pacienții fără cateter, tractul urinar este colonizat, de obicei, de microorganisme de origine enterică. Prezența unui cateter creează un mediu favorabil pentru persistența microorganismelor și formarea de biofilme, ceea ce crește probabilitatea ca tractul urinar să fie colonizat de microorganisme nosocomiale nonenterice. Prin urmare, este important să cunoaștem spectrul agenților patogeni asociați cu prezența unui cateter urinar.

Scop. Evaluarea spectrului și rezistenței la antimicrobiene a tulpinilor microbiene izolate din infecțiile tractului urinar asociate cateterizării.

Material și metode. Studiul realizat este unul secundar-sinteză narativă a literaturii. Informația a fost selectată din bazele de date electronice internaționale, din 2018 până în 2023, cu privire la spectrul și rezistența la antibiotice a infecțiilor urinare asociate cateterizării (ITUAC). În acest scop au fost folosite următoarele cuvinte-cheie în diferite combinații: cateter, infecție urinară, bacteriurie, rezistență la antimicrobiene. În studiu au fost analizate cele 38 de publicații selectate, precum și datele, și recomandările Asociației Europene de Urologie, Centrului de Prevenire și Control al Bolilor (CDC), inclusiv Ghidul pentru prevenirea infecțiilor urinare asociate cateterizării.

Rezultate. Cateterismul permanent, care durează 30 de zile sau mai mult, este definit ca „pe termen lung” sau „cronic”. Durata prelungită a cateterizării instantaneu duce la formarea biofilmului pe suprafața acestuia. La pacienții cateterizați pe termen lung, bacteriuria polimicrobiană apare în ~95% din cazuri. Cei mai frecvenți agenți patogeni asociați cu prezența unui cateter permanent sunt *E. coli* (21,4%) și *Candida* spp. (21,0%), urmați de *Enterococcus* spp. (14,9%), *P. aeruginosa* (10,0%), *K. pneumoniae* (7,7%), *Enterobacter* spp. (4,1%) și *A. baumannii* (1,2%). În rezumatul anual al datelor raportate de CDC, 24,8% dintre izolatele de *E. coli* și 33,8% dintre izolatele de *P. aeruginosa* au fost rezistente la fluorochinolone. Tulpinile de *E. coli* și de *K. pneumoniae* au prezentat rezistență în 5,5% din cazuri, inclusiv 21,2% la ceftriaxonă. Ratele de rezistență au fost relativ înalte chiar și la carbapeneme: *E. coli* 4%, *K. pneumoniae* 10%, *P. aeruginosa* 25% și *A. baumannii* 25,6%. Rezistență semnificativă a fost înregistrată la vancomicină (6,1%) și la ampicilină (3,1%) în cazul *E. faecalis*.

Concluzii. Cateterile urinare sunt recunoscute ca factor de risc major pentru dezvoltarea infecțiilor urinare asociate asistenței medicale. Spectrul microorganismelor în ITUAC este foarte diferit, iar din cauza formării biofilmelor rezistența la antimicrobiene a acestor tulpini este înaltă. Agenții patogeni din biofilme sunt bine protejați de antimicrobiene și de apărarea gazdei. Deoarece terapia antimicrobală la pacienții cateterizați duce la dezvoltarea rezistenței la antimicrobiene, strategia prudentă de administrare a antibioticelor, gestionarea cateterului și prevenirea ITUAC trebuie considerate prioritare.

Studiul este realizat în cadrul proiectului JPIAMR „Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters”; (PhageLand), cifrul proiectului - 22.80013.8007.1M.

CALITATEA MICROBIOLOGICĂ A PRODUSELOR FARMACEUTICE NESTERILE

Nicolae PUȘCAȘ

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Nicolae Pușcaș, e-mail: nicolae.puscas@usmf.md

Cuvinte-cheie:

controlul calității, produse farmaceutice, contaminare, microorganisme.

Introducere. Evaluarea microbiologică a produselor farmaceutice nesterile este relevantă, deoarece contaminarea microbiană reduce sau anulează efectul lor terapeutic și poate provoca infecții. Microorganismele prezente în medicamente nu numai că le fac periculoase din punct de vedere infecțios, dar pot să modifice proprietățile chimice, fizice și organoleptice ale acestora sau conținutul ingredientelor active. În plus, microorganismele pot produce metaboliți cu proprietăți toxice.

Scop. Analiza rezultatelor obținute în urma testelor de puritate microbiologică a medicamentelor nesterile de către diferite companii farmaceutice și prezentarea neconformităților înregistrate în grupele de medicamente studiate.

Material și metode. A fost realizat un studiu secundar-sinteză narativă a literaturii. Informația a fost selectată din bazele de date electronice internaționale folosind următoarele cuvinte-cheie în diferite combinații: produse farmaceutice, controlul calității, contaminare microbiologică. Prin căutare, au fost identificate 26 de publicații.

Rezultate. Există multe rapoarte internaționale cu privire la neconformitățile în procesul de producere a medicamentelor care au ca rezultat acordarea autorizațiilor de introducere pe piață a produselor de proastă calitate. Długaszewska și colab. au raportat că pe o perioadă de 10 ani procentul mediu de probe neconforme a fost de 0,7%. O analiză a rezultatelor testelor de puritate microbiologică a medicamentelor combinate a arătat că până la 5,6% dintre acestea nu corespund standardelor aplicabile. Printre neconformitățile majore ies în evidență numărul excesiv de bacterii, de fungi și de bacterii gramnegative. Charnock a evaluat conținutul microbian al 77 de produse farmaceutice nesterile înregistrate ca mărci comerciale distribuite în Norvegia. Toate produsele examinate corespundeau normativelor aplicabile în ceea ce privește numărul și tipurile de microorganisme izolate, ceea ce indică la eficacitatea practicilor de producere în conformitate cu standardele existente. Majoritatea bacteriilor izolate au fost bacili grampozitivi care formează endospori. Deși bacili gramnegativi au fost puși în evidență foarte rar, unii dintre ei aparțineau unor specii indicate anterior ca agenți patogeni oportuniști inadmisibili în produsele farmaceutice. Într-un studiu efectuat de Ratajczak și colab., din 1285 de probe de medicamente studiate 24 de probe au prezentat neconformități. Cea mai frecventă neconformitate a fost depășirea numărului maxim acceptabil de fungi. Fungii izolați au aparținut genurilor: *Aspergillus*, *Rhizopus*, *Alternaria*, *Mucor*. Levuri nu au fost detectate. Micetele pot produce micotoxine cancerigene și mutagene, de asemenea pot provoca intoxicații acute și cronice, alergii, boli ale sistemelor respirator, digestiv și leziuni hepatice.

Concluzii. Rezultatele obținute pot îmbunătăți calitatea producerii în fabricile farmaceutice, pot informa/conștientiza necesitatea controlului microbiologic al procesului de producție al fiecărei serii de medicamente și, prin urmare, pot îmbunătăți siguranța și calitatea medicamentelor.

IMPACTUL METODELOR MICROBIOLOGICE ASUPRA DIAGNOSTICULUI INFECȚIEI CU CLOSTRIDIODES DIFFICILE

Anastasia ALEXANDROV, Greta BĂLAN

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Anastasia Alexandrov, e-mail: alexandrovastasia@gmail.com

Cuvinte-cheie:

Clostridioides difficile, metode, diagnostic, algoritm.

Introducere. Bacteria *Clostridioides difficile* este o cauză frecventă a diareei asociate asistenței medicale. Forma clinică depinde de factorii ce țin de gazdă și de virulența tulpinii implicate în proces. Acest microorganism provoacă boală care variază în severitate de la colonizare asimptomatică la diaree severă, colită pseudomembranoasă, megacolon toxic, perforație de colon și deces. Depistarea și raportarea cazurilor de ICD depinde de metodele de diagnostic utilizate. În unele țări, în special în cele cu venituri mici și medii, nu există cazuri de ICD raportate și, respectiv, nu se cunoaște amploarea poverii ICD. O altă provocare în diagnosticul de laborator al ICD o reprezintă și numeroasele metode propuse, fără a fi stabilit un algoritm de diagnostic bine determinat.

Scop. Evaluarea impactului metodelor microbiologice de diagnostic asupra diagnosticului infecției cu *C. difficile*.

Material și metode. Studiul reprezintă o sinteză narativă a literaturii de specialitate. Informația a fost selectată din bazele de date electronice internaționale folosind următoarele cuvinte-cheie în diferite combinații: *Clostridioides difficile*, metode, diagnostic, algoritm, standarde. Criteriul de bază de selectare a surselor bibliografice a fost disponibilitatea integrală și gratuită a articolelor. Pe baza acestor criterii au fost selectate 14 articole științifice.

Rezultate. Diferitele în strategiile de testare de laborator utilizate au un impact substanțial asupra ratelor de ICD raportate. Într-un studiu s-a constatat că la testarea independentă bazată pe PCR a fost obținut un număr dublu de rezultate pozitive, în comparație cu testarea independentă a toxinelor prin analiza imunoenzimatică (AIE). În mod similar, un alt studiu a demonstrat că testarea bazată pe PCR a probelor GDH-pozitive și toxine-negative aproape a dublat numărul de rezultate pozitive, în comparație doar cu testarea GDH și a toxinelor prin AIE. Testarea de laborator pentru ICD este un domeniu în schimbare permanentă și nu există un singur standard de referință acceptat sau un singur test considerat cel mai bun. Un test de diagnostic este evaluat în funcție de sensibilitate, de specificitate, de timpul de realizare, de costul și de disponibilitatea acestuia. Testul de neutralizare a citotoxicității celulare și de izolare a agentului în cultură pură sunt considerate teste de referință pentru diagnosticul de laborator al ICD. Din cauza timpului îndelungat de obținere a rezultatelor și a cerințelor tehnice, aceste teste nu sunt utilizate pe larg. De asemenea, a fost demonstrat că la utilizarea testelor de sine stătător pentru diagnosticarea ICD nu se obțin rezultate fiabile, iar implementarea algoritmului în doi pași a redus numărul de rezultate fals pozitive și a permis divizarea pacienților în cei fără ICD, cei cu ICD și potențiali purtători de *C. difficile*.

Concluzii. Diagnosticul de laborator este foarte important pentru a diferenția ICD de alte cauze de diaree și pentru a stabili prezența infecției versus colonizare. Alegerea metodelor de diagnostic de laborator are un impact semnificativ asupra diagnosticului ICD și, prin urmare, asupra ratelor raportate de ICD.

PROBLEMA REZISTENȚEI LA ANTIBIOTICE ÎN MEDIUL OCUPAȚIONAL AL LUCRĂTORILOR MEDICALI: SINTEZĂ NARATIVĂ

Ana VÎLCOVA

Spitalul Clinic Republican „Timofei Moșneaga”, Chișinău, Republica Moldova

Autor corespondent: Ana Vîlcova, e-mail: ana.vilcova1@gmail.com

Cuvinte-cheie: rezistența la antibiotice, factori de risc, mediul ocupațional, lucrători medicali.

Introducere. Rezistența la antibiotice reprezintă una dintre cele mai serioase provocări la nivel global în tratarea bolilor infecțioase. Fenomenul de rezistență la antibiotice, când agenții patogeni suferă modificări care reduc sau elimină eficacitatea tratamentelor medicamentoase, devine o problemă din ce în ce mai urgentă la nivel mondial. Lucrătorii din domeniul medical se confruntă cu riscul de a contracta infecții severe și, uneori, fatale, care devin rezistente la tratamentele disponibile. Deși întreaga comunitate este expusă acestui pericol, anumite ocupații sunt mai expuse acestui pericol.

Scop. Studiarea literaturii de specialitate pentru elucidarea antibiorezistenței ca factor de risc prezent la locul de muncă al angajaților din sectorul medical.

Material și metode. Studiul a fost fundamentat pe o analiză narativă a 21 de surse științifice din baze de date internaționale care abordează factorii de risc din mediul ocupațional, inclusiv rezistența la antibiotice, și care au impact asupra stării de sănătate a lucrătorilor medicali din instituțiile medicale din Republica Moldova.

Rezultate. În spitalele și în unitățile de terapie intensivă, se conturează un mediu propice pentru proliferarea și răspândirea bacteriilor rezistente la antibiotice. Această situație este generată de utilizarea intensivă a antibioticelor în cadrul unei populații dense de pacienți, expunerea repetată a personalului medical și condițiile specifice din aceste instituții. Transmiterea bacteriilor rezistente includ poate avea loc prin contactul direct cu mâinile contaminate ale personalului, cu suprafețele infectate (mânerele ușilor și echipamentele utilizate), precum și prin contactul direct cu pacienții sau cu fluidele corporale ale acestora, care sunt o sursă primară de infecție. Numeroși agenți biologici, inclusiv bacteriile din aerul expirat sau toxinele eliberate de micete, sunt transmise prin intermediul aerului. Deficiențele în construcția clădirilor și în proiectarea sistemelor de aer condiționat nu asigură condiții optime de ventilație și de uscare a aerului.

Concluzii. Starea reală din instituțiile medicale subliniază necesitatea unei abordări multidisciplinare și a unor măsuri preventive robuste pentru a gestiona rezistența la antibiotice în mediul ocupațional al lucrătorilor medicali. Astfel, promovarea unor practici riguroase de igienă, gestionarea adecvată a echipamentelor și a suprafețelor, îmbunătățirea sistemelor de ventilație și a infrastructurii sunt aspecte esențiale în asigurarea unui mediu de lucru sănătos și sigur pentru personalul medical și pacienți.

RESISTANCE OF PATHOGENS CAUSING URINARY TRACT INFECTIONS IN CHILDREN

Lucia TURCAN, Svetlana LATUS, Anastasia CARACAS

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Anastasia Caracas, e-mail: anastasia.caracas@usmf.md

Keywords: urinary tract infection, children, microbial resistance.

Introduction. Urinary tract infections are among the most common bacterial infections in children. Limited data on the pharmacokinetic and pharmacodynamic characteristics of antibacterial drugs in pediatric patients may lead to their excessive and irrational use, resulting in the development of complications. Currently, there is an alarming level of antimicrobial resistance among causative pathogens due to the inappropriate and widespread use of antibacterials. Resistant infections are associated with higher morbidity, mortality, and increased healthcare costs.

The aim of this study was to identify the causative pathogens of urinary tract infections in children and analyze their susceptibility to antibacterial preparations for optimal therapeutic management.

Material and methods. This analytical-retrospective study involved analyzing the results of bacteriological urine examinations in children admitted to the specialized wards of Valentin Ignatenco Children's Municipal Clinical Hospital in 2022, focusing on the identification of microorganisms and evaluation of susceptibility to antibacterial preparations.

Results. According to the data obtained, 39% positive urocultures were identified in children and the most common pathogen detected was *Escherichia coli* (43% cases), followed by *Staphylococcus epidermidis* (40%), *Enterococcus* (6%), *Proteus mirabilis* (5.5%), *Klebsiella pneumoniae* (4.5%), *Pseudomonas aeruginosa* (1%). *Escherichia coli* showed resistance to cephalosporins-cefaclor (47%), cefuroxime (51%), ceftazidime (40%), cefoperazone (61%), fluoroquinolones-ciprofloxacin (52%), ofloxacin (62%) and, amoxicillin/clavulanic acid in 42% cases. *Staphylococcus epidermidis* detected in 39% cases, was resistant to ceftriaxone (33%), ceftazidime (28%), cefuroxime (31%), ciprofloxacin (37%), amoxicillin/clavulanic acid in 53% cases. *Enterococcus* was resistant to ceftriaxone (32%), cefuroxime (37%), cefaclor (30%), ciprofloxacin (29%), ofloxacin (35%), amoxicillin/clavulanic acid (22%). *Klebsiella pneumoniae* was resistant to ceftazidime (35%), cefoperazone (27%), ceftriaxon (23%), cefuroxime (31%), cephalixin (27%), ciprofloxacin (38%), ofloxacin (46%), amoxicillin/clavulanic acid (27%), and *Pseudomonas aeruginosa* was resistant to ceftazidime (27%), ceftriaxon (20%), cefuroxime (40%), cephalixin (27%) ciprofloxacin (47%).

Conclusions. Urinary tract infections in children pose a significant challenge due to the specific features of the pediatric population, including the difficulty in conducting studies, limited therapeutic options, contraindications, variability of causative pathogens, and increased resistance to antibacterial therapy. *Escherichia coli* was the most commonly detected pathogen, with an elevated rate of resistance to amoxicillin/clavulanic acid and cephalosporins, which are commonly used for the treatment of urinary tract infections in children. Rational selection of antibacterials is essential to ensure effective and safe treatment and to prevent urinary tract infections with multidrug-resistant agents.

MALADII BACTERIENE CU MANIFESTĂRI NEUROLOGICE INFLUENȚATE DE SCHIMBAREA CLIMEI

Ioana CALIGA

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Ioana Caliga, e-mail: ioana.gradinari@gmail.com

Cuvinte-cheie:

schimbarea climei, maladii bacteriene, maladii neurologice, sănătate mintală, neuroinfecții.

Introducere. Schimbările climatice reprezintă una dintre cele mai mari și mai urgente provocări ale secolului XXI. Creșterea temperaturilor medii și a nivelului oceanelor, modelele modificate ale precipitațiilor și sporirea evenimentelor meteorologice extreme afectează nu numai peisajul și ecosistemul global, ci și sănătatea umană. Sănătatea creierului este în pericol ca urmare a creșterii incidenței infecțiilor bacteriene, influențate de schimbările climatice.

Scop. Cercetarea realizată a avut ca scop argumentarea legăturii infecțiilor bacteriene ale creierului cu schimbarea climei.

Material și metode. A fost realizat un studiu bibliografic, fiind căutate îmbinările de cuvinte „schimbarea climei”, „maladii bacteriene” și „maladii neurologice” în motorul de căutare disponibil gratuit, care oferă căutare de tip text-integral de publicații științifice open-acces – *Google Scholar*. Ca rezultat au apărut peste 40 de surse. Din ele au fost analizate 17, care au fost relevante tematicii.

Rezultate. În ultimii câțiva ani, incidența afecțiunilor bacteriene, care afectează sistemul nervos central (SNC), este în creștere. În pofida faptului că joacă un rol-cheie în controlul schimbărilor climatice, bacteriile sunt rareori obiectul de studii în cercetările tematice și nu sunt luate în considerare la dezvoltarea de noi strategii. Bacteriile reacționează la schimbările climatice prin reacții de feedback atât pe termen lung, cât și pe termen scurt și care pot fi atât pozitive, cât și negative. Neuroinfecțiile creează un micromediu inflamator care poate avea consecințe negative asupra calității vieții umane, inclusiv disfuncții cognitive, modificări comportamentale, depresie, convulsii, și deficiențe fizice. Simptomele neurologice în bolile infecțioase care afectează SNC sunt, de obicei, neglijate. Printre primele zece boli infecțioase care cauzează deces la nivel mondial se regăsesc encefalita și meningita – infecții bacteriene ale sistemului nervos. Cei mai importanți agenți patogeni, care provoacă aceste afecțiuni, sunt *S. pneumoniae*, *Streptococcus agalactiae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Listeria monocytogenes*. Sepsisul polimicrobian este de asemenea o afecțiune medicală severă care provoacă simptome neurologice și se agravează în timpul valurilor de căldură. Infecțiile pneumococice se pot răspândi prin aerosoli și evoluează asimptomatic în colonizarea cavității nazale, de unde se răspândesc în alte organe, inclusiv în creier. Ajungând în fluxul sanguin și, traversând bariera hematoencefalică, provoacă meningită. Recent a fost stabilită o relație între creșterea conținutului de mercur în aerul atmosferic și sporirea numărului pacienților afectați de encefalită cauzată de *Naegleria fowleri* în SUA și în sud-estul Asiei. Pacienții afectați suferă de meningoencefalită, a cărei rată a mortalității a rămas în jur de 98%, cu mai puțin de cinci supraviețuitori care au trecut de 50 de ani. Acești agenți patogeni pot provoca, și o boală a sistemului nervos central numită encefalită granulomatoasă.

Concluzii. Schimbările climatice au impact și asupra bacteriilor, contribuind la prelungirea ciclului lor de viață, la sporirea agresivității și a consecințelor pe sănătatea umană, agravând sau chiar determinând unele afecțiuni neurologice.

BENEFITS AND CHALLENGES IN USING WETLANDS FOR WASTEWATER TREATMENT

Alina FERDOHLEB¹, Elena BUCATA^{1,2}, Vladimir BERNIC^{1,2}

¹*Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova*

²*National Agency for Public Health, Chisinau, Republic of Moldova*

Corresponding author: Elena Bucata, e-mail: elena.bucata@ansp.gov.md

Keywords: *waste-water, constructed wetlands, sewage, public health.*

Introduction. Being a sustainable and eco-friendly method of treating wastewater, constructed wetlands use microorganisms and natural processes to eliminate pollutants. Depending on how they are built, put into use, and maintained, they may offer a number of advantages as well as disadvantages.

The aim of the study was to improve the management of constructed wetlands by promoting their benefits and minimizing the associated risks.

Material and methods. A review of national and international scientific bibliographic sources on best practices for implementing constructed wetlands in wastewater treatment was conducted.

Results. Constructed wetlands are ecological infrastructures designed to replicate the advantages and functions of natural wetlands. These areas effectively clean and manage water, including wastewater, in a sustainable manner by harnessing the power of bacteria and natural processes. They also serve as habitats for aquatic life, including fish, plants, and microbes, which work together to filter, clean, and regenerate water. Compared to conventional wastewater treatment methods, constructed wetlands use less energy, require fewer staff for maintenance, effectively treat wastewater with dispersed pollution, help preserve biodiversity, and provide habitat for a variety of plants and animals. Additionally, they can enhance the visual appeal of metropolitan areas and offer higher resilience to climate change and extreme events. However, despite the numerous benefits of constructed wetlands, there are also challenges. These include the need for more space than traditional technologies due to the use of extensive areas of vegetation and soil, potentially longer implementation and installation times, and the potential for the development and spread of antibiotic resistance. Local conditions such as soil type, climate, and hydrological features can influence the efficiency of constructed wetlands, necessitating adjustments for each unique circumstance. These challenges can be addressed through effective design, meticulous material and plant selection, and the application of engineering techniques to enhance efficiency. Furthermore, the implementation of new biotechnologies focused on combating antibiotic-resistant pathogenic flora can help mitigate these challenges.

Conclusions. Constructed wetlands remain a valuable choice for sustainable water resource management and environmental protection, despite the challenges involved. With proper integration and management, they can serve as sustainable solutions for issues related to water quality, flood management, and biodiversity conservation.

The research was conducted as part of the JPIAMR projects: "Phage treatment and wetland technology as an intervention strategy to prevent dissemination of antibiotic resistance in surface waters" (*PhageLand*).

ASPECTE EPIDEMIOLOGICE A INFECȚIILOR DE SITUS CHIRURGICAL: ANALIZĂ NARATIVĂ

Angela PARASCHIV, Vasili GALBEN

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Galben Vasili, e-mail: galbenvasilii66@gmail.com

Cuvinte-cheie: *infecții asociate asistenței medicale, infecție de situs chirurgical, infecții postoperatorii, infecții de plagă.*

Introducere. Infecțiile la nivelul locului chirurgical sunt infecții frecvente asociate cu îngrijirea sănătății, care pot provoca daune severe pacientului, inclusiv deces, și cresc costurile de îngrijire. Rezultatele unui studiu din 2017 au arătat că ratele de readmitere asociate cu aceste infecții variau între 1,45% și 6,34%. Lipsa conformității cu ghidurile de bune practici acceptate pentru îngrijirea perioperatorie poate crește riscul pacientului de a dezvolta o infecție de situs chirurgical.

Scopul lucrării a fost evaluarea legităților de manifestare a procesului epidemic și factorii de risc în infecțiile asociate asistenței medicale (IAAM) la pacienții cu situs chirurgical bazându-ne pe datele de literatură.

Material și metode. S-a realizat studiu de tip secundar, sinteză narativă, cu utilizarea publicațiilor din bazele de date PubMed, Med ONE, NLM, NCBI, raporte anuale de activitate a spitalului de nivel republican. Perioada de referință – 2015-2022.

Rezultate. S-a stabilit, că infecțiile de situs chirurgical sunt responsabile de 38% din decesele cauzate de complicațiile post-operatorii, iar durata medie a spitalizării pacientului cu infecție de situs chirurgical crește, în dependență de țară și zonă geografică cu 5-20 de zile. Costul suplimentar al tratamentului infecțiilor de situs chirurgical se situează între 170 și 29600 \$ în țările cu venituri mici și medii și pot ajunge la 35000 \$ în țările cu venituri mari. Incidența generală a infecțiilor de situs chirurgical la nivel global ajunge la 2,5%, cu incidența cea mai înaltă în Regiunea Africană (aprox. 7%). Studiile au arătat că cea mai crescută incidență se înregistrează în Tanzania (26%), iar cea mai mică – în China (0,2%). Cele mai frecvent izolate microorganisme din secrețiile de plagă, la nivel mondial, sunt *S.aureus*, stafilococi coagulazo-negativi, *Enterococcus sp.* și *E.coli*. Etiologia infecțiilor postoperatorii depinde în primul rând de sediul anatomic al intervenției și de tipul de plagă chirurgicală. Astfel, din infecții ale „plăgilor curate” se izolează cel mai frecvent *S. aureus*, iar din infecții ale „plăgilor contaminate” și ale „plăgilor murdare” se izolează în special bacili gram-negativi: *E. coli*, *Proteus spp.*, *Klebsiella spp.*, *Enterobacter spp.*, *Pseudomonas spp.* etc. În cazul „plăgilor contaminate”, a „plăgilor murdare” s-a constatat deseori o etiologie polimicrobiană aerobă și anaerobă, asemănătoare cu flora endogenă a organului rezecat. Prevalența consumului de antimicrobiene constituie 42,7%. Fiecare al 3-a pacient spitalizat primește cel puțin un preparat antimicrobian. În mediu la un pacient sunt administrate 1,3 antimicrobiene. Pacienții cu intervenții chirurgicale invazive fac IAAM de circa 3 ori mai frecvent, prevalența IAAM constituind 6,9% și de 2 ori mai frecvent consumă antimicrobiene, cu o prevalență de 99% de cazuri.

Concluzii. Infecția de situs chirurgical se numără printre cele mai frecvente complicații postoperatorii și este responsabilă de ratele mari de morbiditate și mortalitate. Prevenirea acestor infecții este o sarcină majoră și necesită eforturi deosebite cu utilizarea complexă a mai multor măsuri, inclusiv este nevoie de mai multe cercetări. Determinarea legităților procesului epidemic în IAAM la pacienții internați în secțiile cu profil chirurgical, factorii de risc, spectrul de microorganisme izolate și rezistența/sensibilitatea față de preparate antimicrobiene ne permite să obținem limite de securitate postoperatorie și argumentează necesitatea elaborării „Ghidul de prevenire și control al IAAM”.

ANALIZA DIVERSITĂȚII GENETICE A VIRUSULUI SARS-CoV-2: REVISTA LITERATURIISvetlana COLAC¹, Mariana ULINICI², Olga BURDUNIUC^{1,2}¹Agencia Națională pentru Sănătatea Publică, Chișinău, Republica Moldova²Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Svetlana Colac, e-mail: colac.svetlana92@gmail.com

Cuvinte-cheie:

SARS-CoV-2,
COVID-19, monitorizarea genetică, variante de mutații, secvențierea, proteina S.

Introducere. Pandemia COVID-19, provocată de SARS-CoV-2, un agent patogen din familia *Coronaviridae*, a evidențiat necesitatea înțelegerii evoluției virusului. De la secvențierea inițială în ianuarie 2020, virusul a acumulat mii de mutații, majoritatea în proteina S și domeniul său de legare la receptor (RBD). Aceste mutații influențează afinitatea pentru receptorul celular ACE2, crescând infectivitatea și generând noi variante. Secvențierea genomului reprezintă una dintre metodele optime pentru monitorizarea variantelor de COVID-19, identificarea și studierea rapidă a modificărilor în structura genomului virusului și evoluția acestuia.

Scop. Studiul vizează analiza variabilității genetice a SARS-CoV-2 pe parcursul pandemiei, cu accent pe mutațiile semnificative și impactul lor.

Material și metode. Pentru realizarea studiului, a fost efectuată analiza narativă a literaturii, selectând articole relevante publicate între 2020-2023, folosind cuvintele: „genome sequencing”, „SARS-CoV-2”, „mutation analysis” și „genovariants”. În total, au fost examinate 48 de surse bibliografice, utilizând baze de date precum Embase, PubMed, Hinari, Google Academic și bibliotecile naționale.

Rezultate. Monitorizarea genetică a relevat cinci variante de îngrijorare conform OMS: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) și Omicron (B.1.1.529). Aceste variante prezintă mutații multiple în proteina S, în special în RBD, conducând la contagiozitate crescută și evaziunea imunitară. Alpha, detectată inițial în Regatul Unit al Marii Britanii, are așa mutații ca N501Y în RBD, care îmbunătățesc afinitatea pentru receptorul ACE2. Beta, identificată în Africa de Sud, prezintă mutații precum K417N și E484K, crescând evaziunea imună. Gamma, cu origine în Brazilia, are mutații similare cu Beta, influențând atât transmisibilitatea, cât și recunoașterea imunitară. Delta, apărută în India, cu mutații ca L452R și P681R, a generat rate mai mari de infectare și de replicare virală. Varianta Omicron provine din linia genetică B.1.1. Genomul variantei Omicron are mai mult de 30 mutații în proteina S, în comparație cu tulpina de referință Wuhan-Hu-1, dintre care 15 substituții de aminoacizi în domeniul de legare la receptor (RBD), zonele asociate cu răspunsul imun. Mutațiile prezente în Omicron pot fi asociate cu transmisibilitate mai mare, legare alterată la receptor și evaziune imună. Studiul subliniază importanța proteinelor structurale în adaptarea virusului la noi gazde și în patogeniza COVID-19, esențială pentru dezvoltarea strategiilor de control al pandemiei.

Concluzii. Analiza datelor din literatură evidențiază importanța monitorizării mutațiilor pentru înțelegerea dinamicii pandemiei și dezvoltarea strategiilor de control, inclusiv îmbunătățirea vaccinurilor. Proteina S, în particular, joacă un rol crucial în patogeniza infecției și este un punct focal în cercetările viitoare.

MARKETING SOCIAL ÎN CAMPANIILE DE VACCINARE

Iana COVACI, Ludmila GOMA

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Ludmila Goma, e-mail: ludmila.goma@usmf.md

Cuvinte-cheie:

sanatatea publică, ezitare la vaccinare, marketing social „4P”, promovarea sănătății.

Introducere. Vaccinurile sunt considerate una dintre cele mai importante realizări ale medicinei moderne. La nivel mondial, în fiecare an, vaccinările previn până la trei milioane de decese. Studiile au arătat că vaccinurile sunt printre cele mai sigure injecții disponibile, reacțiile adverse fiind rare. Totuși, în pofida creșterii disponibilității vaccinurilor, o bună parte a populației nu se vaccinează și nu vaccinează copiii din motive ce nu țin de contraindicații medicale.

Scop. Analiza impactului marketingului social în companiile de vaccinare.

Material și metode. Studiu secundar, sinteză narativă. Din bazele de date electronice internaționale, inclusiv Scopus, PubMed, Web of Science și Google Scholar, au fost analizate 180 de surse, cele mai actuale informații, ghiduri, publicații recente în limbile română, rusă, engleză, privind aplicarea principiilor de marketing social în promovarea vaccinării. Perioada de referință au fost anii 2012-2023. Ultima căutare a literaturii a fost efectuată în decembrie 2023. Metodele de cercetare utilizate: descriptivă, analitică.

Rezultate. Imunizarea sistematică a populației reduce în mod semnificativ morbiditatea, mortalitatea și invaliditatea cauzate de bolile infecțioase care pot fi prevenite prin vaccinare, reducând astfel semnificativ daunele sociale și economice induse de acestea. Principiile marketingului social privind promovarea campaniilor de vaccinare devine una din activități principale în contextul ezitării populației privind vaccinarea. Sistemele de comunicare publică și de masă, utilizate pentru a promova administrarea vaccinurilor, se încadrează în categoriile de activități promoționale: publicitate, relații publice. În condițiile actuale, strategiile de modificare a percepțiilor publicului cu privire la vaccinuri ar trebui să includă furnizarea de informații imparțiale și cuprinzătoare, adaptate nevoilor de informare a populației și transmise prin tehnologii de comunicare multiple și noi precum mass-media socială, intervențiile electronice – serviciile de mesagerie text și rețelele sociale, aspecte ce țin de marketing.

Concluzii. În formularea strategiilor de promovare a vaccinării, în marketingul social, ca și în cel comercial, se recurge la mixul de marketing, reprezentat de 4P: produs, preț, plasament, promovare. Marketingul social în sănătate reprezintă un potențial important pentru atingerea unui grup de persoane cât mai mare posibil cu costurile cele mai mici, printr-un program eficient, care să satisfacă consumatorii cât mai mult. Este necesar ca specialiștii în marketing să fie incluși în grupurile de lucru desemnate să elaboreze planuri și politici de promovare a sănătății (inclusiv campanii de imunizare) în rândul populației. Aceștia, la rândul lor, vor ține cont de elementele de fundamentare a strategiei de marketing social pentru a atinge cele mai bune rezultate în campaniile de promovare a vaccinării.

CYTOGENETIC STUDY IN MEN FROM THE POPULATION OF THE REPUBLIC OF MOLDOVAStela RACOVITA¹, Veaceslav MOSIN¹, Mariana SPRINCEAN^{1,2}¹*Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova*²*Institute of Mother and Child, Chisinau, Republic of Moldova**Autor corespondent: Stela Racovita, e-mail: stela.racovita@usmf.md*

Keywords: *karyotype, chromosomal abnormalities, male, infertility.*

Introduction. Globally, it is estimated that 15% of couples experience infertility, with male factors contributing to half of these cases. The causes of male infertility are highly diverse, often stemming from disorders in spermatogenesis, which are clinically characterized by severe oligozoospermia and azoospermia. Genetic factors account for approximately 30% of male infertility cases associated with spermatogenesis disorders. Among the numerous genetic causes of spermatogenic insufficiency, chromosomal anomalies are particularly significant from a clinical standpoint. Approximately 15% of men with non-obstructive azoospermia and 4% of men with severe oligozoospermia have chromosomal abnormalities.

The aim of this study is to evaluate the profile of chromosomal variations in male infertility with severe oligozoospermia and azoospermia, in order to confirm the importance of exploring their cytogenetics for both diagnosis and treatment, as well as for assessment and prognosis.

Material and methods. The study involved a retrospective descriptive analysis of cytogenetic results in men with oligozoospermia and azoospermia in the Moldovan population from 2014 to 2022. The participants were individuals from infertile couples who sought assistance at the National Center for Reproductive Health and Medical Genetics. The patient group comprised 32 individuals with oligozoospermia and 156 with azoospermia. All patients underwent cytogenetic analysis using the classical G-banding technique on peripheral blood lymphocytes. Results were reported using the nomenclature outlined in the 2016 International System of Cytogenetic Nomenclature (ISCN).

Results. The average age of men was 33.8 ± 5.3 years, (95% CI: 32.7-34.9; median 33.0) (percentile 25 – 75: 30.0-36.0). Among the 156 men with azoospermia, 101 (64.7%) had a normal karyotype of 46,XY, while variations in the number or structure of chromosomes were observed in 55 individuals (35.3%; 95% CI: 27.8-42.8). Of these, 43 patients (27.6%) exhibited variations in the X or Y sex chromosomes, and 12 patients (7.7%) showed variations in the autosomal chromosomes. Among the 43 azoospermic patients with sex chromosomal abnormalities, 32 cases involved chromosomal number abnormalities, and 11 cases involved structural variations. Among the number of chromosomal abnormalities, 29 cases were attributed to X aneuploidy (Klinefelter Syndrome), 2 cases were mosaic 45,X/46,XY, and one case presented a 46,XX karyotype in a male. The structural variations of the sex chromosomes included 9 cases of duplications of the distal arm of the Y chromosome (Yqh+) and 3 cases of deletions of the distal arm of the same chromosome (Yqh-). Among the 32 men with oligozoospermia, 28 (87.5%; 95%CI: 76.0-99.0) had a normal karyotype of 46,XY, while 4 (12.5%; 95% CI: 1.0-24.0) exhibited variations in the sex chromosomes.

Conclusions. In this study, the prevalence of chromosomal abnormalities identified in azoospermia was 35.3% and in oligozoospermia was 12.5%. Given the high frequency of chromosomal abnormalities in men with infertility, as well as the genetic risks for future generations, it is important to assess the profile of chromosomal variations before resorting to Assisted Reproduction Techniques, for diagnosis, treatment, as well as assessment and prognosis.

RISCU VARICELOR RECIDIVANTE ȘI VARIANTELE ANATOMICE ALE VENEI SAFENE MARIAnastasia BENDELIC¹, Valentin BENDELIC¹, Ilia CATERENIUC¹

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Anastasia Bendelic, e-mail anastasia.bendelic@usmf.md

Cuvinte-cheie:

vena safenă mare, afluenți, vena safenă mare dublă, vene safene accesorii, jonctiunea safenofemurală.

Introducere. Conform surselor bibliografice, rata varicelor recidivante ale membrului inferior după intervenția chirurgicală variază de la 20-40% până la 50-60% sau chiar 80% din cazuri. Cauzele dezvoltării acestora pot fi greșelile tehnice și tactice, progresarea maladiei, neovascularizarea, precum și prezența variantelor anatomice ale venei safene mari – vena safenă mare dublă și venele safene mari accesorii.

Scopul lucrării a fost de a evalua frecvența variantelor anatomice ale venei safene mari la nivelul coapsei și a afluenților acesteia în apropiere de jonctiunea safenofemurală.

Material și metode. În vederea elucidării temei abordate, a fost organizat un studiu descriptiv transversal în cadrul căruia au fost disecate 22 de vene safene mari la nivelul coapsei și afluenții acestora. Studiul a fost efectuat pe cadavre formolizate în cadrul Catedrei de anatomie și anatomie clinică, a Universității de Stat de Medicină și Farmacie Nicolae Testemițanu din Republica Moldova.

Rezultate. Segmentul femural al venei safene mari, situat pe fața anteromedială, urca cranial pe coapsă și se vărsa în vena femurală, formând jonctiunea safenofemurală. În nouă cazuri (40,9%), vena safenă mare era solitară la nivelul coapsei, în trei cazuri (13,6%) se dubla la nivelul tuberozității tibiale, iar zece cazuri (45,5%) era însoțită de vene safene accesorii (anterioară și/sau superficială), plasate paralel cu vena safenă mare. Vena safenă mare accesorie superficială a coapsei, întâlnită în două cazuri (9,1%), era separată de vena safenă mare prin fascia safenă.

Vena safenă mare accesorie posterioară, cu un traiect ascendent pe fața posterioară a coapsei, a fost depistată în 15 cazuri (68,2%). Ea înconjura medial coapsa, dar se vărsa în vena safenă mare evident distal de jonctiunea safenofemurală.

Segmentul terminal al venei safene mari, situat în proximitatea jonctiunii safenofemorale, a primit următorii afluenți: vena circumflexă iliacă superficială – în 72,7 % din cazuri, vena epigastrică superficială – în 68,2%, vena pudendală externă superficială – în 68,2%, vena pudendală externă profundă – în 9,1%, vena safenă mare accesorie anterioară a coapsei în – 40,9%, vena safenă mare accesorie superficială a coapsei – în 4,55%.

Concluzii. Venele superficiale ale membrului inferior prezintă o variabilitate anatomică înaltă, încă puțin studiată. Segmentul femural al venei safene mari, în aproape jumătate din cazuri, este însoțită de vene safene accesorii (anterioară și/sau superficială) cu un traiect paralel. Vena safenă mare accesorie posterioară a coapsei, prezentă în 68,2% din cazuri, se varsă în vena safenă mare în treimea mijlocie a coapsei.

Imposibilitatea ligaturării sau ligaturarea incompletă și/sau greșită a tributarelor venei safene mari, prezența venei safene duble sau a venelor safene accesorii pot duce la apariția recidivei varicelor membrelor inferioare.

ASSESSMENT OF THE LIFE QUALITY AFTER SURGERY FOR PERFORATED GASTRODUODENAL ULCER

Elina SHOR

¹Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

²Emergency Medicine Institute, Chisinau, Republic of Moldova

Corresponding author: Elina Shor, e-mail: elina.sor@usmf.md

Keywords: perforated ulcer, surgery, quality of life, GSRS, MOS SF-36.

Introduction. Quality of life is a cornerstone in the assessment of modern medicine, surgery, and healthcare practices. This aspect is becoming increasingly important in healthcare due to the rapidly increasing power, variety, and cost of modern drugs and surgical techniques.

The aim of this study was to assess and compare the quality of postoperative recovery in patients undergoing surgery for perforated ulcer.

Material and methods. This observational, prospective study was conducted on 231 patients undergoing emergency surgery. Postoperative recovery was assessed using the GSRS and MOS SF-36. The control group for the studied parameters consisted of average data obtained from 42 healthy individuals from the general population, with similar socioeconomic status and age to the main group of the study.

Results. The research presents an analysis of 231 patients, mostly men, which is considered statistically conclusive ($p < 0.0001$), with a diagnosis of perforated gastroduodenal ulcer resolved by various surgical interventions. The majority of the patients were of working age, highlighting the significant social and economic impact of these issues. The remote follow-up period extended up to 10 years (average 7 years) after the primary surgery. The correlation between the life quality index and the surgical approach applied was statistically significant ($p < 0.001$). In the comparative analysis, it was noted that, among all the surgical intervention methods, the groups undergoing ulcer excision, ulcer excision with vagotomy, and gastric resection yielded the least favorable results ($p < 0.001$). The data obtained confirm that the GSRS and MOS SF-36 indices of life quality in patients undergoing the laparoscopic approach are statistically significantly better and more sustainable, impacting the effectiveness of treatment resolution ($p < 0.001$).

Conclusions. Life quality measures are increasingly used worldwide to assess surgical outcomes, as they focus on specific health conditions and are essential for detecting changes resulting from treatment, thereby assessing its effectiveness. The present study found that the differential selection of treatment tactics using modern minimally invasive technologies, especially laparoscopic suturing of perforated gastroduodenal ulcer, demonstrated significantly better efficiency compared to traditional, especially radical, operations.

INDICII CALITĂȚII VIEȚII LA BOLNAVII CU HEPATOPATII CRONICE DIN REPUBLICA MOLDOVA

Elena BEREZOVSCAIA

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Elena Berezovskaia, e-mail: elenaberezovskaia69@gmail.com

Cuvinte-cheie: calitatea vieții, chestionarul SF-36, infecție cronică HBV, boala ficatului gras metabolic asociat.

Introducere. Calitatea vieții prezintă un indicator strategic al sănătății în diferite patologii cronice, în special a celor hepatice. Conceptul general al calității vieții este utilizat pe scară largă, reflectând o corelare directă dintre calitatea vieții și bunăstarea personală.

Scop. Studiarea indicilor calității vieții la bolnavii cu hepatopatii cronice în condițiile Republicii Moldova.

Material și metode. Pentru realizarea scopului au fost examinați 59 de pacienți adulți cu diferite hepatopatii cronice: 34 de pacienți cu infecție cronică cu virusul hepatic B (Lotul HBV), 25 de pacienți cu boala ficatului gras metabolic asociat (Lotul BFG) și 26 de persoane adulte aparent sănătoase (Lotul-martor). Pentru evaluarea calității vieții (QoL) a fost folosit chestionarul SF-36 cu ajutorul căruia au fost apreciate opt scoruri: PF – funcționarea fizică; RF-P – funcționarea determinată de starea fizică; BP – durerea corporală; GH – starea generală de sănătate; VT – vitalitatea; SF – funcționarea socială; RF-E – funcționarea determinată de starea emoțională; MH₂ – sănătatea mintală. Pe baza sumării indicilor acestor scoruri au fost apreciați doi parametri integrali: Indicele de sănătate fizică (PH) și Indicele de sănătate mintală (MH). Datele obținute au fost prezentate în formatul $M \pm m$ și analizate utilizând programul de completare „Analiza datelor” Excel 2016. Pentru a determina nivelul de semnificație statistică (p), a fost aplicat testul Mann-Whitney neparametric. Pentru efectuarea studiului a fost obținut acordul Comitetului de Etică a Cercetării Științifice a USMF „Nicolae Testemițanu”, Chișinău, Republica Moldova, nr.10 din 28.12.2020.

Rezultate. Nivelurile cele mai scăzute ale parametrilor integrali ai QoL s-au înregistrat în lotul HBV: $PH=46,69 \pm 1,22$, $MH=38,97 \pm 1,56$. În lotul BFG s-au atestat următoarele valori ale acestor parametri: $PH=47,02 \pm 1,37$ și $MH=45,91 \pm 1,55$. Veridicitatea diferențelor între loturi pentru PH și MH a fost de 95% și de 99%, respectiv. În lotul-martor, valorile medii pentru acești parametri au fost $PH=53,01 \pm 0,91$ și $MH=51,51 \pm 1,50$, existând diferențe veridice ale acestor parametri cu ambele loturi de studiu ($p < 0,01$; $p < 0,01$). Analiza rezultatelor scorurilor reflectă menținerea tendinței valorilor minimale în lotul HBV. O scădere mai accentuată se observă în scorurile RF-E al MH. Acest indicator a fost apreciat cu punctaje scăzute în loturile HBV și BFG ($37,25 \pm 4,83$ și $66,67 \pm 7,45$) versus lotul-martor $93,59 \pm 3,71$ ($p < 0,01$; $p < 0,01$; $p < 0,01$). Scorurile PH ale QoL demonstrează o scădere mai slabă a punctajelor. Cel mai afectat scor s-a dovedit a fi RF-P: $52,94 \pm 5,76$ în lotul HBV și $68,00 \pm 5,69$ în lotul BFG, versus $89,42 \pm 3,45$ în lotul-martor. Scorul GH a fost apreciat cu punctaje scăzute în loturile HBV și BFG ($52,32 \pm 2,84$ și $53,88 \pm 3,50$), versus lotul-martor: $70,54 \pm 3,05$ ($p < 0,01$; $p < 0,01$).

Concluzii. În hepatopatiile cronice descresc toate componentele ce caracterizează calitatea vieții, cel mai mult fiind afectată componenta mintală. Scăderi mai semnificative ale calității vieții se înregistrează în lotul de pacienți cu infecție cronică cu VHB.

EFECTELE SCHIMBĂRILOR CLIMATICE ASUPRA CALITĂȚII APEI POTABILE

Elena CIOBANU

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Elena Ciobanu, e-mail: elena.ciobanu@usmf.md

Cuvinte-cheie:

schimbări climatice, apa potabilă, sănătate, maladii hidrice.

Introducere. Schimbările climatice, una dintre cele mai presante probleme ale secolului nostru, afectează profund calitatea apei potabile. Modificările în precipitații, temperatură și evenimente meteorologice extreme au un impact semnificativ asupra disponibilității și purității apei, ceea ce constituie o provocare majoră pentru sănătatea publică și sustenabilitate.

Scop. Studiul își propune să analizeze efectele schimbărilor climatice asupra calității apei potabile, examinând modificările în compoziția chimică și microbiologică, și impactul acestora asupra sănătății umane.

Material și metode. S-au folosit date din rapoarte din domeniul sănătății și a mediului, studii climatologice și analize ale calității apei din diverse țări. Metodologia include analiza comparativă a datelor istorice și actuale privind calitatea apei, cu un accent special pe zonele afectate de secetă, de inundații sau de alte fenomene climatice extreme.

Rezultate. Rezultatele studiului subliniază o deteriorare semnificativă a calității apei în diverse regiuni ale lumii. În India, în ultimii 20 de ani, nivelurile de nitrați din apele subterane au depășit valorile normate cu peste 50% din cauza perioadei de secetă prelungită. Mai mult de atât, rapoartele recente indică o creștere cu 35% a contaminării bacteriene în aceleași surse de apă. În Europa, creșterea medie a temperaturilor cu 2°C în ultimele decenii a accelerat proliferarea algelor toxice în lacuri și în rezervoare, afectând astfel calitatea a 30% din sursele de apă potabilă. Studii efectuate în bazinul Rinului au arătat o creștere cu 40% a concentrațiilor de fitoplancton nociv. În Africa, analizele de după inundații au relevat că peste 60% din sursele de apă testate în zonele afectate sunt contaminate cu *E. coli* și cu alte bacterii patogene, sporind riscul de boli diareice, care afectează anual milioane de persoane. În America de Nord, modificările modelului de precipitații au determinat o creștere alarmantă, cu 25, a concentrațiilor de plumb și de alte metale grele în anumite surse de apă. Rapoarte recente din Statele Unite ale Americii indică faptul că peste 18 milioane de oameni sunt expuși la niveluri de contaminare cu plumb care depășesc limitele recomandate de Agenția pentru Protecția Mediului. Aceste tendințe au un impact direct asupra sănătății publice. De exemplu, în regiunile afectate de contaminarea cu nitrați și cu metale grele, s-a înregistrat o creștere cu 20% a cazurilor de afecțiuni renale și cu 15% a cazurilor de cancer asociate cu calitatea apei. Aceste cifre subliniază importanța unei gestionări mai eficiente a resurselor de apă și a implementării de soluții adaptate la schimbările climatice pentru a asigura accesul la apă potabilă de înaltă calitate.

Concluzii. Schimbările climatice au un impact evident și alarmant asupra calității apei potabile. De aceea, este esențial să se intensifice eforturile de monitorizare și de purificare a apei, precum și să se dezvolte strategii adaptative pentru gestionarea resurselor de apă în contextul noilor provocări climatice. Protejarea calității apei este vitală pentru sănătatea și securitatea populațiilor la nivel global.

INVESTIGATION OF PANCREATIC ACTIVITY PARAMETERS IN PATIENTS DURING COVID-INFECTION IN REPUBLIC OF MOLDOVA

Iulianna LUPASCO, Tatiana GHELIMICI, Ludmila GOLOVATIUC

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Corresponding author: Iulianna Lupasco, email: labgastroenterologie@usmf.md

Keywords: chronic diffuse liver disease, pancreatic function, COVID-19 disease, viral infection.

Introduction. Chronic diffuse liver diseases continue to rank high among the issues contributing to high mortality rates worldwide. The Republic of Moldova holds the leading position globally in terms of the highest age-standardized incidence rate of liver cirrhosis and related mortality cases. The 2019 coronavirus (COVID-19) pandemic has posed yet another significant challenge for healthcare systems worldwide, given its potential to affect internal organs and cellular mechanisms. The investigation of metabolic interrelations between different organs and systems of the organism, particularly those with an injured liver affected by this new virus, has garnered significant scientific interest in recent years.

The aim. The study of pancreatic activity parameters in chronic liver patients during SARS-CoV2 infection in Republic of Moldova.

Material and methods. Our study represents a retrospective analysis of consecutively hospitalized patients in the COVID-19 unit at the *Timofei Moşneaga* Republican Clinical Hospital in Chişinau, Republic of Moldova, during the period from March 2020 to February 2021. A total of 73 patients' electronic medical records were examined, comprising 40 men (54.8%) and 33 women (45.2%), with a mean age of 57.29 years. All patients were categorized into three main groups: group 1 (13) consisted of individuals with chronic hepatitis (CH) of viral etiology (HBV, HCV); group 2 (13) included patients with liver cirrhosis (LC); and Comparison group 3 (CG) comprised patients (23) without liver pathology but with some functional issues related to the pancreas. Patients with metabolically associated liver disease (2) and nonspecific reactive hepatitis (22) were not considered in this analysis. Blood serum levels of glucose, amylase, and lipase were investigated in all patients. The analysis involved the use of percentages, means, and standard error of the mean for evaluation and statistical analysis, with the significance of differences (p) assessed using the Mann-Whitney U test.

Results. Elevated blood glucose levels, indicative of disrupted carbohydrate metabolism, were observed in patients with liver cirrhosis (6.38 ± 1.23 mmol/L) and in the Comparison group (CG) (8.11 ± 0.79 mmol/L), exceeding the normal reference values of 4.11-5.89 mmol/L. Amylase activity was within normal limits across all patient groups. In contrast, the level of lipase, a more sensitive indicator of pancreatic function, was elevated in the CG (112.13 ± 82.16 u/L) compared to the normal range of 13-60 u/L. These findings align with the main hypothesis and recent literature, suggesting that COVID-19 may induce pancreatic injury in patients with chronic liver disease and those with a history of pancreatic issues, highlighting the human pancreas as another potential target for the virus.

Conclusions. COVID-19 can provoke functional abnormalities in pancreatic function in patients with chronic diffuse liver disease, as well as in patients with a history of underlying pancreatic dysfunction. Further investigation of pancreatic function is needed in a larger group of patients with different liver pathologies.

DENTAL EDUCATION FOR MEDICAL STUDENTS

Elena STEPICO¹, Maria PATRANAC¹, Alexandrina FERDOHLEB¹, Cristina DUMITRAS²

¹*Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova*

²*Carol Davila University of Medicine and Pharmacy, Bucharest, Romania*

Corresponding author: Elena Stepico, e-mail: elena.stepico@usmf.md

Keywords: *medical students, Dental medicine discipline*

Introduction. Oral health disparities constitute a significant public health challenge, with far-reaching consequences for the overall health of the population and economic ramifications for any nation. Introducing medical students to the field of dentistry and equipping them with essential knowledge about risk factors and preventive measures for common dental conditions can foster greater responsibility within the medical community towards oral health and enhance communication among healthcare specialists.

The objective of this study was to assess the opinions of students at the Faculty of Medicine regarding the Dental Medicine discipline.

Material and methods. This study involved conducting a survey among medical students in two stages: Stage I, before the commencement of the Dental Medicine module, and Stage II, upon its completion. In Stage I, data were collected from 356 fourth-year students at the Faculty of Medicine. Among them, 77% were high school graduates, 20% graduated from medical colleges, and 3% from other educational institutions. In Stage II, 386 students who had completed the Dental Medicine module were surveyed. The questionnaire consisted of general information about the participants and inquiries about the necessity and significance of including this discipline in the curriculum at the Faculty of Medicine.

Results. According to the gathered data from Stage I, 63.6% of respondents confirmed that Dental Medicine was a new subject for them. Additionally, 60.1% expressed their willingness to study it, 67.8% believed it would be beneficial, and 85.8% recognized a close connection between oral and general health. Regarding its inclusion in the curriculum, 65% considered it should be mandatory, while 35% suggested it be optional. After completing the module, 100% of participants acknowledged a strong correlation between oral health and general health. They asserted that Dental Medicine should be a compulsory discipline in the Faculty of Medicine's curriculum and is indispensable for medical students.

Conclusions. Introducing medical professionals to the field of dentistry, coupled with comprehensive knowledge of anatomical structures, physiological functions, and pathological conditions, enhances patient trust in the medical profession and fosters better inter-professional communication. Given that many oral conditions are preventable or treatable with early intervention, training physicians and actively involving them in oral disease prevention efforts can help mitigate oral health disparities and their adverse effects on overall health. Through oral screenings, preventive measures, referrals for dental assessments, and collaborations with dentists, physicians can positively impact oral health outcomes, especially in vulnerable populations.

STRATEGII DE PROMOVARE ÎN MARKETINGUL CABINETULUI STOMATOLOGIC

Ludmila GOMA

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu”, Chișinău, Republica Moldova

Autor corespondent: Ludmila Goma, e-mail: ludmila.goma@usmf.md

Cuvinte-cheie:

marketing social,
promovare, man-
agementul mar-
ketingului, strate-
gie.

Introducere. Piața serviciilor stomatologice este una foarte competitivă. În prezent, problema medicilor stomatologi este fluxul de pacienți. Pentru atragerea acestora, cabinetele stomatologice se ocupă de publicitate în diverse moduri: în cabinetele mici și mijlocii această misiune și-o asumă proprietarul, iar în cele mari pot exista subdiviziuni specializate în publicitate care dispun de buget propriu și organizează acțiuni de publicitate cu participarea companiilor specializate. Rolul marketingului în domeniul serviciilor de sănătate este de a contribui la furnizarea de informații de valoare clienților.

Scop. Analiza instrumentelor publicitare și recomandarea unor tehnici moderne de promovare a cabinetului stomatologic.

Material și metode. Populația studiului: pacienții a cinci cabinete stomatologice cu următoarele specializări: terapie, ortopedie, chirurgie dentoalveolară, parodontologie. Cei 138 de pacienți care și-au dat acordul verbal de a participa la studiu, au completat un chestionar autoadministrat, compus din 22 de întrebări grupate în șase categorii. Perioada de colectare a datelor: decembrie 2022 – februarie 2023. În cadrul studiului a fost studiată și documentația internă a cabinetelor stomatologice precum: raportul de autoevaluare semnat de conducătorul cabinetului; copia regulamentului de organizare și de funcționare; organigrama; schema sistemului informațional; planul de dezvoltare strategică; planul de control a calității serviciilor prestate. Metode de cercetare utilizate: descriptivă, analitică, comparativă.

Rezultate. Strategiile de marketing se propun ca o modalitate sigură de a construi relații cu publicul cabinetului stomatologic. Pentru un stomatolog, strategia de marketing înseamnă a convinge pacienții că se oferă o experiență fără durere și cu rezultate așteptate. Conform studiului, există următoarele modalități de promovare: recomandarea – 31%, rețelele de socializare – 25%, google – 17%, televiziunea – 15%, plasarea – 12%. Satisfăcuți de condițiile prestate de cabinetele stomatologice au fost 73,18% din persoanele intervievate, 92,75% au fost mulțumite de atitudinea personalului medical, iar 56,52% au ales cabinetul stomatologic în baza reputației medicilor. Aplicarea unui sistem de marketing contribuie la formarea categoriilor de pacienți planificați și pacienți continuu. La întrebarea ce îl face pe pacient să fie fidel unui anumit cabinet stomatologic, 32 % au numit aplicarea unui plan de marketing, 25% – condiții favorabile de muncă ale medicilor. S-a constatat că pacienții doresc mai multă computerizare a serviciilor medicale.

Concluzii. Publicitatea în stomatologie oferă pacienților posibilitatea de a alege tratamentul, clinica, medicul. Dintre metodele și instrumentele de promovare analizate s-au evidențiat recomandarea medicului din parte pacienților, strategiile legate de promoții și cele privind prețul, prezența saului propriu. O strategie eficientă s-a dovedit a fi promovarea în mediul online îmbinată cu cea offline. Aplicarea unor strategii de marketing eficiente duce nu numai la creșterea satisfacției clienților, dar și a personalului – un element component în managementul unui cabinet stomatologic.

